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Abstract 
The current bottleneck preventing the wider application of time-resolved structural 
techniques is the ability to quickly and accurately trigger protein function across an 
ensemble of molecules either in solution or in crystallo. The fastest and most accurate 
approach to achieve protein function synchronisation is by using protein photocaging 
approaches. During this project, a new class of protein photocleavable crosslinking 
reagents was designed and synthesised. This novel crosslinking scaffold carries two α-
bromoacetate groups, which were shown to react with protein surface cysteines 
efficiently and cleanly. The crosslinker is released from the protein by UV irradiation, 
by photolysis of ortho-nitrobenzyl groups, cleaving the surface “staple” from the 
cysteine residues, leaving only a small methyl carboxylate group on the cysteine side 
chains. The cysteine “anchors” can be easily introduced by site-directed mutagenesis. 
This new set of reagents were developed as a new approach to protein photocaging 
which decouples the protein activation step from the protein chemistry being 
investigated. The photocage does not target residues directly involved in function but 
rather aims to restrict the conformational space explored by the protein, limiting 
essential dynamics and preventing function. This approach opens avenues for more 
widely applicable protein triggering methodology, potentially allowing for time-
resolved experiments to be performed in wider variety of protein classes than those 
investigated to date. 
To test these reagents, aspartate α-decarboxylase (ADC) was chosen as a model system. 
This enzyme catalyses the conversion of aspartate to β-alanine, a precursor of coenzyme 
A. ADC is expressed as an inactive zymogen which cleaves post-translationally, 
yielding a catalytic pyruvoyl group. The cleavage requires an additional activating 
partner, PanZ. Protein homogeneity is an essential requirement for a successful time-
resolved experiment and, therefore, the mechanism by which PanZ activates ADC was 
investigated. The crystal structure of the ADC-PanZ protein-protein complex was 
determined at high-resolution, as well as those of several ADC mutants. With the aid of 
complementary techniques (SAXS, ITC, MS, NMR, in cellulo studies) the molecular 
mechanism by which this protein-protein interaction promotes ADC activation was 
elucidated. The protein complex formation causes the formation of a strained, 
activation-competent conformation of the ADC peptide backbone at the site of 
cleavage. Furthermore, a novel negative feedback mechanism for pantothenate and CoA 
biosynthesis regulation in bacteria was discovered and proposed.  
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1 Introduction 
1.1 Structural studies of biomacromolecules 
The last century has seen the discovery and development of biophysical techniques that 
have allowed for the structure of (bio)molecules to be determined with great accuracy. 
The rate of development of the techniques and instrumentation has been exponential; in 
1912 the first X-ray diffraction studies allowed for the structures of simple metal 
halides to be determined (Bragg, 1913) and the first structure of a small organic 
molecule, hexamethylenetetramine, was solved a decade later in 1923 (Dickinson and 
Raymond, 1923). It took almost 50 years from these initial discoveries until the first 
protein structure was determined, that of myoglobin, in 1958 (Kendrew et al., 1958), 
but since then structural biology techniques have been in constant development and 
there now are more than 97,000 X-ray crystallography structures published in the 
Protein Data Bank (PDB).  
High-resolution structural information of biomacromolecules in combination with 
biochemical data has allowed for a much greater understanding of how macromolecular 
structure is related to function. From such studies structure-activity relationships can be 
extracted, which define the role of essential residues in protein function. For example, 
in the case of enzymes, the architecture of the protein explains how the substrate binds 
to the active site and defines which residues are responsible for the interactions between 
the enzyme and the substrate. The relative spatial arrangement of the functional groups 
of the amino-acid side chains and the substrate allows for a chemically relevant 
mechanism to be proposed. It also explains how the enzyme can recognise the substrate 
and how it is able to modulate the energy landscape of the chemical reaction allowing it 
to occur under physiological conditions. In the case of protein-protein and protein-DNA 
interactions, understanding the structure of the complexes allows for the determination 
of the, often large, binding interfaces and the basis for the high affinity and specificity 
of such interactions.  
These structure-activity relationships have been vital for the understanding of how 
proteins function and misfunction. Protein misfunction can lead to the disregulation of 
biological processes and cause disease. Knowing the structures of medically relevant 
targets has allowed for the design of small molecules that modulate protein activity. 
Many drugs that are currently on the market have been designed and developed to target 
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specific protein binding sites, such as HIV protease inhibitors and DNA replication 
inhibitors (Anderson, 2003, Simmons et al., 2010).  
One further very interesting application of structure-function relationships is the 
possibility of developing new artificial protein machines that are able to mimic protein 
function. As proteins are highly efficient and selective, such molecular machinery can 
have a great impact in industry, especially in making manufacturing processes more 
efficient and reducing waste (Samish et al., 2011, Khoury et al., Yu et al., 2014). 
1.1.1 Why aren’t high-resolution static structures enough? 
Undoubtedly, structural biologists are now proficient at determining high-resolution 
structures of macromolecules and their complexes, and this breadth of structural 
information has allowed for the in-depth study of protein mechanisms. Nevertheless, 
even such detailed, high-resolution information is severely incomplete, as it only 
provides a static, ensemble averaged picture of the system. It is well established that 
biomacromolecules are intrinsically flexible and that dynamics are intimately connected 
to function (Wand, 2001, Henzler-Wildman et al., 2007a).  
The conformational changes that occur during protein function span a wide range of 
time and length scales. Some structural changes are very small, such as the breaking of 
a covalent or a hydrogen bond, or the rotation of an amino acid side chain. Small 
movements are essential during enzyme catalysis, where the protein has to first bind the 
substrate tightly and then adapt its conformation to accommodate the different chemical 
intermediates and transition states along the reaction coordinate (Henzler-Wildman et 
al., 2007b, Klinman, 2013, Klinman and Kohen, 2013, Hanoian et al., 2015). 
Larger protein motions can involve single loops or helices (Malhotra et al., 2013), and 
even whole domains. Hinge motions are involved in the opening and closing of 
membrane proteins (Feld and Frank, 2014, Zhou and Robinson, 2014) and large 
rearrangements can occur during protein-protein interactions (Boehr et al., 2009). 
None of these motions are isolated events, rather they are usually correlated with 
changes across the whole protein (Eisenmesser et al., 2005). The timescales of 
conformational change are also intimately related to the length scale of structural 
change. Bond breaking or isomerisation occurs very rapidly (fs-ps), side-chain rotations 
in the ns time-regime and larger conformational changes on ms-s timescales (Fig. 1.1) 
(Gray et al., 2015, Levantino et al., 2015a). 
  3 
 
Fig. 1.1 Timescales and length-scales of protein conformational changes, showing the biophysical structural probes 
able to capture such transitions by both time-resolved and non-time resolved approaches.  
Changes in protein conformation during function mean that structure-activity 
relationships also change over time and, therefore, the relationships derived from a 
static model are only absolutely valid for that exact conformational state of the protein. 
When structures for multiple conformers of a protein can be obtained, their involvement 
in specific stages of protein function can sometimes be rationalised with the aid of other 
biochemical data (Schnell et al., 2004). Nevertheless, the mechanisms by which 
proteins interconvert between conformations are difficult to probe and the structures of 
short lived, transient states are particularly elusive to standard structural techniques, 
making the static information obtained from routine structural studies severely 
incomplete. To fully understand how biomacromolecules perform their function, 
experiments must be able to probe both the structure and dynamics of the system over 
time. 
1.1.2 The role of protein dynamics in enzyme catalysis 
As well as the understanding of protein function gained from static structures, the 
dynamic properties of biomacromolecules must also be investigated, adding a fourth 
dimension to structural studies, time. For a complete description of a system, each 
conformational state adopted by a protein as it functions and the energy barriers for the 
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interconversion between states have to be defined (Henzler-Wildman and Kern, 2007). 
The dynamics of proteins can be classified according to the energy barriers associated 
with each conformational transition. Higher energy barriers are associated with slower 
movements and wider structural changes which occur at longer timescales (µs or 
slower). Many aspects of biological function occur within these timescales, such as 
catalysis, protein-protein interactions and folding. Such processes are characterised by 
distinct conformational changes that can sometimes be distinguished experimentally, 
such as different structures observed by crystallography or the ensembles of 
conformations obtained by NMR or EM. 
Faster timescales are associated with more local movements, such as loop motions and 
side chain rotations (ns-ps timescales) and even the bond breaking and making events 
that occur during an enzymatic reaction (fs). These faster dynamics are usually 
associated with a constant thermal fluctuation of the protein between structurally similar 
states, which contribute to the entropy of the system and are, therefore, involved in the 
thermodynamics of the system and vital for function. This entropic aspect can 
sometimes be visible in crystal structures from the analysis of temperature factors that 
define the level of displacement of atoms from their average position (Fraser et al., 
2011). 
NMR can provide information about protein dynamics at both short and long timescales 
from relaxation dispersion experiments (Kay, 2005). Recent NMR studies have 
uncovered protein motions of enzymes at various timescales under steady-state 
conditions. Three examples have been chosen to illustrate the importance of protein 
dynamics for enzymatic activity.  
Cyclophilin A 
The timescales of specific conformational oscillations of cyclophilin A during the 
catalysis of cis-trans isomerisation of prolyl peptide bonds (Fig. 1.2), have been 
determined and matched to those of the catalytic step from kinetic experiments 
(Eisenmesser et al., 2005). Residues exhibiting dynamics on timescales similar to the 
rate of catalysis were mutated and shown to affect substrate binding affinities and 
catalytic efficiency, supporting the proposal that the motions observed by NMR are 
directly involved in catalysis. 
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Fig. 1.2 Cyclophilin A enzymatic reaction and dynamics. (Top) the cis-trans isomerisation of proline containing 
peptides by cyclophilin A. A dipeptide is shown, with the general N-terminal amino acid side chain represented as R. 
(Bottom) cyclophilin A (PDB 4N1M), shown as a cartoon (teal) in complex with a Gly-Pro peptide (sticks with 
carbons coloured yellow). The 101Ala-Ser110 loop is shown in orange with Asn102 in sticks and the hydrogen bonds to 
the peptide as black dashed lines.  
This enzyme is a tractable model system to be studied by molecular dynamics, as the 
catalytic step does not involve bond breaking or making, greatly simplifying simulation 
of changes at the active site. Classical mechanics modelling was used to investigate the 
relationship between the conformational dynamics of cyclophilin A and the enzymatic 
reaction (McGowan and Hamelberg, 2013). These simulations have shown that there 
are conformational states shared between the substrate-bound and transition-state forms 
and that the enzyme optimises binding to the transition state by making use of a pre-
organised network of hydrogen bonds that are sampled from the substrate-bound state. 
Beyond the small fluctuations in the positions of active site residues that promote 
catalysis, larger conformational changes were also observed between the apo and bound 
structures, with changes to loops beyond the active site. One particularly interesting 
dynamic change is related to a loop adjacent to the active site (residues 101Ala-Ser110), 
which becomes more flexible upon binding of the substrate, allowing for the backbone 
of asparagine 102 to sample more conformations and form a hydrogen bond to the 
substrate, promoting the turnover step (Fig. 1.2).  
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Dimethylarginine dimethylamino hydrolase 
Dimethylarginine dimethylaminohydrolase (DDAH) catalyses the conversion of N,N-
dimethylarginine to L-citrulline (Fig. 1.3). N,N-dimethylarginine is involved in the 
regulation of nitric oxide synthase (NOS), which, in turn, maintains vascular tension in 
mammals (Leiper and Nandi, 2011). The active site is covered by a dynamic loop, L1 
(residues 17-27), which is unstructured in the apo form of the enzyme but becomes 
ordered upon binding of the substrate, shielding the active site (Fig. 1.3) (Murray-Rust 
et al., 2001).  
 
Fig. 1.3 DDAH enzymatic reaction and dynamics. (Top) the conversion of N,N-dimethylarginine to L-citrulline by 
DDAH. (Bottom) DDAH C254S mutant (PDB 1H70, teal cartoon) in complex with citrulline (sticks with carbons 
coloured yellow), The 17Gly-Asp27 loop is shown in orange, capping the active site. 
A combination of NMR, molecular dynamic simulations and fluorescence studies on the 
dynamics of the L1 loop and the remaining residues lining the active site have 
suggested that the rate limiting step of the reaction is correlated with the substrate 
binding step and, therefore, the conformational change of loop L1 (Rasheed et al., 
2014).     
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Dihydrofolate reductase 
The dynamics of dihydrofolate reductase (DHFR) have been extensively studied, 
characterised and implicated in catalysis (Luk et al., 2015). DHFR catalyses the 
reduction of dihydrofolate (DHF) to tetrahydrofolate in a hydride transfer reaction 
which requires NADPH as a cofactor (Fig. 1.4). Fast vibrational motions (in the fs-ps 
time regime) have been observed for different DHFR mutants and are proposed to 
promote the hydride-transfer step by sampling distances along the reaction coordinate 
through a network of coupled motions throughout the protein (Agarwal et al., 2002). 
DHFR also exhibits three distinct conformations - open, closed and occluded - of the 
highly mobile Met20 loop (residues 9-24), which are associated with the different 
ligand binding states of the enzyme and, therefore, the different steps along the catalytic 
cycle.  
 
Fig. 1.4 The enzymatic activity of DHFR and different Met20 loop conformations. (Top) the reduction of DHF to 
tetrahydrofolate catalysed by DHFR. NADPH is used as the reducing agent. (Bottom) the closed (teal), open (light 
blue) and occluded (dark blue) conformations of the DHFR Met20 loop (PDB 1RX3, 1RA9 and 1RC4 respectively). 
Methotrexate (a transition state mimic) and NADPH are shown as sticks (carbons coloured yellow and green 
respectively). 
The occluded and closed conformations have been previously observed by 
crystallography in different enzyme-ligand complexes, as shown in Fig. 1.5 (Sawaya 
and Kraut, 1997) and the distinct conformations have been associated with cofactor, 
product and substrate binding and release states. An open conformation is also visible in 
certain crystal forms and is thought to be associated with the interconversion between 
 8 
the closed and occluded states, allowing for substrate binding and product release from 
the binding site. 
 
Fig. 1.5 The catalytic cycle of DHFR, showing the different enzyme complexes. The catalytic step reduces DHF 
tetrahydrofolate at the expense of the oxidation of NADPH to NADP+, with a clear conformational change of the 
Met20 loop from a closed to an occluded conformation. The enzyme then releases the oxidised cofactor to bind a new 
molecule of NADPH, which then promotes the release of the product.  
The millisecond Met20 loop motions have been experimentally correlated with rate of 
turnover (Bhabha et al., 2011), but the hypothesis that they’re directly correlated has 
been refuted by computational work (Adamczyk et al., 2011). This is one example of 
the potential pitfalls of the studies described in this section, where dynamic aspects of 
enzymes have been indirectly correlated with the rates of catalytic steps. Without the 
direct experimental visualisation of the conformational changes over the course of the 
catalytic cycle, incorrect associations can be made. Dynamics of enzymes are clearly 
essential for efficient catalytic activity and determining the correlation between 
structure and dynamics is vital for obtaining a complete understanding of the system. 
Only by direct visualisation of the structural and chemical changes of the protein in real 
time can these correlations be fully founded and irrefutable. This can be done by using 
time-resolved techniques, where the conformations and chemical steps adopted by the 
protein, as it functions, can be captured in real time. 
1.1.3 Time-resolved structural techniques 
A typical “pump-probe” time-resolved experiment is depicted in Fig. 1.6. The ensemble 
of molecules in a resting state is first triggered to initiate function (t = 0). The reaction is 
allowed to proceed for a specific amount of time, defined as Δt. After the first defined 
time-delay, Δt1, a probe pulse is applied, providing information about the exact 
conformational state of the system at t1. The experiment is repeated multiple times for 
each time point to increase both the quality and completeness of the data. The 
experiment is also repeated at different time delays (Δt2, Δt3… Δtn), providing sequential 
DHFRDHFNADPH DHFR
THF
NADP+
DHFR THF
DHFR THFNADPH
DHFRNADPH
Closed conformation
Occluded conformation
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conformational information along the reaction pathway. This information can be 
interpreted as a “stop-motion” type movie, which, although simplified, describes the 
molecular motions of the protein as it functions.  
 
Fig. 1.6 Overview of a time-resolved experiment. Each coloured protein represents the ensemble of molecules in a 
distinct chemical or conformational state. At time 0, the ensemble is rapidly, and ideally uniformly triggered, starting 
the biological process. After a defined time delay (Δt1) the ensemble is probed to investigate the conformational state 
at that Δt after triggering. The experiment is repeated multiple times to increase the signal to noise and provide 
complete datasets and also repeated at different time points (Δt1-Δtn), revealing the sequential conformations adopted 
during function. 
A variation of this set-up can be defined as a “pump-probe-probe-probe” approach, 
where the biological process is initiated only once but probed multiple times at 
increasingly longer time delays. This approach is preferable, as it diminishes the amount 
of sample required for the experiment, but its feasibility is completely dependent on the 
experimental setup and, most importantly, on the sample itself. If the sample interacts 
with the probe - for example, if it becomes damaged - then multiple probing pulses must 
be used with caution.  
Although the principle behind a trigger-probe experiment is simple, the experimental 
set-up is not trivial and requires a highly interdisciplinary approach. When designing a 
time-resolved experiment many different aspects have to be considered (Levantino et 
al., 2015a), related to sample preparation, instrumentation and experimental 
requirements, as summarised in Fig. 1.7. The design and set-up of a time-resolved 
experiment requires a multitude of skills and relies on scientific teams that include 
hardware scientists and software specialists working alongside the chemists and 
structural biologists. The detailed intricacy of such an experiment is beyond the scope 
of this thesis, but some of the aspects are discussed below. 
Time
Trigger
t=0
Probe Probe Probe Probe
Different states
Δt1 Δt2 Δt3 Δt4 Δt5
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Fig. 1.7 Overview of important considerations for the design of a time-resolved experiment. The experiment has been 
divided into 3 main aspects: experimental requirements, sample and instrumentation, shown as 3 circles coloured 
blue, green and red respectively. Some detailed considerations regarding each section are shown. Where an aspect of 
the set-up is shared between different sections, it occupies the area shared by the circles. The possible triggering and 
probing techniques are grouped in dashed boxes under the corresponding header.  
The sample 
As in all structural studies of biomacromolecules, obtaining a suitable sample is the first 
concern. The protein needs to be available in sufficient quantities and, if overexpressed 
the protein constructs have to be stable and represent a biologically relevant state of the 
protein. The sample has to be homogeneous as the experiments are performed on 
ensembles of molecules, making a good purification protocol an essential requirement. 
The sample must also be active, which may require post-translational modifications or 
the presence of ligands or cofactors. For NMR studies, the protein has to be isotopically 
labelled and for diffraction experiments, it must be crystallised. Crystallisation is still an 
empirical process, where extensive screening may be necessary to obtain conditions that 
yield well-diffracting, homogeneous crystals that can also accommodate the 
conformational changes occurring during function. 
 
Detectors 
 
 
Time-
resolved 
experiment Sample 
Instrumentation 
Experimental 
requirements 
Activity 
Homogeneity 
Stability 
Purification 
Crystallisation 
Production/Expression 
                  Trigger 
Temperature jump 
                Photolysis 
Rapid mixing 
Sample delivery Data analysis 
             Probe 
Diffraction 
Scattering 
Microscopy 
Spectroscopy 
Labeling 
  11 
Instrumentation 
When collecting time-resolved data, the main consideration is the required signal to 
noise ratio: how to accurately collect sufficient data for each time-point to make a 
meaningful measurement. Recent developments in hardware, such as brighter X-ray 
sources, more powerful electron microscopes as well as sensitive detectors, have made 
time-resolved diffraction, scattering and microscopy experiments feasible (Levantino et 
al., 2015a).  
The integration of sample delivery systems within the experimental set-up can also be 
challenging. In many cases, the sample has to be continuously exchanged (due to 
radiation damage or if the reaction of interest is irreversible). 
Data analysis is also non-trivial; merging of the data from repeated measurements at 
each time-point to give complete and meaningful datasets can be difficult, especially for 
diffraction and microscopy experiments. In addition, if more than one conformational 
state is present at any time-point, accurate deconvolution of the states is also necessary.  
The experiment  
The probe 
Biomolecular structural techniques can be divided into distinct classes, depending on 
the resolution and extent of information that can be obtained from the experiments. 
Solution based techniques such as small-angle X-ray scattering (SAXS) and wide-angle 
X-ray scattering (WAXS), give a global view of the biomolecular structure. SAXS 
provides information about the overall shape of the molecule and is especially useful to 
determine overall macromolecular properties or large conformational changes (Doniach, 
2001, Pollack and Doniach, 2009) whereas WAXS provides information on finer 
structural features, such as subtle changes in fold and secondary structure elements 
(Fischetti et al., 2004, Chen et al., 2008).  
High-resolution structural techniques that give global structural information about the 
system are X-ray diffraction, electron microscopy (EM) and nuclear magnetic resonance 
(NMR). All three techniques have practical limitations:  
- Crystallography requires homogeneous, well diffracting crystals, which can be 
difficult to obtain, especially from large proteins, biomacromolecular complexes 
and membrane proteins.  
- EM is mainly limited by particle size and the large quantity of micrographs 
needed. The protein has to be sufficiently large to be distinguishable within the 
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micrograph, and thousands of images of the particles in different orientations 
have to be averaged together to improve the signal to noise ratio. The achievable 
resolution depends on the amount of data available and the homogeneity of the 
sample.  
- Contrary to X-ray diffraction and EM, where the proteins are used in their native 
state without need for derivatisation, NMR requires the isotopic labelling of the 
sample with NMR active nuclei (15N, 13C). NMR is also limited by sample size, 
with smaller proteins being preferred (<60 kDa), although great advancements 
in isotopic labelling have recently been made to overcome this limitation (Tzeng 
et al., 2012).  
Spectroscopy is also a high-resolution technique, but only provides sparse local 
information. It is very sensitive and thus especially powerful for identifying fine 
changes in protein structures, such as changes in chemical environments of residues and 
bond-lengths. Proteins can be investigated in their native form or chemically modified 
site-specifically with probes. 
The trigger 
The “trigger” has to cause a change in the system that starts its function quickly and 
cleanly. The triggering event must be faster than the process under investigation. As 
mentioned previously, protein dynamics span a wide range of timescales, from fs to 
seconds (Fig. 1.1). Therefore, the triggering method that can be used is completely 
dependent on the speed of the process being investigated. Finally it must affect at least a 
significant fraction of the ensemble, sufficient to be detected by the probe. 
There are two main ways to trigger biological processes: rapid mixing and light 
excitation. Rapid mixing is slower, usually allowing for ms time-resolution (West et al., 
2008, Konuma et al., 2011), with the fastest reported continuous flow devices reaching 
100 µs time-resolution (Akiyama et al., 2002, Trebbin et al., 2014). Solutions of the 
protein of interest and a binding partner (small molecule, DNA or even a second 
protein) are mixed to trigger function. Δt is determined from the flow rate and the 
distance between the mixing point and the probe pulse interaction point (Fig. 1.8, left). 
This technique is applicable to virtually any system and can even tolerate 
microcrystalline slurries for diffraction experiments (Schmidt, 2013). Recent 
developments in microfluidic devices have also allowed for a dramatic decrease in the 
volume of sample required for the experiments.  
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Light excitation (Fig. 1.8, right) allows for much wider range of time-resolutions to be 
probed (fs-ms). Short laser pulses are used to either directly initialise a photochemical 
reaction, through the photolysis or isomerisation of a bond or excitation of a 
chromophore, or to create a temperature jump (Kubelka, 2009). Unsurprisingly, proteins 
that are naturally photoactivatable have been the main focus of recent developments in 
the field of time-resolved studies, but the majority of proteins are not naturally 
photoactivatable. In order to be able to use light as a trigger for non-naturally 
photoactivatable proteins, an artificial photosensitive moiety has to be chemically 
introduced into the system. This is done by photocaging: the introduction of a 
photocleavable protecting group at a strategic site on the protein or its binding partner 
that inactivates the system until the protecting group is removed by photolysis with a 
light pulse. 
 
Fig. 1.8 Triggering methods for reaction initiation. Optical pump pulses are shown as blue rectangles. Probe pulses 
are shown as orange rectangles. (Left) Rapid mixing. Two solutions are mixed together at t=0. Δt is defined by the 
distance between the probe pulse and the point of mixing along the flow tube. The method can be used to trigger 
protein function by delivering binders (both in solution and as microcrystalline slurries) with different binding 
partners (small molecules, proteins, DNA) or by changing conditions, such as pH. (Right) Light activation. The 
diagram shows two possible experimental set-ups: proteins in a rapid flowing solution (top) or static samples 
(bottom). Reaction is triggered by application of a laser pulse at t=0. For the static sample, Δt is simply defined by a 
time delay between the two pulses, whereas in flow, Δt is defined by the distance between the probe pulse and the 
area of the flow tube illuminated by the triggering laser pulse. 
1.1.4 Summary 
Although extremely complex, time-resolved experiments that yield global structural 
information (from X-ray diffraction and scattering and cryo-EM data) can be performed 
(Shaikh et al., 2014, Levantino et al., 2015a), yielding fascinating insights into whole 
protein dynamics and protein motions during function at a variety of timescales.  
For fast dynamic events (sub ms), the only systems that have been investigated with 
these techniques have been naturally photoactivatable proteins, meaning that the current 
bottleneck to making such techniques more widely applicable lies in the triggering 
methodology. For scattering experiments looking at relatively slow biological processes 
(slower than 100 µs), rapid mixing is a reasonable approach. For faster events, reaction 
 
 
 
Flow 
t=0 Δt1 Δt2 
 
Flow 
 
t=0 
   
Δt1 Δt2 Δt3 
Mix 
Time     
  
 14 
initiation has to be done by the use of light pulses, which require a non-trivial case-by-
case development of a photocaging strategy. The following section describes the 
available approaches for non-natural photoactivation of proteins and the problems 
associated with the technology currently available, leading onto the main aim of this 
project. 
1.2 Reaction triggering by light 
1.2.1 Naturally light-activated proteins 
Naturally photoactivatable proteins have been the main focus of time-resolved X-ray 
and scattering experiments, as these can be triggered reliably very fast both in solution 
and in crystals, often with extremely high yields. One such example is photoactive 
yellow protein (PYP), which has been extensively studied using time-resolved X-ray 
diffraction experiments (Schotte et al., 2012, Jung et al., 2013, Tenboer et al., 2014). 
PYP is a small (14 kDa), soluble blue light receptor. It is found in photosynthetic 
bacteria and is thought to be responsible for signalling cascades in the organisms that 
cause them to move away from sources of harmful (blue) wavelengths of light 
(Sprenger et al., 1993). In the ground state, the protein contains a trans-4-
hydroxycinnamic acid cofactor, which is covalently attached to a cysteine residue 
(Cys69) though a thioester bond (Yamaguchi et al., 2009). Upon absorption of a photon 
of light (400-475 nm, λmax=446 nm) (Nielsen et al., 2005), the trans-alkene isomerises 
to a cis-alkene (Fig. 1.9), triggering a cascade of structural changes through the protein, 
which eventually lead to the formation of a signalling state, pB1, which follows pB0 but 
has not been observed by X-ray crystallography due to crystal packing constraints 
(Meyer et al., 1987, Harigai et al., 2003). 
 
Fig. 1.9 The PYP photocycle. (Left) Isomerisation of the ground state (pG) of the trans-4-hydroxycinnamic acid 
cofactor to the cis pB0 intermediate upon absorption of a photon of light. (Right) PYP photocycle intermediates 
structurally characterised by Schotte et al (Schotte et al., 2012). 
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Pump-probe time-resolved Laue X-ray diffraction experiments have allowed for the 
differentiation of the structural intermediates of the PYP photocycle (Fig. 1.9) (Schotte 
et al., 2012). Data were collected on timescales ranging from 100 ps to 1 s, and allowed 
for the visualisation of the first intermediate pR0, a highly strained species which was 
too short lived to have been resolved in previous cryo-trapping (Kort et al., 2004) or 
even ns time-resolved Laue X-ray diffraction experiments (Ihee et al., 2005). The 
diffraction data were fitted to 4 structurally distinct intermediates, starting from a 
previously described kinetic model. The fraction of each intermediate at each time point 
was then calculated to best fit the electron density and these values evaluated to give a 
refined, structurally significant kinetic model. Structural changes are visible across the 
whole protein structure and are not limited to the vicinity of the chromophore. Recent 
studies using time-resolved serial crystallography at an X-ray free-electron laser have 
provided electron density maps with improved resolution and allowed further 
refinement of the relative populations of intermediates pR1 and pR2 at 1 µs post 
photoactivation (Tenboer et al., 2014).  
Other naturally photoactivated systems that have also been investigated by time-
resolved techniques include myoglobin (Schotte et al., 2003, Bourgeois et al., 2006, 
Levantino et al., 2015b), photosynthetic reaction centre (Baxter et al., 2004, Wöhri et 
al., 2010), haemoglobin (Ren et al., 2012, Schotte et al., 2013, Kim et al., 2015), 3-
isopropylmalate dehydrogenase (Hori et al., 2000) and trypsin (Singer et al., 1993). 
However, the vast majority of interesting protein targets are not naturally 
photoactivatable, making them even more challenging systems to work with.  
1.2.2 Photocaging 
A photocaging group is a small organic molecule that can be covalently attached to an 
essential residue within a protein or functional group on a ligand, inactivating the 
biological process. The photocage acts as a protecting group that can be liberated by 
photolysis with a light pulse of specific wavelength. There are many types of photo-
removable protecting groups, but only a few have been employed in the study of 
biological systems so far: ortho-nitrobenzyls (oNB), coumarins (Cm) and para-
hydroxylphenyls (pHP) (Corrie et al., 2005, Hagen et al., 2005, Mayer and Heckel, 
2006, Klán et al., 2013). The wavelength of maximum absorption (λmax), quantum 
yields (Φ) and rates of cleavage vary considerably for each class of compounds (see 
sections 4.1 and 9.6 for a detailed description of the spectroscopic properties, 
advantages and disadvantages of each of the three photocaging groups).  
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Substrate/ligand caging 
When a small molecule ligand or substrate is required for function, the photocleavable 
protecting group can be introduced by chemically synthesising a substrate/ligand 
derivative. This approach is widely applicable, but can be very challenging and has to 
be designed on a case-to-case basis. Firstly, the photocage has to be introduced at a site 
within the small molecule that inhibits function without completely inhibiting binding 
of the ligand to the protein, otherwise the time-resolution of the experiment becomes 
dependent on the post-photolysis rate of diffusion of the free ligand into its binding site. 
Once the photocaged molecule has been designed, the synthetic availability and ease of 
synthesis of the compound has to be evaluated. Even for simple chemicals, a good 
knowledge of synthetic chemistry is necessary to produce such molecules. 
Nevertheless, photocaged biochemically or physiologically active compounds have 
been in use for the last 3 decades. The first biologically relevant photocaged molecule 
was adenosine 5’-triphosphate (ATP), bearing either a 2-nitrobenzyl group (oNB, Fig. 
1.10, 1) or a 1-(2-nitrophenyl)ethyl group (oNPE, Fig. 1.10, 2) (Corrie et al., 2005). 
These compounds were used to investigate the function of a human sodium-potassium 
pump (Kaplan et al., 1978) under continuous illumination for decaging as well as in the 
first flash photolysis experiments to observe the interaction between myosin and actin 
with a ms time-resolution (McCray et al., 1980, Goldman et al., 1982). These initial 
studies, along with the flash photo-isomerisation of azobenzene derivatives (Lester and 
Nerbonne, 1982), were the dawn of the use of flash photolysis for the study of 
biological mechanisms.  
 
Fig. 1.10 Caged ATP with 2-nitrobenzyl and 1-(2-nitrophenylethyl) photoprotecting groups (1 and 2 respectively) 
and corresponding photolysis products: 2-nitrobenzaldehyde and 1-(2-nitrophenylacetone) (3 and 4 respectively), 
ATP and proton. The photocaging group is highlighted in red. 
Cyclic nucleoside monophosphates (cNMPs) bearing both oNB or coumarinyl 
derivatives (Fig. 1.11, 7 and 8 respectively) have been previously used to investigate 
spatial- and time-dependent aspects of signalling pathways inside cells, by measuring 
changes in potentials across cell membranes that occur on a ms timescale after the 
triggering of cyclic nucleotide-gated ion channels (Corrie et al., 2005). The rates of 
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cleavage of the photocaged cNMPs have not been reported for all the compounds, but 
where known vary between 3000 s-1 and 1.7 s-1 (Corrie and Trentham, 1993, Wang et 
al., 2002). 
 
Fig. 1.11 Adenosine 3’,5’-cyclic monophosphate (cAMP, 5) and guanosine 3’,5’-cyclic monophosphate (cGMP, 6) 
protected with 2-nitrobenzyl or coumarinyl photocleavable groups (7 and 8 respectively) used previously in time-
resolved studies. The photocaging moieties are highlighted in red. 
Other examples of previously used photocaged small molecules include glutamate 
(neuronal activity of glutamate-gated ion channels and glutamate transport) (Callaway 
and Yuste, 2002, Takaoka et al., 2004), γ-aminobutyric acid (synaptic events of GABA 
receptors) (Molnár and Nadler, 2000) and hormones (regulation of gene expression) 
(Lin et al., 2002, Link et al., 2004, Shi and Koh, 2004). The majority of photocaged 
biologically active compounds have been used in ex vivo, in cell based studies or on 
membrane bound proteins, for example, by measuring changes in current across the 
membranes or along neurons or triggering apoptosis by releasing toxic proteins in cells 
(Goldmacher et al., 1992, Hagen et al., 2005). Such experiments span µs to s timescales 
and can be done by laser photolysis or continuous illumination. However, although the 
experiment triggers a local increase in concentration of a biologically active molecule, it 
does not require full activation or homogeneous activation as the differences in signal 
are measured over time. A more in-depth discussion of photocaging applications in cell 
biology is beyond the scope of this thesis, as this work is focused on the use of 
photocaged compounds for biophysical studies instead. For more detailed reviews of in 
vivo studies using photocaged compounds see (Hagen et al., 2005, Mayer and Heckel, 
2006, Deiters, 2009, Lee et al., 2009, Yu et al., 2010).  
oNPE-caged guanosine triphosphate (GTP) was used for an early time-resolved 
crystallographic study of the GTPase mechanism of Ras. Ras is a GTP binding protein 
involved in cell signalling transmission pathways, which lead to downstream effects 
such as cell proliferation (Kinbara et al., 2003). GTP hydrolysis leads to the inactivation 
of Ras and its GTPase activity is slow in the absence of a second protein GAP (GTPase-
activating protein). In the absence of GAP, GTP hydrolysis is sufficiently slow that the 
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conformation of the active GTP-bound state and the intermediate GTP/GDP-bound state 
of Ras could be investigated. The experiment was performed by first triggering the 
system by the photolysis of the oNPE-GTP molecule using a xenon flash lamp 
(Schlichting et al., 1989) followed by X-ray diffraction data collection using a 
polychromatic X-ray source at two time-points following GTP de-caging (4 min and 14 
min (Schlichting et al., 1990). 
The first ms time-resolved crystallographic experiment of a single-turnover enzymatic 
reaction was performed in 1998 on isocitrate dehydrogenase (IDH), which catalyses the 
decarboxylation of isocitrate (9) to α-ketoglutarate (11) in the presence of NADP+ and 
Mg2+. The half-life of the enzyme-product complex is 10 ms (extendable to 50 ms by 
lowering the temperature or pH). The reaction was triggered by the photolysis of a 4,5-
dimethoxy-oNPE protected NADP+ molecule (12) using a short (0.5 ms) 450 nm light 
pulse (reported post-photolysis half-life of 0.05 ms) and diffraction data collected for 
10 ms on a polychromatic X-ray source after a 2 ms lag-time (Stoddard et al., 1998). 
 
Fig. 1.12 (Top) Overview of steps in the catalytic dehydrogenation of isocitrate (9) to α-ketoglutarate (11) by 
isocitrate dehydrogenase (IDH). The first step is the oxidation of isocitrate to oxalosuccinate (10). (Bottom) the 
structure of the photocaged NADP+ moiety (12) used in the time-resolved crystallographic study. The photocleavable 
moiety is highlighted in red. 
Protein photocaging 
As well as photocaging a substrate or ligand, the protein itself can also be photocaged. 
Site-specific incorporation of photocleavable protecting groups can be done via two 
distinct approaches – genetic incorporation of unnatural amino acids or using 
bioorthogonal reactions.  
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The site-specific* genetic incorporation of photocaged amino acids can be done using 
amber suppression, where an aminoacyl-tRNA synthetase and the corresponding tRNA 
are evolved to accept the desired unnatural amino acid and insert it into the protein 
sequence during mRNA translation in response to an amber stop codon integrated into 
the expression vector using site-directed mutagenesis (Fig. 1.13) (Lang and Chin, 
2014). The current library of photocaged unnatural amino acids that have successfully 
been genetically incorporated into proteins is very limited, although it continues to 
slowly expand with the recent advances in the field. Efforts have mainly focused on the 
incorporation of amino acids caged with oNB derivatives. Fig. 1.14 shows all the 
photocaged amino acids that have been successfully genetically incorporated into 
proteins (Young and Schultz, 2010, Davis and Chin, 2012, Lang and Chin, 2014). 
 
Fig. 1.13 Schematic of the genetic incorporation of unnatural amino acids (Lang and Chin, 2014). An orthogonal 
tRNA-synthetase/tRNA pair is evolved to accept an unnatural amino acid. During transcription, the unnatural amino 
acid is incorporated into the nascent protein polypeptide chain in response to an amber stop codon.  
  
Fig. 1.14 Overview of all the photocaged protein residues introduced site-specifically by amber suppression to date. 
oNB derivatised amino acids are most common: with L-alanine (13), L-serine (15), L-cysteine (16 and 17), L-lysine 
(18 and 19, releasing carbamate derivatives) and L-tyrosine (20 and 21). Coumarin photocaging has been 
incorporated into L-aminobutyric acid (14) (Young and Schultz, 2010, Davis and Chin, 2012, Lang and Chin, 2014). 
                                                
* Residue-specific incorporation of unnatural amino acids is also possible through selective pressure 
incorporation, leading to the substitution of all positions of a specific amino acid by an unnatural variant. 
This approach has not been used for photocaging and is undesirable as it causes global changes to the 
protein as well as the introduction of multiple chromophores which may lead to the observation of 
structural changes unrelated to protein function as well as decreasing the amount of available photons 
Johnson et al. (2010). 
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Alternatively, under specific circumstances, bioorthogonal reactions can be used to site-
specifically photocage a protein residue (Fig. 1.15). Cysteines are the most nucleophilic 
amino acids, and can be targeted by electrophilic photocaging reagents, such as α-
bromo methyl derivatives (22). Cysteines can also be selectively modified to 
dehydroalanines (24) post-translationally (Chalker et al., 2011), and further modified by 
a thiol containing photocage (25), such as 2-nitrobenzenemethanethiol or 4-
thiomethylcoumarin (Akita et al., 2005).  
 
Fig. 1.15 Direct bioorthogonal modification of surface cysteine residues with photocaging reagents that can be 
cleaved to yield the free cysteine. The cysteine residue can be reacted with an electrophilic bromo-methyl reagent 
(top, 22) or transformed to a dehydroalanine (24) using 1,4-dibromoadipamide (23) and reacted with a thiol 
containing reagent (bottom, 25). 
A final approach to making chemically modified proteins is native chemical ligation, 
where the protein is produced (semi-)synthetically (Fig. 1.16) (Bang and Kent, 2004, 
Durek et al., 2007). The part of the protein polypeptide chain bearing the desired 
photocaged residue and a C-terminal thioester (26) is synthesised chemically (Blanco-
Canosa and Dawson, 2008) and reacted with a second chemically synthesised or 
expressed peptide bearing an N-terminal cysteine (I, 27). The thioester ligated product 
(28) then undergoes an S-N acyl shift (II), to yield the full protein chain carrying the 
unnatural amino-acid (29). The procedure is performed under denaturing conditions and 
the protein has to be folded in vitro, so this approach is not be suitable for a wide range 
of proteins.  
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Fig. 1.16 Mechanism of native chemical ligation. A peptide carrying a C-terminal thioester group (26) is coupled to a 
second peptide bearing an N-terminal cysteine residue (27). The cysteine side chain attacks the thioester group (I), 
forming a thioester-ligated peptide (28), which undergoes an S-N acyl shift (II) to the desired full length peptide 
chain (29). 
Several classes of proteins have been photocaged using the different methods described 
above, including: 
- Protein kinases, by the direct cysteine chemical modification (Chang et al., 
1998), introduction of a photocaged thiophosphate moiety at an active site 
mutation T197C (Zou et al., 2002) or the genetic incorporation of a photocaged 
lysine at the ATP binding site (Gautier et al., 2011) 
- Cholinesterase, by modification with a photocleavable covalent inhibitor 
(Loudwig et al., 2003) 
- Lysozyme, by the incorporation of photocaged aspartate at the active site, using 
in vitro protein expression (Mendel et al., 1991) 
- Ion channels, by genetic incorporation of a caged tyrosine (Tong et al., 2001) 
- Immunoglobulin, by residue-specific lysine derivatisation (Kossel et al., 2001) 
-  Inteins, by the genetic incorporation of a photocaged cysteine (Ren et al., 2015).  
In all these examples, the modified proteins were shown to be de-activated (fully or 
exhibiting only very low residual activity) and activity could be recovered upon 
photolysis.  
Summary 
Photocaging of biological systems has been shown and used for the past few decades. 
There is enormous potential for the use of oNB, coumarin and pHP groups in the caging 
of proteins, substrates and ligands for efficient reaction triggering for time-resolved 
biophysical studies. Nevertheless, targeting protein-ligand binding-sites is challenging. 
The portfolio of current chemical probes for chemical modification of proteins is 
extensive, but residue-specific modifications with photocleavable groups that can be 
photolysed releasing the original amino acid side chain are limited to the chemical 
modification of cysteines or the genetic incorporation of the unnatural amino-acid. 
Labelling of ligands or substrates is much more widely applicable, but the synthesis of 
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the modified compounds can be very challenging, especially since many of the 
cofactors and ligands essential for protein  function contain stereocenters and multiple 
functional groups.  
The instrumentation and data analysis software necessary for time-resolved structural 
studies are continuously and rapidly evolving and have proven to be sufficiently 
powerful to allow for these studies to be successfully performed. Reaction triggering is 
clearly now the major bottleneck hindering the broader use of time-resolved techniques. 
Making protein photocaging technology widely applicable would relieve this bottleneck 
and greatly decreasing the complexity of the design of such experiments.  
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2 Project overview, objective and impact 
The aim of this project was to design photocaging reagents that could become widely 
applicable for the photocaging and photo-triggering of proteins, regardless of the nature 
of the protein, ligands or cofactors, by decoupling the reaction-triggering chemistry 
from the protein processes being observed during the time-resolved experiments. In 
practical terms, this means moving the photocaging moiety out of the protein active site, 
i.e. neither photocaging essential amino acids involved in function nor the substrate or 
ligands.  
Making a general reagent would decrease the complexity of the chemical synthesis 
currently involved in making specific photocaged substrates or ligands. Also, by 
making use of surface-cysteines as the target for bioconjugation of the photocaging 
reagents, the steps for protein modification would be simplified to the introduction of 
bioconjugational moieties by site-directed mutagenesis rather than requiring complex 
genetic incorporation of unnatural moieties.  
Instead of targeting active site groups, the new photocaging reagents developed here are 
intended to make use of the intrinsic protein dynamics known to be involved in 
function. Proteins are plastic and therefore adopt multiple conformations, some of 
which are active and some inactive. Using crosslinking compounds, dynamic regions 
can be rigidified, locking the protein in an inactive state. Release of this conformational 
“lock” by photolysis would then allow the protein to resume its normal dynamic 
behaviour and resume activity.  
The proposed novel approach for protein photocaging presented in this thesis is 
depicted in Fig. 2.1. The crosslinking reagents can be regarded as “conformational 
staples” which target engineered residues on the protein surface rendering the protein 
inactive, but retaining a substrate binding conformation. Upon cleavage of the “staple”, 
the protein is able to relax to its active conformation and on to all the conformational 
states required during function. 
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Fig. 2.1 Overview of the proposed new protein photocaging approach. Surface cysteine residues are introduced to the 
target protein by site-directed mutagenesis. The photocleavable crosslinker targets available cysteines specifically, 
“stapling” the protein in an inactive conformation. Upon photolysis, the crosslinker is cleaved and the protein allowed 
to resume function. Photolysis acts as the trigger which precedes the time-resolved measurements. 
A second advantage of this “allosteric” approach compared to traditional active-site 
photocaging approaches is that it removes the interference of the photocleavage by-
products with the system once it is triggered. The most widely used photocaging 
moieties (coumarin and ortho-nitrobenzyl groups) are of similar size to the side chains 
of the largest natural amino acids (tryptophan or tyrosine). The presence of such large 
fragments in the protein’s active site post-photocleavage can alter the conformations 
adopted by the protein or even block protein function until the by-product has diffused 
out of the active site, leaving the triggering under diffusion control and abolishing all 
efforts for fast synchronisation of the system.  
Aspartate α-decarboxylase (ADC) was chosen as the model protein for the crosslinking 
and cleavage studies of the photocleavable “stapling” reagents developed, as it has been 
well studied within the Webb group and can be overexpressed and purified easily 
(Webb et al., 2004, Webb et al., 2014). One of the main aim of this project was to make 
the technology available for time-resolved diffraction studies as well as solution studies, 
ADC has also been reproducibly crystallised within the Webb and Pearson groups, 
yielding consistently well diffracting crystals. The main disadvantage of using this 
system is that it requires a post-translational modification to become fully active. For X-
ray diffraction time-resolved studies, it is important to obtain fully active, homogeneous 
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protein for crystallisation and so understanding protein post-translational activation 
became an additional essential objective of this project.  
This thesis is therefore split into three main sections:  
- Understanding ADC activation in order to obtain clean, homogeneous and fully 
active protein 
- The design and synthesis of a novel class of protein photocleavable crosslinking 
reagents 
- The crosslinking and photo-release of ADC using the developed crosslinkers. 
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3 A molecular understanding of aspartate α-decarboxylase 
activation 
3.1 Introduction 
3.1.1 Pantothenate biosynthesis 
Pantothenate (vitamin B5) is an essential vitamin synthesised by a common pathway in 
bacteria, yeast and plants. The β-alanine biosynthetic pathway for incorporation into 
pantothenate differs between organisms, and only that of bacterial will be discussed 
here. In bacteria, β-alanine (30) is obtained from the decarboxylation of L-aspartate (31) 
by aspartate α-decarboxylase (ADC) (Fig. 3.1).  
 
Fig. 3.1 The biosynthetic pathway of pantothenate, showing the biosynthetic intermediates and enzymes involved in 
each step. α-ketoisovalerate (34) is hydroxymethylated to ketopantoate (35), which is reduced to D-pantoate (32). L-
aspartate (31) is decarboxylated to β-alanine (1) by ADC. D-pantoate (32) is condensed with β-alanine (30) to 
pantothenate (33), which is phosphorylated to phosphopantothenate (37). Phosphopantothenate regulates the 
biosynthesis of CoA (36) by a negative feedback mechanism. The PanD zymogen matures to its active form ADC in 
the presence of PanZ. 
β-Alanine is then condensed with D-pantoate (32) (by pantothenate synthetase, PanC) to 
give pantothenate (33). α-Ketoisovalerate (34) is hydroxymethylated to ketopantoate 
(35) by ketopantoate hydroxymethyl transferase (PanB), which is then reduced to D-
pantoate (32) by ketopantoate reductase (PanE). As these last two reaction steps are 
reversible and α-ketoisovalerate is also a precursor in L-valine biosynthesis (Maas and 
Vogel, 1953), the decarboxylation of L-aspartate to β-alanine becomes the first 
committed step towards pantothenate synthesis in bacteria, and onwards to the synthesis 
of coenzyme A (CoA, 36) and its thioesters (Fig. 3.2). Pantothenate is phosphorylated 
to phosphopantothenate (37) by pantothenate kinase (PanK), which is inhibited by CoA, 
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creating a negative feedback loop mechanism for the regulation of CoA biosynthesis 
(Rock et al., 2003).  
 
Fig. 3.2 The relationship between the biosynthetic pathways of pantothenate and L-valine. The precursors to both L-
valine and L-aspartate are in equilibrium in the cell. The decarboxylation of L-aspartate to β-alanine is irreversible 
and, therefore, the first committed step in the biosynthesis of pantothenate and CoA. 
3.1.2 PanD activation to ADC 
ADC was first purified in 1979 (Williamson and Brown, 1979). It was shown to be 
involved in β-alanine biosynthesis in E. coli and contains a covalently linked, 
catalytically active, pyruvoyl group. Pyruvoyl-dependent enzymes (van Poelje and 
Snell, 1990) are a small subset of enzymes which include various decarboxylases such 
as histidine decarboxylase (Snell, 1986) and S-adenosylmethionine decarboxylase 
(Pegg, 2009). The pyruvoyl is synthesised post-translationally by the rearrangement and 
cleavage of the protein backbone. ADC is expressed as an inactive pro-protein, PanD, 
which consists of a single chain, the π-chain, and assembles into a homotetramer. The 
post-translational modification starts with an N-O acyl shift between Gly24 and Ser25 
(Fig. 3.3). The hydroxyl group of Ser25 attacks the carbonyl carbon of Gly24 (I), 
forming an oxyoxazolidine ring (II), which ring-opens to an ester intermediate (III) 
(Albert et al., 1998). The ester then cleaves by β-elimination, to a C-terminal glycine 
(Gly24) and a dehydroalanine (IV), which then hydrolyses to the desired N-terminal 
pyruvoyl group (V). The resulting two peptide chains are termed the β-chain (1Met-
Gly24) and the α-chain (25Pyr-Ala126).  
The PanD residues essential for activation of PanD to ADC have been explored by site-
directed mutagenesis (Gelfman et al., 1991, Schmitzberger et al., 2003, Webb et al., 
2012, Webb et al., 2014). As expected, mutation of Ser25 to alanine yields a non-
activatable PanD mutant, while other mutations along the activation peptide greatly 
decrease the processing ability of ADC, likely due to distortions of the conformation of 
the loop. In the zymogen crystal structure, the carbonyl carbon of Gly24 is seen 
hydrogen-bonding to the fully conserved Thr57 side-chain (Schmitzberger et al., 2003). 
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This interaction may act to polarise the carbonyl group, aiding the nucleophilic attack 
by Ser25, and also stabilise the oxyoxazolidine ring intermediate (II). Site-directed 
mutation of Thr57 to valine yields a completely non-activatable PanD mutant (Webb et 
al., 2014). Thr57 is the only proximal residue besides Gly24 and Ser25 found to be 
essential for PanD activation. 
 
Fig. 3.3 Accepted mechanism for the activation of PanD to ADC at the start of this project (Webb et al., 2004). The 
Ser25 hydroxyl side-chain attacks the backbone carbonyl of the adjacent residue (Gly24), which is hydrogen-bonded 
to Thr57 in the zymogen crystal structure (PDB 1PPY, I) (Schmitzberger et al., 2003). The oxyoxazolidine ring 
opens (II) to the ester intermediate (III), which can then cleave by elimination to a dehydroalanine intermediate (IV). 
The dehydroalanine residue can then hydrolyse to the required pyruvoyl group, giving the fully active enzyme (V).  
Other residues, such as Tyr58, His11 and Asn72 (Webb et al., 2012) have also been 
investigated, but in all cases PanD activation was still observed (Schmitzberger et al., 
2003). This was surprising as it was expected that other residues would be involved as 
general acids or bases for the deprotonation of Ser25 (I), protonation of the amine 
during opening of the oxyoxazolidine ring (II) and β-elimination of the ester (III). At 
the time this study began, it was thought that the water molecules surrounding the 
activation site might act as general bases or that a large conformational rearrangement 
might be required for activation, which could involve more distal residues, not yet 
investigated by mutagenesis, in the mechanism. 
Post-translational rearrangements leading to backbone cleavage have been observed in 
other systems, such as the processing of inteins (Fig. 3.4, A) (Paulus, 2000), activation 
of N-terminal nucleophile (Ntn) hydrolases (Kim et al., 2006, Buller et al., 2012) and 
the autoproteolysis of SEA domains (Fig. 3.4, B) (Levitin et al., 2005, Johannson et al., 
2009). In most protein systems, post-translational cleavage or rearrangement of the 
backbone is auto-catalytic (Paulus, 2000), with the exception of a small subset of 
  29 
proteins, for which the rate of modification is accelerated by accessory proteins 
(McDonald et al., 1998, Trip et al., 2011).  
 
Fig. 3.4 General mechanism of post-translational cleavage of Inteins (A) and other systems, such as Ntn hydrolases 
and SEA domains (B). X can be oxygen (Ser or Thr residues) or sulphur (cysteine residue).  
ADC is such a case, requiring an accessory protein is required for its full maturation. 
Overexpressed E. coli PanD activates slowly in vitro at 37 °C. The protein has to be 
incubated overnight at this temperature before significant levels of protein cleavage are 
observed (Nozaki et al., 2012). Furthermore, thermal activation of PanD leads to the 
formation of both the desired pyruvoyl cofactor, as well as a N-terminal serine by-
product, from the direct hydrolysis of the ester intermediate (Fig. 3.3, II) (Ramjee et al., 
1997). The presence of this by-product is clearly visible in the electron density of the 
published ADC crystal structure (PDB 1AW8) (Albert et al., 1998) and it has also been 
commonly found in other structures solved during the course of this investigation (i.e. 
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PDB 4ANO, Yorke, B.A. & Monteiro, D.C.F, unpublished results), but which will not 
be discussed in this thesis. Nevertheless, the formation of the serine by-product is a 
major problem with regard to the production of homogeneous and fully activated 
enzyme for biophysical studies and even more so for time-resolved structural studies, 
where the signal-to-noise ratio as well as the interpretation of the data can be 
challenging. Therefore, understanding the molecular basis of activation of PanD to 
ADC will allow for both a more in-depth understanding of the system as well as 
providing the means for the design of a robust protocol for the isolation of the fully 
active enzyme. 
The slow thermal activation suggests that an activating factor that accelerates PanD 
maturation to ADC (with clean pyruvoyl group formation) must be present in vivo 
(Ramjee et al., 1997). Despite this, for decades the post-translational rearrangement of 
ADC, and all other pyruvoyl-dependent enzymes, has been presumed to be 
autocatalytic. However, recently the accessory proteins for the activation of pyruvoyl-
dependent histidine decarboxylases, HdcB (Trip et al., 2011), as well as for the 
activation of PanD, PanZ (Nozaki et al., 2012, Stuecker et al., 2012a, Stuecker et al., 
2012b) have been discovered. 
3.1.3 PanZ: the activating factor for PanD maturation in vivo 
The gene panZ was first identified in 1990, in a region of the E. coli genome containing 
the genes for branched amino-acid transporters. The gene is located downstream of a 
region coding for proteins involved in branched chain amino acid transport but its 
deletion leads to pantothenate auxotrophy (Adams et al., 1990). PanZ, also known as 
YhhK, was subsequently found to be indirectly linked to the production of β-alanine, as 
mutations to the gene (in S. typhimurium) (Primerano and Burns, 1983) or its knockout 
(in E. coli) (Nozaki et al., 2012) cause β-alanine auxotrophy (Fig. 3.5). The mechanism 
of this remained unclear as all the enzymes involved in the pantothenate biosynthetic 
pathway (Fig. 3.1 PanB, PanE, PanC and ADC) had been overexpressed and purified 
and shown to catalyse each of the steps of the pathway without the need for further 
accessory proteins (Webb et al., 2004).  
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Fig. 3.5 Growth defects of ΔpanZ E. coli cells and growth recovery with hexaHis-tagged PanZ complementation, 
adapted from (Nozaki et al., 2012). Cell cultures were grown overnight in M9 glucose medium containing the 
indicated additives and show that ΔpanZ cells are β-alanine auxotrophs. 
A possible role for PanZ was proposed to be in PanD maturation. To test this 
hypothesis, Nozaki et al. investigated the role of PanZ in PanD activation in vivo by 
examination of the extent of PanD cleavage in ΔpanZ cells with and without 
complementation with PanZ (Fig. 3.6) (Nozaki et al., 2012). ΔpanZ cells showed no 
PanD activation, but complementation of the PanZ knockouts with a plasmid 
harbouring hexaHis-tagged PanZ recovered PanD cleavage, indicating that PanZ is the 
accessory protein necessary for efficient PanD activation in vivo (Fig. 3.6).  
 
Fig. 3.6 SDS-PAGE analysis of the activation of PanD in vivo showing the requirement of PanZ for cleavage 
(adapted from (Nozaki et al., 2012). PanD is detected by imunoblot analysis using an anti-FLAG antibody. PanD 
expressed in ΔpanZ cells is not activated. Cleavage is restored with the expression of PanZ by induction with IPTG. 
The PanZ sequence was annotated as a putative acyl-transferase as it carries a CoA 
binding motif. The 3D structure of PanZ was determined by NMR by J. Cort et al. 
(unpublished data, PDB 2K5T), confirming the binding of CoA. Nevertheless, no 
evidence of PanZ acetyltransferase activity could be observed using a radiometric assay 
with [1-14C]acetyl coenzyme A and site-directed mutagenesis of PanD-lysine residues 
did not affect PanD maturation (Stuecker et al., 2012a). 
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3.1.4 β-Alanine biosynthesis and CoA regulation 
A possible role of PanD in CoA biosynthesis regulation was first proposed in 1982 by 
Cronan and co-workers (Cronan et al., 1982). Supplementation of E. coli cultures with 
β-alanine led to increased cellular levels of CoA. Pantothenate supplementation did not 
have as strong an effect on CoA biosynthesis as β-alanine, and therefore β-alanine 
supply was proposed to regulate CoA production. Nevertheless, a mechanism for such a 
regulatory role of ADC was not identified. The only regulatory step for CoA 
biosynthesis that has been so far identified and characterised is the phosphorylation of 
pantothenate (Fig. 3.1, 33) to phosphopantothenate (Fig. 3.1, 37) by pantothenate 
kinase, which is allosterically regulated by CoA (Yun et al., 2000, Rock et al., 2003). 
No other regulatory mechanisms involved in the production of earlier metabolites on the 
route to pantothenate had been identified when this project began.  
3.2 Results and Discussion 
The main aim of this project was to elucidate the mechanism by which PanZ promotes 
PanD maturation in vivo, as ADC was the test system chosen for the testing and 
application of the novel photocleavable crosslinkers. Obtaining a cleanly activated, 
homogeneous enzyme preparation is as important as adopting the correct caging 
strategy or collecting and interpreting the data in time-resolved studies.  
The PanD.PanZ interaction was investigated using a range of biophysical techniques, 
including X-ray crystallography and isothermal titration calorimetry (ITC). The results 
obtained allowed the proposal of a revised mechanism of activation of PanD to ADC. 
They also provided insight into a new mode of regulation of CoA biosynthesis in 
bacteria and the observation of previously unreported X-ray-induced protein chemistry. 
The methods used, observations and results are described in the following sections. 
3.2.1 Protein overexpression and purification 
ADC is a tetrameric enzyme, each 13.8 kDa protomer consisting of a six-stranded, 
double-ψ β-barrel. The overall complex is 50 Å in diameter and doughnut shaped, with 
a large central pore open to solvent. The four active sites are located at the protomer-
protomer interfaces. As discussed in the introduction to this chapter, the PanD(T57V) 
site-directed mutant does not undergo the post-translational modification that leads to 
activation to ADC. This mutant was therefore chosen for the biophysical 
characterisation of the PanD.PanZ protein complex to allow for a clear investigation of 
the protein-protein interaction with no interference from the activation reaction. 
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PanD(T57V) is expressed as the intact π-chain and does not undergo in vivo activation 
or thermal cleavage. The structure of this site-directed PanD mutant has recently been 
reported, showing the intact and unmodified protein backbone in the activation region 
(Webb et al., 2014).  
PanD(T57V) and PanZ were overexpressed and purified as described in sections 8.5 and 
8.6. Details regarding the optimisation of protein overexpression, SDS-PAGE analysis 
of the purified proteins and the size-exclusion chromatography traces can be found in 
section 9.1. In summary, N-terminally hexaHis-tagged PanD(T57V) was overexpressed 
in auto-induction media from previously transformed E. coli MG1655 ΔpanZ ΔpanD 
(DE3) cells and purified by nickel affinity chromatography and size exclusion 
chromatography. C-Terminally hexaHis-tagged PanZ (Nozaki et al., 2012) was initially 
overexpressed from E. coli BL21 Gold (DE3) cells using arabinose induction in the 
presence of pantothenate. The requirement for pantothenate during overexpression was 
later rationalised as overexpression of PanZ leads to β-alanine auxotrophy (see section 
3.2.6 for further discussion). N-Terminally and C-terminally hexaHis-tagged PanZ 
(Cort, 2009) was subcloned by Chris Bartlett (Wellcome Trust rotation student) into the 
pET28a vector for overexpression by auto-induction in E. coli MG1655 ΔpanZ ΔpanD 
(DE3) cells. The N-terminally tagged variant was found to be unable to interact with 
PanD. The inhibition of the interaction by the N-terminal hexaHis-tag was later 
rationalised, as the PanZ Met1 residue is involved in the protein-protein interface (see 
section 3.2.5 for details). Therefore, only the C-terminally tagged PanZ was used during 
this project.  
3.2.2 Calorimetry studies of PanZ.Coa and PanD(T57V).PanZ 
The binding affinity of PanZ for CoA was investigated by ITC. CoA was titrated into 
two different PanZ samples, from different purification runs (Fig. 3.7). The titrations 
show that ~60% of the protein is purified with CoA already bound and that the KD for 
the interaction is approximately 6.2 µM. The ability of PanZ to bind CoA is consistent 
with both the published structure of PanZ by NMR (PDB 2K5T), which shows a 
PanZ.CoA complex, and the initial annotation of the PanZ sequence as a putative acyl 
transferase. Dialysis of the protein against SEC buffer A allowed for partial removal of 
CoA, as seen by the decrease in the incompetent fraction for a CoA titration into PanZ 
(Fig. 3.7 C). Full removal of CoA from the sample by longer dialysis times caused 
precipitation of the protein. 
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Fig. 3.7 Titration of CoA into PanZ. All samples were in 50 mM Tris (pH 7.5), 100 mM NaCl and 0.1 mM DTT 
(SEC buffer A). (A) and (B) titration of 800 µM CoA into two different 100 µM PanZ samples, showing 0.60 and 
0.62 equivalents of CoA co-purified with the protein and KD values of 6.2 ± 0.5 µM and 5.2 ± 0.2 µM respectively. 
(C) titration of 400 µM CoA into dialysed 57 µM PanZ showing a KD of 9.40 ± 0.4 µM. 
The PanD.PanZ interaction was next investigated by ITC. It was expected that the 
PanD.PanZ interaction would compete with CoA binding to PanZ as this would be 
consistent with a model in which ADC activation is negative feedback regulated by the 
concentration of CoA in the cell. In this model, at high CoA concentrations CoA would 
compete with PanD for PanZ binding, lowering the amount of fully matured ADC in the 
cell. In turn, less β-alanine (and subsequently CoA) would be produced, down-
regulating the concentration of CoA in the cell. But, contrary to expectation, the 
titration of PanD(T57V) into PanZ showed a binding coefficient equal to the fraction of 
PanZ.CoA rather than apo-PanZ (PanD protomer to PanZ monomer, Fig. 3.8, A). 
Saturation of PanZ with CoA showed a clear upwards shift in the binding stoichiometry 
(Fig. 3.8, B), suggesting that the PanD(T57V).PanZ interaction is CoA dependent, 
rather than competitive (Monteiro et al., 2012). The binding affinity between the two 
proteins in the presence of CoA was found to be 240 nM.  
The protein-protein interaction was also investigated by ITC in the presence of acetyl 
CoA (AcCoA) instead of CoA, in order to improve the consistency of the titrations. 
Thermodynamic parameters from ITC varied slightly between runs and it was 
hypothesised that CoA may form disulphide-linked dimers in solution, disrupting the 
protein-protein interaction. Acetyl CoA is unable to form such dimers, and was 
therefore used in place of CoA in all subsequent experiments. The subsequent 
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PanD(T57V).PanZ titrations performed in the presence of AcCoA were more accurate, 
reproducible and showed a binding stoichiometry closer to 1 (Fig. 3.9).  
 
Fig. 3.8 ITC traces for the titration of (A) 400 µM PanD(T57V) (by protomer) into 60 µM PanZ without excess CoA 
and (B) 394 µM PanD(T57V) into 59 µM PanZ in the presence of 100 µM CoA. All samples were in 50 mM Tris 
(pH 7.5), 100 mM NaCl and 0.1 mM DTT (SEC buffer A). In the presence of excess CoA, the binding stoichiometry 
increases, indicating that the interaction is mediated by CoA. The KD for the protein-protein interaction in the 
presence of CoA was calculated to be 241 ± 38 nM. 
 
Fig. 3.9 Pairwise titration of PanD(T57V) into PanZ in the presence of 394 µM AcCoA (excess). All samples were in 
50 mM Tris (pH 7.5), 100 mM NaCl and 0.1 mM DTT (SEC buffer A). (A) 263 µM PanD(T57V) (protomer 
concentration) titrated into 35 µM PanZ. (B) 263 µM PanZ titrated into 35 µM PanD(T57V) (protomer 
concentration). The KD for the protein-protein interaction was found to be 35 ± 9 nM from globally fitting both 
titrations. 
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3.2.3 The PanD(T57V).PanZ interaction is CoA dependent 
To confirm the stoichiometry of the PanD(T57V).PanZ complex and unambiguously 
determine the dependence upon CoA for interaction, both mass-spectrometry and NMR 
experiments were conducted.  
Electrospray mass spectrometry (ESMS) was used to observe three protein complexes 
in the gas phase: the PanZ.CoA complex, the PanD(T57V) homotetramer and the 
PanD(T57V).PanZ.CoA complex (Monteiro et al., 2012). Dr Dale Shepherd collected 
the mass spectrometry data and assisted with interpretation of the spectra. The PanZ 
sample containing 1 eqv. of CoA showed three species corresponding to apo-PanZ, 
PanZ.CoA and PanZ.2CoA (15.614, 16.381 and 17.148 kDa respectively). This 
revealed that the protein retained sufficient tertiary structure to bind CoA in the gas 
phase. The ternary species was rationalised as a possible CoA dimer, from disulphide 
formation. The PanD(T57V) sample revealed two tetrameric species corresponding to 
the PanD(T57V) homotetramer and a smaller heterotetrameric species, thought to 
correspond to partial proteolysis of PanD(T57V) (63.0 and 61.7 kDa respectively). This 
hypothesis was confirmed by MS-MS to dissociate the heterotetramer into its 
constituents: the full protein (15.753 kDa) and a truncated polypeptide (14.442 kDa). 
Finally, the PanD(T57V).PanZ heterooctamer was investigated in the presence of 
excess CoA. Once again, two species were visible in the spectrum, corresponding to the 
PanD(T57V) tetramer bound to 3 and 4 equivalents of PanZ.CoA (128.8 kDa and 
112.43 kDa respectively). The 4:3 heteroheptameric species was thought to be 
correlated with the contamination of the PanD(T57V) sample with the truncated 
polypeptide. A simulated spectrum of the 4:4 and 4:3 PanD(T57V).PanZ.CoA species 
was compared to the experimental data and found to be in good agreement. The data 
supported the hypothesis that the PanD(T57V).PanZ complex only forms in the 
presence of CoA (Monteiro et al., 2012). 
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Fig. 3.10 ESMS studies of the PanD(T57V).PanZ interaction. (A) PanD(T57V) sample, showing two species 
corresponding to the expected homotetramer (63.012 kDa, blue) and a smaller heterotetramer (61.701 kDa, red). (B) 
PanD(T57V).PanZ.CoA sample in the presence of excess CoA, showing two species corresponding to PanD(T57V) 
with 4 PanZ.CoA (blue) and 3 PanZ.CoA (red) species bound (128.827 kDa and 112.428 kDa respectively). (C) 
simulated spectrum of the PanD(T57V).4PanZ.4CoA and PanD(T57V).3PanZ.3CoA complexes, matching the 
experimentally obtained spectrum in (B). 
To confirm the absolute requirement of CoA for the PanD(T57V).PanZ protein-protein 
interaction, an NMR experiment was devised. As the PanD(T57V).PanZ.CoA complex 
is ~120 kDa, it was expected that, upon binding of the two proteins, the slow tumbling 
rate of the resulting complex would cause severe broadening of the NMR signals, 
effectively making the spectrum disappear. Chris Bartlett (Wellcome trust PhD rotation 
student) overexpressed 15N-labelled PanZ from minimal media containing 15NH4Cl, 
purified the protein by nickel-affinity chromatography and SEC as described previously 
(Monteiro et al., 2015) and recorded four different 1H-15N HSQC NMR spectra, shown 
in Fig. 3.11: (A) a spectrum of the sample obtained from the purification of the protein, 
which shows multiple species in solution, confirming the presence of apo and CoA-
bound PanZ fractions; (B) a spectrum of PanZ in the presence of excess CoA, showing 
a single species corresponding to PanZ.AcCoA; (C) a spectrum of the apo-
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PanZ/PanZ.AcCoA sample mixed with 1 eqv. of PanD(T57V) (PanD protomer to PanZ 
monomer), showing a different spectrum to that of PanZ.AcCoA, therefore 
corresponding to the apo-PanZ fraction of the sample; and (D) a spectrum of AcCoA-
saturated PanZ mixed with 1 eqv. of PanD(T57V) (PanD protomer to PanZ monomer), 
showing obliteration of the PanZ protein signals and full complex formation. 
 
Fig. 3.11 NMR spectra of 15N-labeled PanZ (0.2 mM in SEC buffer A). Purified protein (grey) showed multiple 
species in solution, PanZ.AcCoA and apo.PanZ. Addition of AcCoA simplifies the spectrum (blue) to a single 
species, PanZ.AcCoA. Addition of PanD(T57V) to purified PanZ also simplifies the spectrum (red), but to a different 
species, apo.PanZ. Addition of PanD(T57V) to PanZ.AcCoA causes loss of all signals, indicating full complex 
formation (green). 
The addition of PanD(T57V) to the apo.PanZ/PanZ.AcCoA mixture yields a different 
spectrum to that of PanZ.AcCoA, meaning that only the PanZ.AcCoA fraction is 
capable of binding to PanD(T57V), causing the disappearance of PanZ.AcCoA signals 
and leaving a spectrum that corresponds to the unbound apo.PanZ fraction. Full 
spectrum disappearance, and, therefore, complete complexation of PanZ to 
PanD(T57V) is only observed when PanD(T57V) is added to a AcCoA saturated PanZ 
sample. This experiment confirmed that full PanD(T57V).PanZ protein complex 
formation only occurs in the presence of excess AcCoA, proving that the 
PanD(T57V).PanZ interaction is CoA dependent. 
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The CoA dependence of PanD binding to PanZ and, therefore, of the activation of PanD 
to ADC, opened two further questions beyond the understanding of the mechanism of 
PanD activation by PanZ: what is the role of CoA in the formation of the protein-
protein interaction, and whether PanD.PanZ complexation has an effect on CoA 
regulation in vivo. Alongside investigating the mechanism of PanD maturation by PanZ, 
the role of this protein-protein interaction in the regulation of CoA biosynthesis was 
also investigated. 
3.2.4 The PanD.PanZ protein complex structure 
Initial crystallisation screen 
PanD(T57V) and PanZ were mixed in a 1:1 (protomer to monomer) ratio in the 
presence of 2 equivalents of CoA * . The protein complex was concentrated to 
~4 mg mL-1. A 96 condition sparse matrix crystallisation screen (Crystal Screen I and 
II, Hampton Research) was set-up and very small crystals were obtained in 200 mM 
Li2SO4, 100 mM Tris pH 8.5 and 30% w/v PEG 4000 (18 °C). The crystallisation 
conditions were optimised and larger bipyramidal crystals (50 µm) were obtained in 100 
mM Tris pH 7.8-8.0, 180-220 mM Li2SO4 and 20% w/v PEG 4000 (Fig. 3.12, A).  
The crystals were cryo-protected by soaking for a few seconds in mother liquor 
containing 20% w/v glycerol, mounted on cryo-loops or meshes and flash cooled in 
liquid nitrogen. The crystals did not diffract on the in-house source. Preliminary data 
were collected at beamline I03 at Diamond Light Source (DLS) at 100 K with 
maximum resolution varying between 9.5 and 4.6 Å (see section 9.2). Data reduction in 
Xia2 (the automated integration, scaling and merging pipeline at DLS) (Winter, 2010) 
showed the protein crystallised in space group I422 (a=b=84.5 Å, c=154 Å, 
α=β=γ=90°).  
Phasing of the data was attempted using both Molrep (Vagin and Teplyakov, 1997) and 
Phaser (McCoy et al., 2007), using an ADC protomer as a search model (modified PDB 
1PPY) (Schmitzberger et al., 2003). In multiple datasets, apparent solutions for the 
tetramer could be found, some clearly incorrect, as the imposed 4-fold crystallographic 
symmetry did not yield the ADC tetramer. In all cases, no reasonable electron density 
was available for the PanZ monomers.  
                                                
* The initial crystallisation trials were performed concomitantly with the initial ITC binding assays and, 
therefore, excess CoA was used instead of AcCoA. The first batch of optimised crystals were obtained 
with excess CoA, but all the following crystallisation trays were set with excess AcCoA, as this coincided 
with the confirmation of PanD(T57V).PanZ binding in the presence of AcCoA by ITC. 
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As an alternative to phasing by molecular replacement, experimental phasing by 
anomalous diffraction was attempted, with both heavy metal and selenium 
derivatisation. Firstly, heavy metals were incorporated by soaking the crystals in mother 
liquor containing Os, W, Pt and Hg salts for a few minutes followed by back soaking 
for a few seconds. Data were collected at beamline I24 (DLS), but the anomalous signal 
obtained was insufficient for phasing. Nevertheless, three higher resolution datasets, to 
2.5-2.7 Å, were obtained from Hg(OAc)2-derivatised crystals. The crystal symmetry 
appeared to be P42212 with a much larger unit cell (a=b=176.1 Å, c=161.3 Å, 
α=β=γ=90°), containing 2 PanD(T57V).PanZ.AcCoA* octamers in the asymmetric unit 
cell (the unit cell contents were calculated using the Matthews coefficient calculator in 
CCP4) (Kantardjieff and Rupp, 2003). Data scaling and merging proved difficult, with 
bad statistics from Aimless (Evans and Murshudov, 2013). Closer analysis of the 
automated data reduction outputs from FastDP and Xia2 (Winter, 2010) showed space 
group ambiguity, with different data reduction strategies outputting varying crystal 
symmetries (P422 and I422). Data reduction in alternative space groups was attempted, 
followed by similar phasing strategies as previously described for the apo-crystals, but 
without success. Data were also collected for crystals derivatised with other metal salts 
((NH4)10H2(W2O7)6 and K2OsCl6). These had lower diffracting power and had, once 
again, ambiguous crystal symmetries (C2221 or P42212 for tungstate and P42212 or I422 
for osmium).  
Following the unsuccessful structure solution by heavy metal derivatisation,  
selenomethionine (SeMet) labelled PanZ was produced. SeMetPanZ was overexpressed 
in SeMet supplemented M9 minimal media using methionine auxotrophic E. coli B834 
(DE3) cells (see sections 9.1.3 and 8.5.3) (Sreenath et al., 2005) and the 
PanD(T57V).PanZ(SeMet).CoA complex was prepared similarly to the 
PanD(T57V).PanZ.CoA complex used previously. Unfortunately, the protein complex 
precipitated during crystallisation attempts using the established conditions. 
Second crystallisation screen 
A new 96 condition sparse matrix crystallisation screen (Crystal Screen I and II, 
Hampton Research) of the PanD(T57V).PanZ.AcCoA complex at a concentration of 
8 mg mL-1 yielded small square plates (Fig. 3.12, B)  in 100 mM sodium cacodylate 
                                                
*  The crystals used for these experiments were obtained during the second batch of optimised 
crystallisation, which coincided with the AcCoA ITC experiments. Therefore, the crystals were grown in 
excess AcCoA, rather than CoA as used in the previous batch. 
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pH 6.5, 1.4 M sodium acetate. Crystals were cryo-protected and cryo-cooled as before 
and initial data were collected at 100 K at beamline I24 (DLS), to a maximum 
resolution of 2.3 Å (see section 9.2). Indexing was ambiguous, with multiple possible 
solutions (I4, C222, P4222 and P422) obtained from automatic data reduction with Xia2 
(Winter, 2010). All the crystals were heavily twinned, with twin fractions calculated by 
Pointless (Evans, 2006) varying between 0.371 and 0.5. Space group ambiguity may be 
an artefact of twinning, where the twin axis can be misassigned as a crystal symmetry 
axis. Reducing the data in the correct space group is essential for correct structure 
solution. Data from the two highest resolution datasets, initially thought to be in space 
group P4222 were integrated again in P1 using XDS and scaled and merged in different 
space groups (P4, C222, P222, P21, P1) in Aimless (Evans and Murshudov, 2013). The 
best merging statistics (Rmerge and Rp.i.m.) were obtained in space group P21 (a=b=84.8 
Å, c=82.4 Å, α=β=γ=90°). Molecular replacement of the PanD protomer using Molrep 
(Vagin and Teplyakov, 1997) or Phaser (McCoy et al., 2007) in P21 and P1 was 
successful, but once again the PanZ monomer could not be placed. The phased data 
were analysed with Zanuda (Lebedev and Isupov, 2014) which suggested a further two 
possible space groups (P4212 and P21212).  
 
Fig. 3.12 Cryo-cooled PanD(T57V).PanZ.AcCoA crystals in nylon loops, aligned to the synchrotron beam. In both 
cases, the beam is 70 µm wide (red ellipse). (A) bipyramidal crystals obtained from 100 mM Tris pH 8.0, 200 mM 
Li2SO4 and 20% w/v PEG 4000. (B) square plates obtained from 100 mM sodium cacodylate, pH 6.5, 1.4 M sodium 
acetate. 
All other datasets collected from the further optimised crystallisation conditions 
suffered from similar pathologies as described. Although several methods were 
attempted to obtain correct indexing, no unambiguous solution for the whole protein 
complex showing defined electron density for PanD(T57V) as well as PanZ was 
obtained. It was suggested that some of the crystal pathologies observed could be 
associated with the 4-fold rotational symmetry of the PanD(T57V).PanZ.AcCoA 
complex, as described in the next section. 
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Twinning and structure solution 
Although twinning is a relatively common occurrence in protein crystallography and 
can cause difficulties during indexing and phasing, the fact that some of the datasets 
collected during the course of this project showed reasonable solutions for the ADC 
complex but no interpretable electron density for PanZ could also indicate crystal lattice 
perturbations. As the ADC tetramer has a 4-fold axis that could be associated with a 
crystallographic symmetry axis, if there were even small changes in the conformation of 
the PanZ molecules surrounding the tetramer, this could have resulted in the poorly-
defined electron density observed for PanZ. A pictorial representation of possible lattice 
deformations is shown in Fig. 3.13. 
 
Fig. 3.13 Potential source for PanD(T57V).PanZ.AcCoA crystal lattice deformations. The PanD(T57V) tetramer is 
shown in green and different positions/conformations of PanZ in different shades of blue. The PanD(T57V) has a 
four-fold axis which may be associated with crystal symmetry. In a perfect crystal, PanZ would adopt the same 
conformation through the lattice. If PanZ adopts different conformations, lattice deformations may arise. 
To overcome these problems, three approaches were suggested. Firstly, avoid 
cryo-cooling-induced conformational changes of the relative protein orientations (i.e. 
collect the data at room temperature, RT). If PanZ is mobile, collecting the data at RT 
could allow for a single orientation to be captured, whereas cryo-cooling may lock the 
protein in several different conformational landscape energy minima, “blurring” the 
electron density for PanZ. A second option was to attempt lattice tightening by 
dehydration. Decreasing the water content in the crystal may restrict the flexibility of 
the proteins, at the risk of destroying the lattice completely if the crystal is too 
dehydrated. Successful lattice tightening can be translated into an increase in diffraction 
resolution or changes in crystal symmetry (Bowler et al., 2015). To achieve this, the 
crystals are mounted under a humidifying air stream and diffraction quality is monitored 
over a slow decrease in water content in the crystal. This is achieved by slowly 
decreasing the relative humidity of the air stream surrounding the crystal in 0.5 or 1% 
steps. The last approach is to screen for further crystallisation conditions that may yield 
an untwinned, well-diffracting crystal.  
90°
Perfect crystal Lattice deformationsADC tetramer with flexible PanZ
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A further seven 96-well sparse matrix commercial crystallisation screens were set-up 
[Crystal Screen HT 1 and 2, Index, Salt RX (Hampton Research), Morpheus (Molecular 
Dimensions) and Wizard I and II (Emerald Biosciences)], using 
PanD(T57V).PanZ.AcCoA at a concentration of 10 mg mL-1 with 2 eqv. of AcCoA (per 
PanZ monomer) to help stabilise the complex. From these, more than 120 potential 
crystallisation hits were obtained, and well-formed crystals from 5 conditions were 
chosen for initial screening and data collection at ID29 at ESRF. The data were to be 
collected at RT, to avoid cryo-cooling, and dehumidification was also attempted using 
the HC1 instrument (Sanchez-Weatherby et al., 2009).  
From all the crystals screened, one diffracted extremely well (crystallised in 200 mM 
potassium thiocyanate, 100 mM Bis-Tris propane pH 6.5, 20% w/v PEG 3350) and data 
were collected at RT, at 99.5% relative humidity, to 1.6 Å resolution (see section 9.2). 
Data were integrated in space group I4 (a=b=86.4 Å, c=81.0 Å, α=β=γ=90°) with Xia2 
(Winter, 2010) and scaled and merged using Aimless (Evans and Murshudov, 2013) 
with good statistics (Table 1). Molecular replacement using Molrep (Vagin and 
Teplyakov, 1997) successfully placed one PanD protomer (PDB 4AZD, with a contrast 
of 14.68) followed by one PanZ protein in the asymmetric unit cell (PDB 2K5T, with a 
contrast of 5.19). The structure was refined using Refmac5 (Murshudov et al., 2011) 
and manually rebuilt in Coot (Emsley et al., 2010). 
The new crystallisation conditions were then optimised to give square pyramidal 
crystals up to 300 µm in size, by varying the protein to mother liquor ratios. 10 µL 
hanging drops containing 4:1 protein:mother liquor ratios gave the largest crystals (Fig. 
3.14). A second dataset from these crystals was collected in-house at RT, to 1.7 Å 
resolution (see section 9.2). The data were integrated using HKL3000 (Otwinowski and 
Minor, 1997), scaled and merged using Aimless (Evans and Murshudov, 2013) and 
phased by molecular replacement using Molrep (Vagin and Teplyakov, 1997) using the 
structure obtained from the synchrotron dataset as a search model (Table 1). The in-
house structure was refined using Refmac5 (Murshudov et al., 2011) and manually 
rebuilt in Coot (Emsley et al., 2010) and found to be isostructural to the synchrotron 
structure. 
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Table 1 PanD(T57V).PanZ.AcCoA X-ray diffraction data reduction and refinement statistics 
 PanD(T57V).PanZ.AcCoA PanD(T57V).PanZ.AcCoA 
Data collection synchrotron in-house 
Space group I4 I4 
Cell dimensions     
    a, b, c (Å) 86.4, 86.4, 81.0 86.3, 86.3, 80.9 
    α, β, γ  (°)  90.0, 90.0, 90.0 90.0, 90.0, 90.0 
Resolution (Å) 59.1-1.61 (1.64-1.61) 33.7-1.70 (1.75-1.70) 
Rmerge (%) 5.8 (49.8) 3.7 (39.8) 
Rp.i.m. (%) 4.4 (41.2) 3.6 (36.6) 
<I> / sI 11.8 (1.6) 13.3 (2.2) 
Completeness (%) 97.4 (80.1) 99.7 (99.7) 
Redundancy 4.1 (2.6) 2.4 (2.3) 
Absorbed dose (kGy)* 70 20 
   
Refinement   
Resolution (Å) 59.1-1.61 (1.65-1.61) 29.52-1.70 (1.75-1.70) 
No. reflections 35579 (2180) 30609 (2242) 
Rwork (%)  12.9 (24.8) 14.4 (32.7) 
Rfree (%) 15.0 (26.2) 17.5 (36.2) 
No. atoms   
    Protein 2090 2064 
    Ligand/ion 53 65 
    Water 126 145 
B-factors   
    Protein (main chain) (Å2) 22.27 20.35 
    Protein (side chain) (Å2) 28.91 25.99 
    Ligand/ion (Å2) 28.19 20.35 
    Water (Å2) 35.55 32.45 
R.m.s. deviations   
    Bond lengths (Å) 0.029 0.023 
    Bond angles (°) 3.290 2.33 
 
 
Fig. 3.14 Optimised crystallisation conditions for the PanD(T57V).PanZ.AcCoA complex gave large (300 µm in the 
longest dimension), clean, square-pyramidal crystals. 
                                                
* Calculated using RADDOSE-3D (Zeldin et al., 2013) 
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3.2.5 Structural analysis of the in-house PanD(T57V).PanZ.AcCoA complex 
Overall architecture of the protein-protein complex 
As expected from the ITC binding studies, the PanD(T57V).PanZ.AcCoA complex is a 
heterooctamer. The complex is cross-shaped, with four PanZ protomers bound adjacent 
to the ADC loops that are cleaved post-translationally to form the active site. The 
AcCoA binding site is also adjacent to the protein-protein interface, consistent with the 
previously observed CoA-dependent complex formation. 
A 1:1 mixture of PanD(T57V) and PanZ was concentrated to ~10 mg mL-1, 2 eqv. of 
AcCoA were added and SAXS data collected at varying dilutions on beamline 4-2 of 
the Stanford Synchrotron Radiation Light Source (SSRL) by Dr Thomas Grant, Dr 
Edward Snell and Prof. Arwen Pearson to confirm that the heterooctameric structure of 
the PanD.PanZ.AcCoA complex obtained from X-ray diffraction corresponded to the 
true architecture of the complex in solution. The data were analysed with the help of Dr 
Thomas Grant (Monteiro et al., 2015). The experimental solution scattering data 
matched the crystallographic heterooctamer structure both at high and low scattering 
angles (Fig. 3.16, A). Fig. 3.16 shows the plot of the change in calculated scattering of 
the complex (I) with scattering angle (q) compared to the experimental data. Small 
deviations from the experimental data could be accounted for by including a small 
amount (32%) of a heterooctamer dimer, consistent with the packing in the crystal (Fig. 
3.16, B) along with the eight unresolved hexaHis-tags (one for each protomer) with 
each amino acid modelled as a sphere (Fig. 3.16, C). The modelled purification tags and 
calculated SAXS envelope are shown in Fig. 3.17. 
 
 46 
 
 
Fig. 3.15 Architecture of the PanD(T57V).PanZ.AcCoA complex. PanD(T57V) protomers are shown in light and 
dark green, PanZ in blue and AcCoA in sticks coloured by atom colours (carbons in grey). PanZ binds next to the 
PanD(T57V) protomer interface, at the PanD processing (and active) site. AcCoA is found adjacent to the protein-
protein interface. The a and b axes of the unit cell are represented as black lines along with the 4-fold rotation axis as 
a black square. 
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Fig. 3.16 Plot of ln q vs q (Å-1) of experimental and calculated SAXS data for the PanD(T57V).PanZ.AcCoA 
complex. The experimental data are shown in black. (A), (B) and (C) show the calculated scattering of the 
crystallographic heterooctamer (green) with 32% of octamer dimers (blue) and also the modelled 8 
crystallographically-unresolved hexaHis-tags (red) fitted against the experimental data. (D) shows the residuals of the 
fits. 
 
Fig. 3.17 Calculated SAXS envelope overlaid with the PanD(T57V).PanZ.AcCoA complex structure obtained by X-
ray crystallography. PanD(T57V) is shown in green, PanZ in blue, CoA as sticks (coloured by atom and with carbons 
in grey) and the modelled crystallographically unresolved hexaHis tags as orange spheres. The purification tags were 
modelled as single spheres for each residue of the peptide chain. 
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Acetyl coenzyme A binding places PanZ in a PanD(T57V)-binding competent 
conformation 
The solution structure of PanZ was previously elucidated by NMR spectroscopy in the 
presence of excess CoA by Cort et al. (Northeast Structural Genomics Consortium, 
PDB 2K5T, Fig. 3.18). The structure of PanZ in the PanD(T57V).PanZ.AcCoA 
complex was found to be very similar to that of CoA-bound PanZ in in solution. The 
Pan 26Tyr-Val33 loop is the most dynamic region in the solution data and it also 
corresponds to a region with high B-factors in the X-ray structure. As the AcCoA 
binding site is directly involved in the protein-protein interface and AcCoA is required 
for binding (as shown by ITC, ESMS and NMR in sections 3.2.2 and 3.2.3), it is likely 
that binding of CoA (or its thioesters) places PanZ in a PanD-binding competent 
conformation. The acetyl group of AcCoA points away from the protein-protein 
interface, supporting the findings of Stuecker et al. that PanZ does not act as an acetyl 
transferase during PanD activation (Stuecker et al., 2012a). 
 
Fig. 3.18 Overlay of the structure of PanZ in complex with PanD(T57V) and AcCoA (dark blue) with the previously 
reported solution structure of PanZ in the presence of CoA (light blue, PDB 2K5T, 3 lowest energy conformers 
shown). The 26Tyr-Val33 loop (black circle, right) is poorly resolved in the X-ray electron density and also adopts 
multiple conformations in the NMR structure ensemble. 
Binding of AcCoA to PanZ appears to stabilise the PanZ 66Leu-Gly76 loop (Fig. 3.19) 
through several hydrogen bonds (Leu66, Val68, Gly76, Gln79), electrostatic 
interactions (Arg74 to the pyridoxal phosphate), metal chelation (Mg2+ to Thr72 and the 
pyrophosphate) and cation-π interactions (Arg74 to the adenosine ring). This loop then 
forms part of the interface with PanD, crossing above the ADC C-terminal tail. 
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Fig. 3.19 Stereo images of the AcCoA binding site in PanZ, showing the interactions between the residues, the CoA 
moiety and Mg2+. Mg2+ is shown as a grey sphere and AcCoA in sticks coloured by atom (carbons in grey). PanZ is 
shown in blue, with residues interacting with AcCoA as sticks, coloured by atom (carbons in blue). Hydrogen bonds 
and electrostatic interactions are shown as black lines and cation-π interactions as red lines. 
The PanD(T57V) C-terminal tail is an integral part of the protein-protein interaction 
The PanZ 66Leu-Gly76 loop, 43Arg-Leu48 loop and N-terminus sandwich the 
PanD(T57V) C-terminal tail (Fig. 3.20), bridging the protein-protein interface, through 
electrostatic interactions (PanZ-Arg75 to PanD(T57V)-Glu40), direct hydrogen bonds 
(PanZ-Thr72 to PanD(T57V)-Val123, PanZ-Glu46 to PanD(T57V)-Tyr22 and PanZ-
Asn45 to PanD(T57V)-Gly23), van der Waals interactions (PanZ-Phe44 to 
PanD(T57V)-Pro122) and several water mediated hydrogen-bonding interactions. The 
PanZ-Asn45 to PanD(T57V)-Gly23 hydrogen bond is of considerable importance and 
will be discussed in the section dedicated to the mechanism of PanD post-translational 
modification (section 3.2.7). 
 50 
 
 
 
Fig. 3.20 Stereo-views of the PanD(T57V).PanZ.AcCoA interaction. PanD(T57V) is shown in green, PanZ in blue 
and AcCoA as sticks coloured by atom (carbons grey). Interacting residues from PanD(T57V) and PanZ are shown as 
sticks coloured by atom (carbons green and blue respectively). Hydrogen bonds as black dotted lines, cation-π 
interactions as red dotted lines and van der Waals interactions as orange dotted lines. (Top) the PanZ 66Leu-Gly76 and 
43Arg-Leu48 loops and N-terminus sandwich the PanD C-terminal tail above and below. (Middle) The main 
interactions of AcCoA with the PanZ 66Leu-Gly76 loop, organising it to bridge the protein-protein interface. (Bottom) 
The interactions between the PanZ 43Arg-Leu48 loop and N-terminus and PanD. 
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On binding of PanZ, the PanD(T57V) C-terminal tail (120Ala-Ala126) becomes an 
integral part of the protein-protein interface. This was surprising as the hydrophobic 
C-terminal chain of ADC is intrinsically disordered and is unstructured in the majority 
of published ADC crystal structures, with the exception of that of the ADC(N72A) site-
directed mutant, where it becomes ordered due to a crystal packing interaction (Webb et 
al., 2012). Therefore, the importance of the C-terminus of ADC for binding of PanZ 
was investigated by ITC. A truncated mutant, PanD(T57V/K119STOP) was generated 
by site-directed mutagenesis, overexpressed in auto-induction media and purified as 
previously described for the PanD(T57V) mutant (see sections 9.1 and 8 for further 
details).  
Titration of PanD(T57V/K119STOP) against PanZ.AcCoA (Fig. 3.21, B) showed no 
measurable binding compared to the titration of PanD(T57V) against PanZ.AcCoA 
(Fig. 3.21, A), confirming that the PanD C-terminal tail is essential for the protein-
protein interaction. Interestingly, the alignment of ADC protein sequences across 
different bacteria shows that the C-terminal peptide is fully conserved across all PanZ 
producing bacteria (Fig. 3.22), further supporting its role as an essential component in 
PanD.PanZ protein complex formation. 
 
 
Fig. 3.21 ITC titrations of (A) 263 µM PanD(T57V) into 35 µM PanZ.AcCoA in the presence of excess AcCoA 
(400 µM) and (B) 35 µM PanD(T57V/K119STOP) intro 263 µM PanZ.AcCoA in the presence of excess AcCoA 
(394 µM). All samples were in 50 mM Tris (pH 7.5), 100 mM NaCl and 0.1 mM DTT (SEC buffer A).  Truncation of 
the PanD C-terminal tail shows no measurable binding to PanZ compared to the full-length protein. 
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P. aeruginosa    110 NQLSHTSEAIPIQVA                126 
E. coli          110 NEMKRTAKAIPVQVA                126 
E. carotovora    110 NELQRQAKAIPVQVA                126 
Y. pestis        110 NQLQRKAKAVPVQVA                126 
C. glutamicum    110 NRIVALGNDLAEALPGSGLLTS-RSI     136 
S. coelicolor    110 NRIVGLGADASEPVPGSDQERSPQAVSA   139 
M. tuberculosis  110 NKPIDMGHDPAFVPENAGELLDPRLGVG   139 
T. thermophilus  110 NRILEVRKG                      120 
L. pneumophila   111 NRLKEIRPERIGVKSRIPYPA          133 
C. crescentus    110 NLIKKAA                        118 
B. subtilis      110 NQIIEMLGAEKAGTIL               127 
S. aureus        110 NVIIEMIHEKENTIVL               127 
H. pylori        110 NEILEK                         116 
 
Fig. 3.22 PanD sequence alignment. The conserved C-terminal region across all PanZ producing bacteria (P. 
aeruginosa, E. coli, E. carotovora and Y. pestis) is highlighted in yellow. 
3.2.6 The ADC.PanZ complex is involved in CoA biosynthesis regulation 
The data obtained to this point in the project suggest a positive feedback role of PanZ in 
regulating CoA biosynthesis, as the PanD.PanZ interaction is CoA dependent. At low 
CoA concentrations, PanZ exists as apo-PanZ, which is not able to bind to PanD. PanD 
activation to ADC, does not occur, halting β-alanine and, consequentially, CoA 
production. At high CoA concentrations, PanZ exists mainly as the PanZ.CoA species, 
which is able to bind to and promote PanD activation to ADC. Therefore, at high CoA 
concentrations ADC should be mainly activated and able to catalyse the conversion of 
L-aspartate to β-alanine, which, in turn, would lead to an uncontrolled increase in the 
cellular pools of pantothenate and CoA (Fig. 3.23). 
 
Fig. 3.23 PanZ-mediated, positive feedback loop of CoA biosynthesis suggested by ITC, NMR and X-ray 
crystallography data. At high CoA concentrations, PanZ mainly exists as PanZ.CoA which is able to bind to the PanD 
zymogen, activating it to ADC. ADC then catalyses the conversion of L-aspartate to β-alanine, a precursor to CoA.  
As CoA biosynthesis is negatively feedback regulated downstream of aspartate by the 
interaction of CoA with pantothenate kinase, which phosphorylates pantothenate, (Rock 
et al., 2003), β-alanine would be continuously produced and excess pantothenate 
excreted out of the cell (Jackowski and Rock, 1981), while still keeping the 
concentration of CoA roughly constant. This mechanism for the production of CoA is 
both unexpected and unreasonable in a biological context, as it would lead to the 
exhaustion of the cellular pools of aspartate. Therefore, further investigations were 
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carried out in order to determine whether the PanD.PanZ interaction could act to 
negatively regulate CoA biosynthesis, potentially via a mechanism unrelated to the 
PanZ-mediated PanD activation. 
As PanZ is a CoA sensor (it binds CoA) it was hypothesised that it could perform a 
secondary function, beyond the acceleration of PanD activation, in regulating CoA 
biosynthesis. As the structures of PanD(T57V) (PDB 4AZD) (Webb et al., 2014) and 
ADC (PDB 1PPY) (Schmitzberger et al., 2003) are similar, PanZ.CoA could possibly 
also bind to the activated enzyme and, since the protein-protein interaction surface is 
adjacent to the active site, potentially act as an inhibitor of ADC. Under these 
circumstances, then PanZ would perform two distinct functions: activation and 
inhibition of ADC. As the PanD.PanZ interaction is CoA dependent, then this 
secondary function would lead to a negative feedback loop mechanism of CoA 
biosynthesis. To explore this hypothesis, the binding affinity of PanZ.CoA to the 
activated enzyme, WT ADC, was investigated by ITC, the structure of the WT 
ADC.PanZ.AcCoA complex solved by X-ray crystallography and the effect of 
PanZ.AcCoA upon ADC catalysis assessed both in vitro and in vivo.  
Protein purification 
WT PanD was overexpressed in auto-induction media using the same protocol as for 
PanD(T57V) and previously transformed E. coli C41 (DE3) cells harbouring a pRSETa 
plasmid encoding the protein. Using WT E. coli cells allows for the overexpressed 
PanD protein to be efficiently activated to ADC by heating the collected cell pellet at 
37 °C overnight prior to storage at -80 °C (see section 9.1.6). This is hypothesised to be 
due to the presence of endogenous PanZ, which can activate the zymogen. Therefore, 
WT PanD was obtained from non-heated cell pellets and WT ADC from heated cell 
pellets. The purification was carried out as previously described for PanD(T57V) and 
the extent of cleaved WT ADC analysed by tris-tricine SDS-PAGE (see sections 9.1.5, 
and 8).  
WT PanD.PanZ.AcCoA and WT ADC.PanZ.AcCoA crystal structures 
The non-activated protein was crystallised with PanZ.AcCoA (WT PanD.PanZ.AcCoA 
complex) using the same crystallisation conditions as for the PanD(T57V).PanZ.AcCoA 
complex. The crystals were cryo-protected by soaking for a few seconds in mother 
liquor containing increasing concentrations of glycerol (5%, 10% and 20% w/v) and 
cryo-cooled in liquid nitrogen. Data were collected at beamline I04-1 (DLS), to 1.2 Å 
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resolution. Data were integrated with Xia2 (Winter, 2010), scaled and merged using 
Aimless (Evans and Murshudov, 2013) and did not appear to be twinned, suggesting 
that the previous twinning problems were either not caused by cryo-cooling but rather 
are related to the crystal form, or that the affinity of PanZ for the WT protein is tighter, 
limiting the conformational flexibility of the complex. Data were phased by molecular 
replacement using Molrep (Vagin and Teplyakov, 1997) with the 
PanD(T57V).PanZ.AcCoA structure as a model. The structure was refined using 
Refmac5 (Murshudov et al., 2011) and rebuilt manually using Coot (Emsley et al., 
2010) (Table 2).  
The WT PanD.PanZ.AcCoA complex was very similar to the 
PanD(T57V).PanZ.AcCoA complex. PanZ binds ADC across the active site (Fig. 3.24), 
supporting, from a structural point of view, the hypothesised inhibitory effect of PanZ 
on ADC catalysis. As expected, WT PanD is seen to be completely activated, 
confirming that PanZ.AcCoA is able to efficiently promote the maturation of the 
zymogen to the active enzyme, though, surprisingly, residue 25 shows a tetrahedral 
moiety, rather than the expected planar geometry of the catalytic pyruvoyl group. The 
density was best modelled as a hydrated pyruvoyl (Fig. 3.24), which could arise from 
changes in the electrostatic environment around the active site upon binding of PanZ or 
be due to the crystallisation buffer composition.  
To determine whether the tetrahedral centre formed upon the interaction of the two 
proteins or if it was in fact correlated with the activation process, thermally-activated 
WT ADC was also complexed with PanZ in the presence of 2 eqv. of AcCoA (per PanZ 
monomer) and crystals grown under the same conditions as for the WT 
PanD.PanZ.CoA complex. The crystals were handled, data collected and reduced and 
the structure solved as described for the WT PanD.PanZ.AcCoA complex. Once again, 
the active site showed clean cleavage of the peptide backbone at residue Gly24, with the 
presence of the tetrahedral moiety at residue 25, showing that this is associated simply 
with the formation of the protein complex, rather than with the activation process. This 
structure also confirms that thermal activation of PanD to ADC can be done in cellulo, 
without the formation of serine hydrolysis by-products as described in section 3.1.2 and 
visible in the first ADC crystal structure (PDB 1AW8) (Albert et al., 1998). In practical 
terms, the fastest and easiest protocol for the production of fully active ADC from PanD 
overexpression is by expressing the protein in WT E. coli cells and then heating the cell 
pellets at 37 °C overnight, rather than by incubation of PanD and PanZ.AcCoA.     
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Lastly, it was important to determine whether the hydrated pyruvoyl appears only at 
cryo-temperatures or if it was a genuine, stable feature of the complex, even at RT. A 
second dataset for the WT ADC.PanZ.AcCoA complex from a crystal from the same 
crystallisation batch was collected at RT on the in-house X-ray source. Data were 
integrated with XDS (Kabsch, 2010) and scaled, merged, phased and refined as 
described for the cryo-temperature synchrotron dataset (Table 2). The electron density 
at the pyruvoyl centre was once again clearly tetrahedral, confirming that it was the 
electrostatic environment surrounding the ADC active site in the crystal that stabilises 
the hydrated form of the pyruvoyl preferentially to the α-ketoamide.   
 
Fig. 3.24 The WT ADC.PanZ.AcCoA complex, showing the interaction of the two proteins at the active site. WT 
ADC is shown in yellow, PanZ in blue and CoA as grey sticks. 2Fo-Fc map contoured at 1 σ. (A) PanZ.AcCoA binds 
adjacent to the ADC active site. The main residues in the enzyme active site are shown as sticks (Lys9, His11, Tyr22, 
Glu23, Glu24, Pyr25, Arg54, Tyr58) and the hydrogen bond between ADC-Glu23 and PanZ-Asn45 is shown as 
dashes. (B) and (C) the ADC active site showing the pyruvoyl in a hydrated form. The electron density shows a clear 
tetrahedral moiety. The hydrated pyruvoyl (Pyr25) is stabilised by a network of hydrogen bonds to adjacent residues. 
One hydroxyl group is a H-bond acceptor from Thr57 and the second hydroxyl group a H-bond donor to Asn72-CO 
backbone and a H-bond acceptor from Gly24-NH backbone.  
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Table 2 WT PanD.PanZ.AcCoA X-ray diffraction data reduction and refinement statistics 
 WT PanD. 
PanZ.AcCoA 
WT ADC. 
PanZ.AcCoA 
WT ADC. 
PanZ.AcCoA 
Data collection synchrotron synchrotron in-house 
Temperature 100 K 100 K RT 
Space group I4 I4 I4 
Cell dimensions      
    a, b, c (Å) 85.9, 85.9, 80.1 86.6, 86.6, 79.9 86.4, 86.4, 81.1 
    α, β, γ  (°)  90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0 
Resolution (Å) 29.28-1.16 
(1.18-1.16) 
42.78-1.25 
(1.27-1.25) 
43.19-1.85 
(1.89-1.85) 
Rmerge (%) 7.7 (56.7) 9.2 (76.3) 15.4 (77.1) 
Rp.i.m. (%) 5.4 (39.5) 5.4 (47.4) 12.3 (55.5) 
<I> / sI 9.0 (2.1) 7.4 (7.0) 5.8 (1.6) 
Completeness (%) 99.6 (93.7) 99.8 (99.9) 100.0 (100.0) 
Redundancy 5.1 (4.4) 3.6 (3.4) 4.4 (4.4) 
    
Refinement    
Resolution (Å) 60.72 (1.16) 42.78 (1.25) 43.18 (1.85) 
No. reflections 99822 (6688) 75141 (5473) 24079 (1752) 
Rwork (%)  10.8 (19.1)  11.4 (20.9) 14.91 (28.9) 
Rfree (%) 11.5 (20.2) 14.4 (23.9) 18.89 (25.1) 
No. atoms    
    Protein 2126 2118 2129 
    Ligand/ion 112 92 58 
    Water 290 269 124 
B-factors    
    Protein (main chain) 
(Å2) 15.11 14.75 26.20 
    Protein (side chain) (Å2) 21.50 19.48 31.17 
    Ligand/ion (Å2) 21.74 22.63 31.33 
    Water (Å2) 33.14 32.10 35.42 
R.m.s. deviations    
    Bond lengths (Å) 0.034 0.034 0.019 
    Bond angles (°) 2.86 2.84 2.15 
 
PanZ inhibits ADC catalysis 
The active site of ADC is composed of residues from two adjacent subunits. The 
enzyme contains a number of fully conserved residues, the vast majority of which are 
located close to the active site (Webb et al., 2004). The catalytic mechanism of ADC 
starts with the condensation of L-aspartate with the pyruvoyl group, forming an iminium 
intermediate (Fig. 3.25, II). The β-carboxylate forms a salt-bridge to Arg54 and the α-
carboxylate makes an ionic interaction with Lys9, which, in turn, is hydrogen-bonded to 
His11 and Tyr58. The C-terminus of the β-chain of ADC (24Gly-Tyr22) is mobile and 
can adopt different conformations, visible in the structure of the enzyme (PDB 1AW8) 
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(Albert et al., 1998) and also in the crystal structures of ADC with different ligands 
bound to the active site (Yorke, Monteiro et al., unpublished results)*. Once bound, L-
aspartate undergoes decarboxylation at the α-carboxylate (Williamson and Brown, 
1979) to an enolate (III), which is then protonated by Tyr58 (Saldanha et al., 2001) to 
the β-alanine iminium intermediate (V). The product is then released by hydrolysis, 
regenerating the pyruvoyl group (VI).  
 
Fig. 3.25 Mechanism of L-asparate decarboxylation by ADC (Webb et al., 2004). L-Aspartate binds at the ADC 
active site, forming a salt bridge to Arg54 (I), promoting the formation of the iminium intermediate (II). The α-
carboxylate is cleaved to give the enolate intermediate (III), which is protonated by Tyr58 (IV) (Saldanha et al., 
2001) to the β-alanine iminium intermediate (V). The product is then released by hydrolysis (VI). 
In vitro assays 
The assay for ADC catalysis is difficult due to the lack of a suitable chromophore in the 
enzyme, substrate or product. One way to assay the turnover rate is to monitor the heat 
of reaction. Heat evolution can monitored directly by ITC (Todd and Gomez, 2001) and 
is directly proportional to enthalpy. Enthalpic changes during catalysis are mainly 
dominated by the cleavage of the substrate to release CO2 (Fig. 3.25, II) and also from 
the protonation of the enolate intermediate (Fig. 3.25, IV). This method has been 
previously shown to be a good method to assay a range of enzymatic reactions, 
                                                
* Crystal structures of ADC with different ligands bound at the active site show a large degree of 
flexibility for the C-terminus of the β-chain. These structures will not be discussed in this thesis but are 
currently being prepared for publication. 
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including those of DHFR, trypsin, creatine phosphokinase and urease (Todd and 
Gomez, 2001).  
The activity of ADC in the presence of different PanZ concentrations was investigated 
by ITC using a multiple injection approach. The titrations and data fitting were 
performed by Dr M. E. Webb as part of this project. Twenty-five aliquots of L-aspartate 
were injected into ADC, allowing just enough time for the system to equilibrate 
between the injections. The titration was repeated in the presence of 0.5 and 2 
equivalents of PanZ.AcCoA. Fig. 3.26 shows the data fitted from the titrations. Upon 
addition of 0.5 eqv. of PanZ.AcCoA ADC activity is reduced to 50% and with 2 eqv. of 
PanZ.AcCoA only 10% activity is recovered. This assay clearly shows that, not only 
does PanZ.AcCoA bind to activated ADC, but complex formation results in ADC 
inhibition.  
 
Fig. 3.26 Relative rates of turnover of WT ADC (2.5 µM, protomer concentration) at varying L-aspartate 
concentrations in the presence of 0, 0.5 and 1.0 eqv. of PanZ.AcCoA (per ADC protomer). In the presence of 0.5 eqv. 
of PanZ.AcCoA (1.3 µM), the relative rate of catalysis is approximately halved, whereas in the presence of 2 eqv. of 
PanZ.AcCoA, only 10% of activity is recovered. 
The concentrations of ADC and PanZ.AcCoA used in this ITC assay were considerably 
above the binding affinity between the proteins. To investigate PanZ inhibition of ADC 
further, a second assay was set up where ADC turnover over the course of several hours 
was monitored by 1H NMR spectroscopy. As the enzyme has a slow turnover rate and 
the substrate and product are simple organic molecules, a 1H NMR spectrum of the 
reaction mixture can be recorded and the percentage turnover extrapolated from the 
ratio between the aspartate Cα/Cβ and β-alanine CH2 signals. 
WT ADC (100 nM) was mixed with varying concentrations of PanZ (200 nM, 1 µM 
and 10 µM) with 2 equivalents of AcCoA (400 nM, 2 µM and 20 µM respectively). 
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0.5 mM L-aspartate (~3×KM) was added to the protein mixtures and the samples 
incubated at 37 °C. Aliquots were taken at 2, 4 and 24 h intervals, mixed with D2O and 
1H NMR spectra collected immediately with a water suppression pulse sequence. Three 
experiments were run with excess AcCoA added (100 µM) and three without. Two sets 
of spectra for two ADC turnover time-courses in the presence of low PanZ 
concentrations are shown in Fig 3.27. The spectra show a decrease in L-aspartate 
concentration and an increase in β-alanine concentration, meaning that ADC is able to 
catalyse the reaction and that the percentage turnover can be estimated from the NMR 
integrals. The experiments showed that at low PanZ concentrations (200 nM and 1 µM), 
ADC is not inhibited, and the majority of the substrate had been consumed after 24 
hours. Nevertheless, at 10 µM PanZ, the enzyme is almost completely inhibited, with 
only 5% turnover occurring after 24 hours in the presence of excess AcCoA (Fig. 3.28). 
The concentration dependence of the inhibition of ADC by PanZ may indicate a 
possible competitive mode of inhibition. Further experiments using different substrate 
concentrations would have to be performed to support this hypothesis. 
 
Fig. 3.27 Representative traces of 1H NMR experiments to follow the conversion of L-aspartate to β-alanine by ADC, 
in the presence of different PanZ concentrations. Spectra were recorded in 10% D2O with a water suppression pulse 
sequence. The traces correspond to two experiments with and without excess AcCoA added. Both experiments were 
run with 100 nM WT ADC, 200 nM PanZ and 0.5 mM L-aspartate in 50 mM phosphate buffer (pH 7.4), 100 mM 
NaCl. The signals corresponding to L-aspartate and β-alanine are labelled. The excess AcCoA complicates the 
spectrum but does not obscure the amino acid signals. 
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Fig. 3.28 The percentage inhibition of WT ADC by PanZ calculated from 1H NMR spectra. WT ADC is able to 
catalyse the conversion of L-aspartate to β-alanine in the presence of 1 µM and 10 µM PanZ, but is inhibited in the 
presence of 10 µM PanZ. All experiments were carried out with 100 nM WT ADC in 50 mM phosphate buffer (pH 
7.4), 100 mM NaCl and 0.5 mM L-aspartate. Spectra were recorded in 10% D2O with a water suppression pulse 
sequence. 
In cellulo assays 
The effect of PanZ upon ADC catalysis was also investigated in vivo. This work was 
performed by Dr S. Nozaki as part of this project. ΔpanZ knockout cells were 
transformed with a pBAD24.PanZ-his plasmid and grown in M9 minimal media agar 
plates with and without β-alanine supplementation. ΔpanZ cells are β-alanine 
auxotrophs and, therefore, cannot grow without β-alanine supplementation, as PanD 
cannot be activated to ADC in vivo in the absence of PanZ and β-alanine is essential for 
bacterial production of pantothenate and CoA. Uninduced ΔpanZ cells carrying the 
pBAD24.PanZ-his plasmid recovered growth in the absence of β-alanine 
supplementation, due to leaky overexpression of PanZ which complements the 
knockout strain. The experiment was repeated in M9 minimal media containing 
arabinose, which triggers overexpression of PanZ. When PanZ is overexpressed, the 
cells became β-alanine auxotrophs once again, showing that higher concentrations of 
PanZ also act to inhibit ADC catalysis in vivo. 
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Fig. 3.29 In cellulo investigation of the effect of PanZ on ADC catalysis. Serial dilutions of E. coli cells were grown 
in M9 minimal media with and without β-alanine supplementation. ΔpanZ knockout cells are β-alanine auxotrophs 
and do not grow in the absence of β-alanine. When complemented with a pBAD24.PanZ-his plasmid, leaky 
expression of PanZ recovers cell growth in the absence of β-alanine. Under overexpression conditions (agar with 
arabinose), cells containing the pBAD24.PanZ-his plasmid become β-alanine auxotrophs once again. 
Conclusion 
The inhibitory effect of PanZ on ADC catalysis, observed both in vitro and in cellulo, 
indicates a role for PanZ in negatively regulating CoA production in vivo. In fact, this 
regulatory mechanism may be the primary function of PanZ. These data suggest a 
model where PanZ acts primarily as a CoA sensor, binding tightly to ADC when the 
CoA concentration in the cell is high, inhibiting ADC catalysis and slowing down the 
production of β-alanine. As CoA is depleted, the ADC.PanZ.CoA complex dissociates, 
releasing ADC and restoring β-alanine production. Higher concentrations of β-alanine 
then lead to increased concentrations of CoA, eventually promoting once again the 
complexation of ADC with PanZ.CoA, therefore creating a negative feedback loop 
mechanism for CoA biosynthesis (Fig. 3.30). Two further mechanisms related to this 
feedback loop act to control the concentrations of β-alanine, L-aspartate and CoA. First, 
at high L-asparate concentrations, PanZ.CoA must compete for ADC binding and 
pantothenate will still be produced, any excess of which can be excreted from the cell 
(Jackowski and Rock, 1981). Second, ADC undergoes inactivation after ~300 
turnovers, which also allows for a more gentle equilibration of the cellular pools of 
these metabolites (Webb et al., 2004, Konst et al., 2009). 
The X-ray structures give two possible mechanisms for the inhibition of ADC by PanZ: 
PanZ occludes the binding site, preventing the formation of the substrate-enzyme 
complex, and appears to promote the stabilisation of the pyruvoyl group in a hydrated 
form, which is unsuitable for catalysis. By binding at the ADC active site for inhibition, 
PanZ may have evolved a secondary function in accelerating PanD activation in some 
organisms. As this activation step is irreversible, PanZ has only to bind once and 
transiently to ADC to catalyse enzyme activation, and this can thus still occur even at 
low CoA concentrations.  
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Fig. 3.30 Proposed mechanism for the regulation of CoA biosynthesis in vivo. PanZ binding to CoA is dependent on 
CoA concentration in the cell.  PanZ.CoA is able to bind to PanD, activating it to ADC in a irreversible step. Even at 
low CoA concentrations, PanD activation should still occur, although the binding of PanZ.CoA to PanD/ADC would 
be only transient. PanZ.CoA is able to stay bound to ADC, inhibiting catalysis, until the concentration of CoA drops, 
causing the complex to dissociate and allowing ADC to resume catalysis. Increased levels of β-alanine would 
increase the levels of CoA once more, promoting the association of the proteins and generating a negative feedback 
loop mechanism. 
3.2.7  How PanZ accelerates PanD activation 
A close comparison of the structure of PanD(T57V).PanZ.AcCoA complex with the 
previously published structure of the PanD zymogen (PDB 1PPY) (Schmitzberger et 
al., 2003) gave insight into the mechanism of PanD activation by PanZ. Both structures 
are isostructural throughout for PanD, with the exception of the PanD 17His-Tyr22 loop 
in the free zymogen, which precedes the region of activation PanD-23Glu-Cys26. The 
loop is unstructured in the free PanD zymogen (Fig. 3.31, yellow, Fig. 3.32 A). Upon 
binding to PanZ, the loop is shifted 6.4 Å upwards, adopting a beta-sheet conformation, 
as seen in the PanD(T57V).PanZ.AcCoA complex (Fig. 3.31, green). From the 
structural overlays, the position of the PanD-17His-Tyr22 loop in the free zymogen is 
incompatible with the position of PanZ-Asn45 in the complex. PanD-Tyr22 is fully 
conserved (sequence alignment shown in section 9.7.1) and has not, so far, been shown 
to be involved in ADC catalysis. Its conservation may, therefore, indicate a function in 
promoting PanD post-translational cleavage, and this was indeed observed in the 
PanD(T57V)-PanZ.AcCoA structure. The aromatic ring of Tyr22 packs against the side 
chain of PanZ-Asn45 and the Cγ carbon of PanD-Glu19 (Fig. 3.33). These interactions 
promote the formation of the β-sheet at PanD residues 17His-Gly19.  
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Fig. 3.31 Overlay of the PanD(T57V).PanZ.AcCoA complex structure (PDB 4CRZ, green) (Monteiro et al., 2015) 
with the major conformer of the PanD zymogen structure (PDB 1PPY) (Schmitzberger et al., 2003), focusing on the 
processing loop. The 23Glu-Ser25 region is similarly structured, whereas the preceding region corresponding to 
17His-Tyr22 is shifted 6.4 Å upwards upon binding of PanZ (shown in blue).  
 
Fig. 3.32 Conformations of the mobile loop of the PanD zymogen in the previously reported X-ray structure (PDB 
1PPY) (Schmitzberger et al., 2003). (A) The free, unstructured chain, well resolved in the electron density. (B) The 
second structure corresponds to the higher energy conformation of the chain, noticeable by the poorly defined 
electron density. 
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Fig. 3.33 Packing of residues in PanD upon binding of PanZ. PanD(T57V) (Monteiro et al., 2015) is shown in green 
and PanZ in blue. The PanD processing conformation is maintained by the formation of two parallel and an anti-
parallel β-sheets (residues 16Thr-Asp19, 68Ile-Asn72 and 29Asn-Tyr22). PanZ-Asn45 stacks against the fully conserved 
PanD-Tyr22, which, in turn, interacts with PanD-Glu19, promoting the formation of the β-sheet and the 
reorganisation of the PanD-23Glu-Cys26 activation peptide. 
As the unstructured conformation of the PanD-17His-Tyr22 loop is preferentially adopted 
by the free, non-processed PanD zymogen, it is clearly an incompetent conformation for 
activation of PanD to ADC. The structured conformation, consisting of three β-sheets, 
is adopted by both the PanD(T57V)-PanZ.AcCoA as well as the free fully activated 
enzyme (PDB 1AW8) (Albert et al., 1998), indicating that adoption of this 
conformation is essential for enzyme maturation. Interestingly, this activation-
competent PanD conformation of the PanD-17His-Tyr22 loop can also be observed in a 
small percentage of the uncleaved WT zymogen structure in one of the two proteins 
present in the asymmetric unit (Schmitzberger et al., 2003). The electron density from 
which this minor conformation was modelled is badly defined (Fig. 3.32, B), an 
indication that the conformation is unstable. As the enzyme activates slowly in vitro 
(Ramjee et al., 1997) it is hypothesised that, once the zymogen is expressed, the PanD-
17His-Cys26 loop can adopt multiple conformations in the absence of PanZ and that the 
activation-competent conformation, although unfavoured, is still thermally accessible, 
which would account for many of the early reports of PanZ-independent PanD 
activation. 
The conformational changes within the PanD-17His-Tyr22 loop, along with the direct 
interaction of PanZ-Asn45 with the backbone amide of PanD(T57V)-Glu23 (Fig. 3.20), 
cause subtle, but crucial downstream conformational changes to the PanD-23Glu-Cys26 
processing loop. The PanZ-Asn45 residue had been previously reported to be essential 
for PanZ to promote PanD maturation (Nozaki et al., 2012). These changes are 
responsible for promoting the N-O acyl shift required for post-translational cleavage of 
PanD to ADC. 
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The conformation of unstructured PanD-17His-Tyr22 loop seen in the free zymogen 
clearly shows why this conformation is activation-incompetent. The first step in the 
N-O acyl shift mechanism is the nucleophilic attack of the PanD-Ser25 hydroxyl on the 
adjacent PanD-Gly24 carbonyl carbon. The relative spatial arrangement of the reactive 
centres in the major conformation seen in the zymogen structure is clearly incompatible 
with the required nucleophilic attack as the PanD-Ser25(OH) and PanD-Gly24(CO) are 
4.2 Å apart and parallel to each other (Fig. 3.34, left). Upon binding of PanZ, the 
carbonyl group of PanD-Gly24 rotates more than 90° upwards, hydrogen bonding to 
PanD-Tyr58* instead of PanD-Thr57 (Fig. 3.34, right)†. The hydroxyl of PanD-Ser25 
forms a hydrogen bond to the backbone carbonyl of PanD-Glu23. In the new 
conformation, the distance between the PanD-Ser25 hydroxyl and the carbonyl of 
PanD-Gly24 is reduced to 3.2 Å and the reaction centres are placed in an almost 
perpendicular position relative to each other. This new arrangement of the reaction 
centres is much more compatible with the conformation required for orbital overlap for 
the nucleophilic attack.  
 
Fig. 3.34 Conformations of the free WT ADC zymogen (yellow) (Schmitzberger et al., 2003) and PanD(T57V) 
(Monteiro et al., 2015) in complex with PanZ (green). In the WTADC zymogen, Gly24 hydrogen bonds to Thr57. 
The carbonyl group of Gly24 and the hydroxyl group of Ser25 are parallel to each other and 4.2 Å apart, in a 
conformation incompatible with nucleophilic attack. Upon binding of PanZ, Gly24 rotates upwards, hydrogen 
bonding to Tyr58 and is placed perpendicular to the hydroxyl group of Ser25. The two groups are now 3.1 Å apart in 
a conformation more compatible with nucleophilic attack.  
                                                
* Previous studies have shown that mutation of Tyr58 to phenylalanine does not abolish ADC activation. 
The hydrophilic environment surrounding the activation peptide can likely provide a new hydrogen-
bonding partner to Gly24 even in the absence of Tyr58. 
† The orientation of the side chain of Asn72 differs between the two models. As N and O atoms are 
indistinguishable in the electron density, the correct assignment of rotamers has to be based on chemical 
observations. In 4CRZ structure, Ans72 has been built with a rotamer that satisfies the hydrogen-bonding 
requirements of Ser25.  
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The 24Gly-Ser25 amide bond is severely distorted in the PanD(T57V).PanZ.AcCoA 
complex, with the orientation of the N-H and C=O bonds diverging from planarity. The 
distortion is also visible in the conformation adopted by PanD-Ser25, which occupies a 
Ramachandran disallowed region (Fig. 3.35). These distortions and deviations suggest 
that the activation loop of PanD is held in a high-energy conformation when binding to 
PanZ.  
 
Fig. 3.35 Ramachandran plot of PanD(T57V).PanZ.AcCoA (Monteiro et al., 2015), showing two outliers: Ser25, 
located in the activation loop of PanD(T57V) and Ser30, located in a mobile loop in PanZ, with poorly-defined 
electron density. Plot made using RAMPAGE (Lovell et al., 2003). 
Such conformationally-induced post-translational modifications have already been 
described for other systems, such as Ntn-hydrolases, where active-site peptides can 
explore multiple conformations, only one of which can undergo autoproteolysis (Buller 
et al., 2012). This class of enzymes uses cis-autoprocessing to cleave an internal peptide 
bond which yields a catalytically active N-terminal amine (Dodson and Wlodawer, 
1998). The N-O acyl shift can use threonine, serine or cysteine residues, but the specific 
geometries of the reactive conformations of each nucleophile are still unknown. The 
mechanisms and structural constraints of auto-catalytic post-translational modifications 
are difficult to study due to the difficulty of trapping a biologically relevant cleavage 
precursor. Recently, Buller et al. were able to elucidate the structure of an unprocessed 
Ntn-hydrolase. The slow, but activation competent mutant T282C, where the threonine 
nucleophile is mutated to a cysteine nucleophile, was trapped in two conformations at 
the cleavage site. From the geometrical analysis of the arrangement of the residues, one 
of the conformations was suggested to be competent for autoproteolysis whereas the 
other was incompetent. This flexibility of the cleavage peptide suggests that the protein 
can explore multiple conformations and that cleavage is initiated when the correct 
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geometry is adopted. The reactive conformation is favoured as it relieves steric clashes 
and torsion strains. 
3.2.8 The PanD(S25A).PanZ.AcCoA complex 
To verify that the observed distorted conformation of the PanD(T57V).PanZ.AcCoA 
activation peptide was caused by PanZ binding to PanD(T57V) rather than being an 
effect of the site-directed mutagenesis, the interaction of a second non-activatable PanD 
mutant, PanD(S25A), with PanZ.AcCoA was investigated. Binding of the two proteins 
was first investigated by ITC: pairwise titrations of PanD(S25A) into PanZ.AcCoA and 
PanZ.AcCoA into PanD(S25A) showed a 4-fold decrease in binding affinity of the 
proteins compared to the binding of PanD(T57V) to PanZ.AcCoA (KD=157 nM 
compared to 35 nM for PanD(T57V), Fig. 3.36). The difference in binding affinity was 
mainly due to a difference in the entropic contribution to binding (ΔS=-26.6 cal 
mol-1 K-1 for PanD(S25A) compared to -5.8 cal mol-1 K-1 for PanD(T57V)), rather than 
enthalpic contributions (ΔH=-10.2 kcal for PanD(S25A) compared to -9.3 kcal mol-1 for 
PanD(T57V)). The activating loop may be more flexible in PanD(S25A), suffering a 
higher entropy change upon binding to PanZ.AcCoA. 
 
Fig. 3.36 Pairwise titration of PanD(S25A) into PanZ.AcCoA and PanZ.AcCoA into PanD(S25A). (A) titration of 
257 µM PanD(S25A) into 32 µM PanZ in the presence of 394 µM AcCoA. (B) titration of 263 µM PanZ.AcCoA into 
35 µM PanD(S25A) in the presence of 400 µM AcCoA. 
The PanD(S25A).PanZ.AcCoA complex was crystallised using the previously 
optimised protocol. Smaller, square pyramidal crystals (50 to 100 µm) were obtained 
from the same crystallisation conditions used for the previous complexes and data were 
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collected in-house at RT to 2.1 Å resolution. The data were processed and the structure 
solved in the same way as the PanD(T57V).PanZ.AcCoA in-house structure (Table 3). 
Table 3 PanD(S25A).PanZ.AcCoA in-house X-ray diffraction data reduction and refinement statistics 
 PanD(S25A).PanZ.AcCoA 
Data collection in-house 
Space group I4 
Cell dimensions    
    a, b, c (Å) 86.3, 86.3, 80.8 
    α, β, γ  (°)  90.0, 90.0, 90.0 
Resolution (Å) 33.7-2.10 (2.15-2.10) 
Rmerge (%) 18.1 (62.1) 
Rp.i.m. (%) 15.5 (51.7) 
<I> / sI 5.7 (1.8) 
Completeness (%) 99.5 (99.8) 
Redundancy 3.2 (3.1) 
  
Refinement  
Resolution (Å) 33.7-2.10 (2.15-2.10) 
No. reflections 16351 (1238) 
Rwork (%)  17.27 (24.5) 
Rfree (%) 23.7 (32.2) 
No. atoms  
    Protein 2021 
    Ligand/ion 62 
    Water 62 
B-factors  
    Protein (main chain) (Å2) 24.29 
    Protein (side chain) (Å2) 28.57 
    Ligand/ion (Å2) 28.47 
    Water (Å2) 26.86 
R.m.s. deviations  
    Bond lengths (Å) 0.019 
    Bond angles (°) 2.09 
 
The complex was once again identical to the previously solved structures, with only 
small deviations in the activation peptide region. Strain is again observed as a 
Ramachandran disallowed conformation, this time of Gly24 instead of Ser25 (Fig. 
3.37). PanZ-Asn45 binds to the backbone of PanD(S25A)-Glu23 as in the 
PanD(T57V).PanZ.AcCoA structure, causing the 17His-Tyr22 loop to adopt the 
activation-competent conformation. Due to the smaller size of alanine compared to 
serine a different conformation of residues 24 and 25 is seen. The carbonyl carbon of 
Gly24 is rotated away from Tyr58 and the methyl group of Ala25 points towards Thr57 
(Fig. 3.38). The previously reported structure of the PanD(S25A) mutant also shows a 
different conformation for the activation loop to that adopted by the PanD(S25A) 
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mutant when in complex with PanZ.CoA, confirming that the strained conformation 
adopted by the PanD.PanZ.AcCoA complexes is promoted by PanZ binding and that the 
high-energy conformation observed is not caused by the site-directed mutation of Thr57 
or Ser25. 
 
Fig. 3.37 Ramachandran plot of PanD(S25A).PanZ.AcCoA, showing Gly24, located in the activation loop of 
PanD(S25A), as an outlier. 
 
Fig. 3.38 Comparison of the PanD(S25A).PanZ.AcCoA complex to the previously reported structure of PanD(S25A) 
(PDB 1PQE (Schmitzberger et al., 2003)). In the PanD(S25A).PanZ.AcCoA complex, PanD(S25A) is shown in dark 
blue and PanZ in teal. 1PQE is shown in orange (Left) The PanD(S25A).PanZ.AcCoA activation loop showing the 
2Fo-Fc map contoured at 1 σ. (Right) detail of the activation loop, showing the structural differences that occur upon 
PanZ binding to S25A, causing the strained conformation, with hydrogen-bonds in black dashed lines. 
3.2.9 PanZ promotes PanD activation by “mechano-chemistry” 
The Ramachandran disallowed conformation adopted by Ser25 in the 
PanD(T57V).PanZ.AcCoA complex suggests that binding of PanZ to PanD(T57V) 
promotes strain and distorts the activation region of ADC. This strain was captured 
more clearly in the PanD(T57V).PanZ.AcCoA dataset collected with the synchrotron 
X-ray source. The in-house and synchrotron structures are virtually identical, with the 
exception of the activation site. The in-house collected dataset showed the 24Gly-Ser25 
peptide intact, as expected, as PanD(T57V) cannot undergo activation or cleavage by 
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PanZ or thermally (Webb et al., 2014). Surprisingly, the synchrotron dataset showed a 
clear break in the electron density between the two residues (Fig. 3.39). With no prior 
indication of post-translational cleavage of this ADC mutant in any biochemical or 
X-ray structural data collected either in-house or with a synchrotron source, the 
cleavage must be promoted due to the complexation of PanD(T57V) with PanZ.AcCoA. 
 
Fig. 3.39 The activation peptide in the PanD(T57V).PanZ.AcCoA complexes. PanD(T57V) is shown in green, PanZ 
in teal and the 2Fo-Fc map as a grey mesh contoured at 1 σ. (Left) in-house dataset, showing the intact peptide chain; 
(Right) synchrotron dataset showing the cleaved chain. In the synchrotron dataset, the electron density map shows 
two alternate conformations for both the terminal methyl carboxylate in Gly24 and the hydroxyl side-chain of Ser25. 
To distinguish whether the cleavage was caused by X-ray dose-dependent 
fragmentation of the polypeptide backbone during data collection or whether 
complexation of PanD(T57V) with PanZ could lead to the formation of some ester 
intermediate (Fig. 3.3, III) which could be more easily hydrolysed during data 
collection, both the PanD(T57V).PanZ.AcCoA and PanD(S25A).PanZ.AcCoA 
complexes in solution were treated with hydroxylamine. Hydroxylamine is a good 
nucleophile and reacts readily with esters. Solutions of both complexes and individual 
proteins with and without AcCoA were incubated at 37 °C overnight with added 
hydroxylamine. The samples were boiled at 100 °C for 10 min, SDS-PAGE loading 
buffer was added and the samples boiled for a further 10 min. The solutions were 
loaded onto 10% Tris-tricine SDS-PAGE gels. All proteins ran intact through the gel, 
showing single bands for each of the proteins at the expected molecular weight (~15 
kDa), confirming that PanZ binding to PanD(T57V) or PanD(S25A) does not generate a 
unstable or easily hydrolysable species and that peptide bond cleavage must have 
occurred during X-ray irradiation of the complex in the crystal. 
The crystal structure shows clear formation of a C-terminal carboxylate at Gly24 and a 
Ser25 residue (both visible in two distinct conformations). The cleavage did not 
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promote pyruvoyl formation and, as PanD(T57V).PanZ.AcCoA is not easily 
hydrolysable, a different cleavage mechanism must occur in the X-ray beam.  
 
Fig. 3.40 SDS-PAGE analysis of the treatment of PanD(T57V) and PanD(S25A) and corresponding complexes with 
hydroxylamine. Lane 1: protein ladder; then, from left to right, lanes 2-11: PanD(T57V).PanZ.AcCoA with HONH2, 
PanD(S25A).PanZ.AcCoA with HONH2, PanD(T57V) with AcCoA and HONH2, PanD(S25A) with AcCoA and 
HONH2, PanZ.AcCoA with HONH2, PanD(T57V) with AcCoA, PanD(S25A) with AcCoA, PanZ.AcCoA, 
PanD(T57V) with PanZ, PanD(S25A) with PanZ. 
X-ray radiation can interact in different ways with a (protein) crystal (Shmueli, 2010). 
First, the X-ray photons can collide elastically with the atoms, the resulting coherent 
scattering giving rise to the diffraction pattern. The X-rays can also collide inelastically, 
where some of the energy is transferred to electrons, resulting in an excited state which 
then relaxes back to the ground state releasing a lower energy photon. And finally, the 
X-ray photon can be completely absorbed by the atom, causing the expulsion of a 
photoelectron from the inner electron shells. This expulsion of photoelectrons is the 
major source of radiation damage during X-ray diffraction experiments.  
Photoelectrons cause a cascade of ionization events (estimated at ~500 events per 12 
keV photoelectron), as well as thermal heating, disruption of the crystal lattice and bond 
scissions (O'Neill et al., 2002). Radiation damage manifests globally as a reduction in 
diffraction intensity and resolution, increase in unit cell size, worse data reduction 
statistics (Rmerge) and increased disorder (Wilson B value) with increasing X-ray dose. It 
also manifests locally as site-specific chemical changes which may lead to biologically 
irrelevant artefacts that can make interpretation of the biological structure difficult 
(Garman, 2010). Damage is considerably more pronounced at RT compared to cryo-
temperatures, as ionised species can diffuse easily through the crystal. With the recent 
great increases in synchrotron source brilliance, radiation damage at cryo-temperatures 
has also become more pronounced, as more photoelectrons are produced and these can 
still diffuse through the crystal at 100 K.  
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Specific structural damage within the biomacromolecule occurs by the cleavage of 
covalent bonds. Certain bonds are more susceptible to radiation damage, and, therefore, 
specific functional groups will undergo chemical changes at different rates (Weik et al., 
2000). At cryo-temperatures, damage is dominated by the tunnelling of electrons 
through the protein backbone until an electron-affinic site is found. Disulphide bonds 
break first (Weik et al., 2002), followed by decarboxylation of glutamate and aspartate 
residues, tyrosine dehydroxylation and cleavage of the methyl group in methionines.  
As the protein crystal is composed of 20% to 80% mother liquor by volume, water 
molecules account for a large percentage of photoionization events, producing !OH 
radicals as well as solvated electrons, H! radicals and other species (Ward, 1988). At 
cryo-temperatures, radicals are unable to diffuse through the crystal. But, at RT, the 
ionised species can diffuse and interact with the protein, spreading the radiation-induced 
changes quickly.  
The PanD(T57V).PanZ.AcCoA structure obtained from synchrotron data collection did 
not show any evidence of global radiation damage. The data collection strategy was 
designed carefully to maximise the crystal life-time, but even during careful data 
collection at RT, radiation damage is common. A careful analysis of the structure and 
electron density (both Fo-Fc and 2Fo-Fc) maps showed only minor cleavage of the 
PanZ-Cys127-PanZ-Cys94 disulphide bond and partial cleavage of PanZ-Met1. Neither 
decarboxylation of glutamates or aspartates nor oxidation of the AcCoA phosphate 
groups was observed. One clear radiation-induced chemical change was the full 
oxidation of the PanD(T57V)-Cys78 (Fig. 3.41). As electrons are strongly reducing and 
!OH radicals oxidizing (Ravelli and McSweeney, 2000), these observations suggest that 
the main source of radiation-induced chemical modifications to the proteins during this 
RT synchrotron data collection was caused by !OH radical chemistry.  
As the crystal tolerated the full data collection and no “typical” radiation induced 
damage is visible, the cleavage of the 24Gly-Ser25 amide bond, clearly visible as 
negative difference electron density when the intact chain is modelled, is a completely 
novel radiation-induced chemical event, specific to this protein complex system. To 
date, no instances of radiation-induced cleavage of protein backbone amide bonds have 
been reported. Amide bonds are not good electron sinks or easily susceptible to radical 
chemistry. As discussed previously, binding of PanZ to PanD(T57V) causes a 
conformational change in the cleavage peptide, placing Gly24 and Ser25 in the correct 
geometry for nucleophilic attack and also in a strained conformation, reflected in the 
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Ramachandran disallowed conformation of Ser25. The cleavage of the amide bond in 
the synchrotron dataset confirms the high-energy state of the new conformation of the 
peptide chain, as a ground state amide bond would not undergo radiation-induced 
cleavage. The chemistry is likely promoted by a hydroxyl radical attack on the carbonyl 
carbon of the highly distorted, high-energy amide bond, causing cleavage of the bond to 
the N-terminal serine and C-terminal glycine residues. 
The amount of radiation dose absorbed by a crystal during X-ray data collection is 
measured in Grays (1 Gy=1 J Kg-1). The dose absorbed by the crystals during in-house 
and synchrotron data collection was calculated with RADDOSE 3D (Zeldin et al., 
2013), and found to be 20 kGy and 70 kGy respectively. Dose is the only significant 
difference between the two datasets collected and so this cleavage event seems to be 
dose-dependent. This observation is in accordance with previous studies (Southworth-
Davies et al., 2007), that show that X-ray radiation-induced chemical and structural 
changes to protein crystals during data collection is dose-dependent. 
From the structural information and radiation-induced chemistry described here, a 
revised mechanism for the activation of PanD can now be proposed. First, the PanD 
activation loop, 23Glu-Cys26 (Fig. 3.42, I), undergoes a conformational rearrangement 
upon binding of PanZ. This forces the loop into a high-energy, “activating” 
conformation: the Gly24-Ser25 amide bond is severely distorted and susceptible to 
nucleophilic attack and the hydroxyl group of Ser25 is placed close proximity and in the 
correct conformation for nucleophilic attack upon the Gly24 carbonyl (II). Tyr58 
hydrogen bonds to the carbonyl of Gly24, aiding the formation of the oxyoxazolidine 
ring intermediate (III). Thr57 can then act both as proton donor and acceptor during the 
ring opening and β-elimination steps  (III, IV). This new proposed role of Thr57 as the 
hydrogen donor/acceptor, couples the final two steps leading to the dehydroalanine 
intermediate, avoiding the possible direct hydrolysis of the ester intermediate, 
commonly seen as a side reaction during the thermal activation of PanD. The 
conformation observed in the PanD(T57V).PanZ.AcCoA structure also shows a clear 
hydrogen bond between the Ser25 hydroxyl and the backbone carbonyl of Glu23, which 
acts as a proton shuffling residue to aid the deprotonation of Ser25. 
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 the clear difference density m
ap indicating full cleavage. 
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Fig. 3.42 Proposed revised mechanism of PanD activation to ADC in PanZ producing bacteria. The mechanism can 
be generalised to all PanD homologues, if the first conformational change is caused by folding of the protein 
backbone after translation. The PanD backbone adopts the reactive conformation upon binding of PanZ (II) which 
allows for the nucleophilic attack of Ser25 on the distorted Gly 24 carbonyl. Tyr58 stabilises the ring intermediate 
(III), which collapses to the ester intermediate (IV) with protonation from the Thr57 hydroxyl. Ester cleavage occurs 
by β-elimination mediated by Thr57 to a dehydroalanine (V), which then hydrolyses to the pyruvoyl group. 
Conformational strain leading to amide distortions, which, in turn, translate into a loss 
of resonance stabilisation of the amide bond, making it susceptible to attack, have been 
suggested in recent structural and theoretical studies of the Muc1 SEA domain 
(Johansson et al., 2008, Sandberg et al., 2008). Like ADC, the SEA domain undergoes 
autoproteolysis by an N-O acyl shift mechanism, employing a serine as the nucleophile. 
The uncleaved protein chain cannot be easily accommodated in the folded protein. As a 
consequence of folding, the cleavage peptide is distorted, lowering the free energy 
barrier of activation and placing the residues in the correct geometry for the initial 
nucleophilic attack. Mutations to the core of the protein that lower the melting 
temperature of the protein also affect the rate of cleavage of the peptide. 
3.3 Conclusion 
This project was initiated parallel to the photochemical work to understand the 
molecular basis of the maturation of PanD to ADC and the involvement of PanZ as an 
activation catalyst. Using ITC, the two proteins were shown to interact tightly and to 
form a heterooctameric protein complex. The binding interaction was also shown to be 
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CoA dependent, firstly from the ITC data and then later supported by both native mass 
spectrometry and NMR.  
Novel X-ray structures of WT ADC in complex with PanZ as well as two PanD mutants 
(PanD(T57V) and PanD(S25A)) in complex with PanZ, confirming the requirement of 
CoA for the interaction, were determined. The crystallographic studies were non-trivial 
and required extensive screening and the careful design of diffraction experiments to 
overcome the crystal pathologies encountered (low resolution, twinning and lattice 
deformations). With the introduction of cryo-cooled techniques for crystal handling and 
improvement of crystal life-times during data collection, RT data collection has fallen 
into misuse. It is a more time-consuming and labour intensive way of collecting data at 
synchrotrons but, with the current advancements in hardware and software, it is a 
technique that is gaining some revival. For this project, it was resorted to as an attempt 
at improving diffraction quality but the data also captured much more interesting 
aspects of the system. A clear, radiation-induced backbone cleavage of the 
non-processing mutant PanD(T57V) in complex with PanZ.AcCoA allowed for the 
proposal of a new cleavage mechanism of PanD to ADC, where the 23Glu-Ser25 loop 
region adopts a high-energy, strained, cleavage-competent conformation upon the 
binding of PanZ. The distortion of the 24Gly-Ser25 amide bond, as well as the tightening 
of the loop and placement of the nucleophilic Ser25-OH group in a better position for 
attack on the Gly24 carbonyl group explain, from a chemical point of view, how this 
N→O acyl shift is efficiently promoted in vivo. 
Crystallisation of PanD with PanZ.AcCoA showed complete activation of the enzyme, 
which indicates that PanZ.CoA is able to efficiently catalyse the maturation of PanD to 
ADC, without the formation of hydrolysed side-products. The complex was structurally 
similar in the PanD(T57V), PanD(S25A) and WT ADC complexes: PanZ binds to the 
same interface in all cases, across the active site. PanZ binds to ADC, regulating its 
activity, as shown by the decrease of catalytic activity of ADC in the presence of PanZ 
in vitro (by ITC and 1H NMR assays) as well as a β-alanine auxotrophic phenotype in 
E. coli cells overexpressing PanZ, and this has led to a proposal for a new mode of 
regulation of the CoA biosynthetic pathway.   
As both the PanD.PanZ.AcCoA and ADC.PanZ.AcCoA structures were isostructural 
they show that PanD can be efficiently activated to ADC either thermally, by heating 
the expression E. coli cell pellet containing the overexpressed zymogen at 37 °C prior to 
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purification, or by incubation with PanZ.CoA. For simplicity and ease, thermal 
activation was chosen as the preferred method for the preparation of fully active ADC.   
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4 Synthesis of photocleavable crosslinkers 
4.1 Introduction 
Photocaging of bioactive molecules is a non-trivial process and, although the first 
studies date back to the 1970s (Kaplan et al., 1978) and numerous papers regarding the 
synthesis, photolysis and use of these compounds are available, the information about 
the spectroscopic and chemical properties of caged biomolecules is scarce and 
incomplete. This lack of information is mainly due to the nature of the work. Most 
photocaged compounds have been used in cellular studies where fast time-resolution is 
not a requirement and the photocages are released using continuous, low-power 
illumination (Hagen et al., 2005). The described rates and yields of cleavage of these 
compounds are difficult to compare as, usually, the percentage of cleavage is quoted 
without a reference to the power of the illumination source used. Furthermore, similar 
photocaging groups have been photolysed at varying wavelengths in different studies. 
With the scarcity of comparable information, in most cases, the relative efficiency of 
different photocaging approaches can only be evaluated qualitatively.  
Nevertheless, some studies about the effect of substituents, leaving groups and cleavage 
conditions on the efficiency of photolysis and product release of photocages have been 
previously reported (Corrie et al., 2005, Klán et al., 2013). Most of the information 
available is qualitative, where different scaffolds are compared under dissimilar 
conditions. In cases where both rate and yield of photocleavage information is available, 
the values are usually calculated from the fragmentation of the compounds following a 
short (ns) high-power pulse of light. In many studies though, the yield of cleavage has 
only been determined using continuous, low-power irradiation, and the time necessary 
for release of the compound is quoted instead. This information is useful for compounds 
employed in cellular studies, where the processes being investigated are slow (seconds 
to minutes) but not for fast time-resolved studies, where a well-defined triggering time 
is necessary.  
The efficiency of cleavage is defined as the percentage of release of compound after the 
photolysing light pulse and is influenced by both the extinction coefficient (ε, 
proportion of photons absorbed) and quantum yield (ϕ, fraction of molecules that cleave 
following absorption of a photon) of the photocaged system. The quantum yield is 
dominated by the nature of the photocaging scaffold (e.g. ortho-nitrobenzyl, coumarin 
or para-hydroxyphenyl, Table 4) as this determines the de-caging mechanism. Higher 
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extinction coefficients improve the photolysis efficiency, as the compound is able to 
absorb light more strongly, although this must be balanced with the sample thickness. 
Although the time-resolved X-ray diffraction experiments for single turnover systems 
require a significant percentage of the molecules in the ensemble to be triggered 
simultaneously and this can be promoted by a higher ε, compounds with very high ε 
will absorb light so strongly that laser penetration through the sample will be very low.  
The extinction coefficient can be modulated by the addition of substituents to the 
chromophoric centre, where electron-donating groups tend to lead to an increase in the 
value of ε (see section 4.1.1) (Corrie et al., 2005, Klán et al., 2013). Even with these 
general guidelines, the exact spectroscopic and chemical properties of a photocaged 
compound can only be fully determined once the compound is synthesised. 
Nevertheless, a small overview of the aspects to consider when designing a 
photocleavable scaffold is given below. For a more extensive description of some of the 
trends observed for ortho-nitrobenzyl (oNB), coumarin (Cm) and para-hydroxylphenyl 
(pHP) photoprotecting group scaffolds see section 9.6.*  
Table 4 General properties of photocaging groups 
 
   
group o-nitrobenzyl coumarin p-hydroxyphenyl 
λmax (nm) 254-345 320-390 280-304 
εmax (M-1cm-1) 600-27000 6000-20000 9000-15000 
φ† 0.64-0.01 0.02-0.30 0.9-0.03 
k (s-1) 10 - 3×104 1×108 - 2×109 1×107 - 2×109 
solubility (H2O) Poor-Medium Poor-Medium Good 
 
The focus of this project was on the design and synthesis of novel and stable 
photocleavable crosslinking reagents that can be used to crosslink a protein and also that 
can release two cysteine residues upon photolysis. The choice of photocage was mainly 
based on the synthetic availability of the general designed scaffold, but, nevertheless, it 
is important to understand how altering photocaging groups affects their performance 
during photolysis. 
                                                
* For a non-exhaustive list of examples of caged compounds to date, please see section 9.5. 
† The range of values is quoted as a trend relative to the range of λmax. ϕ tends to decrease with increasing 
λmax for oNB and p-hydroxyphenyl groups and tends to increases with λmax for coumarins. 
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4.1.1 Photocaging scaffolds 
The main considerations guiding the design of new photocaging strategies are: 
Wavelength of photolysis  
Proteins and nucleic acids have absorption maxima at wavelengths of 280 nm and 
260 nm respectively. Ideally, a photocaged compound will absorb light at longer 
wavelengths, to avoid filtering of the laser light by the macromolecule which 
lowers the number of photons available to be absorbed by the photocage and may 
also lead to UV-induced chemical damage to the protein (Bensasson et al., 1993). 
Especially for time-resolved experiments, the laser power and pulse length used has 
to be optimised to obtain rapid and uniform decaging across all the molecules in the 
sample and avoid radiation damage.  
Rate of photolysis 
The timescales of the processes that can be observed during a time-resolved 
experiment are completely dependent on how quickly the system is triggered. The 
rate of decaging has to be faster than that of the reaction of interest. The timescales 
achievable are completely dependent on the photocaging moiety used, as the 
chemical mechanism of decaging dictates how fast the product can be released 
(Table 4). oNB photocages are the slowest (ms-µs, see section 9.6.1), followed by 
coumarins and pHP groups (ns, see sections 9.6.2 and 9.6.3). 
Yield of compound release 
Ideally, all the product molecules should be released from the photocaged 
derivatives upon irradiation. A low decaging yield can be caused by low penetration 
of the triggering laser through the sample, which is especially problematic for dense 
samples (such as crystals) or when targeting highly absorbent samples (with very 
high ε). Another cause for partial decaging is a low quantum yield of the photocage, 
which is a property of the compound itself. Nevertheless, it is still possible to obtain 
useable data from fractional triggering of the sample, as long as the event is well 
synchronised and sufficient molecules are released to obtained a good 
signal-to-noise ratio, by accounting for the unreacted fraction of the sample during 
data analysis, as long as the level of excitation can be determined (Ren et al., 1999).  
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Solubility and stability 
Photocaging groups are aromatic and, in most cases, poorly soluble in aqueous 
buffers. A small percentage of organic solvent (dimethyl sulfoxide or dimethyl 
formamide preferentially) may have to be used to aid solubility, but the 
concentration of organic solvent tolerated is dependent on the protein and the 
sample conditions. Furthermore, the photocaged compounds must be stable in the 
specific buffer used for at least the duration of the experiment, but preferentially for 
several days to aid sample preparation. 
Synthetic availability 
Taking all of the above considerations into account, in principal optimal 
photocaged compounds for each specific experiment can be designed, but it is also 
important to ensure that the compound can be synthesised easily and cleanly, and in 
sufficient quantity for characterisation and use in the time-resolved experiment. 
4.2 Photocleavable crosslinker design and rationale 
Beyond the aspects related to the photocaging moiety, several other details must be 
considered when designing the photocleavable crosslinker scaffolds. The proposed 
compounds aimed to fulfil as many of the following requirements as possible: 
- Bioconjugation reactivity: two cysteine-reactive moieties to selectively and 
cleanly crosslink to engineered protein surface cysteine residues; 
- Length: variable crosslinking length through an extendable linker to afford a 
high degree of control over conformational locking; 
- Photolysis: clean cleavage of the crosslinker and release of the conformational 
lock; 
- Photolysis products: cleavage should yield a minimally modified protein, 
releasing two free cysteines where possible.  
Two general scaffolds that could accommodate these requirements were designed (Fig. 
4.1). In the first design, both caged cysteines are attached to a single photolabile group. 
The cage may release each cysteine sequentially to yield the fully deprotected protein, 
although such compounds have not been described in literature and, therefore, the exact 
mechanism of cleavage of such a scaffold can only be extrapolated. The second design 
resembles a more typical photocaging strategy, where each cysteine residue is released 
by the cleavage of one photocage. In this case, two photolabile moieties are linked 
through an inert and extendable linker and each carry one cysteine-reactive moiety. 
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Fig. 4.1 Cartoon representation of two possible photocleavable crosslinker scaffolds that fulfil the specifications 
described above. In both cases, the chromophore is represented as a blue box, the cysteine-bioconjugating moiety as 
an orange circle, the possible extendable linker regions as dashed, green lines and the photocleavable bonds crossed 
with a red line. 
4.3 Alkyl bis-α-bromo-oNB crosslinkers 
 
Fig. 4.2 General structure of the previously published alkyl bis-α-bromo-oNB crosslinkers, showing the different 
components: 4,5-dimethoxy-oNB chromophore (blue), extendable alkyl linker (green), cysteine-reactive secondary 
bromides (orange) and the photocleavable bond in red. 
At the start of this project, only one family of compounds had been previously reported 
in the literature that matched this desired set of characteristics (Omran and Specht, 
2009b, Omran and Specht, 2009a). The reported scaffold contained two 4,5-dimethoxy-
oNB (DMoNB) groups connected by an extendable alkyl linker (38, Fig. 4.2). The 
DMoNB Cα is brominated, which should selectively react with surface cysteine 
residues. The compounds cleave upon UV irradiation at 364 nm, releasing the free 
cysteines, and the expected mechanism of cleavage is shown in Fig. 4.3 (Il'ichev et al., 
2004). Crosslinker 38 is first bioconjugated to the protein via two surface cysteines 
(39). The “stapled” protein can then be irradiated with UV light, causing the excitation 
of the photocage (40), which decays to the aci-nitro intermediate 41. Intermolecular 
rearrangement leads to a cyclic intermediate (42) which can cleave, releasing a cysteine 
reside to give the nitrobenzyl ketone by-product (43).  
This family of bis-α-bromo-oNB compounds (Fig. 4.2) was synthesised first. The 
described synthetic route varied depending on the length of the linker group and initial 
work was carried out on the shorter (n=1 and n=2) crosslinkers. The shortest 
crosslinkers were investigated first (n=1), as these would yield the tightest control over 
conformational locking, with reduced flexibility compared to the longer scaffolds (n=3). 
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Fig. 4.3 Expected reaction and cleavage mechanism for the crosslinkers. The di-bromo crosslinker (38) reacts with 
cysteine residues on the protein surface, stapling the protein (39). Upon UV irradiation, the compound is placed in a 
singlet excited state (40), which decays to an aci-nitro intermediate (41). This intermediate then cyclises to a 
benzisoxazoline ring (42), which opens, releasing the cysteine residues and yielding the nitroso by-product (43). 
4.3.1 Synthesis of 1,3-dibromo crosslinkers 
 
The synthetic route to the 1,3-dibromo-oNB crosslinker (44) is shown in Fig. 4.4 
(Omran and Specht, 2009a). Claisen condensation of ethyl 3,4-dimethoxy benzoate (45) 
with 3,4-dimethoxy acetophenone (46) yields the first intermediate, a 1,3-diketone (47). 
The reported reaction conditions used benzene at reflux temperature. To avoid the use 
of benzene, the reaction was attempted in toluene instead. The 1,3-diketone (47) was 
obtained in moderate yields with longer reaction times (36 h) and at higher temperatures 
(110 °C). 1,3-Diketone 47 had to be reduced to the corresponding 1,3-diol (48) prior to 
nitration, as the 1,3-unsaturated system leads to deactivation of the ring towards 
electrophilic aromatic substitution. The 1,3-diol 48 was obtained quantitatively using a 
standard sodium borohydride reduction protocol but the following nitration step to 
compound 49 was unsuccessful. To avoid over-nitration of the highly activated ring 
(due to the two methoxy substituents), the reaction was performed at low temperature 
(-50 °C). LC-MS analysis of the reaction showed the presence of tetra-nitrated species, 
even with low-temperature quenching of the reaction mixture, possibly from the 
formation of unstable alkyl-nitrates from the alcohols as the crude products decomposed 
during flash chromatography. 
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Fig. 4.4 Proposed synthetic route to 1,3-bis(bromo)-1,3-bis(oNB) crosslinker (44). a) NaH (1.1 eqv.), dry PhMe, 110 
°C, 36 h, 33%; b) HNO3, AcOH, 0 °C-RT, 24 h, 60%; c) Ac2O, HNO3, 0 °C-RT, 3 h, 69%; d) NaBH4 (3 eqv.), 
CH2Cl2, MeOH, RT, 40 min, 99%. 
To overcome the nitration problems, a second synthetic route was designed, starting 
from ethyl 2-nitro-4,5-dimethoxy benzoate (50) and 2-nitro-4,5-dimethoxy 
acetophenone (51). The precursors were easily nitrated using HNO3/AcOH (Knesl et 
al., 2006) and HNO3/Ac2O (Dyer and Turnbull, 1999) mixtures respectively, but the 
Claisen condensation step to 1,3-diketone 52 was unsuccessful using the previously 
employed conditions, with both starting materials recovered and no evidence of 
conversion visible by either TLC or LC-MS. 
In the interest of time, and because it was important to investigate early on whether this 
class of compounds had the desired reactivity for protein conjugation, the short 
crosslinkers were abandoned at this stage and instead the longer crosslinkers (53, n=3) 
were synthesised. In contrast to the shorter 1,3-crosslinkers, the nitration step for the 
longer 1,5-crosslinkers could be performed on the 1,5-diketone intermediate instead of 
the 1,5-diol, and it was therefore expected that the previously described synthetic 
problems would not be encountered. 
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4.3.2 Synthesis of 1,5-dibromo crosslinkers 
 
The synthetic route to the 1,5-crosslinker (53) is shown in Fig. 4.5 and is applicable to 
all compounds of this scaffold with linker lengths of 3 or more carbons. The 1,5-
diketone homodimer (54) was synthesised from the Friedel Crafts acylation of vetrarole 
(55) with glutaryl chloride (56) in moderate yields. The work-up of the reaction proved 
challenging, with the formation of emulsions from aluminium complexes. Quenching of 
the reaction using Rochelle salts did not improve the work-up but quenching into a 2 M 
HCl/ice slurry with very slow warming to RT (overnight stirring) gave clear layers 
which could be better extracted, although without improvement of the isolated yield. 
The 1,5-diketone (54) was nitrated to compound (57) using a TFA/HNO3 mixture at 0 
°C, reduced quantitatively to the 1,5-diol (58) using a standard sodium borohydride 
reduction protocol and easily brominated using acetyl bromide with catalytic HBr to 
give the desired 1,5-dibromo crosslinker (53) as a 1:1 mixture of diastereomers.  
 
Fig. 4.5 Synthetic route to 1,5-bis(bromo)-1,5-bis(oNB) crosslinker (53). a) AlCl3 (2.4 eqv.), -10 °C – 0 °C, 5 h, 22%; 
b) HNO3 (2.6 eqv.), TFA (8 eqv.), CH2Cl2, -15 °C - 0 °C, 2 h, 53%; c) NaBH4 (4 eqv.), CH2Cl2, MeOH, RT, 45 min, 
99%; d) acetyl bromide (3 eqv.), HBr (20 mol%), 0 °C-RT, 1.5 h, 99%. 
4.3.3 Reactivity studies 
Omran et al. performed the crosslinking experiments, in the presence of 20 eqv. of N-
benzoylcysteine methyl ester as a surrogate for protein surface cysteines, in 50% EtOH 
in phosphate buffer (pH 7.3). This protocol was considered unsuitable for protein 
modification for several reasons: firstly, the high percentage of ethanol will probably 
not be compatible with most proteins. The high equivalents of protein would also be a 
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problem, as protein expression yields may not be sufficient and separating the modified 
and unmodified proteins would be very difficult. 
The crosslinking reactions were therefore performed with two eqv. of cysteine or other 
thiol containing small molecule (Fig. 4.6) and followed by LC-MS. Crosslinker 
consumption was monitored using the UV trace for each run. An overview of the 
experiments performed is summarised in Table 5.  
 
Fig. 4.6 Schematic of derivatisation of the 1,5-dibromo crosslinker (53) with thiols, to give 1,5-dithiols (59). 
In all cases, the crosslinker was still visible after 4 h – none of the reactions went to 
completion. Cysteine was used first as the nucleophile, followed by cysteine ethyl ester 
as it was thought that cysteine might not be fully soluble if in its zwitterionic form. No 
change was visible when performing the reaction in the same buffer/EtOH conditions 
described in the literature, using only 2 eqv. of nucleophile. The following reactions 
were attempted with benzyl mercaptan (BnSH), so the reactions could be followed 
better using UV absorption. Tetrabutylammonium iodide (TBAI) was used as an 
additive, to see if some exchange of the bromides to iodides could occur and accelerate 
the reaction, but no change was observed between conditions with and without TBAI. 
Some single crosslinking was visible in most cases, occurring faster at higher pH (pH 
8.0 rather than 7.4), as expected for a nucleophilic substitution. Higher concentrations 
also increased the rate of reaction and the compounds tolerated DMSO:buffer mixtures. 
As none of the conditions attempted led to complete consumption of the crosslinkers or 
clean formation of the doubly substituted product, it was concluded that these 
compounds bearing secondary bromides were not sufficiently reactive for protein 
bioconjugation. Nevertheless, differences were noticed when exchanging the organic 
solvent and pH, indicating better reactions in DMSO rather than EtOH and at pH 8.0 
compared to pH 7.4, which should be taken into account when performing future 
crosslinking experiments. 
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Table 5 Investigation of crosslinking ability of 1,5-dibromo crosslinkers (CL, 53) 
Solvent Thiol [thiol] (mM) 
[CL] 
(mM) Additive pH Conclusions 
1:1 
EtOH:buffer Cys 2 1 - 7.4 
Cysteine and CysOEt are sparingly 
soluble in 50% ethanol 
1:1 
EtOH:buffer CysOEt 2 1 - 7.4 
1:1 
EtOH:buffer CysOEt 2 1 TBAI 7.4 
CH2Cl2 BnSH 2 1 - - 
Crosslinking does not occur in the 
absence of buffer. 
CH2Cl2 BnSH 2 1 TBAI - 
1:4 
CH2Cl2:EtOH 
BnSH 2 1 - - 
1:4 
CH2Cl2:EtOH 
BnSH 2 1 TBAI - 
1:1  
DMSO:buffer BnSH 2 1 - 7.4 
The crosslinking is very slow with 1 mM 
crosslinker.  
Addition of TBAI has no effect. 1:1  DMSO:buffer BnSH 2 1 TBAI 7.4 
1:1  
DMSO:buffer BnSH 5 2.5 - 7.4 
Reaction is faster at pH 8.0. 
Changing the concentration of DMSO 
from 50% to 33% has no effect on rate of 
reaction. 
1:1  
DMSO:buffer BnSH 5 2.5 - 8.0 
1:2  
DMSO:buffer BnSH 5 2.5 - 7.4 
1:2  
DMSO:buffer BnSH 5 2.5 - 8.0 
 
4.4 α,α-Di(bromoacetyl) toluene crosslinkers 
In order to improve the reactivity of the crosslinkers towards thiol containing 
compounds and, therefore, cysteines, a more reactive bioconjugation moiety had to be 
engineered into the scaffold. α-Bromoacetates are not as reactive as α-iodoacetates, but 
still react readily and exclusively with sulfhydryl groups when used in equimolar 
concentrations (Hermanson, 2008a). Furthermore, as carboxylates are good leaving 
groups, photolytic cleavage of the crosslinkers to the cysteine methyl carboxylates 
should be fast. Therefore, the newly designed scaffold carries two α-bromoacetate 
groups, both attached to the same photocleavable moiety (Fig. 4.7). Such compounds 
have not been previously described in the literature and the possible hydrolysis of the 
ci-esters in buffer was of concern in the design of the crosslinker. Nevertheless, cyclic 
acetals bearing benzyl groups have been previously used as linkers for protein affinity 
purification. 6-Membered ring cyclic acetals were shown to be stable in buffer, even in 
the presence of TFA 1% (Lee et al., 2015). 
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Fig. 4.7 General scaffold design for the α,α-di(bromoacetyl) toluene photocleavable crosslinkers. One photocaging 
moiety is attached to two α-bromoacetates which can react readily with cysteines and cleave sequentially to methyl 
carboxylates. 
As these photocleavable di-bromoacetyl compounds are completely novel, the cleavage 
mechanism of the crosslinkers can only be speculated. In the case of oNB based 
crosslinkers, the first moiety is likely to be released by a typical oNB photolysis 
mechanism as shown in Fig. 4.3 (Klán et al., 2013). The α,α-di(bromoacetyl)-ortho-
nitrotoluene (60) is reacted with two cysteines to give the crosslinked moiety (61). 
Upon absorption of a photon, the nitrobenzyl moiety cleaves, releasing the first cysteine 
methyl carboxylate group (62) and forming a nitroso-anhydride intermediate (63). This 
nitroso intermediate is no longer photocleavable and, therefore, the anhydride will have 
to fragment, possibly by hydrolysis to 2-nitrobenzoic acid (64), to release the second 
methyl carboxylate (Fig. 4.8). Therefore, although the crosslinking reagent is 
symmetrical, the cleavage mechanism is expected to occur in two distinct steps, which 
are expected to have very different rates as the hydrolysis step is likely to be slow (c.f. 
k~3×10-3 s-1 for acetic anhydride in H2O) (Gold, 1948) in comparison to the first 
photolysis reaction, which is expected to occur on ms timescales (see section  9.6.1). 
 
Fig. 4.8 α,α-Di(bromoacetyl)-ortho-nitrotoluene (60) reaction and cleavage. The crosslinker (60) reacts with two 
surface cysteines to yield the crosslinked protein (61). Photolysis of the chromophore leads to the release of one of 
the cysteine anchors as a cysteine methyl carboxylate (62) and yields a 2-nitrosobenzyl anhydride group (63), which 
is still attached to the second cysteine residue. The anhydride intermediate then slowly hydrolyses to 2-nitroso 
benzoic acid (64), releasing the second cysteine residue. 
In the case of coumarinyl crosslinkers, a different cleavage profile is expected (Fig. 
4.9). The 4-(α,α-dibromo)methyl coumarin (65) is reacted with the two surface cysteine 
residues to yield the crosslinked protein (66). Upon absorption of a photon, the 
coumarin is promoted to an excited state (67), which undergoes heterolytic cleavage 
releasing the cysteine methylcarboxylate (62). The resulting carbocation (68) is 
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quenched by the buffer, giving an alcohol intermediate (69). This species should then 
still be able to absorb a second photon (70), releasing the second cysteine methyl 
carboxylate residue (62) in a similar fashion to the first. Diol 72 would probably be 
short lived, collapsing to aldehyde 73. Although the photolysis events would have to be 
sequential, coumarins have higher absorption cross-sections and generally much faster 
cleavage rates (10s of ns) compared to oNB derivatives. A second possible mechanism 
involves the direct fragmentation of alcohol intermediate 67 to diol 64. 
 
Fig. 4.9 7-(α,α-Di(bromoacetyl))-methylcoumarin reaction (65) and cleavage. The crosslinker (65) reacts with two 
surface cysteines to yield the crosslinked protein (66). Photolysis of the chromophore leads to the release of one of 
the cysteine anchors as a cysteine methyl carboxylate (62) and yields a coumarinyl carbocation (68), which 
hydrolyses to an alcohol (69) in buffer. This intermediate is still attached to the second cysteine residue but is able to 
absorb a second photon, undergoing a similar cleavage mechanism to release the second cysteine residue and another 
coumarinyl cation intermediate (71). The carbocation hydrolyses to a diol (72), which quickly interconverts to the 
coumarinyl aldehyde (73). 
In order to simplify the initial synthesis and to allow for rapid testing of this novel class 
of crosslinkers for reactivity towards cysteines and stability in aqueous solutions, a non-
cleavable, benzyl crosslinker was synthesised first. 
4.4.1 Synthesis 
The non-cleavable α,α-(dibromoacetyl) toluene crosslinker (74) was synthesised from 
benzaldehyde (75) and bromoacetic anhydride (Fig. 4.10). Previously reported 
procedures for the synthesis of diacetyl toluene require heating benzaldehyde in neat 
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acetic anhydride. As bromoacetic anhydride is a solid and considerably more expensive 
than acetic anhydride, reactions in solvent (CCl4 and MeCN) with silica-supported 
sulphuric acid as a catalyst were investigated first, but no conversion was observed 
(Table 6). Bromoacetic anhydride melts at 40 °C, and therefore the reaction was 
attempted in neat anhydride. It was found that high temperatures gave better yields, and 
the dibromoacetyl toluene compound was obtained in excellent yield from overnight 
heating at 85 °C. The product was a slow-crystallising, colourless oil, which could be 
triturated in cold hexane to remove any traces of anhydride and bromoacetic acid. Since 
the 1H NMR spectra of a mixture of the starting materials and of the product are very 
similar, product formation was confirmed by IR, where the C=O stretch frequencies 
shift from 1832 cm-1 for bromoacetic anhydride to 1763 cm-1 for the product. 
 
Fig. 4.10 Synthesis of the α,α-di(bromoacetyl) toluene non-photocleavable crosslinker. a) bromoacetic anhydride 
(1.5 eqv.), 85 ° C, 16 h, 75%. 
Table 6 Attempted reaction conditions for the synthesis of di-(bromoacetyl) toluene 
Solvent [PhCO] (mM) 
(BrAc)2O 
(eqv.) 
T 
(°C) catalyst 
Time 
(h) Conclusions Ref. 
CCl4 720 1 RT H2SO4/SiO2 48 Silica supported 
sulphuric acid is not an 
efficient catalyst 
(Olah and 
Mehrotra, 
1982) 
MeCN 1150 1 60 H2SO4/SiO2 20 
(Kavala and 
Patel, 2005) 
Neat - 1.5 60 - 16 High temperatures and 
longer reaction times are 
required 
 
(Rahman and 
Jahng, 2007) Neat - 1.5 85 - 3 
Neat - 1.5 85 - 16 
4.4.2 Reactivity and stability studies 
The α,α-di(bromoacetyl) toluene crosslinker (74) was first investigated for reactivity 
towards thiols. The reaction was followed by LC-MS, so a dilution series of the 
crosslinker in MeCN was carried out first to check the detection limits of the 
spectrometer. Good UV and MS traces were obtained down to 5 mM crosslinker 
concentration in MeCN (Fig. 4.11).  
O
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Fig. 4.11 LC-MS run of a 5 mM solution of the α,α-(dibromoacetyl)toluene crosslinker (74) in MeCN. From top to 
bottom: base-peak chromatogram showing the counts on the ion detector during the LC run, showing one major peak 
at 2.05 min retention time; UV chromatogram during the LC run showing one main UV peak corresponding to the 
main peak on the chromatogram; extracted ion chromatogram for the expected mass for the crosslinker, matching 
both the UV and MS peaks; m/z spectrum of the major peak, showing a mass of 389.0, corresponding to the 
crosslinker adduct with Na+. 
The compound was dissolved to a concentration of 5 mM in buffer (50 mM potassium 
phosphate pH 8.0, 100 mM NaCl, 5 mM TCEP) containing a varying concentration of 
MeCN (10-35%) and found to be insoluble up to 30% MeCN, with the appearance of 
heavy oil emulsions. The same procedure was used to check for solubility in 
buffer/DMSO mixtures instead, where white suspensions were visible up to 15% 
DMSO, but with no oily droplets formed.  
Crosslinking experiments in 35% MeCN/buffer or 35% DMSO/buffer mixtures with 
2 eqv. of mercaptopropionic acid (76) were set up and the reaction followed by LC-MS. 
The reaction was slow in MeCN with both crosslinker and mono-substituted product 
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(77) still visible after 30 min. The LC trace also showed several impurities, including 
the formation of an additional heavier by-product. The reaction did not proceed to 
completion, even with prolonged reaction times.  
 
Fig. 4.12 The reaction of the α,α-(dibromoacetyl)toluene crosslinker (74) with mercaptopropionic acid (76), through 
the mono-substituted intermediate (77) to the expected di-substituted product (78).  
The reaction was much faster and cleaner in 35% DMSO/buffer, reaching completion 
within 30 min with no observable mono-substituted intermediate (77). Only two species 
were visible after this time, corresponding to the desired di-substituted product (78) and 
a small amount of the same heavy by-product observed in the reaction in MeCN.  
Although the reactions were run in high percentages of DMSO, this was mainly due to 
the high concentrations needed for observation of the compounds by LC-MS. In 
practice, the reactions with proteins will be carried out at much lower concentrations 
(down to ~10 µM), which should allow for a much lower percentage of organic solvent 
to be used. Therefore, it was concluded that the new crosslinkers bearing α-acetyl 
bromides were sufficiently reactive and compatible with protein bioconjugation.  
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Fig. 4.13 LC-MS traces of the reaction of α,α-(dibromoacetyl)toluene (74) with mercaptopropionic acid (76), in 35% 
MeCN and 35% DMSO in buffer. Both the UV and base peak chromatograms are shown. The starting material (blue, 
74), mono-substituted intermediate (yellow, 77), product (green, 78) and heavy by-product (orange) are highlighted. 
The reaction in DMSO is much cleaner and faster than that in MeCN. 
For further characterisation of the crosslinker, α,α-(dibromoacetyl)toluene (74) was 
derivatised with ethane thiol on a larger scale, in MeCN in the presence of triethylamine 
(Fig. 4.14).  
 
Fig. 4.14 Reaction of α,α-(dibromoacetyl)toluene (74) with ethane thiol. a) EtSH (20 eqv.), NEt3 (4 eqv.), MeCN, 3 
h, RT, 33%. 
The stability of both the crosslinker (74) and α,α-di(ethanethiol) toluene (79) in buffer 
at different pH was investigated next, using 1H NMR spectroscopy. The compounds 
were dissolved in 50% d6-DMSO in buffer at varying pH (50 mM potassium phosphate 
pH 3.0-8.0, 100 mM NaCl) and the 1H NMR spectrum recorded with a water 
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suppression pulse sequence at different time intervals. The α-proton signal of the 
crosslinker was compared to the PhC2/C6 proton signal of the aldehyde to give a ratio 
of the two species and, therefore, an approximate measure of hydrolysis. The α-proton 
signal overlays with the PhC3/C5 aldehyde proton signals so the integral was calculated 
as the difference between the total signal for both protons and that of the PhC2/C6 
proton.  
The crosslinker (74) was found to be unstable across the whole pH range, with full 
hydrolysis to the aldehyde within 1 h at pH 7.0-8.0. Hydrolysis was slower at lower pH, 
but 30% hydrolysis was still observed within 2.5 h at pH 3.0. The decomposition of the 
di(bromoacetate) mainly occurs from base-catalysed hydrolysis, but the compound is 
still susceptible to acid-catalysed hydrolysis. 
 
Fig. 4.15 1H NMR spectra of the α,α-(dibromoacetyl) toluene crosslinker (74) in 50% d6-DMSO in buffer at different 
pH (50 mM potassium phosphate pH 3.0-8.0, 100 mM NaCl). 1H NMR spectra were recorded between 1h and 2.5 h 
after sample preparation. From top to bottom: 100% d6-DMSO; pH 3.0 at 160 min, pH 4.0 at 140 min, pH 5.0 at 120 
min, pH 6.0 at 100 min, pH 7.0 at 80 min, pH 8.0 at 60 min, and benzaldehyde in at pH 7.0. 
The thiol derivative (79) was more stable, hydrolysing to give benzaldehyde only after 
16 h at pH 8.0 and not showing any hydrolysis at pH 5.0 and below (Fig. 4.16). The 
presence of the α-bromides promotes faster hydrolysis rates and allows for acid-
catalysed hydrolysis of the di(acetate) core. Although the bioconjugated crosslinker was 
still not stable above pH 7.0, hindering its wider application, especially in 
crystallographic studies where the pH of the crystallisation conditions can be an 
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essential factor in obtaining well-diffracting crystals, it was nevertheless deemed 
important to investigate the synthetic availability of the photocleavable derivatives. 
 
Fig. 4.16 1H NMR spectra of the stability studies of the α,α-(di(ethylthio)acetyl) toluene derivative (79) in 50% d6-
DMSO in buffer at different pH. From left to right: spectra at 20 min, 150 min and 16 h. From top to bottom: pH 3.0, 
pH 4.0, pH 5.0, pH 6.0, pH 7.0, pH 8.0 and benzaldehyde at pH 7.0. 
4.4.3 Synthesis of photocleavable derivatives 
Although the synthesis of the toluene crosslinker was simple and high yielding, 
attempts at synthesising the corresponding 7-methoxy coumarinyl and 4,5-dimethoxy-2-
nitrobenzyl crosslinkers (80 and 81 respectively) were unsuccessful, mainly due to 
solubility issues. Both aldehyde precursors (4-formyl-7-methoxycoumarin, 82, and 4,5-
dimethoxy-2-nitrobenzaldehyde, 83) were synthesised as described in sections 4.5.3 and 
4.5.4, respectively, and subjected to the same reaction conditions used for the synthesis 
of the toluene crosslinker (74), by heating in bromoacetic anhydride.  
 
Fig. 4.17 Attempted synthesis of the coumarinyl and oNB crosslinkers (80 and 81 respectively). 
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4-formyl-7-methoxycoumarin (82) was sparingly soluble in bromoacetic anhydride, 
with solutions only obtained after several hours of heating. Overnight heating at 85 °C 
showed no consumption of the starting materials and heating at 120 °C led only to the 
decomposition of the anhydride, with no consumption of the coumarin. Several reaction 
conditions were attempted, as shown in Table 7, including acid and base catalysis and 
microwave irradiation. Heating the coumarin in 10 equivalents of bromoacetic 
anhydride at 85 °C led to the formation of product 80 (as seen by LC-MS), but the 
compound decomposed during purification by flash chromatography. Trituration of the 
crude mixture in hexane and distillation of the excess anhydride did not yield pure 
products, and the crude mixture decomposed back to the starting material over time, 
indicating that the product was unstable. Simultaneously, a similar approach was taken 
to obtain the oNB crosslinker (81) from 4,5-dimethoxy-2-nitrobenzaldehyde (83) 
although also unsuccessfully. The reaction conditions attempted are shown in Table 8.  
 
Table 7 Reaction conditions attempted for the synthesis of the 7-methyl-α,α-(dibromoacetyl) coumarin (80) 
Solvent (BrAc)2O (eqv.) 
T 
(°C) catalyst 
Time 
(h) Notes Ref. 
CH2Cl2 3 RT Cu(OTf)2 16 Reaction does not proceed in 
solvents in the presence of a 
strong Lewis acid. 
(Lata 
Chandra et 
al., 2000) MeCN 3 RT Cu(OTf)2 16 
Neat 1.5 85 BrCH2COBr 16 
Reaction may require more 
(BrAc)2O eqv. 
 Neat 1.5 85 BrAcNa 16 
Neat 2.5 85 BrAcNa 16 
Neat 1.5 85 - 16 Longer reaction times and more 
(BrAc)2O eqv. lead to product 
formation. Product does not 
tolerate flash chromatography. 
(Rahman 
and Jahng, 
2007) 
Neat 4 85 - 4 
Neat 10 85 - 24 
Neat 10 100 - 16 Starting materials decompose above 85 °C. 
 
Neat 10 80+140 - 0.5+0.5 
Microwave irradiation. Product 
is visible by LC-MS but does 
not tolerate flash 
chromatography. 
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Table 8 Reaction conditions attempted for the synthesis of the α,α-(dibromoacetyl)-ortho-nitrobenzene (81) 
Solvent (BrAc)2O (eqv.) 
T 
(°C) catalyst 
Time 
(h) Notes Ref. 
Neat 1.5 85 BrCH2COBr 16 The reaction does not proceed 
with up to 3 eqv. of (BrAc)2O – 
the starting material is even less 
soluble than the oNB derivative. 
 
Neat 1.5 85 - 18 (Rahman 
and Jahng, 
2007) Neat 3 85 - 16 
MeCN 3 RT Cu(OTf)2 16 
Reaction does not proceed in 
solvent with strong Lewis acid 
catalysis. 
(Lata 
Chandra et 
al., 2000) 
Neat 10 80+120 - 1 
Microwave irradiation. Product 
visible by LC-MS but starting 
materials mainly decomposed. 
 
 
The synthesis of the photocleavable derivatives required considerable optimisation. 
Their apparent instability to flash chromatography indicated an inherent instability of 
the scaffolds and, along with the instability of the non-cleavable compound in aqueous 
solutions at pH 7.0 and above, the di(acetyl) scaffold was considered not suitable for 
further development. Since ester functional groups are found in a number of biological 
small molecules (such as acetyl coenzyme A), it was proposed that the instability of this 
scaffold was due to the gem-di(acetyl) group rather than generally caused by the 
introduction of the (bromo)acetate bioconjugating groups.  
A singly-bromoacetylated toluene derivative was synthesised to check for stability. 
Benzyl-1-methyl-1-bromoacetate (83) was easily synthesised from α-methyl benzyl 
alcohol (84) and bromoacetyl bromide in the presence of NaHCO3 as a base. 83 was 
reacted with ethanethiol in MeCN with NEt3 to give the thiol derivative. 
 
Fig. 4.18 Synthesis of benzyl 1-methyl-1-bromoacetate (83) and benzyl 1-methyl-1-(ethylthio)acetate (85). a) 
bromoacetyl bromide, NaHCO3 (3 eqv.), MeCN, 0 °C-RT, 2 h, 82%; b) EtSH (10 eqv.), NEt3 (2 eqv.), MeCN, RT, 
3 h, 94%. 
Both compounds were subjected to stability studies similar to those carried out with the 
dibromoacetyl crosslinker (74). 5 mM solutions of each compound in 50% d6-
DMSO/buffer mixtures at varying pH (50 mM potassium phosphate pH 3.0-8.0, 
100 mM NaCl) were prepared and 1H NMR spectra collected with a water suppression 
pulse sequence at 1 h and 16 h intervals. The percentage hydrolysis was accounted for 
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using the ratio of the integral of the signal corresponding to the methyl group, as it was 
easily distinguishable from the remainder chemical shifts.  
For the bromoacetyl compound (83), the signal shifts from 1.45 ppm to 1.31 ppm for 
the hydrolysis of the acetate group at the carbonyl carbon (84). A shift of the same 
signal to 1.46 ppm was suspected to correspond to hydrolysis of the α-bromide instead 
(86).  
 
Fig. 4.19 Hydrolysis of benzyl 1-methyl-1-bromoacetate (83), showing the changes in chemical shifts of the methyl 
group, depending on the hydrolysed moiety. Hydrolysis at the ester carbonyl causes a shift from 1.45 ppm to 
1.31 ppm (84) and at the α-bromide group a shift from 1.45 ppm to 1.46 ppm (86). 
The single bromoacetate (83) compound is much more stable than the dibromoacetyl 
compound (74), where no hydrolysis of the acetate group is visible after 16 h in solution 
at pH up to 6.0 and 22-50% hydrolysis at pH 7.0-8.0, whereas the dibromoacetyl 
compound hydrolysis completely within 1 h at pH 7.0-8.0 and also undergoes rapid 
hydrolysis at lower pH (Fig. 4.20). The α-bromide group is also partially hydrolysed 
over 16 h (25-50% across pH 3.0-8.0). Since the bioconjugation reaction should occur 
much faster than the hydrolysis of the conjugating group (Hermanson, 2008a), this was 
not considered detrimental. The ethanethiol derivative (85) was found to be very stable, 
with no hydrolysis observable by 1H NMR spectroscopy after 16 h in solution (Fig. 
4.21). Therefore, the α-bromide group activates the ester moiety towards base-catalysed 
hydrolysis, which is no longer observed once the compound is derivatised to the α-
thiother.  
From these studies, it was concluded that the α-bromoacetyl bromide moieties were 
appropriate for bioconjugation to cysteine residues, with better reactivity profiles in 
DMSO/buffer mixtures compared to MeCN/buffer mixtures. Although the 
dibromoacetyl compound (74) was unstable, the single bromoacetate was considerably 
more stable and completely stable when derivatised to the thioether. A new scaffold was 
designed bearing α-bromoacetate groups as bioconjugation moieties, with a spacer 
group linker in-between, as described in the next section.  
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Fig. 4.20 1H NMR spectra of the stability studies of benzyl 1-methyl-1-bromoacetate (83) in 50% d6-DMSO in buffer 
at different pH. From left to right: spectra at 120 min and 16 h. From top to bottom: pH 3.0, pH 4.0, pH 5.0, pH 6.0, 
pH 7.0 and pH 8.0. 
 
Fig. 4.21 1H NMR spectra of the stability studies of benzyl 1-methyl-1-theylthioacetate (85) in 50% d6-DMSO in 
buffer at different pH. From left to right: spectra at 120 min and 16 h. From top to bottom: pH 3.0, pH 4.0, pH 5.0, 
pH 6.0, pH 7.0 and pH 8.0. 
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4.5 Third generation crosslinkers 
4.5.1 Design and rationale 
In order to obtain a cysteine-reactive and stable crosslinker, two α-bromo acetyl 
moieties had to be engineered at two distinct cleavage sites into the new scaffold design. 
Therefore, the new compound contained two photocages, connected by an extendable 
linker chain, as shown in Fig. 4.22. For simplicity of the synthesis, the linker chain was 
designed as an alkene moiety as two symmetrical photocaging groups could be joined 
through a metathesis step.  
 
Fig. 4.22 General scaffold design for the α-bromo acetyl photocleavable crosslinkers. Two photocages are linked 
through an extendable alkene chain and each is flanked by an α-bromo acetyl moiety for attachment to cysteines and 
easy release as a carboxylate. 
4.5.2 Synthesis of bis-phenyl non-cleavable crosslinker 
As done for the previously designed scaffolds, a non-cleavable compound, using a 
phenyl ring in place of the photocaging group, was synthesised first to test for the 
synthetic route, stability of the compound in buffer and reactivity towards thiols. The 
synthetic route is shown in Fig. 4.23. The racemic 1-phenylprop-2-en-1-ol (87) was 
synthesised from benzaldehyde (75) via a Grignard reaction with vinylmagnesium 
bromide (Cornil et al., 2014) and resolved kinetically using a non-specific lipase from 
Candida antarctica B (Štambaský et al., 2008). The chirality and enantiomeric excess 
of the resolved S-alcohol ((S)-87) was confirmed by reaction with both R and S 
Mosher’s acyl chlorides to give the diastereomeric (S,R)- and (S,S)-Mosher’s esters 
(Fig. 4.24, 88 and 89) (Mallavadhani and Rao, 1994). The 1H NMR spectra of the two 
diastereomers obtained was analysed and compared to that of the parent secondary 
alcohol to give ΔδS-R – differences in chemical shifts between the diastereomers, 
especially noticeable for the alkenyl protons – which were used to assign the relative 
spatial arrangement of the substituents, and, therefore, the chirality of the parent alcohol 
((S)-87). Mosher’s esters preferentially adopt conformations as shown in Fig. 4.24 and 
the benzene ring on the MTP moiety shields the closest group, causing a lower chemical 
shift. As is clearly visible in insert a from Fig. 4.25, the chemical shifts for the alkenyl 
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protons are shifted downfield for the S-ester (89) compared to the R-ester (88), which 
means that the alkene group is shielded in the R-ester (88), indicating that the alcohol is 
the S-enantiomer, as shown in Fig. 4.24.  
 
Fig. 4.23 Synthesis of the alkenyl bis-toluene non-cleavable crosslinker (94). a) Vinylmagnesium bromide (1.2 eqv.), 
dry THF, 0 °C, 4 h, 81%; b) Novozyme 435 (26 mg/mmol), isopropenyl acetate (4.2 eqv.), dry PhMe, 4 Å molecular 
sieves, 40 °C, 16 h, 72%; c) KOH (1.05 eqv.), MeOH, 50 °C, 2 h, 90%; d) Pyridine (2 eqv.), bromoacetyl bromide (2 
eqv.), dry CH2Cl2, 0 °C, 2 h, 83%; e) i) Hoveyda-Grubbs II catalyst (10 mol%), dry CH2Cl2, 45 °C, 40 h, ii) 
CNCH2CO2K (22 mol%), MeOH, RT, 1 h, 45%; f) Pyridine (2 eqv.), bromoacetyl bromide (2 eqv.), dry CH2Cl2, 0 
°C, 2 h, 82%; N-acetyl cysteine (1.1 eqv.), NEt3 (2.2 eqv.), MeCN, RT, 1 h, 86%. 
 
Fig. 4.24 Pictorial representation of the method for the confirmation of the chirality of (S)-1-phenylprop-2-en-1-ol 
((S)-87) by Mosher’s ester derivatisation and 1H NMR analysis. 
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Fig. 4.25 1H
 N
M
R
 spectra of M
osher’s esters. The (S,S)-diastereom
er (89) is show
n in red (top) and the (S,R
)-diastereom
er (88) in blue (bottom
). The m
ain spectra show
 the com
pounds after flash 
chrom
atography. Insert a show
s the overlaid spectra and b the (R
,R
)-diastereom
er prior to flash chrom
atography, w
hich w
as used to calculate the enantiom
eric purity of the alcohol (62%
 ee). 
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The enantiomeric excess of the S-alcohol ((S)-87) was determined using the 1H NMR 
spectrum of the crude (S,R)-diastereomer compound, prior to flash chromatography. 
Two signals for the alkenyl CH are clearly visible, corresponding to the two different 
(S,R) and (R,R) diastereomers. From the integrals a 62% ee was calculated. 
Upon confirmation of the chirality of the (S)-alcohol ((S)-87), the (R)-acetate ((R)-90) 
was hydrolysed using KOH in MeOH with heating and the (R)-alcohol obtained 
((R)-87) used to test the bromoacetylation step (Fig. 4.26). Initial reactions of the (R)-
alcohol ((R)-87) with bromoacetyl bromide and sodium hydrogen carbonate in MeCN 
yielded an unexpected major product 91, which was thought to arise from the 
rearrangement of the allyl bromoacetate. This problem was overcome by using pyridine 
in CH2Cl2 instead (Sawant and Jennings, 2006).* For further characterisation, the (R)-
bromoacetate ((R)-92) was also reacted with N-acetyl cysteine in MeCN in the presence 
of triethylamine to give the cysteine derivative 93. From the 1H NMR spectrum only 
one diastereomer was visible, confirming that the (R)-alcohol ((R)-87), and, therefore, 
the (R)-α-bromoacetate ((R)-92), had high enantiomeric purity (>90% ee). 
 
Fig. 4.26 Reaction of the (R)-allyl alcohol ((R)-87) with bromoacetyl bromide (2 eqv.) and the two products observed 
by 1H NMR using different reaction conditions. a) NaHCO3 in MeCN yielded the rearranged product 91. b) Pyridine 
(2 eqv.) in CH2Cl2 yielded the desired bromoacetate (R)-92 in 83% yield. c) reaction of allyl bromoacetate (R)-92 
with N-acetyl cysteine (1.1 eqv.), NEt3 (2.2 eqv.) in MeCN, 86% yield.  
The allyl-bromoacetate (R)-92 was subjected to similar stability studies as described 
previously, and found to be stable across the same pH range (3.0-8.0) with no apparent 
hydrolysis over 20 h. The (S)-allyl alcohol ((S)-87) was then derivatised to the (S)-allyl 
bromoacetate ((S)-92) using the same conditions as for the synthesis of the (R)-allyl 
bromoacetate ((R)-92). The first metathesis experiment was carried out with the (R)-
allyl alcohol ((R)-87), followed by the (S)-bromoacetate ((S)-92). A summary of the 
conditions attempted is shown in Table 9. Initial conditions for the metathesis of the 
allyl alcohol compound showed no conversion in the presence of 2nd Generation Grubbs 
catalyst (GII). Metathesis of the bromoacetate was attempted instead, as it was thought 
                                                
*  It was also important to note that yields improved considerably when using freshly purchased 
bromoacetyl bromide, which hydrolyses over time to bromoacetic acid and HBr. 
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that the ester group may allow for further coordination to the Ru centre. Some 
conversion was visible in the presence of GII. 1st Generation Grubbs catalyst (GI) did 
not promote any metathesis, with no product visible by TLC or LC-MS. 2nd generation 
Hoveyda-Grubbs catalyst gave the highest yield for the dibromoacetate product (94) and 
cleaner reactions with longer reaction times. HGII catalyst is known to be more efficient 
at coupling electron deficient alkenes (Chatterjee et al., 2003). The catalyst was easily 
removed by treatment of the reaction mixture with potassium isocyanoacetate, which 
complexes with Ru metal and can be easily removed by flash chromatography, giving 
clean products as off-white solids.  
Table 9 Metathesis reaction conditions attempted for the synthesis of the non-cleavable crosslinker 
SM [SM]
* 
(mM) Catalyst 
[cat.] 
(mol%) 
T 
(°C) 
Time 
(h) 
Yield 
(%) 
Ru 
chelation Notes 
R-
OH 200 GII 5 40 16 0 - 
Alcohol does not undergo 
cross-metathesis but α,α-
bromoacetate does. Flash 
chromatography not suitable 
for Ru removal. 
S-
AcBr 78 GII 5 40 16 35 - 
R-
AcBr 78 GII 5 40 16 20 - 
R-
AcBr 400 GII 10 40 16 40 - Higher GII catalyst loading 
needed. S-
AcBr 400 GII 5 40 40 - THMP
† 
S-
AcBr 400 GI 5 40 16 - THMP GI is not a suitable catalyst 
S-
AcBr 200 HGII 5+5 40 40 45 KICAc
‡ 
HGII gives highest yield. 
KICAc chelation protocol is 
best for reaction clean-up. 
 
1H NMR stability studies of the (S,S)-di(bromoacetate) crosslinker (94) were attempted, 
but the compound was very insoluble in 50% d6-DMSO in buffer at the concentrations 
necessary for clear signal detection using the water-suppression pulse sequence. 
Nevertheless, the compound was taken through to protein modification studies (see 
section 5.3). Concomitantly, the synthesis of cleavable crosslinkers carrying oNB or 
coumarinyl moieties was initiated, as described in the following sections. 
                                                
* Reactions were run in dry and degassed CH2Cl2. 
† Tris(hydroxymethyl)phosphine. 10×catalyst loading in NEt3. Stirred at RT. (Maynard and Grubbs, 
1999) 
‡ Potassium 2-isocyanoacetate. 4×catalyst loading as a solution in MeOH. Stirred at RT. (Galan et al., 
2007) 
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4.5.3 Synthesis of oNB crosslinker 
A route to the oNB crosslinker (95) based on the synthesis of the benzyl version was 
developed by C. Forde (MChem student with the Warriner group) and then repeated as 
part of this project to provide material for protein crosslinking studies. The oNB 
photocleavable crosslinker was synthesised as shown in Fig. 4.27.  
 
Fig. 4.27 Overall synthesis of the alkenyl bis-oNB photocleavable crosslinker (95). a) HNO3 (15 eqv.), 0 °C, 3 h, 
85% yield; b) Vinylmagnesium bromide (1.5 eqv.), dry THF, -78 °C-RT, 16 h, 70%; c) i) Hoveyda-Grubbs II catalyst 
(5 mol%), dry CH2Cl2, 45 °C, 16 h, ii) CNCH2CO2K (25 mol%), MeOH, RT, 1 h, 93%; d) bromoacetyl bromide (2 
eqv.), pyridine (2 eqv.), CH2Cl2, 0 °C, 1 h, 26%, 9:1 mixture of diastereomers. 
The parent 4,5-dimethoxy-2-nitrobenzaldehyde (83) was easily obtained from the 
nitration of commercially available 3,4-dimethoxybenzaldehyde (96) in neat nitric acid. 
The aldehyde was reacted with vinylmagnesium bromide at low temperature to give the 
racemic allylic alcohol (97). C. Forde attempted a variety of strategies for the kinetic 
resolution of the racemic oNB allylic alcohol, including enzymatic resolution (Chen and 
Xiang, 2011) and alternative routes using Ir-catalysed reactions (Lyothier et al., 2006, 
Roggen and Carreira, 2011). However, the kinetic resolution attempts were 
unsuccessful and the synthesis was continued with the racemic mixture. The 1,4-diol 
scaffold (98) was obtained in very good yield as a mixture of diastereomers from the 
metathesis of the racemic alcohol in the presence of 2nd generation Hoveyda-Grubbs 
catalyst. This compound was found to be extremely insoluble and was isolated by 
gravity filtration of the metathesis reaction mixture (after treatment with potassium 
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isocyanoacetate in methanol for the removal of Ru contaminants). Bromoacetylation to 
the final crosslinker (95) was carried out as previously described, in a lower yield than 
expected, due to contamination of some of the fractions from flash chromatography 
containing the desired product with an unidentified, coloured impurity. The identity of 
the final product was confirmed by both HRMS and NMR. The 1H NMR spectrum 
showed a 9:1 mixture of the two diastereomers. As the two compounds show the same 
retention value by thin layer chromatography in hexane:ethyl acetate mixtures and no 
separation by LC-MS, the apparent separation of the diastereomers by flash 
chromatography was surprising.  
Due to the very low solubility of the final compound, no stability studies of the 
crosslinker in solution were attempted, but the crosslinker was taken forward to test for 
protein crosslinking and cleavage as described in section 5.3. 
4.5.4 Synthesis of bis-coumarinyl scaffold 
The synthesis of the coumarinyl crosslinker (99) was attempted simultaneously with 
that of the oNB crosslinker (95). A similar synthetic route to that previously described 
was followed (Fig. 4.28).  
The parent 4-methyl-7-methoxycoumarin (100) was first synthesised in large scale 
using a Pechman condensation of 3-methoxyphenol (101) and the ethylacetoacetate 
(102) in sulphuric acid. Oxidation to the 4-formyl-7-methoxycoumarin (82) was 
initially performed following a common protocol for the allylic oxidation of 4-
methylcoumarins using selenium dioxide (Wang et al., 2007, Huynh et al., 2012), but 
the reactions were found to be difficult to scale-up, mainly due to the large quantities of 
toxic selenium contaminated waste which required bleaching due to stench. The product 
yields also varied, possibly due to the age of the oxidant.  
A second route to the 4-formyl-7-methoxycoumarin (82) was attempted. 4-
chloromethyl-7-methoxycoumarin (103) was synthesised similarly to the 4-methyl-7-
methoxycoumarin (100), from 3-methoxyphenol (101) and ethyl 4-chloroacetoactetate 
(104). Direct hydrolysis of the 4-chloromethylcoumarin (103) to the 4-
hydroxymethylcoumarin (105) in water was attempted, but the procedure found to be 
unreliable in large scale due to the large volume of water needed (very dilute reaction 
mixtures are necessary) and the formation of hydrochloric acid, which causes the 
reaction to stall and slow down, especially when working at larger scales. Neutralisation 
of the acid (up to pH 8) with sodium bicarbonate led to the acceleration of the reaction 
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but also the rapid formation of a by-product from the rearrangement of the coumarin 
under basic conditions. Therefore, the 4-chloromethylcoumarin (103) was instead 
substituted to the coumarinyl acetate (106), which was subsequently hydrolysed in 
EtOH/HCl to the 4-hydroxymethylcoumarin (105) followed by oxidation to the 4-
formylcoumarin (82) in reasonable yield using pyridinium chlorochromate (PCC).  
Although this route increased the number of steps to the final crosslinker and required 
the use of a chromium oxidant (toxic), the yields were consistent and the amount of 
toxic waste produced was reduced considerably. 4-Formyl-7-methoxycoumarin (82) 
was reacted with vinylmagnesium bromide in dry THF to give the allyl alcohol (107), 
which was taken through to the 1,4-methylcoumarin-1,4-diol (108) using the same 
conditions as described previously to obtain the 1,4-oNB-1,4-diol scaffold (Fig. 4.27, 
98). The metathesis product was found to be very insoluble, and was once again 
recovered by gravity filtration of the reaction mixture after treatment with potassium 
isocyanoacetate in MeOH for the removal of Ru contaminants.  
The bromoacetylation of the 1,4-methylcoumarin-1,4-diol (108) to the final coumarinyl 
crosslinker (99) was attempted using the standard conditions employed for all other α-
bromoacetyl compound synthesised previously, but without success, as the 1,4-
methylcoumarin-1,4-diol (108) was even less soluble than the 1,4-(2-nitrobenzyl)-1,4-
diol (98). Several conditions were attempted, including DMF/CH2Cl2 mixtures (Tang et 
al., 2012), PTSA catalysis (Dhakane et al., 2014) and neat bromoacetyl bromide, but in 
all cases heavy emulsions appeared during work-up and the crudes could not be purified 
by flash chromatography. HPLC was also attempted, but with only 3% yield.  
Coumarinyl allyl alcohol 107 was converted to the corresponding bromoacetate (109) 
and cross-metathesis attempted using the same conditions as described previously for 
the benzyl bromoacetate (94), but no product was formed. Therefore, the coumarinyl 
crosslinker was abandoned. 
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Fig. 4.28 Overall synthetic route to the alkenyl bis-coumarinyl photocleavable crosslinker scaffold 99. a) H2SO4, 0 
°C, 3 h, 60%; b) NaOAc (3 eqv.), AcOH, 120 °C, 20 h, 64%; c) 3:1 EtOH:HCl, 78 °C, 45 min, 98%; d) PCC (1 eqv.), 
MgSO4, dry CH2Cl2, RT, 16 h, 49%; e) Vinylmagnesium bromide (1.2 eqv.), dry THF, 0 °C, 3 h, 34%; f) i) Hoveyda-
Grubbs II catalyst (5 mol%), dry CH2Cl2, 45 °C, 16 h, ii) CNCH2CO2K (25 mol%), MeOH, RT, 1 h, quantitative; g) 
bromoacetyl bromide (2 eqv.), pyridine (2 eqv.), CH2Cl2, 0 °C, 1 h, 38%. 
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4.6 Conclusion 
During the course of this project, three different photocleavable crosslinker scaffolds 
were investigated. The first scaffold had been previously described by Omran et al. and 
was composed of two cleavable oNB moieties capable of releasing two cysteine 
residues upon UV irradiation (Omran and Specht, 2009a, Omran and Specht, 2009b). 
The crosslinker was designed to be bioconjugated by reaction of cysteine amino acids 
on the protein surface with secondary bromides at the benzylic positions of the oNB 
groups. One of the described compounds, bearing a propyl linker between the two 
chromophores (53), was synthesised according to the literature and tested for reactivity 
towards thiols in solution. The secondary bromides were found to be insufficiently 
reactive towards thiol containing molecules and, therefore, not useful for the clean 
modification of proteins by crosslinking.  
To overcome the lack of reactivity, a novel crosslinker carrying two α-bromoacetate 
bioconjugating moieties to be cleaved by UV irradiation of one single chromophore was 
designed (Fig. 4.7). Both acetates would cleave from the benzylic position, making the 
overall molecule an acetal derivative. Although cyclic acetals have been previously 
described as suitable groups in linkers for protein affinity purification tags (Lee et al., 
2015), the α,α-dibromoacetate toluene crosslinker synthesised here (74, section 4.4) was 
found to be susceptible to hydrolysis in buffer, especially at high pH (8.0). This 
observation along with difficulties encountered in the synthesis and isolation of both the 
oNB and coumarinyl derivatives (81 and 80 respectively) rendered these compounds 
unsuitable for further development. Nevertheless, the α-bromoacetates were tested for 
reactivity towards mercaptopropionic acid in buffer and found to be suitable moieties 
for bioconjugation. This knowledge was employed in the redesign of the molecules, 
yielding the third generation crosslinkers described. 
A crosslinker carrying two benzyl groups linked by an alkene spacer and one α-
bromoacetate moiety at the benzylic position for protein bioconjugation was designed 
and synthesised (Fig. 4.22, section 4.5.2). The compound was used to test the synthetic 
route and an enantiomerically enriched crosslinker was obtained (94). The equivalent 
oNB compound was also successfully synthesised (95), although as a mixture of 
diastereomers as the kinetic resolution strategies employed to resolve the first chiral 
intermediate in the synthetic route (97) were unsuccessful. Nevertheless, both 
compounds were taken through to protein modification studies as described in the next 
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section. Unfortunately, attempts to synthesise the faster-cleaving, coumarinyl 
crosslinker were unsuccessful, mainly due to the insoluble nature of the compound.   
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5 Protein crosslinking and photocleavage studies using the 
third generation crosslinking reagents 
5.1 Protein crosslinking in biological investigations 
Protein crosslinking has been used to investigate diverse aspects of protein activity. Its 
most common use is to target protein-protein interactions, where crosslinkers target 
both proteins and the efficiency of crosslinking is distance-dependent. Crosslinking 
between the proteins occurs only when the proteins are in a complex, even if just 
transiently, creating a covalent link that then allows for isolation and characterisation of 
the interacting partners (Trakselis et al., 2005, Tang and Bruce, 2009). Information on 
both the identity of the binding partners and the binding interface can be obtained. The 
chemical crosslinkers can carry a variety of functional groups, which can target specific 
amino acid side chains, such as sulfhydryls, carboxylates or amines, and have variable 
lengths and even photo-reactive groups, where crosslinking only occurs in response to 
UV irradiation (Hermanson, 2008b, Hermanson, 2008c). Chemical crosslinking can also 
offer information about protein structure, by providing distance constraints between 
specific residues in the protein sequence, which allow for the modelling of the 3D shape 
of the protein, supporting protein fold prediction (Mouradov et al., 2008, Leitner et al., 
2010).  
Chemical crosslinking has also been used to probe protein dynamics. Membrane 
transporters are known to adopt very distinct conformations during function and X-ray 
crystallographic structures of such proteins in “inward-open” and “outward-open” states 
have been previously published (Forrest et al., 2011, Waight et al., 2013, Zhou et al., 
2014). Crosslinking of residues that are in close proximity in one conformation but 
distal in a different conformation has been shown to block or hinder transport activity 
for nucleoside transporters (Valdés et al., 2012), serotonin transporters (Tao et al., 
2009) and glutamate transporters (Jiang et al., 2011). All these studies have looked at 
activity of the transporters, rather than the dynamic or structural changes that occur as a 
result of crosslinking. Dutta et al. have used crosslinking to show that the blocking of 
the interconversion between the “inward-open” and “outward-open” conformations of 
an E. coli multidrug transporter, EmrE, leads to protein inactivation (Dutta et al., 2014). 
By using a hetero-bifunctional crosslinker capable of reacting with a cysteine residue 
(S107C, introduced by site-directed mutagenesis) and a lysine residue 7.3 Å away, the 
transporter conformation was locked (determined by NMR), preventing the 
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interconversion between the inner and outward open conformations and inhibiting 
transport of ethidium (in-cell assay). 
5.2 Aspartate α-decarboxylase as a test system 
The final stage of this project was to test the crosslinking and photolysis properties of 
the novel crosslinkers described in section 4.5. The test system chosen for the study was 
aspartate α-decarboxylase (ADC, see section 3). The C-terminus of the β-chain of ADC, 
residues 22Tyr-Glu24, is highly flexible and can be seen in two distinct conformations in 
the crystal structure of the WT enzyme (PDB 1AW8) (Albert et al., 1998). The 
flexibility of this region is a known characteristic of ADC and has been seen in several 
structures of the enzyme bound to different ligands, including glutamate, serine, cysteic 
acid and 1-methyl-L-aspartate (unpublished results). The loop flanks the active site of 
the enzyme, shielding the substrate from the bulk solvent. It was hypothesised that the 
mobility of the loop is related to substrate binding and product release and that during 
decarboxylation, Gly24 caps the active site to exclude water molecules. 
 
Fig. 5.1 Schematic representation of the two conformations of the ADC 22Tyr-Gly24 loop. (A) “closed” conformation. 
The residues close across the binding pocket opening, shielding it from water. Rotation around the Cα-N bond of 
Tyr22 gives the “open” conformation, shown in (B), where the binding pocket is exposed. 
Locking of the loop into a non-active conformation has the potential to slow or block 
ADC turnover. Three initial pairs of sites for the introduction of cysteine residues for 
crosslinking were chosen. Each pair of cysteines should react with one crosslinker 
molecule, effectively stapling the loop into a fixed conformation. The three pairs also 
afforded different crosslinking lengths. Alongside the introduction of the cysteine 
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“anchors”, two native cysteine residues (Cys26 and Cys78) were also mutated to avoid 
side reactions with the crosslinker. 
5.2.1 Site-directed mutagenesis 
This work was carried out in parallel with the structural studies. Three site-directed 
PanD mutants were generated by mutagenesis, each containing two residues mutated to 
cysteine and two cysteines removed: 
- PanD H17C/E23C/C26S/C78A 
- PanD D19C/E23C/C26S/C78A 
- PanD E23C/C26S/A62C/C78A 
Glu23 was chosen as the common cysteine “anchor” for all the PanD mutants as it 
adopts two very distinct conformations in the WT enzyme structure (PBD 1AW8). 
His17, Asp19 and Ala62 were then chosen to form the cysteine anchor pairs with 
Glu23. The side-chains of all three residues are located at the surface of the protein, 
rather than towards the core of the fold, and are also in close proximity to Glu23, 
spanning approximate crosslinking distances of 6 to 16 Å, depending on the cysteine 
pair and the conformation of the 21His-Glu24 loop (Fig. 5.2).  
 
Fig. 5.2 The proposed sites for the introduction of cysteine anchors for crosslinking of ADC. ADC is shown as a 
cartoon in green. The mutations have been simulated in Pymol starting from PDB 1AW8 (Albert et al., 1998); the 
figures do not represent a solved crystal structure of the mutant. (A) the two different conformations of loop 
21His-Glu24 an “open” conformation where the residues do not shield the active site, and a “closed” conformation, 
where the active site is shielded from solvent. The “closed” conformation is expected to be the active conformation, 
as it is adopted in ADC-ligand complexes (Yorke & Monteiro, unpublished results) (B) the approximate crosslinking 
distances between the E23C/H17C, E23C/D19C and E23C/A62C cysteine pairs in the open state. (C) the 
approximate crosslinking distances between the E23C/H17C, E23C/D19C and E23C/A62C cysteine pairs in the 
closed state.  
The tetramutants were generated in parallel following a standard site-directed 
mutagenesis protocol (described in detail in section 8.4.3). The mutagenesis primers 
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were designed following standard primer design guidelines as described in section 
8.4.1. Firstly, single PanD mutants (E23C, H17C, D19C, C26S, A62C and C78A) were 
generated from mutagenesis of the pRSETA-ADC-WT vector plasmid (Saldanha et al., 
2001). Following PCR, the mixtures were checked by agarose gel electrophoresis for 
the presence of large DNA fragments, which confirm a successful amplification of the 
plasmid, and transformed into E. coli XL10 cells. The plasmids were extracted from 
minicultured colonies using a miniprep protocol and sequenced to verify whether the 
desired mutation was successfully introduced. If the sequence was correct, the plasmid 
was then transformed into E. coli MG1655 ΔpanD ΔpanZ (DE3) cells ready for 
overexpression of the protein (see section 8.4). 
Gel electrophoresis of the initial PCRs showed high molecular weight species for the 
PanD E23C, H17C and C78A experiments (Fig. 5.3). Although the PCR reactions to 
generate the PanD D19C and C26S mutants were unsuccessful in the first trial, they 
were successfully upon repetition of the reaction. The PanD A62C mutant was obtained 
by addition of 1% v/v DMSO to the PCR mixture, indicating that the primer may be 
prone to secondary structure formation in solution (Fig. 5.4, lane 8). 
 
Fig. 5.3 Agarose electrophoresis gel of ADC site-directed mutagenesis PCR experiments starting from the pRSETA-
ADC-WT vector plasmid. Lane 1 and lane 8: 100 base pairs (bp) and 1 kilobase pairs (kb) molecular weight markers. 
Lanes 2-7: PanD E23C, PanD H17C, PanD D19C, PanD C26S, PanD C78A, PanD A62C.  
PanD H17C/E23C, D19C/E23C, E23C/A62C and C26S/C78A double mutants were 
generated from the initial PanD E23C, C78A, C26S and D19C mutant plasmids using 
the same protocol as for the single mutations. As the E23C point mutation is very close 
to the H17C and D19C mutations, the primers overlap both codons and thus had to 
carry both mutations. Once again, mutations for the introduction of the A62C were 
more successful in the presence of 1% v/v DMSO, as visible from the comparison of 
lanes 9 and 4 in Fig. 5.4 (with and without DMSO respectively). 
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Fig. 5.4 Agarose electrophoresis gel of ADC site-directed mutagenesis PCR experiments. Lane 1 and lane 10: 100 bp 
and 1 kbp molecular weight markers; lanes 2-4: PanD E23C plasmid with D19C/E23C, H17C/E23C and A62C 
primers; lane 5: PanD C78A plasmid with C26S primers; lane 6: PanD C26S plasmid with C78A primers; lane 7: 
PanD D19C plasmid with E23C/D19C primers; lane 8: pRSETA-ADC-WT vector plasmid with A62C primers; lane 
9: PanD E23C plasmid with A62C primer in the presence of 1% v/v DMSO. 
The mutagenesis reactions were chosen to target all possible combinations of plasmids 
and primers. In certain cases, DNA sequencing showed errors and new colonies from 
the E. coli XL10 cell transformations had to be picked, minicultured, miniprepped and 
sequenced before the next round of mutagenesis. Therefore, the choice of parent 
plasmids for further mutations to the triple and quadruple mutants was dependent solely 
on how quickly the plasmid with the correct sequence was isolated. The triple and 
quadruple mutants were obtained using the same site-directed mutagenesis approach as 
for the double mutants and the exact sequence of mutagenesis steps is shown in Fig. 5.5.  
Although gel electrophoresis is an important step to determine whether the DNA 
product of the PCR is of the correct size, it is not very sensitive to very low quantities of 
DNA. In order to streamline this multiple mutagenesis process, all the PCR products 
were subjected to digestion with Dpn1 and transformed into E. coli XL10 cells. In a few 
cases, colonies were obtained even when no clear plasmid DNA band was visible by 
electrophoresis. 
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Fig. 5.5 Strategy for site-directed mutagenesis of the pRSETA-ADC-WT plasmid to generate the ADC tetramutants, 
showing the parent plasmids and the mutations generated at each PCR step. 
5.2.2 Protein overexpression and purification 
Initial overexpression of the three quadruple mutants PanD H17C/E23C/C26S/C78A, 
PanD D19C/E23C/C26S/C78A and PanD E23C/C26S/A62C/C78A was attempted 
using similar conditions to WT PanD described in section 9.1. E. coli MG1655 ΔpanD 
ΔpanZ (DE3) cells harbouring one of the plasmids coding for the mutants were 
minicultured overnight in LB media containing ampicillin. 1 mL of the miniculture was 
used to inoculate 1 L of auto-induction media and the cells grown for 20 h at 37 °C. The 
cells were collected by centrifugation and either frozen at -80 °C for storage or 
incubated for 24 h at 37 °C prior to freezing for activation of PanD to ADC. 
The ADC tetramutants from pellets harvested from 1 L of thermally activated 
overexpression cell culture were purified first and expression levels and protein 
molecular weight were checked by SDS-PAGE (Fig. 5.6). All three mutant proteins 
were obtained predominantly as a single polypeptide chain of ~15 kDa, corresponding 
to the molecular weight of the intact zymogen protein chain, rather than the two smaller 
molecular weight chains (~11 kDa and 4 kDa) expected for the fully activated protein. 
This suggested that the mutations introduced to the protein may have prevented post-
translational processing of the PanD zymogen to its active form, ADC. 
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Fig. 5.6 Overexpression of ADC tetramutants and purification by Ni-NTA. Tris-tricine SDS-PAGE gels, showing a 
band at ~16 kDa in the elution fractions. ADC H17C/E23C/C26S/C78A: Lane 1: protein ladder; lanes 2-4: flow-
through; lane 5: 50 mL wash fraction; lanes 6-10: 5×5 mL elution fractions. ADC D19C/E23C/C26S/C78A: Lane 1: 
protein ladder; lanes 2-3: flow-through; lane 4: 50 mL wash fraction; lanes 5-9: 5×5 mL elution fractions. ADC 
E23C/C26S/A62C/C78A: Lane 1: protein ladder; lanes 2-4: flow-through; lane 5: 50 mL wash fraction; lanes 6-10: 
5×5 mL elution fractions. 
The proteins were subjected to further purification by size-exclusion chromatography. 
Interestingly, the spectroscopy traces for absorption at λ=280 nm showed a different 
profile to that usually seen for the PanD(T57V) and WT ADC proteins (see Fig. 9.2 and 
Fig. 9.10). Both PanD(T57V) and WT ADC show a single peak with a minor shoulder 
which is thought to be an oligomer of the tetramer. For these mutants, the shoulder peak 
to the main protein peak carried a much higher percentage of the purified protein. This 
could indicate either a concentration dependent oligomerisation of the protein or an 
artefact that occurs due to the site-directed mutagenesis.  
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Fig. 5.7 ADC H17C/E23C/C26S/C78A SEC purification 280 nm absorbance trace, showing three protein peaks, and 
SDS-PAGE analysis of the elution fractions. Lane1: protein ladder; lanes 2-3: early peak (29-38 mL retention 
volume), unknown impurity; lanes 4-5: fractions from 39-48 mL retention volume, typically the PanD “shoulder 
peak” from a potential oligomer; lanes 6-7: fractions from 49-58 mL retention volume, typically the PanD “Main 
peak” from the PanD tetramer.  
 
 
Fig. 5.8 ADC D19C/E23C/C26S/C78A SEC purification 280 nm absorbance trace, showing three protein peaks, and 
SDS-PAGE analysis of the elution fractions. Lane1: protein ladder; lanes 2-3: fractions from 39-49 mL retention 
volume, typically the PanD “shoulder peak” from a potential oligomer; lanes 4-6: fractions from 49-60 mL retention 
volume, typically the PanD “Main peak” from the PanD tetramer. 
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Fig. 5.9 ADC E23C/C26S/A62C/C78A SEC purification 280 nm absorbance trace, showing two protein peaks, and 
SDS-PAGE analysis of the elution fractions. Lane1: protein ladder; lanes 2-4: fractions from 39-45 mL retention 
volume; lanes 4-7: fractions from 45-50 mL retention volume. Both peaks correspond to the typical PanD “shoulder 
peak”, with no protein visibly eluting at 50-60 mL retention volume, typically the PanD “main peak”. 
The identities of the purified mutants were confirmed by high-resolution mass-
spectrometry (HRMS). As the Tris-tricine SDS-PAGE gels of the SEC fractions showed 
the same species across both the “main” and “shoulder” peaks for all the proteins, the 
fractions were combined and characterised by LC-HRMS system in 50 mM Tris pH 7.4, 
100 mM NaCl and 0.5 mM TCEP. The LC column separates all the buffer components, 
allowing for clean HRMS spectra to be collected without prior manual buffer exchange. 
One further advantage of the LC system is that it also allows different protein species to 
be separated prior to MS, making it possible to obtain clear mass spectra for each of the 
possible ADC chains: the π-chain (~15 kDa, prior to post-translational cleavage) and the 
α and β-chains (~4 kDa and ~11 kDa, after post-translational cleavage).  
Although Tris-tricine SDS-PAGE analysis shows very low levels of protein cleavage, 
the instrument is sufficiently sensitive to detect the different chains. All three chains for 
the ADC H17C/E23C/C26S/C78A mutant were identifiable. The π-chain and the β-
chains each showed one single mass (Fig. 5.10, A and B). The resolution of the spectra 
was sufficiently high to show that both chains were in an oxidised form, suggesting the 
presence of a disulphide bond between the Cys17 and Cys23. The spectra for the α-
chain was composed of two distinct species (Fig. 5.10, C), one corresponding to the 
post-translationally introduced pyruvoyl group and the other to the serine by-product 
that occurs from the hydrolysis of the ester intermediate during post-translational 
processing. Assuming similar ionisation strengths of the Ser25 and Pyr25-containing α-
chains, the two species appear to be in a 1:1 ratio. This observation, along with the low 
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levels of cleavage seen on the tris-tricine SDS-PAGE of the purified protein indicates 
inefficient processing of the mutant, possibly associated with a change in conformation 
of the activation loop. 
Similar results were obtained for the ADC D19C/E23C/C26S/C78A mutant. The 
spectra for the π and β-chains (Fig. 5.11 A and B) chains shows a 1:1 mix between the 
oxidised and reduced forms of the protein, indicating the possible formation of a 
disulphide bond between D19C and E23C in roughly 50% of the protein. The β-chain 
also shows approximately 50% contamination of the cleaved fraction with the Ser25 by-
product, indicating inefficient post-translational processing of this mutant (Fig. 
5.11, C). 
The HRMS spectra for the ADC E23C/C26S/A62C/C78A mutant showed only the π 
and α-chains (Fig. 5.12, A and B). The β-chain was not visible from the LC-HRMS run, 
possibly due to very low protein concentration. Nevertheless, the two traces obtained 
confirmed that the correct mutant was generated and also that the protein was 
overexpressed in its reduced form, with no apparent disulphide between Cys23 and 
Cys62. From the expected positioning of the two newly introduced cysteine residues, 
this mutant should have the longest distance between the two cysteine anchors (Fig. 
5.2), which explains why the disulphide is not formed. Contrary to the two previous 
tetramutants, the α-chain shows a single species corresponding to the hydrolysis at 
Ser25, with no indication of pyruvoyl formation from cleavage of the protein.  
Although mass spectra for the α and β-chains for the mutants were obtained, according 
to the SDS-PAGE analysis the level of post-translational cleavage of the proteins was 
minimal. The large percentage of contamination by serine cleavage by-products also 
indicates that the mutants did not activate efficiently, especially the A62C mutant, 
which does not show any evidence of pyruvoyl formation. Although probably 
unsuitable for activity studies, the mutants were carried forward for further 
overexpression trials as the inactive constructs could still be used to test for crosslinking 
and photocleavage using the third generation crosslinkers described in section 4.5. 
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Fig. 5.10 HRMS of ADC H17C/E23C/C26S/C78A. The raw spectra for each protein chain are shown in A1, B1 and 
C1 and the corresponding deconvoluted reconstructions in A2, B2 and C2 along with simulated deconvoluted spectra 
underneath for comparison. (A) π-Chain mainly in its oxidised form (15.644 kDa). (B) β-Chain, mainly in its 
oxidised form (4.692 kDa). (C) α-Chain, showing both Pyr25 and Ser25 (10.953 and 10.969 kDa respectively). 
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Fig. 5.11 HRMS of ADC D19C/E23C/C26S/C78A. The raw spectra for each chain are shown in A1, B1 and C1 and 
the corresponding deconvoluted reconstructions in A2, B2 and C2 with the simulated deconvoluted spectra 
underneath for comparison. (A) π-Chain mainly in its oxidised form (15.666 kDa). (B) β-Chain, 50% oxidised and 
50% reduced forms (4.714 and 4.716 kDa respectively). (C) α-Chain, showing both Pyr25 and Ser25 (10.953 and 
10.969 kDa respectively). 
 
  
  123 
 
 
 
 
 
Fig. 5.12 HRMS of ADC A62C/E23C/C26S/C78A. The raw spectra for each chain are shown in A1 and B1 and the 
corresponding deconvoluted reconstructions in A2 and B2 with the simulated deconvoluted spectra underneath for 
comparison. (A) π-Chain mainly in its reduced form (15.711 kDa). (B) α-Chain, showing only Ser25 (11.001 kDa). 
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The yields for the ADC H17C/E23C/C26S/C78A and ADC E23C/C26S/A62C/C78A 
proteins were very poor under the initial overexpression conditions attempted 
(<0.5 mg L-1), whereas the ADC D19C/E23C/C26S/C78A mutant expressed moderately 
better (0.9 mg L-1). To investigate if the low protein yield for the two mutants was a 
consequence of poor overexpression or of protein degradation or unfolding during the 
activation of the pellet at 37 °C, both proteins were purified from non-heated E. coli cell 
pellets. The yield for the PanD H17C/E23C/C26S/C78A protein increased marginally 
(Fig. 5.13, left), indicating that heating the E. coli cell pellet may have caused 
aggregation or proteolysis of the overexpressed protein. Unfortunately, no such 
improvement was visible for the PanD E23C/C26S/A62C/C78A mutant, which still 
expressed very poorly (Fig. 5.13, right).  
 
Fig. 5.13 Overexpression of ADC tetramutants and purification by Ni-NTA. Tris-tricine SDS-PAGE gels, showing a 
band at ~16 kDa in the elution fractions. ADC H17C/E23C/C26S/C78A: Lane 1: protein ladder; lanes 2-3: flow-
through; lane 4: 50 mL wash fraction; lanes 5-9: 5×5 mL elution fractions. ADC E23C/C26S/A62C/C78A: Lane 1: 
protein ladder; lanes 2-3: flow-through; lane 4: 50 mL wash fraction; lanes 5-9: 5×5 mL elution fractions.  
Due to time constraints, only one more overexpression trial was attempted to try to 
increase protein yields. All three tetramutants were overexpressed in auto-induction 
media at 20 °C for 24 hours. The cells were incubated at a lower temperature than 
before to attempt to improve folded protein yields by avoiding possible aggregation and 
proteolysis of the misfolded proteins in the cells. The PanD H17C/E23C/C26S/C78A 
mutant expressed very well (10 mg L-1) under these conditions and a small 
improvement in yield for the PanD E23C/C26S/A62C/C78A (2 mg L-1) mutant was also 
visible. Interestingly, the yield for the PanD D19C/E23C/C26S/C78A protein was 
poorer than before.  
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Fig. 5.14 Overexpression of ADC tetramutants and purification by Ni-NTA. Tris-glycine SDS-PAGE gels, showing a 
band at ~16 kDa in the elution fractions. ADC H17C/E23C/C26S/C78A: Lane 1: protein ladder; lanes 2: 
overexpression cell pellet; lane 3: overexpression cell pellet (1:100 dilution); lanes 4-6: flow-through; lane 7: 50 mL 
wash fraction; lanes 8-11: 4×5 mL elution fractions. ADC D19C/E23C/C26S/C78A: Lane 1: protein ladder; lanes 2: 
overexpression cell pellet; lane 3: overexpression cell pellet (1:100 dilution); lanes 4-6: flow-through; lane 7: 50 mL 
wash fraction; lanes 8-11: 4×5 mL elution fractions. ADC E23C/C26S/A62C/C78A: Lane 1: protein ladder; lanes 2: 
overexpression cell pellet; lane 3: overexpression cell pellet (1:100 dilution); lanes 4-6: flow-through; lane 7: 50 mL 
wash fraction; lanes 8-11: 4×5 mL elution fractions. 
The conditions for the overexpression of all three tetramutant proteins differ. In two of 
the cases, lower temperatures (20 °C) seemed to result in higher yields, possibly due to 
better protein folding within the cells. In the case of ADC D19C/E23C/C26S/C78A the 
protein overexpressed in much higher yields at higher temperatures (37 °C) and, 
therefore, overexpression conditions have to be evaluated on a case-by-case basis. Even 
though none of the tetramutants express as well as WT ADC or any of the single ADC 
mutants described previously in this thesis, overexpression under these conditions 
yields sufficient protein for the testing of the crosslinking compounds. 
Mutations to the mobile loop also have detrimental effects on the protein 
post-translational modification. Contrary to WT PanD, heating of the overexpression 
pellets led to very low levels of cleavage and high amounts of contamination of the 
cleavage products with the serine hydrolysis by-product instead of the desired catalytic 
pyruvoyl.  
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5.2.3 In vitro activation of ADC H17C/E23C/C26S/C78A with PanZ 
Although enzyme activation did not occur cleanly by heating the overexpression E. coli 
cell pellets, the activation of ADC H17C/E23C/C26S/C78A was attempted in vitro in 
the presence of PanZ after protein purification. The protein was incubated at 37 °C for 
72 h and the extent of cleavage monitored at 16 h, 48 h and 72 h (Fig. 5.15). ADC 
H17C/E23C/C26S/C78A was incubated in the presence of PanZ and CoA as well as 
TCEP, to check if disulphide formation between Cys17 and Cys23 had any effect in 
protein activation. Protein cleavage was only visible in samples containing both the 
ADC mutant protein and 1.1 eqv. of PanZ but, even at prolonged incubation times, only 
a fraction of the protein underwent cleavage. Higher amounts of cleavage were 
observed in samples containing TCEP, indicating that the constraining of the loop by 
the disulphide bond hinders activation. Addition of AcCoA had no effect, probably due 
to the partial loading of PanZ with CoA from overexpression. The low amount of 
protein cleavage obtained from these studies indicates that this PanD mutant cannot be 
efficiently matured post-translationally. This is not optimal for the activity studies 
required to evaluate the extent of inhibition caused by crosslinking of the protein. The 
protein could potentially be fully activated by incubation with more equivalents of 
PanZ.AcCoA, but this could cause problems during purification as the proteins may not 
dissociate fully and contamination may occur. One other option would be to attempt the 
activation by incubation of the purified protein at 60 °C overnight (Ramjee et al., 1997), 
but as thermal activation of the purified WT protein leads to contamination with 
hydrolysis by-products and the HRMS of the β-chain of the H17C/E23C/C26S/C78A 
tetramutant already shows close to ~50% contamination (Fig. 5.10), this method may 
yield low levels of catalytically competent enzyme. Both strategies would require both 
optimisation and accurate quantification of enzyme activation. Unfortunately, due to 
time constraints, this activation study has not yet been carried out. Nevertheless, the 
PanD(H17C/E23C/C26S/C78A) mutant could still be used to investigate the protein 
modification ability of the crosslinkers described in section 4.5 and was used to show 
that the crosslinkers could efficiently staple and release proteins as described in the 
following sections.   
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Fig. 5.15 The cleavage of ADC H17C/E23C/C26S/C78A by PanZ.AcCoA. 12.5 µM ADC in 50 mM potassium 
phosphate buffer (pH 7.4, 100 mM NaCl, 0.5 mM TCEP) was incubated at 37 °C for 72 in the presence of PanZ, 
AcCoA and TCEP (as described for each lane) and samples were analysed at 16 h, 48 h and 72 h incubation periods. 
Partial cleavage is visible in the presence of PanZ, with increasing levels up to 48 h.  
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5.3 Protein modification studies 
5.3.1 Protein crosslinking studies 
Initial protein modification experiments were performed on ADC 
H17C/E23C/C26S/C78A using (S)-1-phenylprop-2-enyl bromoacetate ((S)-92) to test 
for the ease of protein modification using allyl bromoacetates. The protein was first 
concentrated to ~1.1 mg/mL in phosphate buffer (50 mM pH 8.0, 100 mM NaCl, 
0.5 mM TCEP). As the HRMS of the sample showed that the protein was 2 Da lighter 
than expected (Fig. 5.10), indicating a possible disulphide between the two surface 
cysteines (Cys17-Cys23), TCEP was added to a final concentration of 5.5 mM and the 
protein incubated at 37 °C for 30 min to fully reduce the disulphide. A solution of the 
bromoacetate (S)-92 in DMF was added to the protein sample to give a final 
concentration of 1 mM bromoacetate (~20 eqv.) in 10% v/v DMF in buffer. The mixture 
was incubated at 37 °C for 1 h. The HRMS spectrum (Fig. 5.16, A) showed one single 
protein species present in solution, with increased molecular weight corresponding to 
the labelling of the protein with two allyl benzyl ester groups (15.994 kDa compared to 
15.646 kDa for the reduced protein). This indicated complete and clean labelling of both 
cysteines with the allyl bromoacetate, proving that allyl bromoacetate groups are 
efficient labelling agents under these conditions. 
Following the successful labelling of ADC H17C/E23C/C26S/C78A with allyl 
bromoacetate (S)-92, protein crosslinking using the non-cleavable crosslinker (94) was 
attempted next following the same experimental procedure. The protein was first 
incubated with 5 mM TCEP for 30 min to reduce the disulphide bond and the 
crosslinker was added as a solution in DMF to give a final concentration of 0.5 mM 
crosslinker (~10 eqv.) in 10% v/v DMF in buffer. Once again, analysis by HRMS (Fig. 
5.16, B) showed a single protein species in solution, with a molecular weight 
corresponding to that of the crosslinked protein (15.966 kDa). The spectrum showed 
neither evidence of labelled but not crosslinked protein nor of double protein labelling, 
proving that the bioconjugation reaction with the di-bromoacetate crosslinker (50) was 
clean and comparable to that with the single benzyl-bromoacetate species ((S)-47). 
Finally, the cleavable oNB crosslinker (95) was tested for its crosslinking ability under 
the same conditions as before. Reaction of the reduced protein with 0.5 mM oNB 
crosslinker (~10 eqv.) for 1 h at 37 °C also led to clean and complete protein 
crosslinking, as shown by the single protein species visible by HRMS in Fig. 5.16 (C) 
(molecular weight of 16.176 kDa).  
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Fig. 5.16 ADC H17C/E23C/C26S/C78A protein modification results. The raw LC-HRMS spectra for each modified 
protein species are shown in A1, B1 and C1 and the corresponding deconvoluted reconstructions in A2, B2 and C2 
along with the simulated deconvoluted reconstructions underneath for comparison. A pictorial representation of the 
different protein modifications is also provided under each reconstruction. (A) modification with 20 eqv. of the allyl 
benzyl bromoacetate compound ((S)-92). (B) modification with 10 eqv. of the benzyl non-cleavable crosslinker (94). 
(C) modification with 10 eqv. of the oNB cleavable crosslinker (95). The reactions were carried out by incubation of 
the protein in potassium phosphate buffer (50 mM pH 7.4, 100 mM NaCl, 5 mM TCEP) at 37 °C for 1 h. 
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5.3.2 Cleavable oNB-crosslinker studies 
Freshly oNB-crosslinked ADC H17C/E23C/C26S/C78A was first buffer exchanged 
from the 10% DMF/buffer mixture into phosphate buffer (50 mM pH 7.4, 100 mM 
NaCl, 0.5 mM TCEP) to remove the excess crosslinker and DMF. The sample was 
placed in a short path quartz cuvette (5 mm) and exposed to UV light using a mercury 
lamp (UVP PenRay® 11SC-1, 1 mW, λ=254 nm). Cleavage of the crosslinker was 
monitored by HRMS at time intervals corresponding to 1, 6, 16, 31 and 46 min total 
irradiation time. The HRMS spectra showed the intact protein (1 min irradiation) 
cleaving cleanly to the expected methyl carboxylate doubly labelled protein. Assuming 
similar ionisation strengths of the different protein species, the relative intensities of the 
deconvoluted MS peaks were used to estimate the ratio of crosslinked to cleaved protein 
at each time point. 50% cleavage occurred in roughly 10 min irradiation time. The rate 
of cleavage appears to slow down over time, only reaching completion after 46 min of 
irradiation, probably due to the formation of strongly absorbing oNB ketone by-
products which can act as UV filters (Klán et al., 2013).  
If the two photocleavable groups were independent of each other, the slow rate of 
photolysis should allow for the observation of an intermediate species corresponding to 
the cleavage of only one side of the staple, with formation of the corresponding nitroso 
species, and, therefore, without full release of the reagent from the protein. Since no 
cleavage intermediates were visible, once the first oNB group is cleaved off the protein, 
the crosslinker may fragment, releasing the second methyl carboxylate group in a 
“dark” reaction without requiring the second oNB group to undergo photolysis to 
release the protein. Of course, this photocleavage-fragmentation coupled mechanism 
may be promoted by the low intensity of the UV lamp used and a different mechanism 
may occur at higher light intensities, where a double photocleavage event may dominate 
instead, promoted by the higher number of photons available to be absorbed by the oNB 
moieties.   
 
  
13
1 
 
Fi
g.
 5
.1
7 
Ti
m
e-
co
ur
se
 o
f t
he
 c
le
av
ag
e 
of
 c
ro
ss
lin
ke
d 
A
D
C
 H
17
C
/E
23
C
/C
26
S/
C
78
A
 (o
N
B
 c
ro
ss
lin
ke
r 9
5)
 u
nd
er
 U
V
 ir
ra
di
at
io
n.
 A
 6
4 
µM
 so
lu
tio
n 
of
 th
e 
cr
os
sl
in
ke
d 
pr
ot
ei
n 
in
 p
ho
sp
ha
te
 b
uf
fe
r (
50
 m
M
 
pH
 7
.4
, 1
00
 m
M
 N
aC
l, 
0.
5 
m
M
 T
C
EP
) i
n 
a 
5m
m
 p
at
h 
le
ng
th
 q
ua
rtz
 c
uv
et
te
 p
la
ce
d 
at
 a
 d
is
ta
nc
e 
of
 1
 c
m
 fr
om
 th
e 
la
m
p 
w
as
 c
on
tin
uo
us
ly
 ir
ra
di
at
ed
 u
si
ng
 a
 H
g 
la
m
p 
(U
V
P 
Pe
n-
R
ay
®
, 1
 m
W
 a
t s
am
pl
e 
po
si
tio
n)
. T
he
 a
m
ou
nt
 o
f 
cl
ea
va
ge
 w
as
 q
ua
nt
ifi
ed
 o
ve
r 
tim
e 
by
 L
C
-H
R
M
S 
by
 c
om
pa
rin
g 
th
e 
in
te
ns
iti
es
 o
f 
th
e 
de
co
nv
ol
ut
ed
 p
ea
ks
 f
or
 t
he
 c
ro
ss
lin
ke
d 
an
d 
cl
ea
ve
d 
sp
ec
ie
s. 
(A
) 
ra
w
 M
S 
sp
ec
tra
 a
t 
di
ff
er
en
t t
im
e-
po
in
ts
 (1
, 6
, 1
6,
 3
1 
an
d 
46
 m
in
). 
(B
) d
ec
on
vo
lu
te
d 
sp
ec
tra
 sh
ow
in
g 
th
e 
pe
ak
 fo
r t
he
 c
ro
ss
lin
ke
d 
pr
ot
ei
n 
on
 th
e 
rig
ht
 (1
6.
17
6 
kD
a)
 a
nd
 fo
r t
he
 c
le
av
ed
 p
ro
te
in
 o
n 
th
e 
le
ft 
(1
5.
76
2 
kD
a)
.  
 132
5.4 Conclusion 
Although the ADC H17C/E23C/C26S/C78A mutant could not be post-translationally 
processed to the active enzyme and, therefore, assays to establish whether crosslinking 
can inhibit protein activity could not be carried out, these studies have shown that that 
the third generation crosslinkers performed as expected from the design stage. These 
reagents bearing two phenyl or oNB moieties linked through an alkene chain were able 
to crosslink the protein rapidly and cleanly, without any visible side-products (such as 
doubly-labelled species). The crosslinking ability of the compounds did not seem to 
change with increased size of the oNB group compared to the non-cleavable phenyl 
derivative and α-bromoacetates were shown to be good protein labelling reagents. The 
cleavable oNB crosslinker was shown to be cleanly photocleaved by UV irradiation of 
the sample, even using a low intensity lamp. Although cleavage by UV irradiation of 
the crosslinked protein leaves a methyl carboxylate group attached to the engineered 
surface cysteines, it is hypothesised that the dynamics of the protein will dominate 
post-photolysis and that the small size of this appended group should not influence the 
behaviour of the free protein. Nevertheless, this assumption will only be verified once 
the compounds are tested on a fully functioning enzyme construct. 
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6 Discussion 
The last few decades have seen great technological advancements in structural biology 
techniques, such as X-ray diffraction and scattering, electron microscopy, spectroscopy 
and NMR. These techniques have allowed for the study of proteins and 
biomacromolecules with unprecedented structural detail. But even when atomic-
resolution is possible, the information obtained is severely incomplete as data on the 
properties of the system are very scarce. Some efforts have been made to obtain this 
dynamic information, but the majority of the studies have only provided information on 
the dynamics of the systems under equilibrium conditions and, although this 
information can be indirectly correlated with function, the actual states adopted by the 
protein along the reaction coordinate are unknown. 
Very recently, especially since the commission of ultra-bright X-ray sources (free 
electron lasers as well as synchrotrons), structural biologists have taken a renewed 
interest in time-resolved structural studies. Such experiments allow for the direct 
coupling of structural information with function, by observing the states adopted by 
proteins, in real-time, during function. This approach bridges the gap between 
functional and structural studies and is capable of finally delivering a much more 
comprehensive and accurate picture of the involvement of protein motions in function, 
clarifying the role of protein dynamics. Nevertheless, these techniques are still in their 
infancy, suffering from challenges mainly related to the synchronisation of protein 
activity across the ensemble of molecules that make up the sample. 
In order to perform a time-resolved measurement, the molecules constituting the sample 
(as a crystal or solution) have to be triggered, initiating function. Triggering has to be 
homogeneous and synchronised across the ensemble and is done by changing the 
sample environment, either by rapid mixing or using light pulses (Fig. 1.8). The main 
disadvantage of rapid mixing is the time-resolutions that can be achieved, which are 
defined by the diffusion limit. The fastest mixing currently achievable is in the region of 
100s of microseconds. On the other hand, light triggering is only limited by the length 
of the pulse necessary to deliver sufficient photons to trigger the reaction. It can, 
therefore, span a much wider time-resolution, down to femtoseconds. However, in order 
to use a laser-based activation of a protein, a photochemical moiety directly involved in 
protein function has to be accessible. Due to this limitation, it is unsurprising that the 
fastest and highest impact time-resolved structural studies have focused on naturally 
photoactivatable systems, where a naturally occurring chromophore can be activated 
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using light (section 1.2.1). Nevertheless, the vast majority of proteins are not naturally 
photoactivatable, requiring the introduction of an artificial chromophore. 
Photocaging can be used to provide a method for light-induced protein function of 
non-naturally photoactivatable systems. This approach focuses on the introduction of a 
photolabile chemical protecting group at a strategic site on the protein, ligand or 
substrate, which prevents function until removed. Photolysis of the protecting group is 
promoted by the absorption of a photon of light of a specific wavelength. Current 
approaches for the introduction of such chemistry rely either on the full chemical 
synthesis of a substrate or ligand derivative, carrying the desired photocage, or the 
direct photocaging of protein residues (section 1.2.2). For photocaged ligands and 
substrates, the compound has to be carefully designed so that the location of the 
photocaging protecting group hinders function without completely abolishing binding 
of the ligand to the protein. Once designed, the compound also has to be synthesised, 
which can be a non-trivial process, in addition to which the spectroscopic and cleavage 
properties of the new ligand cannot be absolutely predicted beforehand. Alternatively, 
protein photocaging can be performed by the introduction of an unnatural amino acid 
during protein expression, but the current library of photocaged amino acids available 
for genetic incorporation is very limited, mainly focusing on oNB based photocages 
(Fig. 1.14). Although this technology is developing rapidly, the time required to 
diversify this library of genetically incorporable photocaged amino acids is completely 
unpredictable. 
With the limitations of the photocaging technology currently available, there is scope 
for the development of new photocaging strategies that are more widely applicable and 
less system-dependent. Such advancements would liberate the current bottleneck for 
time-resolved structural studies of single turnover, non-naturally photoactivatable 
proteins.  
During the course of this project, a new class of photocaging reagents was developed. 
The reagents were designed to work as protein crosslinkers that could staple across two 
surface cysteines which can be introduced using standard site-directed mutagenesis. In 
order to efficiently photocage the protein, the cysteine mutations have to be carefully 
chosen to make use of the intrinsic dynamic properties of the protein. By surface 
“stapling”, the protein is confined to a smaller conformational space and is unable to 
access states known to be essential for function. Upon photolysis of the “staple”, the 
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protein is liberated and allowed to resume its normal dynamic behaviour, triggering 
function. 
Three main crosslinking scaffolds were investigated, synthesised and tested for protein 
bioconjugating activity and stability and, when a suitable compound was found, for 
cleavage under UV irradiation. The first synthesised crosslinker (section 4.3) contained 
two oNB photolabile moieties connected by an extendable alkyl chain and two 
secondary bromides at the benzylic position for protein bioconjugation (Omran and 
Specht, 2009a, Omran and Specht, 2009b). Despite some synthetic difficulties, one 
compound of this class was synthesised (53) but found not to be sufficiently reactive 
towards thiols to be useful for cysteine bioconjugation. Therefore, α-bromoacetates 
were proposed as an alternative to the secondary bromide moieties, as these are much 
more electrophilic and known to react with cysteines (Hermanson, 2008a) and a second 
scaffold was designed to contain two cleavable α-bromoacetate groups (section 4.4). An 
initial non-cleavable surrogate was synthesised (74) in a one-pot reaction and tested for 
reactivity and stability. The crosslinker was found to react quickly and cleanly with 
thiols, supporting the use of α-bromoacetates as bioconjugation moieties but the 
proximity of the two acetyl groups rendered the compound susceptible to hydrolysis, 
especially at higher pH. Although the rate of hydrolysis of the gem-α-thioacetate (79) 
was slower than that of the gem-α-bromoacetate (74), all attempts at synthesising the 
corresponding oNB (81) and coumarinyl (80) derivatives were unsuccessful and to date, 
no alternate routes have been found in the literature. A combination of the synthetic 
difficulties with the hydrolytic propensity of the gem-α-diacetate scaffold led to the 
decision that this class of compound was not suitable for further development. 
A third generation crosslinker was then designed, bearing two chromophores, each 
linked to a single α-bromoacetate group, to improve stability of the compounds in 
buffer. Once again, a benzyl non-photocleavable surrogate (94) was synthesised first to 
test the synthetic route and the stability of the compounds. As the crosslinker contained 
two chiral centres at the benzylic positions, a chiral resolution step was introduced to 
attempt to synthesise an enantiomerically pure crosslinker. Once the first racemic 
intermediate (allyl alcohol 87) was synthesised, the two enantiomers were separated 
using an enzymatic chiral resolution. Although the S-alcohol (S)-87 product from the 
kinetic resolution was not as enantiomerically enriched as expected, it was taken 
forward and the crosslinker was obtained as a single diastereomer, as seen from the 
presence of a single species by 1H NMR. As the compound was purified by flash 
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chromatography, it is possible that the minor diastereomer was separated during 
purification.  
The same kinetic resolution approach was applied to the oNB allyl alcohol (97), but 
with no success. Testing of other enzymes for selectivity towards oNB allyl alcohols 
could potentially yield a suitable enzyme, but since the lipase employed (lipase PS from 
B. cepacia) is one of the most promiscuous lipases and has been shown to be active 
towards bulky, aromatic secondary alcohols (Chen and Xiang, 2011), the probability of 
finding a more active enzyme was low. There are numerous non-enzymatic methods for 
the synthesis of enantiomerically enriched allylic alcohols. Some examples of kinetic 
resolution approaches include the Sharpless epoxidation using titanium catalysts 
(Johnson et al., 1993), selective acylation using Fu’s catalyst with chiral iron-DMAP 
complexes (Ruble et al., 1997, Bellemin-Laponnaz et al., 2000) and selective oxidation 
using ruthenium catalysts (Hashiguchi et al., 1997, Nishibayashi et al., 1999). For this 
project, the methodology developed by the Carreira group was attempted, using iridium 
catalysts for the kinetic resolution of secondary alcohols, where one enantiomer reacts 
preferentially with a primary alcohol to give an enantiomerically pure ether (Roggen 
and Carreira, 2011). Although the method had been shown to be applicable to bulky 
aromatic secondary alcohols, the catalyst could not distinguish between the oNB 
alcohol enantiomers.  
One alternative approach would be the direct stereoselective synthesis of the allyl 
alcohol, by either the stereoselective addition of vinyl groups to the allyl ketone using 
rhodium or iridium catalysts (Skucas et al., 2007) or the stereoselective reduction of 
ketones (Hashiguchi et al., 1995, Corey and Helal, 1998). Another possible solution 
would be to purchase a library of different commercially available enzymes and metal 
catalysts and develop a high-throughput screening method for efficient kinetic 
resolution conditions. This would require the design of a suitably broad set of reaction 
conditions that could be run in parallel (possibly using a 96-well plate set-up) coupled 
with a chiral HPLC protocol that could quantify the efficiency of each resolution 
reaction easily. Such screens are not currently commercially available and, therefore, 
this was not a suitable method within the timescale of this project.  
Albeit inadvertently, some separation of the oNB crosslinker diastereomers was 
achieved during purification by flash chromatography in the last step of the synthesis of 
the oNB crosslinker (95). The 1H NMR spectrum of the purified product showed a 
mixture of diastereomers, in a 9:1 ratio. The identity of the major and minor species 
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could not be obtained from spectroscopic analysis alone, and so chiral HPLC methods 
for the separation of the three possible stereoisomers of the diol precursor 98 (RR, SS 
and the meso compound) are currently being screened. If a successful method is found, 
then the purified di-α-bromoacetate crosslinker (95) will be hydrolysed back to the 
corresponding mixture of alcohols (98) and analysed by chiral HPLC. Once the identity 
of the major and minor species are know, the 1H NMR shifts can be assigned to each 
specific diastereomer. Under such conditions, the meso compound should be separable. 
Although obtaining an enantiomerically pure crosslinker would be preferable, it has 
been hypothesised that the differences in conformation of the stapled protein caused by 
the different enantiomers will be minor and that upon photolysis and release of strain, 
the recovery of dynamic flexibility will dominate the conformations adopted by the 
protein. This hypothesis could be tested using molecular dynamics simulations.  
Aspartate α-decarboxylase was chosen as the model system to test the new crosslinkers 
as the C-terminal loop of the β-chain (residues 17His-Glu24) is highly mobile and can 
adopt two distinct conformations (Albert et al., 1998), only one of which is thought to 
be active (Yorke & Monteiro, unpublished results). Locking the loop in a conformation 
resembling the inactive form should abolish (or at least greatly reduce) its catalytic 
activity. The mutations were designed from inspection of the crystal structure (PDB 
1AW8), which contains the two different conformations. Three cysteine pairs were 
chosen to target different crosslinking lengths and each ADC cysteine double mutant 
also carried two further point mutations to remove two naturally occurring cysteines 
(Cys26 and Cys78 mutated to serine and alanine respectively).  
The first hurdle encountered was that the ADC mutants did not express well under 
standard ADC overexpression conditions. After different expression trials, the yield for 
the H17C/E23C mutant was increased considerably and that for the D19C/E23C mutant 
moderately. In both cases, the protein did not activate efficiently thermally, showing 
very low levels of cleavage of the zymogen and also high levels of contamination of 
Ser25 by-products from hydrolysis of the ester intermediate (Fig. 3.42). The yield for 
the E23C/A62C variant was very poor under all overexpression conditions attempted 
and the very small percentage of protein observed to cleave thermally post-
translationally showed only the hydrolysed by-product with no pyruvoyl cofactor 
formed, indicating that the A62C mutation was possibly detrimental for both 
overexpression and maturation of the protein.  
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It would be important to investigate whether the lower protein overexpression yield and 
maturation inefficiency observed were caused by the additive effects from the 
combination of mutations from any specific point mutations. Each of the single, double 
and triple ADC mutants should be expressed individually using the standard protocol 
described for WT ADC (including maturation of the protein by thermal activation in the 
cell pellet) and the levels of expression and efficiency of maturation (percentage 
cleaved and ratio between pyruvoyl cofactor formation and hydrolysis to the serine 
by-product) evaluated. Whereas Cys78 is on the protein surface (close to the central 
pore) and thus its mutation is not expected to have any major structural impact on the 
protein, Cys26 is buried and located next to the active site. Its mutation to serine could 
be a major cause of the low overexpression yields and inefficient protein maturation, as 
from the sequence conservation of ADC this residue tends to be larger and non-polar 
(cysteine, valine or isoleucine, see section 9.7.1).  
As Glu23 is directly involved in the interaction between PanZ.CoA and PanD, and the 
mobile region is in close proximity to the site of cleavage, targeting the loop by 
site-directed mutagenesis might always have a detrimental effect on protein maturation. 
From inspection of the available crystal structures for the enzyme, no other highly 
dynamic regions can be identified and, therefore, ADC may be a better candidate for 
standard substrate photocaging approaches. Photocaged L-aspartate derivatives have 
been previously synthesised by Dr B. A. Yorke and shown to bind to the ADC active 
site (unpublished results). This work is still on-going, in collaboration with Dr M. V. 
Sans (Hamburg Centre for Ultrafast Imaging). 
Nevertheless, these crosslinking compounds should be suitable for a wide range of 
enzymes and other proteins that show dynamic properties that could be harnessed for 
protein inactivation. Dihydrofolate reductase (DHFR, section 1.1.2) is an obvious 
candidate, as the dynamics of the Met20 loop have been extensively studied and the 
involvement of its three distinct conformations (open, closed and occluded) during the 
different steps involved in catalysis have been thoroughly characterised. Targeting the 
Met20 loop for conformational locking should have the desired effect of decreasing the 
catalytic ability of DHFR. The design of the cysteine anchors could be initially done by 
inspection of the available crystal structures but complementing the study with MD 
simulations would allow for a more informed and careful design of the crosslinking 
sites. Although the dynamic properties of this enzyme have been thoroughly 
investigated there is still scope to further study the system as two main questions remain 
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unanswered: what is the transition state conformation and how does DHFR exchange 
between the closed and occluded conformations. The main conformations have been 
obtained from structural studies of DHFR constructs in complex with substrate or 
cofactor analogues, leaving the exact mechanisms of conformer interchange and the 
corresponding transient structures still unresolved (Venkitakrishnan et al., 2004).  
Although activity studies could not be carried out due to the problems discussed above, 
the crosslinkers were still shown to perform as expected from the design stage. The 
reagents were successfully used to crosslink an ADC mutant and the bioconjugation 
reaction proceeded cleanly and quickly, with no double labelling or hydrolysis visible 
by high-resolution mass spectrometry. Once the protein was crosslinked, low-power 
irradiation with UV light (λmax=254 nm), using a 1 mW mercury lamp, showed that the 
crosslinker cleaved cleanly, leaving the expected small methyl carboxylate groups on 
the cysteine anchors. The rate of cleavage decreased over time, possibly due to the 
absorption from the nitrobenzyl ketone by-products. 
The quantum yield could not be estimated from this experiment as quantifying the 
amount of photons absorbed by the sample is non-trivial. The most efficient way to 
obtain a value for the quantum yield of these compounds will be performing cleavage 
reactions of both a previously characterised compound, such as oNB-ATP (Fig. 1.10), 
and the novel crosslinkers in parallel and under the same conditions (lamp power, 
irradiation time and optical density) and extrapolating the value for the quantum yield 
by comparison of the two experiments.  
The rate of cleavage of the nitrobenzyl upon absorption will be best estimated using 
pump-probe spectroscopy, where the formation of the nitroso product could be 
monitored in real time using either by UV-Vis or IR (Klán et al., 2013). These 
experiments can also help elucidate the mechanism of cleavage of the crosslinker, as 
they could allow for the detection of cleavage intermediates. These measurements are 
also non-trivial, reflected in the lack of information regarding the kinetics of cleavage of 
photocaged compounds (sections 1.2.2 and 9.6).  
The crosslinker synthesised and characterised in this thesis is expected to follow similar 
cleavage rates to previously characterised oNB photocaged compounds (Corrie et al., 
2005), on the order of milliseconds, although the exact rate of cleavage may be faster 
(or slower) due to the influence of the allylic group. To obtain higher time resolutions, a 
different photocaging moiety will have to be used. The synthesis of a coumarinyl 
version of this crosslinker was also attempted, but unfortunately due to the highly 
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insoluble nature of the di-coumarin diol scaffold (108), the final bromoacetylation step 
could not be performed. Grubbs metathesis of the allyl α-bromoacetate intermediate 
(109) also failed, with no observable consumption of the starting material. To date, no 
synthetic solution to these issues has been found and thus the development of a 
coumarin-based crosslinker would depend on the design of a new di-coumarinyl 
scaffold (110), such as the one shown in Fig. 6.1. Once again, solubility problems are 
expected as the scaffold is highly conjugated and the nature of the vinyl coumarin may 
have a detrimental effect on the metathesis step. Nevertheless, the synthesis to the first 
intermediate (111) from the condensation of 2-hydroxy acetophenone (112) with 
3-methylacryloyl chloride (113) has been previously described in literature (Königs et 
al., 2008) and, therefore, the metathesis reaction could be quickly investigated. The high 
conjugation of this scaffold may confer very interesting, although completely unknown, 
spectroscopic properties worth investigating. 
  
Fig. 6.1 A 4th generation photocleavable crosslinker scaffold (110). The design is based on the knowledge gained 
throughout this thesis and attempts to circumvent the problems encountered during the synthesis of the coumarinyl 
crosslinker. The first step to the 3-alkenylcoumarin (111) from the condensation of 2-hydroxy acetophenone (112) 
with 3-methylacryloyl chloride (113) has been reported previously (Königs et al., 2008). The alkenylcoumarin could 
be used to test the metathesis step before any further investment of time in the synthesis of the final crosslinker. 
This thesis describes initial steps towards the design and development of new 
photocleavable crosslinkers. There is still great scope for the development of novel 
photocaging reagents and, also very importantly, for a comprehensive characterisation 
of such compounds. Furthermore, there is also great interest from structural biologists in 
obtaining functional and well-characterised compounds for time-resolved experiments. 
Such work is best carried out in a highly interdisciplinary environment, as a 
collaborative effort between chemists, structural biologists and spectroscopists will 
allow for a targeted approach, from the compound design stage to the characterisation 
and testing of the compounds under relevant experimental conditions.  
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7 Conclusions 
During this project, a new class of photocleavable crosslinking reagents, that allow for 
the stapling across two protein surface cysteine residues, was designed, synthesised and 
tested. These reagents aimed to decouple the triggering step in time-resolved 
experiments from the chemistry and function being observed. Three different scaffolds 
were investigated, each providing information about the stability, synthetic availability 
and reactivity of functional groups and photocaging moieties. An ortho-nitrobenzyl 
crosslinker carrying bromoacetate groups as protein bioconjugation moieties was 
synthesised and found to be stable and able to staple across engineered surface cysteine 
mutations on aspartate α-decarboxylase. The crosslinked protein was subjected to low 
power UV irradiation, which showed that the crosslinker could be cleaved to release the 
protein. Experiments to obtain both the quantum yield and rates of decaging under 
pump-probe conditions using brighter UV sources are currently being designed and will 
be carried out in collaboration with the Hamburg Centre for Ultrafast Imaging.  
The ADC mutants generated for testing the crosslinking and photocleavage of these 
novel reagents could not be fully and cleanly activated, which prevented the 
investigation of crosslinking on enzymatic activity. Nevertheless, the mutants will be 
tested for activation by thermal activation at high temperatures and in cellulo in WT E. 
coli cell lines and the extent of cleavage and pyruvoyl formation quantified by mass 
spectrometry. Once this information is obtained, activity assays will be carried out if the 
protein is found to be sufficiently activated. Current efforts are also focusing on 
targeting a different enzyme, DHFR, for de-activation studies by crosslinking. 
Alongside the development of these new photocleavable crosslinkers, the molecular 
basis of activation of ADC was investigated, as obtaining fully active, homogeneous 
protein is an important step in time-resolved experiments as it greatly decreases the 
levels of heterogeneity during data reduction. The function of PanZ as the activating 
factor for ADC was investigated using several biophysical techniques, such as ITC, 
NMR, MS and SAXS and the ADC.PanZ.AcCoA crystal structure was solved at high 
resolution (1.5 Å) along with two complexes of PanZ with PanD mutants. The 
activation step was found to be promoted by the formation of a strained and 
activation-competent conformation of PanD upon binding to PanZ. This mechanism, 
coined “mechano-chemistry” is supported by the observation of an unprecedented 
backbone cleavage event caused by X-ray radiolysis. The CoA dependence of the 
interaction also allowed for a novel mode of regulation of CoA production in bacteria to 
 142
be proposed, imposing a negative feedback loop mechanism where the formation of the 
enzyme which produces an intermediate (β-alanine) is regulated by a final metabolite. 
This mechanism was confirmed by both in vitro catalytic assays as well as in cellulo 
studies. 
Although the activity studies have not been carried out yet, the designed photocleavable 
crosslinkers were shown to react as expected. It will be important to fully characterise 
the cleavage kinetics of these compounds to establish the timescales the crosslinkers 
could provide for time-resolved studies. Nevertheless, there is still scope for the further 
development of new scaffolds, as well as a more thorough characterisation of the 
kinetics of the currently available photocaging approaches.  
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8 Experimental 
8.1 General information and instrumentation 
The following procedures were used for all the experimental work, unless otherwise 
stated. All reagents and consumables were purchased from known general suppliers, 
including Sigma Aldrich, Alfa Aesar, Merck, Iris Biochem, Fisher Scientific, Acros 
Organics, IDT, GE Healthcare, Hampton Research, Molecular Dimensions, Mitegen 
and Millipore. All water used was filtered to 15 MΩ, except for water used for PCR 
work and crystallisation experiments, which was filtered to 18.2 MΩ. Sterile work was 
performed adjacent to a blue flame or in a flow hood. All glassware, plastic-ware and 
media contaminated with genetically modified bacteria were disposed of by bleaching 
using Virkon or Presept for 24 h or autoclaved (120 °C for 20 min) prior to disposal as 
aqueous waste or by incineration. NMR data were collected using a Bruker Avance 500, 
Bruker DRX500 or Bruker DPX300 spectrometer and analysed using MestReNova 
(Mestrelab Research). Chemical shifts are reported in parts per million (ppm) downfield 
from tetramethyl silane (TMS) and coupling constants (J) are given in Hertz (Hz). 
Infra-red (IR) spectra were recorded using a Bruker alpha with platinum ATR 
spectrometer. High-resolution mass spectrometry was carried out on a Bruker maXis 
Impact spectrometer using electrospray ionisation. Small molecules were analysed as 
solutions in ultrapure solvents. Protein MS was carried out in the original buffers, as the 
samples were purified and denatured by liquid chromatography (LC, 0-95% MeCN in 
H2O over 7 min). The raw mass spectrum was deconvoluted using a maximum entropy 
algorithm, part of the Data Analysis software (Bruker). Routine low-resolution liquid 
chromatography mass spectrometry (LC-MS and LC-MSMS) was performed on a 
Phenomenex Luna C18 50×2 mm column using a gradient of 5-90% MeCN in H2O 
over 1.8 min using electrospray ionisation. Results are quoted as mass-charge ratios 
(m/z). Analytical thin layer chromatography (TLC) was performed using silica gel 
pre-coated plates (Merck) and visualised using UV irradiation or standard staining 
agents (potassium permanganate, dinitrophenylhydrazine, bromocresol green, p-
anisaldehyde and phosphomolybdic acid). Flash column chromatography was carried 
out on silica gel 60 (230-400 mesh, Merck) or on Florisil® (<200 mesh, Sigma). 
Solvents were removed under reduced pressure using a Buchi rotary evaporator at 
diaphragm pump pressure (typically 40-450 mbar). Traces of solvents were removed 
under high vacuum. High performance liquid chromatography (HPLC) analysis was 
carried out on an Agilent HPLC system, using a Thermo Electron Corporation 
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Hyperprep HS C18 column (18 µm, 250×4.6 mm) and diode array as a detector. A 
gradient of water and MeCN (5-95%) was used as solvent at a flow rate of 1 mL min-1.  
8.2 Stock solution recipes 
The recipe components were dissolved in 15 MΩ H2O to the final volume stated. All 
stock solutions, with the exception of 1000×metals, 25×salts and 20×NPS, were 
sterilised by filtration through a 0.22 µm membrane. 
25×salts (1L): 88.7 g Na2HPO4, 85 g KH2PO4, 67 g NH4Cl and 17.8 g Na2SO4. 
1000×metals (100 mL): 1.35 g FeCl3.6H2O, 438 mg CaCl2.6H2O, 198 mg MnCl2.4H2O, 
288 mg ZnSO4.7H2O, 47.6 mg CoCl2.6H2O, 34.1 mg CuCl2.2H2O, 48.4 mg 
Na2MoO4.2H2O, 34.6 mg Na2SeO3, 12.4 mg H3BO3, 52.6 mg NiSO4.6H2O and 500 µL 
HCl (37% in H2O). 
20×NPS (200 mL): 13.2 g (NH4)2SO4, 27.2 g KH2PO4, 29.2 g Na2HPO4 
20×NPS (15N) (200 mL): 13.2 g (15NH4)2SO4, 27.2 g KH2PO4, 29.2 g Na2HPO4 
50×amino acids (50 mL): 500 mg of each: sodium L-glutamate, L-lysine hydrochloride, 
L-arginine hydrochloride, L-histidine hydrochloride, L-aspartic acid, L-alanine, 
L-proline, L-glycine, L-threonine, L-serine, L-glutamine, L-asparagine, L-valine, 
L-leucine, L-isoleucine, L-phenylalanine and L-tryptophan. 
1000×vitamins (no B12) (20 mL): 400 µL 10 mM nicotinic acid, 400 µL pyridoxine 
hydrochloride, 400 µL 10 mM thiamine hydrochloride, 400 µL 10 mM 
para-aminobenzoic acid, 400 µL 10 mM pantothenate, 100 µL 1 mM folic acid and 100 
µL 1 mM riboflavin.  
1000×vitamins (with B12) (20 mL): same as for 1000×vitamins (no B12) with 800 µL 
5 mM vitamin B12.  
50×5052 (50 mL): 12.5 g glycerol, 36.5 mL H2O, 1.25 g glucose and 5 g lactose. 
M9 salt solution (1 L): 6 g Na2HPO4, 3 g KH2PO4, 0.5 g NaCl, 1 g, NH4Cl. 
10% Ampicillin: 1 g ampicillin sodium salt in 10 mL of H2O. Split into 1 mL aliquots 
and stored at -20 °C. 
5% Kanamycin: 5 g kanamycin sulphate in 10 mL of H2O. Split into 1 mL aliquots and 
stored at -20 °C. 
10×PCR buffer: 100 mM Tris (pH 8.3), 500 mM KCl, 15 mM MgCl2. Stored in 1 mL 
aliquots at -20 °C. 
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Pwo polymerase storage buffer: 50 mM Tris (pH 7.9), 50 mM KCI, 0.1 mM EDTA, 1 
mM DTT, 50% glycerol.  
TAE buffer (1L): 4.84 g Tris, 5.71 mL glacial acetic acid and 292 mg EDTA. 
6×DNA loading buffer: 5 mM Tris (pH 8.0), 0.15 % w/v Orange Gelb, 2.5% w/v Ficoll 
400, 10 mM EDTA. 
8.3 Preparation of media for cell growth and cloning 
8.3.1 LB media 
LB media was obtained as a freeze-dried powder. A 25 g L-1 suspension of LB in H2O 
was autoclaved at 120 °C for 20 min. 
8.3.2 LB-agar media 
A suspension of 25 g L-1 LB powder and 15 g L-1 of Agar powder in H2O was 
autoclaved at 120 °C for 20 min. 
8.3.3 Auto-induction media 
10 g of Tryptone, 5g of yeast extract, 40 mL of 25×salts solution, 10 mL of 50% v/v 
aqueous glycerol, 1 mL of 2 M MgCl2 aqueous solution and 200 µL of 1000×metals 
solution were mixed in a 2 L conical flask. H2O was added up to 1L and the suspension 
autoclaved at 120 °C for 20 min. To the cooled sterilised solution was added 1 mL of 
50% w/v aqueous glucose (filtered through a 0.22 µm filter) and 10 mL of 20% w/v 
aqueous lactose (filtered through a 0.22 µm filter). 
8.3.4 SeMet minimal media A  
For 100 mL final volume. 92 mL of H2O, 10 µL of 1000×metals and 1 mL 1 M aqueous 
MgSO4 were mixed thoroughly, 5 mL of 20×NPS were added and the solution 
autoclaved at 120 °C for 20 min. To the sterilised solution were added 1.25 mL of 
40% w/v aqueous glucose, 1 mL of 50×amino acids, 400 µL of 25 mg mL-1 methionine, 
100 µL of 1000×vitamins (with B12) and 100 µL of 10% w/v aqueous ampicillin.  
8.3.5  SeMet minimal media B 
For 500 mL final volume. 450 mL of H2O, 500 µL of 1 M MgSO4 and 50 µL of 
1000×metals were mixed thoroughly, 25 mL of 20×NPS were added and the solution 
autoclaved at 120 °C for 20 min. 10 mL of 50×5052, 10 mL of 50×amino acids, 200 µL 
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of 25 mg mL-1 methionine, 2.5 mL 25 mg mL-1 selenomethionine, 500 µL 10% w/v 
aqueous ampicillin and 500 µL 1000×vitamins (no B12) were added. 
8.3.6 SeMet wash buffer 
For 100 mL final volume. 0.10 g of NaH2PO4, 0.58 g Na2HPO4, 2.92 g NaCl and 20 g 
ethylene glycol were mixed and water added up to 100 mL.  
8.3.7 15N minimal media 
For 500 mL final volume. 450 mL of H2O, 500 µL of 1 M MgSO4 and 50 µL of 
1000×metals were mixed thoroughly, 25 mL of 20×NPS (15N) were added and the 
solution autoclaved at 120 °C for 20 min. To the sterilised solution were added 10 mL 
of 50×5052, 10 mL of 50×amino acids, 100 µL of 1000×vitamins (with B12),  100 µL 
of 10% w/v aqueous ampicillin. 
8.4 Site-directed mutagenesis, cloning and sequencing 
The following protocols were used to generate site-directed mutants of PanD (H17C, 
D19C, E23C, C26S, A62C, C78A, H17C/E23C, D19C/E23C, E23C/A62C, 
C26S/C78A, D19C/E23C/C78A, D19C/E23C/C26S, E23C/C26S/C78A, 
H17C/E23C/C26S/C78A, D19C/E23C/C26S/C78A, E23C/C26S/A62C/C78A, 
T57V/K119STOP). All ADC mutants were generated from the pRSETA-ADC-WT 
vector plasmid (Saldanha et al., 2001), with the exception of the T57V/K119STOP 
mutant which was generated from the pRSETA-ADC(T57V) plasmid (Webb et al., 
2014).  
8.4.1 Primer design 
The overlapping site-directed mutagenesis primers for QuikChange (Papworth et al., 
1996) were designed manually. They were 25-45 bases long (the average number of 
bases was 26). The codon carrying the desired mutation was placed roughly in the 
middle of the primer, with 10-15 bases corresponding to the plasmid sequence on each 
side. The exact sequence was designed in order to obtain a melting temperature (Tm) 
≥78 °C, calculated using 
Tm =81.5+0.41(%GC)−(675/N)−%mismatch 
Where %GC is the percentage of G or C bases, N is the total number of bases in the 
primer and %mismatch the number of mismatched bases compared to the initial 
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sequence. The sequence was also optimised to have a GC content of approximately 40% 
and terminate on one or more C or G bases. 
8.4.2 Primers used for genetic manipulation 
Mutant Sequence 
H17C 5'-CGTGAAAGTGACTTGTGCGGACCTGC-3' 
 3'-CGCAAGAACCTTCATAGTGCAGGTCC-5' 
D19C 5'-GTGACTCATGCGTGCCTGCACTATGAA-3' 
 3'-CAATGGCGCAAGAACCTTCATAGTGC-5' 
E23C 5'-CTCSTGCGGACCTGCACTCTTGTGGTT-3' 
 3'-CAATGGCGCAAGAACCACAATAGTGC-5' 
C26S 5'-CACTATGAAGGTTCTTCCGCCATTGAC-3' 
 3'-CCTGGTCAATGGCGGAAGAACCTTCA-5' 
A62C 5'-CCACTTATGCCATCGCGTGTGAACGC-3' 
 3'-CTCGAACCGCGTTCACACGCGATGGC-5' 
C78A 5'-CGGCGGCCCACGCAGCCAGTGTCGGC-3' 
 3'-GCCGACACTGGCTGCGTGGGCCGCCG-5' 
H17C (E23C) 5'-CGTGAAAGTGACTTGTGCGGACCTGC-3' 
 3'-CGGAAGAACCACAATAGTGCAGGTCC-5' 
D19C (E23C) 5'-GTGACTCATGCGTGCCTGCACTATTGT-3' 
 3'-CAATGGCGCAAGAACCACAATAGTGC-5' 
E23C (C26S) 5'-CTCATGCGGACCTGCACTATTTGTGTT-3' 
 3'-CAATGGCGGAAGAACCACAATAGTGC-5' 
H17C (E23C/C26S) 5'-CGTGAAAGTGACTTGTGCGGACCTGC-3' 
 3'-CGGAAGAACCACAATAGTGCAGGTCC-5' 
D19C (E23C/C26S) 5'-GTGACTCATGCGTGCCTGCACTATTGT-3' 
 3'-CAATGGCGGAAGAACCACAATAGTGC-5' 
K119STOP 5'-GAAACGTACCGCGTAAGCGAT-3' 
 3'-GTACCGGAATCGCTTACGCGG-5' 
8.4.3 Mutagenesis protocol 
Site-directed mutants of ADC were obtained using the standard QuikChange 
mutagenesis protocol published by Agilent Technologies (Papworth et al., 1996). All 
primers were dissolved in 18 MΩ water to a final concentration of 200 µM. Initial 
mutations were performed starting from the expression pRSETA plasmid encoding a N-
terminally hexaHis-tagged WT PanD (Saldanha et al., 2001) or a N-terminally hexaHis-
tagged PanD(T57V) (Webb et al., 2014).  
For each site-directed mutagenesis reaction, the PCR mix was prepared by mixing 20 ng 
of the template plasmid (as a solution in 10 mM Tris-Cl, pH 8.5, from miniprep using 
the Qiagen QIAprep Spin Miniprep Kit), 0.4 µL of 25 nM dNTPs (an equimolar 
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solution of dGTP, dCTP, dTTP, dATP), 5 µL of 10×PCR buffer, 0.2 µL forward primer 
(200 µM solution), 0.2 µL reverse primer (200 µM solution) and 18 MΩ H2O to 49 µL 
followed by 1 µL of 3 U µL-1 Pwo polymerase. PCR was performed using the following 
protocol: 30 s at 95 °C, 16×(30 s at 95 °C, 60 s at 55 °C, 300 s at 68 °C) and 300 s at 
68 °C. 
8.4.4 Agarose gel electrophoresis 
The following protocol is for a standard 1% agarose gel. 0.4 g of agarose was suspended 
in 40 mL of TAE buffer. The suspension was heated (microwave) to obtain a solution. 
TAE buffer was added to compensate for any evaporation followed by 1.5 µL of 
ethidium bromide. The solution was inverted twice, poured into a casting mould and the 
desired comb inserted. Once the gel was set, it was transferred to the electrophoresis 
running tank, submerged in TAE buffer and the DNA samples (5-10 µL of 5:1 v/v 
mixtures of the desired DNA solution and 6×DNA loading buffer) were loaded and the 
gel run at 100 V for 20 min. 
8.4.5 Transformation of chemically competent E. coli cells 
This protocol was used for the transformation of all E. coli strains used, XL10, BL21 
Gold, BL21 Star, C41 (DE3), MG1655 ΔpanZ ΔpanD (DE3) and B834 (DE3). 
1-5 µL of plasmid was mixed with 50 µL (or 10 µL when transforming XL10 cells) of 
chemically competent cells in a sterile 1.5 mL tube on ice. The cells were incubated for 
10 min to allow diffusion of the plasmid, then at 42 °C for 45 s before re-incubation on 
ice for a further 10 min for plasmid uptake. 1 mL of LB media was added and the cells 
incubated at 37 °C for 45 min. 100 µL of culture were used to inoculate sterilised agar 
plates, containing the desired antibiotic for selection (100 µg mL-1 of ampicillin or 
50 µg mL-1 of Kanamycin). The remaining 900 µL of cell culture were centrifuged at 
13,000g for 30 seconds, 800 µL of supernatant removed, the pelleted cells resuspended 
and used to inoculate a second agar plate. The plates were incubated at 37 °C for 16 
hours. 
8.4.6 Miniculture of E. coli cells 
A single colony from transformation of E. coli cells strains harbouring the desired 
plasmid for overexpression purposes was picked and incubated in 5 mL of LB media 
containing the desired antibiotic for selection (100 µg mL-1 of ampicillin or 50 µg mL-1 
of Kanamycin) for 16 hours at 37 °C with shaking. The miniculture was used to 
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inoculate 1L overexpression media as well as to make glycerol cell stocks (1:1 mixture 
with 80% v/v sterilised glycerol (in H2O), flash frozen and stored at -80 °C for later 
use). 
8.4.7 Sequencing of plasmids 
A single colony of E. coli XL10 cells transformed with the desired plasmid was 
minicultured as described above. The cells were harvested by centrifugation at 4,500 
rpm for 10 min and the plasmid harvested with a QIAprep miniprep kit (QIAGEN®), 
using the manufacturer’s protocol and buffers (Sambrook and Russell, 2001). 150 ng of 
T7 sequencing primer was added to 10 ng of plasmid in 50 µL of 18 MΩ H2O. 
Sequencing was performed by GATC® and analysed using Bioedit. 
8.5 Protein overexpression 
N-Terminally hexaHis-tagged WT ADC, PanD(T57V) and PanD(S25A) from vectors 
pRSETA-ADC-WT (Saldanha et al., 2001), pRSETA-ADC(T57V) (Webb et al., 2014) 
and pRSETA-ADC(S25A) (Schmitzberger et al., 2003) respectively. C-Terminally 
hexaHis-tagged PanZ was overexpressed from vector pBAD24-PanZ (Nozaki et al., 
2012) or pET28a-PanZ (Monteiro et al., 2015). All other PanD mutants were expressed 
from pRSETA vectors encoding the desired proteins generated as described in 8.4. 
8.5.1 Overexpression in auto-induction media 
All N-terminal hexaHis-tagged WT PanD was overexpressed in E. coli C41 (DE3) cells 
harbouring a pRSETA-ADC-WT plasmid (Saldanha et al., 2001). N-Terminally 
hexaHis-tagged PanD mutants were overexpressed in E. coli MG1655 ΔpanZ ΔpanD 
(DE3) cells harbouring pRSETA plasmids coding for the desired proteins. C-Terminally 
hexaHis-tagged PanZ was overexpressed in ΔpanZ ΔpanD E. coli C41 cells harbouring 
a pET28a plasmid. Overexpression was done by auto-induction of T7 RNA polymerase 
(Studier, 2005). 1 L of sterilised auto-induction media with antibiotic (100 µg mL-1 
ampicillin for PanD or 50 µg mL-1 kanamycin for PanZ) in a 2 L conical flask was 
inoculated with 1 mL of overnight miniculture. The culture was incubated for 20 h at 
37 °C with shaking (200 rpm). The cells were collected by centrifugation (10,000g for 
10 min) and were stored at –80 °C prior to lysis for protein purification. For activated 
ADC, the cell pellets were incubated at 37 °C overnight prior to storage at -80 °C. 
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8.5.2 Overexpression in LB media by arabinose induction 
 C-Terminally hexaHis-tagged PanZ was overexpressed by induction of the arabinose 
promoter of the pBAD24 plasmid coding for the protein in E. coli BL21 Gold cells. 1 L 
of sterilised LB media with 100 µg mL-1 ampicillin and 250 mM calcium pantothenate 
in a 2 L conical flask was inoculated with 1 mL of overnight miniculture. The culture 
was incubated at 37 °C with shaking (200 rpm) and overexpression induced by addition 
of 5 g of arabinose (0.5% w/v) at OD600=0.6. The cells were incubated for a further 16 
hours. The cells were collected by centrifugation (10,000g for 10 min) and were stored 
at -80 °C prior to lysis for protein purification. 
8.5.3 Overexpression of SeMet PanZ 
C-Terminally hexaHis-tagged PanZ was overexpressed in E. coli B834 (DE3) cells 
harbouring a pBAD24 plasmid coding for the desired protein following a previously 
described protocol (Sreenath et al., 2005). In summary, 3 mL of overnight miniculture 
in SeMet minimal media A was used to inoculate 100 mL of SeMet minimal media A. 
The cell culture was incubated at 37 °C, 200 rpm for 18 h. Following incubation, 20 mL 
of the cell culture were used to inoculate 480 mL of SeMet minimal media B and the 
cultures incubated at 37 °C, 200 rpm for 24 h. The cells were collected by 
centrifugation (10,000g for 10 min), resuspended in SeMet wash buffer to wash any 
remaining SeMet away, collected by centrifugation once again (10,000g for 10 min) and 
then stored at -80 °C prior to lysis for protein purification. 
8.6 Protein purification 
8.6.1 Buffer recipes and preparation 
Buffers used for Ni-NTA chromatography were used directly without sterilisation or 
filtration. Size exclusion chromatography buffers were filtered through a 0.22 µm 
membrane under reduced pressure.  
Ni-NTA stock buffer: 500 mM K2HPO4, 3000 mM NaCl, pH 7.4 (15.0 g KH2PO4, 67.8 g 
K2HPO4, 175.3 g NaCl). 
Ni-NTA lysis buffer: 50 mM K2HPO4, 300 mM NaCl, 10 mM imidazole, pH 7.4 
(100 mL Ni-NTA stock buffer, 681 mg imidazole). 
Ni-NTA wash buffer: 50 mM K2HPO4, 300 mM NaCl, 50 mM imidazole, pH 7.4 
(100 mL Ni-NTA stock buffer, 3.40 g imidazole). 
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Ni-NTA elution buffer: 50 mM K2HPO4, 300 mM NaCl, 250 mM imidazole, pH 7.4 
(100 mL Ni-NTA stock buffer, 17.02 g imidazole). 
SEC buffer A: 50 mM Tris, 100 mM NaCl, 0.1 mM DTT, pH 7.5 (4.93 g Tris, 2.92 g 
Tris-HCl, 11.70 g NaCl, 30.9 mg DTT). 
SEC buffer B: 50 mM KH2PO4, 100 mM NaCl, 0.5 mM TCEP, pH 7.5 (1.24 g 
KH2PO4, 7.11 g K2HPO4, 5.84 g NaCl, 143 mg TCEP). 
8.6.2 Purification of hexaHis-tagged proteins by Ni-NTA chromatography 
E. coli cells collected from 1 L of overexpression cultures were resuspended in Ni-NTA 
lysis buffer (50 mM K2HPO4, 300 mM NaCl, 10 mM imidazole, pH 7.4) with protease 
inhibitor cocktail (cOmplete EDTA-free, Roche) according to the manufacturer’s 
protocol at 4 °C. The cell slurry was lysed mechanically using a Constant Systems cell 
disrupter (20 kpsi). DNase (a few crystals) was added to the cell lysate, which was 
cleared of cell debris by centrifugation (30,000 g, 45 min). The Ni-NTA agarose resin 
(Qiagen, 10 mL) was resuspended in 20 mL of H2O, washed under gravity with 30 mL 
of H2O and equilibrated with 50 mL of Ni-NTA lysis buffer (50 mM K2HPO4, 300 mM 
NaCl, 10 mM imidazole, pH 7.4). The clear lysate was loaded onto the Ni-NTA agarose 
column and low affinity binders removed by washing the resin with 50 mL of Ni-NTA 
wash buffer (50 mM K2HPO4, 300 mM NaCl, 50 mM imidazole, pH 7.4). The protein 
was eluted in 5×5 mL fractions of Ni-NTA elution buffer (50 mM K2HPO4, 300 mM 
NaCl, 250 mM imidazole, pH 7.4). The protein size, overexpression level and purity 
were assessed by SDS-PAGE. 
8.6.3 Ni-NTA column regeneration 
Following protein elution, the Ni-NTA loaded agarose resin was regenerated to remove 
any contaminants. The resin was washed with 30 mL of 0.1% w/v sodium dodecyl 
sulphate (SDS) followed by 30 mL of 0.1 M NaOH. Ni2+ was removed by chelation 
with 30 mL of 10 mM ethylenediaminetetraacetic acid (EDTA), the agarose resin 
washed with 100 mL of H2O and regenerated with 20 mL of 500 mM Ni2SO4. Excess, 
unbound Ni2+ was removed by washing with 100 mL of H2O and the column stored in 
20% v/v EtOH. 
8.6.4 Size-exclusion chromatography 
Elution fractions from Ni-affinity purification containing protein were combined and 
concentrated to 1 mL (Amicon centrifugal concentrator 10 kDa MWCO, 4,000 g). The 
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concentrated protein was loaded onto a Superdex® 75 column (HiLoad® 16/60 or 
26/60, GE Healthcare) and eluted isocratically with SEC buffer A or B (ÄKTA purifier, 
GE Healthcare) in 5 mL (26/60 column) or 3 mL (16/60 column) fractions and stored at 
4 °C. Protein elution was monitored by absorption at 280 nm and the chromatogram 
used to assess purity. 
8.6.5 Determination of protein concentration 
Protein concentration was determined using UV absorbance. 1.5 µL of sample were 
loaded onto the Nanodrop instrument and the absorbance measured at 280 nm. Protein 
concentration was calculated using PanD ε280 15470 M-1 cm-1 or PanZ ε280 
26470 M-1 cm-1, obtained empirically from the protein sequences using the ProtParam 
online platform (Gasteiger et al., 2005). 
8.7 SDS-PAGE analysis  
8.7.1 Buffer recipes 
5×SDS-PAGE Tris-glycine running buffer: 15.1 g Tris base, 94 g glycine, 5 g SDS. 
SDS-PAGE Tris-tricine gel buffer: 3 M Tris, 0.3% SDS, pH 8.45 (the pH was adjusted 
by addition of 4 M NaOH). 
SDS-PAGE Tris-tricine cathode buffer: 0.1 M Tris, 0.1 M tricine, 0.1% SDS, pH 8.23 
(the pH was adjusted by addition of 4 M NaOH). 
SDS-PAGE Tris-tricine anode buffer: 0.2 M Tris, pH 8.90 (the pH was adjusted by 
addition of 4 M NaOH). 
2×SDS-PAGE loading buffer: 50 mM Tris hydrochloride, pH 6.8 (the pH was adjusted 
by addition of 4 M NaOH), 100 mM dithiothreitol, 2% w/v SDS, 0.1% w/v 
bromophenol blue, 10% w/v glycerol. 
Coomassie blue stain: 1.0 g Coomassie blue R-250, 400 mL MeOH, 500 mL H2O, 
100 mL glacial acetic acid. 
Coomassie destain: 400 mL MeOH, 500 mL H2O, 100 mL glacial acetic acid. 
8.7.2 Sample preparation 
Purified protein solutions 
30 µL of protein in buffer was mixed with 2×SDS-PAGE loading buffer. The solutions 
were heated at 100 °C for 10 min (to ensure full denaturation of the protein).  
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E. coli cells 
1 mL of cell culture was centrifuged at 13,000 rpm, the supernatant removed, the cell 
pellet resuspended in Ni-NTA lysis buffer. 30 µL of the suspension was mixed with 
2×SDS-PAGE loading buffer and heated at 100 °C for 10 min (to ensure full 
denaturation of the protein). 
8.7.3 Tris-glycine PAGE 
The 12% separating gel was prepared according the table below. All components except 
for the ammonium persulphate (APS) and tetramethylethylenediamine (TEMED) were 
mixed thoroughly by inversion. Prior to casting, APS was added followed by TEMED 
and the solution mixed carefully between the additions. The mixture was poured and a 
layer of H2O-saturated n-butanol was added to ensure a levelled surface. The stacking 
gel mixture was prepared following the same protocol as for the separating gel. Once 
the separating gel was set, the n-butanol was blotted off, the stacking gel solution added 
and the comb inserted. The gel was loaded with the desired protein samples in 1×SDS-
PAGE loading buffer and run in 1×SDS-PAGE Tris glycine running buffer at constant 
voltage (180 V).  
Tris-glycine PAGE Separating gel (12%) Stacking gel 
1.5 M Tris pH 8.8 3.75 mL - 
1.0 M Tris pH 6.8 - 625 µL 
30 % acrylamide (29:1 
acrylamide:bis-acrylamide 6.00 mL 660 µL 
10% SDS 150 µL 50 µL 
Water 5.10 mL 3.66 mL 
15% APS 200 µL 100 µL 
TEMED 10 µL 10 µL 
8.7.4 Tris-tricine PAGE 
The 10% separating and stacking gels were prepared according the table below. All 
components except for the ammonium persulphate (APS) and 
tetramethylethylenediamine (TEMED) were mixed thoroughly by vortexing and the 
solution allowed to set for 20 min prior to casting, APS was added followed by TEMED 
and the solution mixed carefully between the additions. The separating gel was poured 
followed by the stacking gel, the comb inserted and the gels allowed to set 
simultaneously. Gentle addition of the stacking gel solution was essential to minimise 
disturbances to the separating gel. The gel was loaded with the desired protein samples 
in 1×SDS-PAGE loading buffer and the SDS-PAGE Tris-tricine cathode and SDS-
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PAGE Tris-tricine anode buffers were added. The gel was run at constant current of 30 
mA until the samples entered the separating gel and then at 60 mA.  
Tris-tricine PAGE Separating gel (10%) Stacking gel 
Glycerol 2 mL - 
Tris-tricine gel buffer 5.00 mL 3.10 mL 
30 % acrylamide (29:1 
acrylamide:bis-acrylamide 5.08 mL 1.66 mL 
Water 2.92 mL 7.74 mL 
15% APS 100 µL 100 µL 
TEMED 10 µL 10 µL 
8.7.5 Visualisation of SDS-PAGE gels 
Coomassie blue stain (50 mL) was added to the gel, the solution warmed in a 
microwave (15 s, full 750 W) and the gel incubated at RT for 1.5 h with rocking. The 
stain was removed, Coomassie destain was added, the gel incubated for 3 h with 
rocking, washed with H2O and photographed (Gel Doc XR system, Bio-Rad). 
8.8 Binding assays 
All binding assays were performed using isothermal titration calorimetry (ITC). 
Experiments were performed using a Microcal iTC200 (GE) or Microcal VP-ITC (GE) 
thermostated at 25 °C. For the microcal iTC200, the ligand sample was loaded into the 
sample cell (200 µL) and the titration sample into the sample syringe (40 µL). Each 
titration series consisted of a sacrificial 0.4 µL injection followed by 19 injections of 
2 µL. For the VP-ITC, the ligand sample was loaded into the sample cell (1.5 mL) and 
the titration sample into the sample syringe (300 µL). Each titration series consisted of a 
sacrificial 2 µL injection followed by 29 injections of 10 µL each. The titration sample 
concentration was ~8× that of the ligand sample. The proteins were expressed and 
purified as described in 8.5 and 8.6, and used in SEC buffer A. The titration data were 
analysed using Origin 6.5. After baseline subtraction, data were fitted to a single site-
binding model. For global fitting, data were integrated using NITPIC (Keller et al., 
2012) before global fitting to a one-site binding model in SEDPHAT (Houtman et al., 
2007). For titrations of purified PanZ (a mixture of apo-PanZ and PanZ.CoA) against 
CoA and against PanD(T57V) without excess CoA or AcCoA, binding constants were 
re-calculated accounting for the binding incompetent fractions of PanZ in each case. A 
summary of all the titrations and binding constants obtained can be found in appendix 
9.4. 
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8.9 Protein crystallisation 
8.9.1 Initial crystallisation screens 
The PanD(T57V)-PanZ.CoA protein complex was prepared from solutions of the 
proteins (overexpressed from the pRSETA-ADC(T57V) (Webb et al., 2014) and the 
pBAD24-PanZ (Nozaki et al., 2012) vectors and purified as described in section 8.6) in 
SEC buffer A (50 mM Tris, 100 mM NaCl, 0.1 mM DTT, pH 7.5). The proteins were 
mixed in a 1:1 ratio (protomer to monomer), concentrated to 3.5 mg mL-1 (Amicon 
centrifugal concentrator 10 kDa MWCO, 4,500 g) and 1 PanZ equivalent of CoA was 
added. Sparse matrix screens using Crystal Screen HT 1 and Crystal Screen HT 2 (96 
conditions, Hampton Research) were set up manually in a MRC 96-well plate 
(Molecular Dimensions) by the sitting drop diffusion method with 1.0 µL protein:1.0 µL 
mother liquor sitting drops at 18 °C. Small bipyramidal crystals were obtained in 
100 mM Tris (pH 7.8-8.0), 180-220 mM Li2SO4 and 20% v/v PEG 4000. A second 
crystallisation screen was set up similarly but using the PanD(T57V-PanZ.AcCoA 
complex instead. Small square plates were obtained in 100 mM sodium cacodylate, pH 
6.5, 1.4 M sodium acetate and small bipyramidal crystals were obtained in 100 mM Tris 
(pH 7.8), 200 mM Li2SO4 and 20% v/v PEG 4000. 
8.9.2 Further crystallisation screens 
The PanD(T57V)-PanZ.AcCoA protein complex was prepared from solutions of the 
proteins overexpressed from the pRSETA-ADC(T57V) (Webb et al., 2014) and the 
pET28a-PanZ (Nozaki et al., 2012) vectors and purified as described in section 8.6 in 
SEC buffer A (50 mM Tris, 100 mM NaCl, 0.1 mM DTT, pH 7.5). The proteins were 
mixed in a 10:11 PanD(T57V):PanZ ratio (protomer to monomer), concentrated to ~9 
mg mL-1 (Amicon centrifugal concentrator 10 kDa MWCO, 4,500 g) and 2 equivalent 
of AcCoA were added. Sparse matrix screens using Crystal Screen HT 1 and 2, Index, 
Salt RX (Hampton Research), Morpheus (Molecular Dimensions) and Wizard I and II 
(Emerald Biosciences) were set-up using the Oryx 6 Douglas crystallisation robot 
(Douglas instruments) in MRC 96-well plates (Molecular Dimensions) using 1.0 µL 
protein:1.0 µL mother liquor at 18 °C. More than 120 crystallisation hits were obtained, 
with various salts and buffers. The largest crystals were observed generally in 
conditions containing high molecular weight PEG precipitants, simple salts of mono- or 
divalent cations and Tris or Bis-Tris buffers. 
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8.9.3 Optimisation of initial crystallisation conditions 
Optimisation of crystallisation conditions was carried out by varying salt, buffer and 
precipitant concentrations and buffer pH. Crystals were grown by the hanging drop 
diffusion method, in 2 µL protein:2 µL mother liquor drops in 24-well plates.  
The PanD(T57V)-PanZ.CoA complex was prepared as described in section 8.9.1 and 
crystallised in 200 mM Li2SO4, 100 mM Tris pH 8.5 and 30% v/v PEG 4000. The 
PanD(T57V)-PanZ.AcCoA complex was prepared as described in section 8.9.2 and 
crystallised in 100 mM sodium cacodylate, pH 6.5, 1.4 M sodium acetate and in 
200 mM KSCN, 100 mM Bis-Tris propane pH 6.5, 20% v/v PEG 3350. The 
PanD(S25A)-PanZ.AcCoA was prepared similarly to the PanD(T57V)-PanZ.AcCoA 
complex and crystallised in 200 mM KSCN, 100 mM Bis-Tris propane pH 6.5, 20% v/v 
PEG 3350.  
8.9.4 Heavy-metal derivatisation 
PanD(T57V).PanZ.CoA crystals obtained as described in section 8.9.3 were derivatised 
with heavy-metals. The crystals were harvested from the crystallisation drops using 
CryoLoops (Hampton Research) or MicroMeshes™ (Mitegen) and transferred to a 2 µL 
drop of mother liquor on a glass cover slip containing 10 µM of a heavy-metal salt. 
Hg(OAc)2, (NH4)10H2(W2O7)6, K2OsCl6, (H2NCH2CH2NH2)PtCl2, Pb(CH3CO2)4 and 
K2Pt(CN)4 were screened. The drops were sealed in a 24-well crystallisation plate to 
avoid dehydration. The crystals were allowed to soak for a few minutes and transferred 
to new mother liquor drops without the heavy-metal additives to attempt to remove any 
non-specifically bound metal derivatives.  
8.9.5 X-ray Diffraction experiments 
Evaluation of crystal quality 
Crystal size and quality were evaluated by light microscopy and confirmed by X-ray 
diffraction. Diffraction patterns were collected using either the in-house source 
(MicroMax-007 HF microfocus rotating anode generator, 30 mA, Raxis4++), at both 
RT and 100 K, or at Diamond Light Source (beamlines I24, I03, I04-1 and I02) at 
100 K.  
Synchrotron cryo-temperature data collection 
Small bipyramidal crystals for the PanD(T57V).PanZ.CoA complex were obtained in 
200 mM Li2SO4, 100 mM Tris pH 8.5 and 30% v/v PEG 4000. Some crystals were 
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derivatised as described in 8.9.4. Bipyramidal crystals for the 
PanD(T57V).PanZ.AcCoA, WT ADC.PanZ.AcCoA and WT PanD.PanZ.AcCoA 
complexes were obtained in 200 mM KSCN, 100 mM Bis-Tris propane pH 6.5, 
20% v/v PEG 3350. Square plates for the PanD(T57V).PanZ.AcCoA complex were 
obtained from 100 mM sodium cacodylate, pH 6.5, 1.4 M sodium acetate. The crystals 
were harvested and mounted on CryoLoops (Hampton Research) or MicroMeshes™ 
(Mitegen) on goniometer bases. The crystals were cryo-protected stepwise in mother 
liquor containing 5%, 10% and 20% v/v glycerol by soaking for a few seconds in each 
condition and flash-cooled in liquid nitrogen. Diffraction data were collected at 100 K 
under a cryo-stream of dry nitrogen at beamlines I03, I24 and I04-1 at DLS. For each 
crystal, 3 diffraction patterns were first obtained with an attenuated X-ray beam and 
used to evaluate crystal quality, index the crystal lattice and devise a data collection 
strategy using EDNA (Incardona et al., 2009). A summary of the data collection 
strategy details for the PanD(T57V).PanZ.CoA and PanD(T57V).PanZ.AcCoA 
complex described in section 3.2 can be found in section 9.2.  
Data for the WT PanD.PanZ.AcCoA complex were collected at beamline I03 at DLS at 
λ= 0.9763 Å. 900 frames of 0.2° oscillation, 0.1 s exposure and 30% transmission were 
collected to a maximum resolution of 1.16 Å. The data were integrated in space group 
I4 (a=b=85.9 Å, c=80.1 Å, α=β=γ=90°) using XDS (Kabsch, 2010).  
Data for the WT ADC.PanZ.AcCoA complex were collected at beamline I04-1 at DLS 
at λ= 0.9174 Å. 1000 frames of 0.2° oscillation, 0.2 s exposure and 43% transmission 
were collected to a maximum resolution of 1.25 Å. The data were integrated in space 
group I4 (a=b=85.9 Å, c=80.1 Å, α=β=γ=90°) using XDS (Kabsch, 2010).  
Synchrotron RT data collection 
Bipyramidal crystals for PanD(T57V).PanZ.AcCoA complex were obtained in 200 mM 
KSCN, 100 mM Bis-Tris propane pH 6.5, 20% v/v PEG 3350. The crystals were 
mounted on CryoLoops (Hampton Research) or MicroMeshes™ (Mitegen) on 
goniometer bases. Data for the PanD(T57V)-PanZ.AcCoA were collected at RT at 
beamline ID29 at ESRF. The crystals were placed under a humidifying air stream (HC1 
instrument (Sanchez-Weatherby et al., 2009)) and kept at 95% relative humidity 
throughout the experiment. 3 diffraction patterns were first obtained and used to 
evaluate crystal quality, index the crystal lattice and devise a data collection strategy 
using EDNA Mxv1. 2320 frames of 0.05° oscillation, 0.04 s exposure and 0.12% 
transmission were collected to a maximum resolution of 1.64 Å. The data were 
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integrated in space group I4 (a=b=86.4 Å, c=81.0 Å, α=β=γ=90°) using Xia2 (Winter, 
2010).  
RT in-house data collection 
Bipyramidal crystals for the PanD(T57V).PanZ.AcCoA, WT ADC.PanZ.AcCoA and  
PanD(S25A).PanZ.AcCoA complexes were obtained in 200 mM KSCN, 100 mM 
Bis-Tris propane pH 6.5, 20% v/v PEG 3350. The crystals were harvested and mounted 
on CryoLoops (Hampton Research) or MicroMeshes™ (Mitegen) on goniometer bases. 
The mounted crystals were inserted into plastic sleeves containing a 2 µL plug of 
mother liquor and data collected at RT using the in-house source (Micro-Max-007 HF 
microfocus rotating anode generator, 30 mA and a R-axis 4++ detector) at λ=1.5418 Å. 
2 initial diffraction patterns were collected and used to evaluate crystal quality, index 
the crystal lattice and devise a data collection strategy using HKL3000 (Otwinowski 
and Minor, 1997). 60 frames of 1° oscillation, 30 s exposure and full transmission were 
collected to a maximum resolution of 1.70 Å and 2.10 Å resolution respectively. The 
PanD(T57V)-PanZ.AcCoA data were integrated in space group I4 (a=b=86.4 Å, 
c=81.0 Å, α=β=γ=90°) and PanD(S25A)-PanZ.AcCoA in space group I4 (a=b=86.3 Å, 
c=80.8 Å, α=β=γ=90°) using HKL3000 (Otwinowski and Minor, 1997). The WT 
ADC.PanZ.AcCoA data were integrated in space group I4 (a=b=85.6 Å, c=79.9 Å, 
α=β=γ=90°) using XDS (Kabsch, 2010).  
Structure solution and refinement 
All datasets were scaled and merged in Aimless (Evans and Murshudov, 2013). The 
synchrotron dataset for PanD(T57V).PanZ.AcCoA collected at the ESRF on beamline 
ID29 (PDB 4CRY) was solved by molecular replacement of the PanD(T57V) protomer 
(PDB 4AZD, (Webb et al., 2014) first, followed by the lowest energy conformation of 
the NMR structure of PanZ (PDB 2K5T) using Molrep (Vagin and Teplyakov, 1997). 
The model was subjected to cycles of refinement using Refmac5 (Murshudov et al., 
2011) and manual rebuilding using Coot (Emsley et al., 2010). All subsequent complex 
structures of PanD(T57V).PanZ.AcCoA and PanD(S25A).PanZ.AcCoA from in-house 
datasets and WT ADC.PanZ.AcCoA and WT PanD.PanZ.AcCoA from in-house and 
synchrotron datasets were solved by molecular replacement of the PDB 4CRY model 
using Molrep and were manually rebuilt and refined using Coot and Refmac5 
respectively. Isotropic refinement parameters were used for the 
PanD(T57V).PanZ.AcCoA, PanD(S25A).PanZ.AcCoA and RT WT ADC.PanZ.AcCoA 
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structures. Mixed isotropic/anisotropic refinement parameters were used for the cryo 
WT ADC.PanZ.AcCoA and WT PanD.PanZ.AcCoA structures, where all protein atoms 
were refined anisotropically, with the exception of the PanZ 26Tyr-Val33 loop which is 
mobile. Waters were inspected manually and refined isotropically if considered mobile. 
All ligands were also refined isotropically with the exception of AcCoA.  
8.10 Complementation assays 
The in cellulo assays were performed by Shingo Nozaki and Hironori Niki. The full 
protocol has been described previously (Monteiro et al., 2015). 
8.11 SAXS 
The SAXS data were collected by Dr Thomas Grant, Dr Edward Snell and Prof. Arwen 
Pearson and processed by Dr Thomas Grant according to the previously published 
protocol (Monteiro et al., 2015). 
8.12 1H NMR ADC activity assay 
Activated WT ADC and PanZ were overexpressed and purified as described in sections 
8.5.1 and 8.6. A mixture of 1:2 WT ADC and PanZ (final concentrations of 15.8 and 
31.7 µM respectively) in SEC buffer A with 50 µM AcCoA was diluted into SEC buffer 
B to a final concentration of 100 nM WT ADC and 200 nM PanZ (and consequently 
320 nM AcCoA). The mixture was split into 6 aliquots, supplemented with AcCoA, 
0.5 mM L-aspartate and PanZ, as described in Table 10, and incubated at 37 °C. 1H 
NMR samples were prepared by mixing 630 µL of the enzymatic reaction with 70 µL of 
D2O (10% v/v D2O in H2O final concentration) and the 1D 1H NMR spectrum recorded 
immediately using a water suppression pulse sequence. The reaction progression was 
monitored at 2 h, 4 h and 24 h after the start of incubation. Substrate turnover was 
monitored by analysis of the ratio of the integrals of the L-aspartate CαH and the β-
alanine CH2 signals. The integrals were calculated using Mestrenova (Mestrelab 
research software). The experiment was repeated with a 250 nM WT ADC and 500 nM 
PanZ solution supplemented with AcCoA (100 µM) and 5 mM L-aspartate. 
Table 10 Sample composition for 1H NMR assay of WT ADC catalysis in the presence of PanZ 
 1 2 3 4 5 6 
[PanZ] (µM) 0.20 0.20 1.00 1.00 10.0 10.0 
[AcCoA] (µM) 0.32 100 0.32 100 0.32 100 
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8.13 Synthesis of photocleavable crosslinkers 
Ethyl 3,4-dimethoxybenzoate (45). (Choshi et al., 1992) 3,4-
Dimethoxybenzoic acid (15.0 g, 82 mmol) was dissolved in EtOH 
(100 mL), conc. H2SO4 (2.60 mL) was added and the solution heated 
under reflux for 20 h. The solution was cooled to RT, diluted with H2O (200 mL), 
extracted with EtOAc (3×120 mL), the organic layer quenched with sat. aq. NaHCO3 
(150 mL), washed with brine (100 mL), dried over Na2SO4 and filtered. The solvent was 
removed under reduced pressure, yielding the product as a clear liquid (16.1 g, 93%), 
which was used without further purification. 1H NMR (CDCl3, 300 MHz): 7.69 (1H, dd, 
J 1.8, 8.1, ArC6H), 7.55 (1H, d, J 1.8, ArC2H), 6.89 (1H, d, J 8.1, ArC5H), 4.36 (2H, q, 
J 7.2, CH2), 3.94 (6H, s, OCH3), 1.39 (3H, t, J 7.2, CH3). 13C NMR (CDCl3, 75 MHz): 
166.4 (C=O), 152.8 (ArC4), 148.5 (ArC3), 123.4 (ArC1), 123.0 (ArC6), 111.9 (ArC2), 
110.1 (ArC5), 60.8 (CH2), 55.9 (OCH3), 14.4 (CH3). HRMS: 233.0775 [M+Na]+ 
([C11H14O4Na]+ requires 233.0784), 211.0967 [M+H]+ ([C11H15O4]+ requires 211.0965). 
IR: 1712 cm-1 (C=O). 
 1,3-Bis(3,4-dimethoxyphenyl)-1,3-propanedione (47). 
Prepared using a modified procedure to previously 
described (Omran and Specht, 2009a). NaH (1.75g, 44 
mmol) was washed in dry hexane (2×35 mL) and dry PhMe (35 mL) and suspended in 
dry PhMe (160 mL) under a N2 atmosphere. 3,4-Dimethoxyacetophenone (7.02 g, 39 
mmol) was added and the mixture stirred for 15 min. Ethyl 3,4-dimethoxybenzoate 
(7.74 mL, 43 mmol) was added slowly, the mixture stirred for a further 30 min and 
heated under reflux for 36 h. The solution was cooled to RT, quenched into H2O (150 
mL), the aqueous layer extracted with EtOAc (3×100 mL), the organic extracts 
combined and washed with brine (100 mL), dried over Na2SO4 and filtered. The solvent 
was removed under reduced pressure to yield an orange solid. The crude was purified 
by flash chromatography (150 g SiO2, with a solvent gradient of 30-65% EtOAc in 
hexane) yielding the product as a bright yellow solid (4.38 g, 33%). 1H NMR (CDCl3, 
300 MHz): 7.59 (2H, dd, J 2.0, 8.5, ArC6H), 7.54 (2H, d, J 2.0, ArC2H), 6.91 (2H, d, J 
8.5 Hz, ArC5H), 6.74 (1H, s, CH2), 3.97 (6H, s, OCH3), 3.94 (6H, s, OCH3). 13C NMR 
(CDCl3, 75 MHz): 184.5 (C=O), 152.7 (ArC4), 149.1 (ArC3), 128.4 (ArC1), 121.0 
(ArC6), 110.6 (ArC2), 109.9 (ArC5), 91.8 (C2), 56.0 (OCH3), 55.9 (OCH3). HRMS: 
367.1157 [M+Na]+ ([C19H20O6Na]+ requires 367.1152), 345.1329 [M+H]+ ([C19H21O6]+ 
requires 345.1333). IR: 1736 cm-1 (C=O), 1599 cm-1 (C=C). 
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1,3-Bis(3,4-dimethoxyphenyl)-1,3-propanediol (48). 
(Omran and Specht, 2009a) 1,3-Bis(3,4-
dimethoxyphenyl)-1,3-propanedione (2.55 g, 7.4 mmol) 
was dissolved in CH2Cl2 (37.5 mL) and MeOH (300 mL) was added followed by 
NaBH4 (855 mg, 22.6 mmol). The mixture was stirred at RT for 40 min and the solvent 
removed under reduced pressure, leaving a yellow solid. The solid was redissolved in 
CH2Cl2 (80 mL), washed with H2O (2×50 mL) and brine (50 mL) and the organic layer 
dried over Na2SO4. The solvent was removed under reduced pressure yielding the 
product as a yellow foam (2.58 g, 99%, mixture of diastereomers, 2:1 meso:anti), which 
was used without further purification. 1H NMR (CDCl3, 500 MHz): 6.92 (0.68H, d, J 
1.7, ArC2H), 6.88 (1.32H, d, J 1.4, ArC2H’), 6.87-6.83 (2H, m, ArC6H and ArC6H’), 
6.81 (0.68H, d, J 6.8, ArC5H), 6.79 (1.32H, d, J 8.1, ArC5H’), 4.91 (0.68H, dd, J 10.2, 
2.4, CH), 4.88 (1.32H, t, J 5.8, CH’), 3.86 (6H, s, OCH3 and OCH3’), 3.85 (6H, s, OCH3 
and OCH3’), 3.92 (0.68H, br s, OH), 3.51 (1.32H, br s, OH’), 2.18 (0.66H, dt, J 14.5, 
10.2, C2H), 2.12 (0.68H, t, J 5.8, CH2), 1.91 (0.66H, dt, J 14.5, 2.7, C2H). 13C NMR 
(CDCl3, 75 MHz): 184.5 (C=O), 152.7 (ArC4), 149.1 (ArC3), 128.4 (ArC1), 121.0 
(ArC6), 110.6 (ArC2), 109.9 (ArC5), 74.8 (CH), 71.5 (CH’), 56.0 (OCH3), 55.9 
(OCH3), 47.7 (CH2) 46.6 (CH2’). HRMS: 347.1487 [M-H]- ([C19H23O6]- requires 
347.1500), 371.1474 [M+Na]+ ([C19H24O6Na]+ requires 371.1465). HPLC: 0.32 min. 
IR: 3469 cm-1 (br, OH), 1138 cm-1 (C-OH). 
Ethyl 4,5-dimethoxy-2-nitrobenzoate (50). (Knesl et al., 2006) 
Nitric acid (70%, 6.9 mL) was cooled to 0 °C and a solution of ethyl 
3,4-dimethoxybenzoate (5.17 mL, 28.6 mmol) in AcOH (28.6 mL) 
was added dropwise. The mixture was stirred at 0 °C for 30 min, slowly warmed up to 
RT and stirred for a further 24 h. The solution was poured into an ice/H2O slurry 
(150 mL), extracted with EtOAc (2×50 mL), the organic extracts combined and washed 
with sat. aq. NaHCO3 (3×50 mL) and brine (2×75 mL), dried over Na2SO4, 
decolourised by addition of charcoal, filtered and the solvent removed under reduced 
pressure. The crude product was dried in a desiccator to remove any traces of solvent, 
yielding the product as an off-white amorphous solid (3.95 g, 60%), which was used 
without further purification. 1H NMR (CDCl3, 300 MHz): 7.60 (1H, s, ArC3H), 7.08 
(1H, s, ArC6H), 4.38 (2H, q, J 7.2, CH2), 3.99 (3H, s, OCH3), 3.98 (3H, s, OCH3), 1.36 
(3H, t, J 7.2, CH3). 13C NMR (CDCl3, 75  MHz): 165.8 (C=O), 152.5 (ArC5), 150.3 
(ArC4), 142.0 (ArC2), 122.0 (ArC1), 110.8 (ArC6), 1067.0 (ArC3), 62.4 (CH2), 56.6 
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(OCH3), 56.6 (OCH3), 13.8 (CH3). HRMS: 278.0647 [M+Na]+ ([C11H13NO6Na]+ 
requires 278.0635). IR: 1710 cm-1 (C=O), 1519 cm-1 (NO2). 
4,5-Dimethoxy-2-nitroacetophenone (51). (Dyer and Turnbull, 1999) 
Acetic anhydride (10 mL) was dissolved in nitric acid (70%, 200 mL), 
cooled to 0 °C and a solution of 3,4-dimethoxyacetophenone (11.5 g, 
63.8 mmol) in acetic anhydride (40 mL) was added dropwise. The mixture was allowed 
to warm up to RT and stirred for a further 3 h. The solution was poured into H2O 
(1.5 L), further diluted to 2 L and cooled in an ice bath to yield a heavy yellow 
precipitate. The product was filtered under reduced pressure, washed with water and 
dried in a desiccator (9.89 g, 69%), which was used without further purification. 1H 
NMR (CDCl3, 300 MHz): 7.62 (1H, s, ArC3H), 6.80 (1H, s, ArC6H), 4.02 (3H, s, 
OCH3), 3.99 (3H, s, OCH3), 2.50 (3H, s, CH3). 13C NMR (CDCl3, 75 MHz): 202.4 
(CO), 154.0 (ArC5), 149.6 (ArC4), 138.0 (ArC2), 132.8 (ArC1), 110.8 (ArC6), 107.0 
(ArC3), 56.7 (OCH3), 56.6 (OCH3), 30.4 (CH3). HRMS: 226.0709 [M+H]+ 
([C10H12NO5]+ requires 226.0710), 248.0529 [M+Na]+ ([C10H11NO5Na]+ requires 
248.0529). IR: 1733 cm-1 (C=O), 1494 cm-1 (NO2), 1372 cm-1 (NO2). 
1,5-Bis(3,4-dimethoxyphenyl)-1,5-pentanedione 
(54). (Omran and Specht, 2009a) Aluminium chloride 
(3.20 g, 24.0 mmol) was suspended in CH2Cl2 
(20 mL), the mixture cooled to -10 °C and 1,2-dimethoxybenzene (2.80 mL, 
22.0 mmol) was added dropwise over 10 min. Pentanedioyl dichloride (1.26 mL, 
10.0 mmol) was added at a rate of 20 µL min-1, the solution warmed up to 0 °C and 
stirred at this temperature for 5 h. The mixture was quenched into 2 M aq. HCl 
(100 mL) in ice (200 g) and allowed to warm up to RT. CH2Cl2 (100 mL) was added 
added to give two clear layers. The aqueous layer was further extracted with 200 mL of 
CH2Cl2, the organic extracts combined and washed with H2O (100 mL), 10% w/v aq. 
K2CO3 (3×100 mL) and brine (100 mL), dried over Na2SO4, filtered and the solvent 
removed under reduced pressure. The resulting red oil was purified by flash 
chromatography (100 g SiO2, with a gradient of 0-20% Et2O in CH2Cl2), yielding the 
product as an off-white solid (820 mg, 22%). 1H NMR (CDCl3, 300 MHz): 7.63 (2H, 
dd, J 1.1, 8.2, ArC6H), 7.56 (2H, d, J 1.1, ArC2H), 6.89 (2H, d, J 8.2, ArC5H), 3.95 
(12H, s, OCH3), 3.07 (4H, t, J 6.9, CH2CH2CH2), 2.19 (2H, qn, J 6.9, CH2CH2CH2). 13C 
NMR (CDCl3, 75 MHz): 198.6 (C=O), 153.3 (ArC4), 149.0 (ArC3), 130.1 (ArC1), 
122.7 (ArC6), 110.2 (ArC2), 110.4 (ArC5), 56.1 (OCH3), 56.0 (OCH3), 37.4 
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(CH2CH2CH2), 19.5 (CH2CH2CH2). HRMS: 395.1459 [M+Na]+ ([C21H24O6Na]+ 
requires 395.1471), 373.1659 [M+H]+ ([C21H25O6]+ requires 373.1651). IR: 1661 cm-1 
(C=O). 
1,5-Bis(4,5-dimethoxy-2-nitrophenyl)-1,5-
pentanedione (57). Prepared using a modified 
procedure to previously described (Omran and Specht, 
2009a). HNO3 (70%, 220 µL, 3.48 mmol) was dissolved in CH2Cl2 (2.6 mL) at -15 °C. 
TFA (810 µL, 10.5 mmol) was added dropwise at -15 °C and the mixture stirred for 45 
min at this temperature. 1,5-Bis(3,4-dimethoxyphenyl)-1,5-pentanedione (458 mg, 
1.31 mmol) in CH2Cl2 (1.4 mL) was added dropwise and the mixture warmed up to 
0 °C and stirred for a further 2 h. The reaction was quenched by careful addition of sat. 
aq. NaHCO3 (14 mL), the mixture extracted with CH2Cl2 (14 mL), the organic extract 
washed with brine, dried over Na2SO4, filtered and the solvent removed under reduced 
pressure. The crude was purified by flash chromatography (75 g SiO2, 10% Et2O in 
CH2Cl2), yielding the product as a yellow solid (307 mg, 53%). 1H NMR (CDCl3, 
300 MHz): 7.59 (2H, s, ArC3H), 6.85 (2H, s, ArC6H), 4.00 (6H, s, OCH3), 3.97 (6H, s, 
OCH3), 2.96 (4H, t, J 6.6, CH2CH2CH2), 2.25 (2H, p, J 6.6, CH2CH2CH2). 13C NMR 
(CDCl3, 75 MHz): 202.3 (C=O), 154.3 (ArC5), 149.4 (ArC4), 137.9 (ArC2), 138.0 
(ArC1), 108.7 (ArC6), 106.8 (ArC3), 56.8 (OCH3), 56.6 (OCH3), 41.4 (CH2CH2CH2), 
17.4 (CH2CH2CH2). HRMS: 485.1168 [M+Na]+ ([C21H22N2O10Na]+ requires 485.1172). 
IR: 1694 cm-1 (C=O). 
1,5-Bis(4,5-dimethoxy-2-nitrophenyl)-1,5-
pentanediol (58). (Omran and Specht, 2009a) 1,5-
Bis(4,5-dimethoxy-2-nitrophenyl)-1,5-pentanedione 
(300 mg, 0.68 mmol) was suspended in a mixture of CH2Cl2:MeOH (1:1, 7 mL), and 
NaBH4 (104 mg, 2.74 mmol) was added in one portion. The mixture was stirred for 
45 min, evaporated to dryness and redissolved in CH2Cl2 (12 mL). The solution was 
washed with H2O (2×7 mL) and brine (7 mL), dried over Na2SO4, filtered and the 
solvent removed under reduced pressure to yield the product as a flaky, yellow solid 
(298 mg, 99%)*, which was used without further purification. 1H NMR (CDCl3, 
300 MHz): 7.58 (2H, s, ArC3H), 7.29 (2H, s, ArC6H), 5.45 (2H, m, CH), 4.00 (6H, s, 
OCH3), 3.94 (6H, s, OCH3), 2.46 (1H, d, J 3.9, OH), 2.35 (1H, d, J 3.9, OH), 1.84 (6H, 
                                                
* Only one set of signals was visible by NMR: either the diastereomers have the same NMR spectrum or 
the reduction was stereoselective.  
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m, CH2). 13C NMR (CDCl3, 75 MHz): 153.7 (ArC5), 147.7 (ArC4), 139.6 (ArC2), 
136.1 (ArC1), 109.0 (ArC6), 107.7 (ArC3), 69.4 (CH), 56.4 (OCH3), 56.4 (OCH3), 37.7 
(CH2CH2CH2), 23.0 (CH2CH2CH2). HRMS: 489.1489 [M+Na]+ ([C21H26N2O10Na]+ 
requires 489.1485). IR: 3292 cm-1 (br, OH), 1507 cm-1 (NO2), 1324 cm-1 (NO2). 
1,5-Bis(4,5-dimethoxy-2-nitrophenyl)-1,5-
dibromopentane (53). (Omran and Specht, 2009a) 
1,5-Bis(4,5-dimethoxy-2-nitrophenyl)-1,5-pentanediol 
(45 mg, 0.10 mmol) was dissolved in acetyl bromide (289 µL, 0.29 mmol) at 0 °C and 
HBr (48% aq. solution, 20 µL, 0.02 mmol) was added. The solution was allowed to 
warm up to RT and stirred for 1.5 h. The mixture was quenched by addition of sat. aq. 
NaHCO3 (5 mL), extracted with CH2Cl2 (3×7 mL), the organic extracts combined and 
washed with brine (7 mL), dried over Na2SO4, filtered and concentrated under reduced 
pressure. The crude was filtered through a short bed of Florisil® and the solvent 
removed under reduced pressure, yielding the product as a light yellow foam (55 mg, 
99%, 1:1 mixture of diastereomers). 1H NMR (300 MHz, CDCl3): 7.49 (2H, s, ArC3H), 
7.46 (2H, s, ArC3H’), 7.23 (2H, s, ArC6H), 7.22 (2H, s, ArC6H’), 5.89 (2H, t, J 7.2, 
CH), 5.85 (2H, t, J 5.4, CH’), 4.02 (6H, s, OCH3), 4.01 (6H, s, OCH3’), 3.95 (6H, s, 
OCH3), 3.94 (6H, s, OCH3’), 2.2 (8H, m, CH2CH2CH2/CH2CH2CH2’), 1.80 (4H, m, 
CH2CH2CH2/CH2CH2CH2). 13C NMR (CDCl3, 75 MHz): 153.4 (ArC5), 153.3 (ArC5’), 
148.6 (ArC4/ArC4’), 139.9 (ArC2/ArC2’), 131.4 (ArC1), 131.2 (ArC1’), 111.7 (ArC6), 
111.6 (ArC6’), 107.4 (ArC3/ArC3’), 56.5 (OCH3/OCH3’), 56.4 (OCH3/OCH3’), 48.5 
(CH), 48.2 (CH’), 39.5 (CH2CH2CH2), 39.2 (CH2CH2CH2’), 26.4 (CH2CH2CH2), 26.3 
(CH2CH2CH2’). HRMS: 511.0712 [M-Br]+ ([C21H2479Br1N2O8]+ requires 511.0716), 
628.9533 [M+K]+ ([C21H2479Br2N2O8K]+ requires 628.9536). IR: 1495 cm-1 (NO2), 1345 
cm-1 (NO2). 
 α,α-Di(bromoacetyl) toluene (74). Benzaldehyde (195 µL, 1.92 
mmol) and bromoacetic anhydride (750 mg, 2.89 mmol) were 
mixed and stirred at 85 °C for 16 h under inert atmosphere. The 
mixture was quenched into sat. aq. NaHCO3 (50 mL), the aqueous layer extracted with 
CH2Cl2 (3×50 mL), the organic extracts combined, washed with brine (50 mL), filtered 
and the solvent removed under reduced pressure. The light yellow oil was allowed to 
slowly crystallise at RT, cooled to 0 °C and triturated with Hexane, to give a low 
melting, colourless, crystalline solid (525 mg, 75%). 1H NMR (500 MHz, CDCl3): 7.71 
(1H, s, CH), 7.54 (2H, dd, J 6.1, 7.6, PhC3H/PhC5H), 7.45-7.43 (3H, m, 
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PhC2H/PhC4H/PhC6H), 3.90 (4H, s, CH2). 13C NMR (75 MHz, CDCl3): 165.0 (C=O), 
133.8 (PhC1), 130.4 (PhC4), 128.8 (PhC2/PhC6), 126.7 (PhC3), 91.8 (CH), 25.0 (CH2). 
HRMS: 381.9282 [M+NH4]+ ([C11H1481Br2O4N]+ requires 381.9290), 386.8836 
[M+Na]+ ([C11H1079Br81BrO4Na]+ requires 386.8843), 402.8574 [M+K]+ 
([C11H1079Br81Br O4K]+ requires 402.8583). IR: 1763 cm-1 (C=O). 
α,α-Di((ethylthio)acetyl) toluene (79). Benzyl 1,1-
di(bromoacetate) (488 mg, 1.3 mmol) was dissolved in MeCN 
(6.3 mL) and NEt3 (725 µL, 5.2 mmol) was added followed by 
EtSH (1.97 mL, 26.6 mmol). The mixture was stirred at RT for 3 h and the solvent 
removed under reduced pressure. The crude material was redissolved in CH2Cl2 and 
evaporated twice to remove all traces of EtSH before purification by flash 
chromatography (10% EtOAc in hexane) yielding the product as a colourless liquid 
(140 mg, 33%).  1H NMR (500 MHz, CDCl3): 7.75 (1H, s, CH), 7.58-7.55 (2H, m, 
PhC3H/PhC5H), 7.45-7.43 (3H, m, PhC2H/PhC4H/PhC6H), 3.31 (4H, s, COCH2), 2.66 
(4H, q, J 7.4, CH2CH3), 1.37 (6H, t, J 7.4, CH2CH3). 13C NMR (75 MHz, CDCl3): 168.3 
(C=O), 134.8, 130.0, 128.7 (PhC2/PhC4/PhC6), 126.8 (PhC3/PhC5), 90.7 (CH), 33.0 
(COCH2), 26.5 (CH2CH3), 14.1 (CH2CH3). HRMS: 346.1163 [M+NH4]+ 
([C15H24O4S2N]+ requires 346.1147), 679.1588 [2M+Na]+ ([C30H40O8S4Na]+ requires 
679.1504). IR: 1746 cm-1 (C=O).  
Benzyl 1-methyl-1-bromoacetate (83). NaHCO3 (5.2 g, 62 mmol) was 
suspended in MeCN (100 mL) and cooled to 0 °C. 1-Phenyl ethanol 
(2.5 mL, 20.7 mmol) was added followed by bromoacetyl bromide 
(4.5 mL, 52 mmol), the mixture stirred at 0 °C for 30 min, warmed up to RT and stirred 
for a further 2 h. The suspension was filtered, the solvent removed under reduced 
pressure and the residue purified by flash chromatography (12% EtOAc in hexane) 
yielding the product as a colourless liquid (4.11 g, 82%). 1H NMR (500 MHz, CDCl3): 
7.40-7.32 (5H, m, PhCH), 5.96 (1H, q, J 6.6, CH), 3.86 (2H, s, CH2), 1.61 (3H, d, J 6.6, 
CH3); 13C NMR (75 MHz, CDCl3): 166.4 (C=O), 140.7, 128.5, 128.2 
(PhC2/PhC4/PhC6), 126.2 (PhC3/PhC5), 74.4 (CH), 26.2 (CH2), 21.9 (CH3). HRMS: 
264.9834 [M+Na]+ ([C10H1179BrO2Na]+ requires 264.9840). IR: 1731 cm-1 (C=O).  
Benzyl 1-methyl-1-(ethylthio)acetate (85). (1.0 g, 4.1 mmol) was 
dissolved in MeCN (20 mL) and EtSH (3.1 mL, 41.1 mmol) was added 
followed by NEt3 (1.14 mL, 8.2 mmol) were added. The solution was 
stirred at RT for 3 h and the solvent removed under reduced pressure. The crude 
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material was redissolved in CH2Cl2 and evaporated twice to remove all traces of EtSH. 
The crude material was purified by flash chromatography (10% EtOAc in hexane) to 
yield the product as a colourless liquid (853 mg, 94%). 1H NMR (500 MHz, CDCl3): 
7.32-7.21 (5H, m, PhCH), 5.84 (1H, q, J 6.6, CH), 3.22 (2H, s, COCH2), 2.54 (2H, q, J 
7.4, CH2CH3), 1.50 (3H, d, J 6.6, CHCH3), 1.16 (3H, t, J 7.4, CH2CH3). 13C NMR 
(75 MHz, CDCl3): 168.8 (C=O), 141.3, 128.5, 128.0 (PhC2/PhC4/PhC6), 126.1 
(PhC3/PhC5), 73.3 (CH), 33.5 (COCH2), 26.5 (CH2CH3), 22.1 (CHCH3), 14.1 
(CH2CH3). HRMS: 225.0945 [M+H]+ ([C12H17O2S]+ requires 225.0949), 242.1211 
[M+NH4]+ ([C12H20NO2S]+ requires 242.1215), 247.0766 [M+Na]+ ([C12H16O2SNa]+ 
requires 247.0769), 471.1638 [2M+Na]+ ([C24H32O4S2Na]+ requires 471.1640). IR: 
1724 cm-1 (C=O).  
1-Phenylprop-2-en-1-ol (87). (Štambaský et al., 2008) Benzaldehyde 
(4.86 mL, 47.8 mmol) was dissolved in dry THF (160 mL) and cooled to 0 
°C. Vinylmagnesium bromide (82 mL, 57.4 mmol) was added dropwise and 
the mixture stirred at this temperature for 4 h. The suspension was quenched with sat. 
aq. NH4Cl (250 mL), extracted with EtOAc (2×250 mL), the extracts combined, washed 
with brine (200 mL), dried over Na2SO4, filtered and the solvent removed under 
reduced pressure. The crude material was purified by flash chromatography (10-15% 
EtOAC in hexane) to give the product as a light yellow liquid (5.2 g, 81%). 1H NMR 
(500 MHz, CDCl3): 7.39-7.34 (4H, m, PhCH), 7.30-7.27 (1H, m, PhCH), 6.06 (1H, ddd, 
J 6.1, 10.3, 17.0, HC=CH2), 5.36 (1H, dt, J 1.3, 17.0, HC=CHaCHb), 5.21 (1H, m, CH), 
5.20 (1H, dt, J 1.3, 10.3, HC=CHaHb), 1.93 (1H, d, J 3.7, OH); 13C NMR (75 MHz, 
CDCl3): 140.2 (HC=CH2), 128.6, 128.0, 127.8, 126.2 (Ph), 115.1 (HC=CH2), 75.4 
(CH); HRMS: 291.1347 [M+Na]+ ([C18H20O2Na]+ requires 291.1361). IR: 1642 cm-1 
(C=C), 3357 cm-1 (br, OH).  
Kinetic resolution of 1-phenylprop-2-en-1-ol. (Štambaský et al., 2008) 1-Phenylprop-
2-en-1-ol (5.0 g, 37.3 mmol) was dissolved in dry PhMe (320 mL) and Novozyme 435 
(985 mg) was added followed by 4 Å molecular sieve powder (5.0 g) and isopropenyl 
acetate (17.3 mL, 157 mmol). The suspension was stirred vigorously at 40 °C for 16 h, 
filtered and the solvent removed under reduced pressure. The residue was purified by 
flash chromatography (0-15% EtOAc in hexane) yielding (S)-1-phenylprop-2-en-1-ol 
(1.67 g, 33%, 66% ee) and (R)-1-phenylprop-2-enyl acetate (2.58 g, 39%) as colourless 
liquids.  
HO
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 (R)-1-Phenylprop-2-enyl acetate ((R)-90). 1H NMR (500 MHz, CDCl3): 
7.40-7.27 (4H, m, PhCH), 7.26-7.21 (1H, m, PhCH), 6.26 (1H, dt, J 5.9, 
1.3, CH), 6.01 (1H, ddd, J 5.9, 10.5, 17.1, HC=CH2), 5.29 (1H, dt, J 17.1, 
1.3, HC=CHaHb), 5.25 (1H, dt, J 10.5, 1.3, HC=CHaHb), 2.21 (3H, s, CH3). 13C NMR 
(75 MHz, CDCl3): 169.4 (C=O), 138.9, 128.6, 128.2, 127.1 (Ph), 136.3 (HC=CH2), 
117.0 (HC=CH2), 76.2 (CH), 21.2 (CH3). IR: 1494 cm-1 (C=O) 
 (S)-1-Phenylprop-2-en-1-ol ((S)-87). 1H NMR (500 MHz, CDCl3): 7.39-
7.34 (4H, m, PhCH), 7.30-7.27 (1H, m, PhCH), 6.06 (1H, ddd, J 6.1, 10.3, 
17.0, HC=CH2), 5.36 (1H, dt, J 17.0, 1.3, HC=CHaHb), 5.21 (1H, m, CH), 
5.20 (1H, dt, J 10.3, 1.3, HC=CHaHb), 1.93 (1H, d, J 3.7, OH); 13C NMR (75 MHz, 
CDCl3): 140.2 (HC=CH2), 128.6, 128.0, 127.8, 126.2 (Ph), 115.1 (HC=CH2), 75.4 
(CH). HRMS: 133.0652 [M-H]- ([C9H9O]- requires 133.0653). IR: 1642 cm-1 (C=C), 
3352 cm-1 (br, OH).  
 (R)-1-Phenylprop-2-en-1-ol ((R)-87). (Štambaský et al., 2008) 
(R)-1-Phenylprop-2-enyl acetate (2.58 g, 14.6 mmol) was cooled to 0 °C and 
a solution of KOH (858 mg, 15.3 mmol) in MeOH (12 mL) was added 
dropwise. The mixture was heated to 50 °C and stirred for 2 h. The solution was diluted 
with brine (25 mL) and extracted with EtOAc (3×40 mL), the organic extracts 
combined, dried over Na2SO4, filtered and the solvent removed to give the product as a 
yellow liquid (1.76 g, 90%). 1H NMR (500 MHz, CDCl3): 7.39-7.34 (4H, m, PhCH), 
7.30-7.27 (1H, m, PhCH), 6.06 (1H, ddd, J 6.1, 10.3, 17.0, HC=CH2), 5.36 (1H, dt, J 
17.0, 1.3, HC=CHaHb), 5.21 (1H, m, CH), 5.20 (1H, dt, J 10.3, 1.3, HC=CHaHb), 1.93 
(1H, d, J 3.7, OH). 13C NMR (75 MHz, CDCl3): 140.2 (HC=CH2), 128.6, 128.0, 127.8, 
126.2 (Ph), 115.1 (HC=CH2), 75.4 (CH). IR: 1642 cm-1 (C=C), 3350 cm-1 (br, OH).  
General procedure for the synthesis of Mosher’s esters 
 (S)-1-Phenylprop-2-en-1-ol S-MTPA ester (89). (Mallavadhani 
and Rao, 1994) (S)-1-Phenylprop-2-en-1-ol (5.97 µL, 44.5 µmol) 
was dissolved in dry CH2Cl2 (1.5 mL) and cooled to 0 °C. DMAP 
(10.9 mg, 89 µmol) and Et3N (8.68 µL, 62.3 µmol) were added followed by 
(S)-MTPACl (10 µL, 53.4 µmol). The mixture was stirred for 10 min, quenched with 
sat. aq. NH4Cl (1.5 mL) and diluted with Et2O (2 mL). The organic layer was washed 
with water (1.5 mL) and brine (1.5 mL), dried over Na2SO4, filtered and the solvent 
removed under reduced pressure. The crude was purified by flash chromatography (0-
5% EtOAc in hexane), yielding the product as a colourless oil. 1H NMR (500 MHz, 
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CDCl3): 7.43-7.31 (10H, m, PhCH), 6.49 (1H, dt, J 5.9, 1.3, CH), 5.96 (1H, ddd, J 5.9, 
10.5, 17.0, HC=CH2), 5.29 (1H, dt, J 17.0, 1.3, HC=CHaHb), 5.26 (1H, dt, J 10.5, 1.3, 
HC=CHaHb), 3.47 (3H, s, OCH3). 13C NMR (75 MHz, CDCl3): 165.6 (C=O), 137.6 
(CF3), 134.9 (HC=CH2), 132.3, 129.5, 128.7, 128.3, 127.5, 127.4, 125.3 (Ph), 117.8 
(HC=CH2), 78.3 (CH), 77.2 (CCF3), 55.4 (CH3). HRMS: 368.1473 [M+NH4]+ 
([C19H21NF3O3]+ requires 368.1473), 373.1028 [M+Na]+ ([C19H17F3O3Na]+ requires 
373.1028), 723.2158 [2M+Na]+ ([C38H34F6O6Na]+ requires 723.2157). IR: 1746 cm-1 
(C=O), 1411 cm-1 (C=C).  
 (S)-1-Phenylprop-2-en-1-ol R-MTPA ester (88). 1H NMR 
(500 MHz, CDCl3): 7.42-7.24 (10H, m, PhCH), 6.45 (1H, dt, J 6.3, 
1.2, CH), 6.04 (1H, ddd, J 6.3, 10.4, 17.1, HC=CH2), 5.39 (1H, dt, J 
17.1, 1.2, HC=CHaHb), 5.31 (1H, dt, J 10.4, 1.2, HC=CHaHb), 3.54 (3H, s, OCH3). 13C 
NMR (75 MHz, CDCl3): 165.5 (C=O), 137.6 (CF3), 135.2 (HC=CH2), 132.2, 129.5, 
128.5, 128.5, 128.3, 127.4, 127.1 (Ph), 118.4 (HC=CH2), 78.6 (CH), 77.2 (CCF3), 55.5 
(CH3). HRMS: 368.1455 [M+NH4]+ ([C19H21NF3O3]+ requires 368.1473), 373.1009 
[M+Na]+ ([C19H17F3O3Na]+ requires 373.1028), 723.2148 [2M+Na]+ ([C38H34F6O6Na]+ 
requires 723.2157). IR: 1746 cm-1 (C=O), 1411 cm-1 (C=C).  
 (R)-1-Phenylprop-2-enyl bromoacetate ((R)-92). (R)-1-Phenylprop-
2-en-1-ol (600 mg, 4.47 mmol) was dissolved in dry CH2Cl2 (45 mL) 
and the solution cooled to 0 °C. Pyridine (720 µL, 8.94 mmol) was 
added followed by bromoacteyl bromide (779 µL, 8.94 mmol), forming a white 
suspension. The mixture was stirred at 0 °C for 2 h and quenched with sat. aq. NH4Cl 
(100 mL). The aqueous layer was extracted with CH2Cl2 (3×100 mL), the organic 
extracts combined, washed with sat. aq. CuSO4 (100 mL), dried over Na2SO4, filtered 
and the solvent removed under reduced pressure. The crude material was purified by 
flash chromatography (0-8% EtOAc in hexane), yielding the product as a colourless 
liquid (936 mg, 82%). 1H NMR (500 MHz, CDCl3): 7.38-7.36 (4H, m, PhCH), 7.35-
7.31 (1H, m, PhCH), 6.30 (1H, dt, J 6.0, 1.2, CH), 6.02 (1H, ddd, J 6.0, 10.5, 17.1, 
HC=CH2), 5.36 (1H, dt, J 17.1, 1.2, HC=CHaHb), 5.30 (1H, dt, J 10.5, 1.2, HC=CHaHb), 
3.89 (1H, d, J 12.4, CHaHbBr), 3.86 (1H, d, J 12.4, CHaHbBr). 13C NMR (75 MHz, 
CDCl3): 166.2 (C=O), 138.2 (HC=CH2), 135.1 (PhC1), 128.7, 128.5, 127.2 
(PhC2/PhC3/PhC4), 117.8 (HC=CH2), 78.1 (CH), 26.2 (CH2); HRMS: 276.9834 
[M+Na]+ ([C11H1179BrO2Na]+ requires 276.9834), 278.9812 [M+Na]+ 
([C11H1181BrO2Na]+ requires 278.9814). IR: 1734 cm-1 (C=O), 1644 cm-1 (C=C).  
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 (S)-1-Phenylprop-2-enyl bromoacetate ((S)-92). (S)-1-Phenylprop-
2-en-1-ol (3.93 g, 29.3 mmol) was dissolved in dry CH2Cl2 (30 mL) 
and the solution cooled to 0 °C. Pyridine (4.72 mL, 58.6 mmol) was 
added followed by bromoacetyl bromide (5.10 mL, 58.6 mmol), forming a yellow 
suspension. The mixture was stirred at 0 °C for 2 h and quenched in sat. aq. NH4Cl 
(100 mL). The aqueous layer was extracted with CH2Cl2 (3×100 mL), the organic 
extracts combined, washed with sat. aq. CuSO4 (100 mL) and brine (100 mL), dried 
over Na2SO4, filtered and the solvent removed under reduced pressure. The crude was 
purified by flash chromatography (0-8% EtOAc in hexane), yielding the product as a 
yellow liquid (6.18 g, 83%). 1H NMR (500 MHz, CDCl3): 7.38-7.36 (4H, m, PhCH), 
7.35-7.32 (1H, m, PhCH), 6.29 (1H, dt, J 6.0, 1.2, CH), 6.02 (1H, ddd, J 6.0, 10.5, 17.1, 
HC=CH2), 5.36 (1H, dt, J 17.1, 1.2, HC=CHaHb), 5.30 (1H, dt, J 10.5, 1.2, HC=CHaHb), 
3.89 (1H, d, J 12.4, CHaHbBr), 3.86 (1H, d, J 12.4, CHaHbBr). 13C NMR (75 MHz, 
CDCl3): 166.2 (C=O), 138.0 (HC=CH2), 135.4 (PhC1), 128.7, 128.5, 127.2 
(PhC2/C3/C4), 117.8 (HC=CH2), 78.1 (CH), 26.0 (CH2). HRMS: 276.9831 [M+Na]+ 
([C11H1179BrO2Na]+ requires 276.9834). IR: 1733 (C=O). 
N-acetyl-S-[(R)-1-phenylprop-2-enylacetate]-L-cysteine 
(93). (R)-1-Phenylprop-2-enyl bromoacetate (200 mg, 0.78 
mmol) was dissolved in MeCN (4 mL) and N-acetyl-L-
cysteine (140 mg, 0.86 mmol) was added followed by NEt3 (240 µL, 1.72 mmol). The 
mixture was stirred for 1h, quenched into aq. 1M HCl (25 mL), extracted with EtOAc 
(3×30 mL), the organic extracts combined, dried over Na2SO4, filtered and the solvent 
removed under reduced pressure. The crude was purified by flash chromatography (1% 
AcOH and 5% MeOH in CH2Cl2) yielding the product as a colourless oil (225 mg, 
86%). 1H NMR (500 MHz, CDCl3): 7.38-7.36 (4H, m, PhCH), 7.34-7.32 (1H, m, 
PhCH), 6.91 (1H, d, J 6.7, NH), 6.27 (1H, d, J 6.1, CH), 6.02 (1H, ddd, J 6.1, 10.4, 
17.0, CH=CH2), 5.33 (1H, dt, J 17.0, 1.2, HC=CHaHb) 5.29 (1H, dt, J 10.4, 1.2, 
HC=CHaHb), 4.74 (1H, ddd, J 4.7, 6.0, 6.7, HNCH), 3.40 (1H, d, J 15.7, CHaHb), 3.35 
(1H, d, J 15.7, CHaHb), 3.14 (1H, dd, J 6.0, 14.2, Cys-CHaHb), 3.05 (1H, dd, J 4.7, 14.2, 
Cys-CHaHb), 2.04 (3H, s, CH3). 13C NMR (75 MHz, CDCl3): 176.5 (CO2H), 173.4 
(CONH), 170.1 (CO2CH), 138.1, 128.7, 128.5, 127.2 (Ph), 135.5 (HC=CH2), 117.8 
(HC=CH2), 77.9 (CH), 52.4 (cys-CH), 34.9 (COCH2), 34.5 (cys-CH2), 22.8 (CH3). 
HRMS: 338.10568 [M+H]+ ([C16H20NO5S]+ requires 338.1062), 360.08761 [M+N]+ 
([C16H19NO5SNa]+ requires 360.088), 382.06967 [M-H+2Na]+ ([C16H18NO5SNa2]+ 
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requires 382.0701), 697.18562 [2M+Na]+ ([C32H38NO10S2Na]+ requires 683.1834). IR: 
1713 cm-1 (C=O), 1627 cm-1 (C=O), 3306-2929 cm-1 (br, OH, NH, CH).  
2-Butene-1,4-diol di(bromoacetate) (94). 
(S)-1-Phenylprop-2-enyl bromoacetate (301 µL, 1.60 
mmol) was dissolved in dry CH2Cl2 (7 mL) and the 
solution flushed with N2. Hoveyda-Grubbs II catalyst (50 
mg, 0.08 mmol, 5 mol%) was added, the mixture heated to 45 °C and stirred at this 
temperature for 16 h. The solution was cooled to RT, a second aliquot of Hoyveda-
Grubbs II catalyst was added (50 mg, 0.08 mmol, 5 mol%), the solution re-heated to 45 
°C and stirred for a further 24 h. The mixture was cooled to RT, a solution of potassium 
2-isocyanoacetate (45 mg, 22 mol%) in MeOH (1 mL) was added and the mixture 
stirred for 1 h. The solvent was removed under reduced pressure and the crude purified 
by flash chromatography (5-10% EtOAc in hexane), yielding the product as an off-
white solid (172 mg, 45%). (500 MHz, CDCl3): 7.33-7.21 (10H, m, PhCH), 6.26 (2H, 
dd, J 1.4, 3.1, CH), 5.93 (2H, dd, J 1.4, 3.1, HC=CH), 3.71 (4H, s, CH2). 13C NMR (75 
MHz, CDCl3): 166.1 (C=O), 137.6 (PhC1), 130.6 (HC=CH), 128.8, 128.7, 128.3 
(PhC2/PhC3/PhC4), 76.8 (CH), 25.9 (CH2). HRMS: 504.9481 [M+Na]+ 
([C20H18O479Br81BrNa]+ requires 504.9444). IR: 1741 cm-1 (C=O), 1675 cm-1 (C=C), 
1601 cm-1, 1584 cm-1, 1492 cm-1 (ArC=C), 3029 cm-1, 2982-2908 cm-1 (C-H).  
4,5-Dimethoxy-2-nitrobenzaldehyde (83). Conc. HNO3 (70%, 80 
mL, 903 mmol) was cooled to 0 °C and 3,4-dimethoxybenzaldehyde 
(10.0 g, 60.2 mmol) was added portionwise. The solution was allowed 
to slowly warm up to RT over 3 h, poured into a water/ice slurry (600 mL), the 
precipitate collected by filtration and washed with ice cold EtOH, to give the product as 
a yellow solid (10.9 g, 85%). 1H NMR (500 MHz, CDCl3): 10.46 (s, 1H, COH), 7.62 (s, 
1H, PhC3H), 7.43 (s, 1H, PhC6H), 4.04 (s, 3H, OCH3), 4.03 (s, 3H, OCH3). 13C NMR 
(75 MHz, CDCl3): 187.7 (C=O), 153.3 (PhC5), 152.5 (PhC4), 143.9 (PhC2), 125.6 
(PhC1), 109.8 (PhC6), 107.2 (PhC3), 56.8 (OCH3), 56.8 (OCH3). HRMS: 212.0554 
[M+Na]+ ([C9H10NO5]+ requires 212.0554). IR: 1756 cm-1 (C=O), 2905 cm-1, 2839 cm-1, 
3095-3064 cm-1 (C-H), 1509 cm-1, 1333 cm-1 (NO2).  
1-(4,5-Dimethoxy-2-nitrobenzyl)-prop-2-en-1-ol (97). 
4,5-Dimethoxy-2-nitrobenzaldehyde (2.0 g, 9.47 mmol) was 
dissolved in dry THF (50 mL) and cooled to -78 °C. Vinylmagnesium 
bromide (1M solution in THF, 14.2 mL, 14.2 mmol) was added slowly and the solution 
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stirred and allowed to warm up to RT slowly over 16 h. The solution was poured slowly 
into sat. aq. NH4Cl/ice slurry (100 mL), extracted with EtOAc (3×100 mL), the extracts 
combined and washed with brine (100 mL), dried over Na2SO4, filtered and the solvent 
removed under reduced pressure. The crude mixture was purified by flash 
chromatography (20% EtOAc in hexane) yielding the product as a yellow fluffy solid 
(1.58 g, 70%). 1H NMR (500 MHz, CDCl3): 7.58 (1H, s, PhC3H), 7.21 (1H, s, PhC6H), 
6.08 (1H, ddd, J 17.2, 10.5, 4.7, CH=CH2), 5.93 (1H, d, J 4.7, CH), 5.43 (1H, dt, J 17.2, 
1.3, HC=CHaHb), 5.25 (1H, dt, J 10.5, 1.3, HC=CHaHb), 3.99 (3H, s, OCH3), 3.95 (3H, 
s, OCH3). 13C NMR (75 MHz, CDCl3): 153.6 (PhC5), 148.0 (PhC4), 140.1 (PhC2), 
138.1 (HC=CH2), 133.1 (PhC1), 115.8 (HC=CH2), 109.8 (PhC6), 107.9 (PhC3), 69.8 
(CH), 56.4 (OCH3), 56.4 (OCH3). HRMS: 262.0864 [M+H]+ ([C11H14NO5]+ requires 
240.0867), 262.0689 [M+Na]+ ([C11H13NO5Na]+ requires 262.0686), 501.1486 
[2M+Na]+ ([C22H26N2NaO10]+ requires 501.1480). IR: 3533 cm-1 (OH), 3110-2840 cm-1 
(C-H), 1613 cm-1, 1502 cm-1 (C=C). 
1,4-Di(4,5-dimethoxy-2-nitrobenzyl)-but-2-en-1,4-
diol (98). 1-(4,5-Dimethoxy-2-nitrobenzyl)-prop-2-en-1-
ol (500 mg, 2.1 mmol) was dissolved in dry CH2Cl2 
(7 mL), the solution flushed with N2 and Hoveyda-Grubbs II catalyst (65.5 mg, 
0.10 mmol, 5 mol%) was added. The mixture was heated at 45 °C for 16 h. The solution 
was cooled to RT, a solution of potassium isocyanoacetate (65 mg, 25 mol%) in MeOH 
(2.3 mL) was added and the mixture stirred for 1 h, forming a heavy precipitate. The 
precipitate was collected by filtration and washed with methanol, yielding the product 
as an off-white solid (440 mg, 93%, 45:55 mixture of diastereomers). 1H NMR 
(500 MHz, d6-DMSO): 7.54 (1.8H, s, PhC3H), 7,53 (2.2H, s, PhC3H’), 7.22 (1.8H, s, 
PhC6H), 7.21 (2.2H, s, PhC6H’), 5.86-5.83 (8H, m, C2H, C2H’, C1H, OH), 5.72 (4H, 
br s, C1H’, OH’), 3.86 (5.4H, s, OMe), 3.86 (5.4H, s, OMe), 3.85 (13.2H, s, OMe’, 
OMe’). 13C NMR (75 MHz, d6-DMSO): 152.9 (PhC5), 152.9 (PhC5’), 147.2 
(PhC4/PhC4’), 139.5 (PhC2/PhC2’), 134.3 (C2), 134.2 (C2’), 131.3 (PhC1), 131.3 
(PhC1’), 109.6 (PhC6), 109.4 (PhC6’), 107.4 (PhC3), 107.4 (PhC3’), 67.1 (C1), 67.0 
(C1’), 56.0 (CH3/CH3’), 55.9 (CH3/CH3’). HRMS: 473.1182 [M+Na]+ 
([C20H22N2NaO10]+ requires 473.1167), 923.2450 [2M+Na]+ ([C40H44N4NaO20]+ requires 
923.2442). IR: 3512 cm-1, 3470 cm-1 (OH), 1514 cm-1, 1327 cm-1 (NO2). 
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1,4-Di-O-bromoacetyl-1,4-di(4,5-dimethoxy-2-
nitrobenzyl)-but-2-en-1,4-diol (95). 1,4-Di(4,5-
dimethoxy-2-nitrobenzyl)-but-2-en-1,4-diol (100 mg, 
0.22 mmol) was suspended in CH2Cl2, the suspension 
cooled to 0 °C and bromoacetyl bromide (38 µL, 0.44 mmol) was added followed by 
pyridine (36 µL, 0.44 mmol). The solution was stirred at 0 °C for 1 h, quenched into 
H2O (5 mL), extracted with CH2Cl2 (3×5 mL), the extracts combined and washed with 
sat. aq. CuSO4 (2×5 mL) and the solvent removed under reduced pressure. The crude 
product was purified by flash chromatography (20%-33% EtOAc in hexane), yielding 
the product as a light brown powder (57 mg, 37%, 9:1 ratio of diastereomers). 1H NMR 
(500 MHz, CDCl3): 7.63 (2H, s, PhC3H’), 7.58 (2H, s, PhC3H), 7.05 (4H, dd, J 2.7, 
1.0, C1H/C1H’), 7.04 (4H, s, PhC6H/PhC6H’), 6.09 (2H, dd, J 1.0, 2.7, C2H’), 6.06 
(2H, dd, J 1.0, 2.7, C2H), 4.01 (s, 6H, OCH3’), 4.00 (s, 6H, OCH3), 3.96 (s, 6H, 
OCH3’), 3.94 (s, 6H, OCH3), 3.92 (d, 2H, J 11.9 CHaHbBr), 3.88 (d, 2H, J 11.9 
CHaHbBr’), 3.84 (d, 2H, J 11.9 CHaHbBr), 3.80 (d, 2H, J 11.9 CHaHbBr’). 13C NMR (75 
MHz, CDCl3): 165.5 (C=O), 153.5 (PhC5), 148.6 (PhC4), 140.3 (PhC2), 130.0 (C2), 
127.7 (PhC1), 109.7 (PhC6), 107.8 (PhC3), 71.8 (C1), 56.7 (CH3), 56.4 (CH3), 25.5 
(CH2). HRMS: 710.0043 [M+NH4]+ ([C24H2879Br81BrN3O12]+ 710.0014), 708.0060 
[M+NH4]+ ([C24H2879Br79BrN3O12]+ requires 708.0035), 730.9324 [M+K]+ 
([C24H2479Br81BrN2O12K]+ requires 730.9308), 728.9345 [M+K]+ 
([C24H2479Br79BrN2O12K]+ requires 728.9328). IR: 2844 (C-H), 1743 cm-1 (C=O), 1515 
cm-1, 1330 cm-1 (NO2). 
7-Methoxy-4-methylcoumarin (100). (Fournier et al., 2013) Conc. 
H2SO4 (120 mL) was cooled to 0 °C and 3-methoxyphenol (17.5 mL, 
161 mmol) was added dropwise with vigorous stirring. The solution 
was stirred for 10 min and ethyl acetoacetate (22.4 mL, 177 mmol) was added dropwise, 
keeping the temperature below 6 °C. The mixture was stirred at 0 °C for 3 h, diluted 
into a H2O/ice slurry (600 mL), filtered under suction, dried on the filter and on high 
vacuum overnight, leaving the product as a white solid (37.8 g, quantitative). 1H NMR 
(500 MHz, CDCl3): 7.50 (1H, d, J 8.7, CmC5H), 6.87 (1H, dd, J 2.5, 8.7, CmC6H), 
6.83 (1H, d, J 2.5, CmC8H), 6.14 (1H, br s, CmC3H), 3.88 (3H, s, OCH3), 2.40 (3H, d, 
J 1.2, CH3). 13C NMR (75 MHz, CDCl3): 162.7 (CmC7), 161.4 (CmC2), 155.3 (Cm8a), 
152.7 (CmC4), 125.6 (CmC5), 113.6, 112.3, 111.9 (CmC3/CmC6/CmC4a), 100.8 
(CmC8), 55.8 (OCH3). HRMS: 213.0517 [M+Na]+ ([C11H10O3Na]+ requires 213.0522), 
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381.1332 [2M+H]+ ([C22H21O6]+ requires 381.1333), 403.1151 [2M+Na]+ 
([C22H20O6Na]+ requires 403.1152). IR: 1727 cm-1 (C=O), 1606 cm-1 (C=C).  
4-Chloromethyl-7-methoxycoumarin (103). (Fournier et al., 2013) 
Conc. H2SO4 (130 mL) was cooled to 0 °C and 3-methoxyphenol 
(17.5 mL, 161 mmol) was added dropwise with vigorous stirring. 
The solution was stirred for 10 min and ethyl 4-chloro acetoacetate (23.9 mL, 
177 mmol) was added dropwise, keeping the temperature below 6 °C. The mixture was 
stirred at 0 °C for 3 hours. The mixture was diluted into a H2O/ice slurry (600 mL), 
filtered under suction, dried on the filter and on high vacuum overnight, leaving the 
product as a white flaky solid (21.1 g, 60%). 1H NMR (500 MHz, CDCl3): 7.57 (1H, d, 
J 8.9, CmC5H), 6.90 (1H, dd, J 2.5, 8.9, CmC6H), 6.85 (1H, d, J 2.5, CmC8H), 6.40 
(1H, br s, CmC3H), 4.63 (2H, d, J 2.5, CH2), 3.89 (3H, s, OCH3). 13C NMR (75 MHz, 
CDCl3): 163.0 (CmC7), 160.8 (CmC2), 155.8 (Cm8a), 149.6 (CmC4), 125.2 (CmC5), 
112.7, 112.6 (CmC3/CmC6), 110.8 (CmC4a), 101.0 (CmC8), 55.8 (CH2), 41.3 (OCH3). 
HRMS: 225.0314 [M+H]+ ([C11H1035ClO3]+ requires 225.0313), 242.0573 [M+NH4]+ 
([C11H1335ClNO3]+ requires 242.0578), 247.0130 [M+Na]+ ([C11H935ClNaO3]+ requires 
247.0132). IR: 1720 cm-1 (C=O), 1608 cm-1 (C=C).  
4-Formyl-7-methoxycoumarin  
From SeO2 oxidation (82). (Huynh et al., 2012) 7-Methoxy-4-
methylcoumarin (4.5 g, 23.6 mmol) was suspended in xylenes 
(60 mL) and the mixture heated under reflux. Once the starting material was in solution, 
SeO2 (3.94 g, 35.5 mmol) was added portionwise and the dark solution heated under 
reflux for 16 h. The solution was filtered hot to remove the black selenium and the 
solvent removed under reduced pressure. The dark yellow crude product was purified 
by flash chromatography (20-100% EtOAc in hexane) yielding the product as dark 
yellow fluffy solid (2.48 g, 51%). 1H NMR (500 MHz, CDCl3): 10.07 (1H, s, COH), 
8.50 (1H, d, J 9.0, CmC5H), 6.92 (1H, dd, J 2.5, 9.0, CmC6H), 6.87 (1H, d, J 2.5, 
CmC8H), 6.71 (1H, s, CmC3H), 3.90 (3H, s, OCH3). 13C NMR (75 MHz, CDCl3): 
191.7 (COH), 163.4 (CmC7), 160.7 (CmC2), 156.5 (Cm8a), 143.8 (CmC4), 127.3 
(CmC5), 122.1 (CmC3), 113.3 (CmC6), 108.2 (CmC4a), 101.1 (CmC8), 55.8 (OCH3). 
HRMS: 205.0488 [M+H]+ ([C11H9O4]+ requires 205.0495), 227.0311 [M+Na]+ 
([C11H8NaO4]+ requires 227.0315), 409.0921 [2M+H]+ ([C22H17O8]+ requires 
409.0918). IR: 1722 cm-1 (C=O), 1702 cm-1 (C=O), 1607 cm-1 (C=C), 1592 cm-1 (C=C).  
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From PCC oxidation. Prepared from a modified protocol to that previously described 
(Pisani et al., 2013). 4-Dydroxymethyl-7-methoxycoumarin (2.2 g, 10.7 mmol) was 
suspended in dry CH2Cl2 (200 mL) and stirred for 15 min. MgSO4 (4.6 g) was added 
followed by PCC (4.6 g, 10.7 mmol) and the mixture stirred at RT for 16 h. The dark 
solution was filtered through celite and the solvent removed under reduced pressure. 
The dark brown residue was purified by flash chromatography (25-60% EtOAc in 
hexane) yielding the product as a yellow flaky solid (1.06 g, 49%). 1H NMR (500 MHz, 
CDCl3): 10.07 (1H, s, COH), 8.50 (1H, d, J 9.0, CmC5H), 6.92 (1H, dd, J 2.5, 9.0, 
CmC6H), 6.87 (1H, d, J 2.5, CmC8H), 6.71 (1H, s, CmC3H), 3.90 (3H, s, OCH3). 
HRMS: 205.0489 [M+H]+ ([C11H9O4]+ requires 205.0495), 409.0916 [2M+H]+ 
([C22H17O8]+ requires 409.0918). IR: 1722 cm-1 (C=O), 1703 cm-1 (C=O), 1608 cm-1 
(C=C), 1594 cm-1 (C=C).  
4-Acetoxymethyl-7-methoxycoumarin (107). 4-Chloromethyl-7-
methoxycoumarin (5.5 g, 22.3 mmol) was dissolved in AcOH 
(60 mL) and sodium acetate (5.5 g, 67.0 mmol) was added. The 
solution was heated under reflux 20 h. The solution was diluted into a H2O/ice slurry 
(600 mL), the precipitate collected under suction, dried on the filter and then under high 
vacuum overnight. The product was obtained as a white solid (3.30 g, 64%, 93% purity) 
and used without further purification. 1H NMR (500 MHz, CDCl3): 7.41 (1H, d, J 9.6, 
CmC5H), 6.87 (1H, dd, J 3.5, 9.6, CmC6H), 6.86 (1H, d, J 3.5, CmC8H), 6.34 (1H, s, 
CmC3H), 5.26 (2H, s, CH2), 3.88 (3H, s, OCH3), 2.21 (3H, s, COCH3). 13C NMR 
(75 MHz, CDCl3): 170.1 (COCH3), 162.9 (CmC7), 160.9 (CmC2), 155.6 (CmC8a), 
149.1 (CmC4), 124.4 (CmC5), 112.7 (CmC6), 110.6 (CmC4a), 110.0 (CmC3), 101.2 
(CmC8), 61.2 (CH2), 55.8 (COCH3), 20.7 (OCH3). HRMS: 249.0759 [M+H]+ 
([C13H13O5]+ requires 249.0758), 266.1019 [M+NH4]+ ([C13H16NO5]+ requires 
266.1023), 271.0576 [M+Na]+ ([C13H12NaO5]+ requires 271.0577). IR: 1711 cm-1 
(C=O), 1605 cm-1 (C=C).  
4-Hydroxymethyl-7-methoxycoumarin (106). 4-Acetoxymethyl-7-
methoxycoumarin (2.80 g, 12.0 mmol) was dissolved in 3:1 
EtOH:conc. HCl (43 mL) and the solution heated under reflux for 
45 min. The mixture was allowed to cool to RT and diluted into a H2O/ice slurry 
(400 mL). The white precipitate formed was collected under suction, dried on the filter 
and in high vacuum overnight, yielding the product as a white flaky solid (2.4 g, 98%, 
93% purity). 1H NMR (500 MHz, CDCl3): 7.43 (1H, d, J 9.5, CmC5H), 6.90-6.80 (2H, 
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m, CmC6H/CmC8H), 6.47 (1H, t, J 1.5, CmC3H), 4.88 (2H, d, J 1.5, CH2), 3.88 (3H, s, 
OCH3). HRMS: 207.0650 [M+H]+ ([C11H11O4]+ requires 207.0652). IR: 3380 cm-1 
(OH), 1682 cm-1 (C=O), 1605 cm-1 (C=C), 1085 (C-O).  
4-(1-Hydroxy-2-propenyl)-7-methoxycoumarin (108). 4-Formyl-
7-methoxycoumarin (1.5 g, 7.3 mmol) was suspended in dry THF 
(24 mL) and cooled to 0 °C. Vinylmagnesium bromide (0.7 M in 
THF, 12.5 mL, 8.8 mmol) was added dropwise and the mixture stirred at 0 °C for 3 
hours. The solution was quenched with sat. aq. NH4Cl (100 mL), the aqueous solution 
extracted with EtOAc (3×100 mL), the extracts combined and washed with brine 
(100 mL), dried over Na2SO4, filtered and the solvent removed under reduced pressure. 
The crude was purified by flash chromatography (33-50% EtOAc in hexane) yielding 
the product as a yellow gum (569 mg, 34%). 1H NMR (500 MHz, CDCl3): 7.61 (1H, d, 
J 9.6, CmC5H), 6.83 (2H, m, CmC6H/CmC8H), 6.48 (1H, s, CmC3H), 6.07 (1H, ddd, J 
6.1, 10.3, 17.1, CH=CH2), 5.52 (1H, d, J 17.1, HC=CHaHb), 5.47 (1H, t, J 6.1, CH), 
5.38 (1H, d, J 10.3, HC=CHaHb), 3.81 (3H, s, OCH3), 2.05 (1H, s, OH). 13C NMR 
(75 MHz, CDCl3): 162.5 (CmC7), 161.8 (CmC2), 155.8, 155.6 (CmC8a/CmC4), 137.0 
(CH=CH2), 125.9 (CmC5), 118.6 (CH=CH2), 112.4 (CmC6), 110.9 (CmC4a), 109.4 
(CmC3), 101.0 (CmC8), 71.0 (CH), 55.7 (OCH3). HRMS: 233.0813 [M+H]+ 
([C13H13O4]+ requires 233.0809), 255.0620 [M+Na]+ ([C13H12O4Na]+ requires 255.0628), 
465.1566 [2M+H]+ ([C26H25O8]+ requires 465.1544). IR: 3459 cm-1 (OH), 1704 cm-1 
(C=O), 1607 cm-1 (C=C).  
1,4-Di(7-methoxy-4-methylcoumarinyl)-but-2-en-1,4-
diol (109). 4-(1-Hydroxy-2-propenyl)-7-
methoxycoumarin (1.0 g, 4.3 mmol) was suspended in 
dry CH2Cl2 (30 mL), the solution flushed with N2 and 
Hoveyda-Grubbs II catalyst (135 mg, 0.22 mmol, 
5 mol%) was added. The suspension was heated at 45 °C for 36 h and cooled to RT. A 
solution of potassium isocyanoacetate (135 mg, 20 mol%) in MeOH (3.5 mL) was 
added and the mixture stirred for 1 h, forming a heavy precipitate. The precipitate was 
collected by filtration and washed with methanol, yielding the product as an off-white 
solid (650 mg, 80%, 95% purity, 3:2 mixture of diastereomers). 1H NMR (500 MHz, d6-
DMSO): 7.75 (1H, d, J 8.9, CmC5H), 7.69 (1H, d, J 8.9, CmC5H’), 6.98 (1H, d, J 2.1, 
CmC8H), 6.95 (1H, d, J 2.1, CmC8H’), 6.76 (1H, dd, J 2.1, 8.9, CmC6H), 6.70 (1H, dd, 
J 2.1, 8.9, CmC6H’), 6.33 (1H, s, CmC3H’), 6.31 (1H, s, CmC3H), 6.06 (1H, br s, 
O OMeO
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CH=CH), 6.04 (1H, br s, CH=CH’), 6.01 (2H, m, OH), 5.48 (2H, br s, CH/CH’), 3.85 
(3H, s, OCH3), 3.84 (3H, s, OCH3’). 13C NMR (75 MHz, d6-DMSO): 162.0, 162.0 
(CmC7), 160.6 (CmC2), 157.5 (CmC8a), 155.2, 155.2 (CmC4), 132.4, 132.2 (HC=CH), 
126.9, 126.8 (CmC5), 111.6, 111.5 (CmC6), 110.5, 110.4 (CmC4a), 108.3, 108.1 
(CmC3), 100.8, 100.7 (CmC8), 68.6, 68.5 (CH), 55.8 (OCH3). HRMS: 437.1253 
[M+H]+ ([C24H21O8]+ requires 437.1231), 873.2361 [2M+H]+ ([C48H41O16]+ requires 
873.2390). IR: 1694 cm-1 (C=O), 1611 cm-1 (C=C).   
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9 Appendix 
9.1 PanD and PanZ protein overexpression optimisation and purification 
9.1.1 PanD(T57V) 
HexaHis-tagged PanD(T57V) was overexpressed in auto-induction media (0.01% w/v 
ampicillin) from previously transformed E. coli MG1655 ΔpanZ ΔpanD (DE3) glycerol 
stocks containing the desired plasmid. The cells were disrupted mechanically in the 
presence of EDTA-free protease inhibitor cocktail to prevent proteolysis of the C-
terminus and centrifuged to remove cell debris. The protein was first purified by nickel 
affinity chromatography (Ni-NTA) under gravity as described in section 8.6.3. Protein 
expression levels and purity were assessed by SDS-PAGE (Fig. 9.1), which showed one 
main overexpressed protein band with the expected molecular weight (~15 kDa). 
 
Fig. 9.1 SDS-PAGE gel of PanD(T57V) after Ni-NTA purification. Lane 1: protein ladder, lanes 2-5: flow-through; 
lane 6: 50 mL wash fraction; lanes 7-11: 5×5 mL elution fractions. The protein was overexpressed as single band of 
the expected approximate size (~15 kDa). 
The protein was further purified by size-exclusion chromatography (SEC) and eluted 
into 50 mM Tris buffer, pH 7.4, containing 100 mM NaCl and 0.1 mM DTT (SEC 
buffer A, section 8.6.4). The protein elutes as a single peak with a shoulder, which is 
thought to be an oligomer of the tetramer.  
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Fig. 9.2 SEC trace for the purification of PanD(T57V) on a Superdex® 75 column (HiLoad® 16/60), showing a 
single peak (120-146 mL) with a shoulder (100-120 mL) for the elution of purified PanD(T57V) protein. The 
shoulder is thought to be an oligomer of the tetramer. 
9.1.2 PanZ 
Arabinose-inducible pBAD24 vector encoding C-terminally hexaHis-tagged PanZ 
(Nozaki et al., 2012) was transformed into E. coli BL21 Gold (DE3) cells following a 
standard heat-shock transformation protocol (see section 8.4.5). Initial overexpression 
in LB growth media (20 h, 37 °C, induced using 0.5% w/v arabinose at OD600=0.4) with 
and without pantothenate supplementation was poor. Overexpression trials were set up 
to investigate the effect of both pantothenate supplementation and concentration of 
arabinose on induction, as described in Table 11. In all cases, expression was induced at 
OD600=0.4-0.6. Overexpression levels were quantified over time (1.5 h, 2.5 h and 16 h 
after induction) by SDS-PAGE (Fig. 9.3).  
Higher concentrations of arabinose (0.5%-1%) showed better overexpression with 
contamination of a high molecular weight impurity. Supplementation with up to 
250 mM pantothenate improved expression further at 0.5% arabinose and appeared to 
reduce the amount of high molecular weight contaminants produced. The improvement 
of PanZ expression in the presence of pantothenate was later rationalised as because the 
overexpression of PanZ leads to β-alanine auxotrophy in E. coli cells, which, in turn, 
leads to cell death. Addition of pantothenate to the growth medium decreases the toxic 
effect of PanZ overexpression. It was also noted that PanZ overexpressed in the 
presence of pantothenate ran more slowly on SDS-PAGE than PanZ overexpressed 
without pantothenate supplementation. This could indicate a higher percentage of CoA-
bound PanZ, as CoA.PanZ is 800 Da heavier than apo.PanZ and carries 3 negatively 
charged phosphate groups. 
-500 
0 
500 
1,000 
1,500 
2,000 
2,500 
0 50 100 150 200 250 300 
A
bs
or
pt
io
n 
(a
.u
.) 
Volume (mL) 
280 nm 
260 nm 
  179 
Table 11 PanZ expression trial conditions, related to the SDS-PAGE gels in Fig. 9.3. 
 E. coli strain [arabinose] (w/v %) 
[pantothenate] 
(µM) Culture size (mL) 
1 BL21 Gold 0.5 1000 1000 
2 BL21 Gold 0.5 0 1000 
3 C41 (DE3) 0.5 0 100 
4 BL21 Star (DE3) 0.5 0 100 
5 BL21 Gold (DE3) 0.05 0 100 
6 BL21 Gold (DE3) 0.1 0 100 
7 BL21 Gold (DE3) 0.5 0 100 
8 BL21 Gold (DE3) 1.0 0 100 
9 BL21 Gold (DE3) 0.5 5 20 
10 BL21 Gold (DE3) 0.5 10 20 
11 BL21 Gold (DE3) 0.5 100 20 
12 BL21 Gold (DE3) 0.5 250 20 
 
 
Fig. 9.3 Quantification of protein expression during PanZ overexpression trials by SDS-PAGE. (Top) lane 1 – 
protein ladder; lanes 2 & 3 – trial 1 at 0 h and 16 h; lanes 4 & 5 – trial 2 at 0 h and 16 h; lanes 6-25: trials 3-7 at 0 h, 
1.5 h, 2.5 h and 16 h. (Bottom) lane 1 – protein ladder; lanes 2-21: trials 8-12 at 0h, 1.5 h, 2.5 h, and 16 h. 
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PanZ was successfully overexpressed from 1L overnight culture of E. coli BL21 Gold 
(DE3) cells in LB growth media (37 °C), supplemented with 250 mM pantothenate and 
induced at OD600=0.4-0.6 with 0.5% w/v arabinose. The cells were collected, 
mechanically disrupted and the protein purified by Ni-NTA chromatography as 
described for PanD(T57V). SDS-PAGE of the fractions showed good overexpression 
and the expected molecular weight for hexaHis-tagged PanZ (Fig. 9.4).  
 
Fig. 9.4 SDS-PAGE gel of PanZ purification by Ni-NTA overexpressed from the pBAD24 plasmid. Lane 1: protein 
ladder; lanes 2-4: flow-through; lane 5: 50 mL wash fraction; lanes 6-10: 5×5 mL elution fractions. 
Later in the project, Chris Bartlett (Wellcome Trust rotation PhD student) subcloned C-
terminally hexaHis-tagged PanZ into the pET28a vector from the pBAD24 plasmid, to 
allow for overexpression by auto-induction of the T7 RNA polymerase in E. coli 
MG1655 ΔpanZ ΔpanD (DE3) cells. The protein overexpressed well using auto-
induction and was purified by Ni-NTA chromatography (Fig. 9.5) and SEC and eluted 
into 50 mM Tris buffer, pH 7.4 containing 100 mM NaCl and 0.1 mM DTT (SEC 
buffer A, Fig. 9.6). 
 
Fig. 9.5 SDS-PAGE gel of PanZ purification by Ni-NTA overexpressed from the pET28a plasmid. Lane 1: protein 
ladder; lanes 2-3: flow-through; lane 4: 50 mL wash fraction; lanes 5-9: 5×5 mL elution fractions.  
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Fig. 9.6 SEC trace for the purification of PanZ on a Superdex® 75 column (HiLoad® 16/60), showing a single peak 
for the elution of PanZ between 170-212 mL. 
9.1.3 SeMet PanZ 
SeMet PanZ was overexpressed from E. coli B384 (DE3) cells harbouring a pBAD24 
plasmid coding for C-terminally hexaHis-tagged PanZ, following a previously 
published autoinduction protocol (see section 8.5.3) (Sreenath et al., 2005). The protein 
was purified by Ni-NTA and SEC (Fig. 9.7) as described for PanD(T57V). 
 
Fig. 9.7 SEC trace for the purification of SeMet PanZ on a Superdex® 75 column (HiLoad® 16/60), showing a 
single peak for the elution of the protein between 180-210 mL. 
9.1.4 PanD(T57V/K119STOP) 
PanD(T57V/K119STOP) was generated using a standard site-directed mutagenesis 
protocol as described in section 8.4 using the template vector pRSETA-ADC(T57V) 
(Webb et al., 2014). The pRSETA-ADC(T57V/K119STOP) plasmid was directly 
transformed into E. coli XL10 cells and a colony minicultured overnight in LB media 
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containing 0.01 % w/v ampicillin. The plasmid was miniprepped and sent for 
sequencing. Upon confirmation of the correct mutation, the plasmid was transformed 
into E. coli MG1655 ΔpanZ ΔpanD (DE3) cells for overexpression. The protein was 
overexpressed by auto-induction of the T7 polymerase and purified by Ni-NTA and 
SEC, similarly to PanD(T57V) (Fig. 9.8). 
 
Fig. 9.8 SEC trace for the purification of PanD(T57V/K119STOP) on a Superdex® 75 column (HiLoad® 16/60), 
showing a single peak (120-146 mL) for the elution of the protein.  
9.1.5 Not-activated WT PanD 
WT PanD (not activated enzyme) was overexpressed from previously transformed E. 
coli C41 (DE3) cells harbouring a pRSETA-ADC-WT plasmid (Saldanha et al., 2001) 
by auto-induction of the T7 RNA polymerase (37 °C, 18 h). The cells were collected 
and stored at -80 °C or used directly. The protein was purified by Ni-NTA and SEC as 
described for PanD(T57V) (Fig. 9.9).  
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Fig. 9.9 SEC trace for the purification of WT PanD on a Superdex® 75 column (HiLoad® 26/60), showing a single 
peak (50-60 mL) with a shoulder peak (40-50 mL) for the elution of the protein. 
9.1.6 Activated WT ADC 
WT PanD (not activated enzyme) was overexpressed from previously transformed E. 
coli C41 (DE3) cells harbouring a pRSETA-ADC-WT plasmid (Saldanha et al., 2001) 
as described in the previous section. The cell pellet was collected by centrifugation and 
heated at 37 °C for 24 h for activation of the PanD zymogen to ADC. After activation, 
the cell pellet was stored at -80 °C or used directly for purification of WT ADC by Ni-
NTA and SEC (Fig. 9.10) as described for PanD(T57V). The protein purity, yield and 
extent of activation were determined by SDS-PAGE (Fig. 9.11).  
 
Fig. 9.10 SEC trace for the purification of WT ADC on a Superdex® 75 column (HiLoad® 26/60), showing a single 
peak (50-60 mL) with a shoulder peak (40-50 mL) for the elution of the protein. 
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Fig. 9.11 Tris-tricine SDS-PAGE gel of WT ADC purification by Ni-NTA and SEC. Lane 1: protein ladder; lanes 2-
4: flow-through; lane 5: 50 mL wash fraction; lanes 6-10: 5×5 mL elution fractions; lanes 11-15: SEC fractions. 
The fractions arising from the main SEC peak and the shoulder peak showed that both 
are cleaved ADC. It had been previously proposed that the early peak corresponded to 
the non-activated PanD protein and the later peak to the activated protein, but the SDS-
PAGE analysis shows similar bands across all the elution fractions. The shoulder is 
instead thought to be an oligomer of tetramers. 
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9.3 Calculation of twinning fractions 
Twinning is detected during scaling and merging of the data by using the “L-test” 
(Padilla and Yeates, 2003). This statistical approach analyses the intensity distribution 
of reflections. The intensities of two unrelated reflections that are close in reciprocal 
space (I(h1) and I(h2)) are analysed to give a quantity L, defined as: 
L ≡ ! h! − !(h!)! h! + !(h!) 
where the range of L is -1 to 1. Each pair of reflections should have similar expected 
intensity values when crystals are twinned. As dividing the difference of intensities of 
the spots by their sum leads to normalisation of the values of L, no further normalisation 
is required, for example, across resolution shells. The probability distribution of L, 
N(|L|) is then plotted. For untwinned, acentric data: ! ! = |!| 
which would generate a straight line intersecting the origin. For a perfect twin: 
! ! = |!|(3− !!)2  
giving a different plot of the cumulative distribution of L. Plotting the calculated values 
for a dataset against the theoretical curves gives an indication of the presence of 
twinning as well as of the twin fraction, α (Fig. 9.12). 
 
Fig. 9.12 Plot of the cumulative distribution of |L| (adapted from (Padilla and Yeates, 2003)). The prediction for 
acentric, non-twinned data is shown as a bold line; for perfect twinned, acentric data as a dashed line and the statistics 
for experimental data from a highly twinned dataset as open circles. 
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The twin fraction, α, is defined as: !!,!,! = !!!,!,! crystal1 + (1− !)!!,!,! crystal2  
and can also be calculated using the H-test (Yeates, 1997). In this case, two reflections 
related by a potential twin law, I(h1) and I(h2), are analysed to give the quantity H: 
! = |! h! − ! h! |! h! + ! h!  
The probability distribution of H, P(H), is then plotted and compared against predicted 
distributions for different twinning fractions to give α for the experimental dataset (Fig. 
9.13), where: ! ! = 0!!!for$$$! < 0 
! ! = !1− 2! !!!for$$$0 ≤ ! ≤ 1− 2! ! ! = 1!!!for$$$! > 1− 2! 
 
Fig. 9.13 Probabilty distribution of H (adapted from (Lebedev, 2013)). The predicted cumulative probability 
distribution of H for different twin fractions, α=0.0-0.5 (untwinned to perfectly twinned) are shown as blue lines. The 
calculated cumulative distribution of H for PDB 1KU5 (Li et al., 2003) is shown in red, with an α≈0.2. 
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3,4-dim
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0.07 
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9.6 Photocage scaffolds, properties and cleavage mechanism 
9.6.1 ortho-Nitrobenzyl 
Table 12 Overview and general properties of ortho-nitrobenzyl photocleavable groups 
 
   
 
λmax (nm) 254 254 262 345 
εmax (M-1cm-1) ca. 27000 ca. 27000 ca. 5000 ca. 600 
φ 0.1-0.2 0.1-0.64 0.04-0.14 0.01 
k (s-1) 10 - 200 10 - 1000 9×103 - 3×104 N/A 
solubility (H2O) Poor Poor Good Poor 
 
ortho-Nitrobenzyl photocleavable protecting groups are one of the most used and 
investigated photocages to date. oNB groups absorb mainly in the λ=280 nm region and 
the rate of release of product varies between 10 ms-100 µs depending on the exact 
chromophore being used as well as external factors such as pH. The cleavage 
mechanism (Fig. 9.14) has two distinct stages. The first is the light step, which involves 
the absorption of a photon and the excitation of the chromophore, followed by the dark 
step which then causes release of the product. Upon absorption of a photon, the 
nitrobenzyl group is placed in an excited singlet (I) state which can cross to a longer 
lived triplet state (Schmierer et al., 2010). Both excited states can then decay to the aci-
nitro intermediate (II) which cyclises to a benzisoxazoline ring (IV). The ring 
intermediate then opens to an alcohol (V), which, in turn, hydrolyses to release the 
photoprotected moiety, leaving a nitroso photolysis by-product (VI). The rate of oNB 
cleavage is greatly dependent on pH due to the equilibrium established between the 
protonated and deprotonated aci-nitro species formed after excitation of the 
chromophore (II and III respectively) as only the protonated form (II) is able to ring 
close to the benzisoxazoline intermediate (IV). The rate of aci-nitro decay decreases 
decreases rapidly with increasing pH. 
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Fig. 9.14 Mechanism of photo-cleavage of ortho-nitrobenzyl protecting groups.  
The rate determining step for the release of the product depends on the leaving group. 
At neutral conditions, the rate determining step in the release of poor leaving groups, 
such as alcohols (Il'ichev et al., 2004), is the hydrolysis of the ring-opened intermediate 
(V), whereas for good leaving groups, such as phosphates, the rate of release has been 
found to match that of the decay of the aci-intermediate (II) instead (Walker et al., 
1988). The rate of cleavage of these compounds has been found to be greatly dependent 
upon pH, solvent, substitutions of both the ring and the benzylic position and the 
leaving group. Although the exact effect of changing each of these parameters is 
difficult to predict (Holmes, 1997, Corrie et al., 2005), some general characteristics can 
be determined and are summarised below.   
Electron-donating ring substituents 
 
Fig. 9.15 oNB scaffolds with varying electron-donating groups. 115: 4,5-Dimethoxy-2-nitrobenzyl; 116: 4,5-
Methylenedioxy-2-nitrobenzyl; 117: 4-(2-Ethanoic acid)oxy-2-nitrobenzyl. 
Modification of the aromatic ring causes changes to the absorption spectrum of the 
compounds. The introduction of electron-donating groups in the aromatic ring increases 
the absorption at higher wavelengths. Veratryl and methylenedioxy based nitrobenzyl 
photocages (compounds 115 and 116) have been given considerable attention as these 
have large absorption cross-sections at λ>350 nm. But, the introduction of strong 
electron-donating groups (such as amines) para to the nitro group have been reported to 
significantly lower the decaging efficiency of these compounds (Corrie et al., 2005). 
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One other advantage of introducing polar functional groups on the ring, such as 
carboxylic acids (compound 117) (Allan et al., 1998), is the potential to improve 
solubility of the compounds. 
Substitution at the benzylic carbon 
Substitution of the benzylic position mainly affects the quantum yield of photolysis. 
Furthermore, ring opening of the benzisoxazoline intermediate leads to the formation of 
a carbonyl at the benzylic centre. In the simplest of nitrobenzyl cages, the by-product of 
photolysis is an aldehyde (Fig. 9.16), which is unreactive when at low concentrations, 
but reactive at higher concentrations (Engels and Schlaeger, 1977). The aldehyde by-
product is also coloured, and can act as a light filter. Introduction of a methyl 
substituent at the benzylic position leads to the formation of an unreactive ketone 
photolysis by-product instead (Fig. 9.16).  
 
Fig. 9.16 Photolysis of 2-methyl nitrobenzyl and 2-ethyl nitrobenzyl photoprotecting groups and corresponding 
products. 
Substitutions at this position have also been shown to increase the rates of release of 
product. The introduction of a methyl group has been shown to cause a 7-fold decrease 
in the photolysis half-life of compound 119 vs compound 118 (Fig. 9.17) in PBS buffer 
(Holmes, 1997) and a 5-fold increase in quantum yield of compound 121 vs compound 
120 (Fig. 9.17) in solution (Reichmanis et al., 1985). This effect has also been observed 
for the addition of strongly electron-withdrawing groups (such as CF3) (Specht and 
Goeldner, 2004), although further studies on other electron-withdrawing substituents (in 
particular halogens) did not show such radical improvements in efficiency of the 
compounds 
 
Fig. 9.17 Examples of oNB photocaged acetate (Holmes, 1997) and tert-butylacetate (Reichmanis et al., 1985). 
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Leaving groups 
In general, good leaving groups have increased rates of release. The most common way 
of protecting compounds with nitrobenzyl photocages is to directly attach the 
compound to the benzylic carbon. This approach has been used for the release of 
different groups, such as thiols, carboxylic acids, histidines and phosphates (Corrie et 
al., 2005, Mayer and Heckel, 2006, Klán et al., 2013).  
Poorer leaving groups, such as alcohols and amines, are usually attached as the 
corresponding carbonates or carbamates, increasing the efficiency of cleavage. It is 
important to note that the product of photolysis of these compounds is still the carbonate 
or carbamate derivative of the desired product, which has to undergo post-photolytic 
fragmentation to the amine or carboxylate (Fig. 9.18). The fragmentation step is slow, 
with a rate of roughly 10-3 s-1 (Pocker et al., 1978). 
 
Fig. 9.18 Release of alcohols or amines from oNB protected compounds. Alcohols and amines can be directly 
coupled to the benzylic carbon, but the rate of photolysis of the photocage is slow. The compounds can also be 
photocaged through the corresponding carbonates or cabamates, which increases the rate of photolysis but the 
photolytic products have to undergo fragmentation to the desired alcohol or amine. 
9.6.2 Coumarinyl 
Table 13 Overview and general properties of coumarinyl photocleavable groups 
 
    
λmax (nm) 320 345 375 390 
εmax (M-1cm-1) 6000-12000 1000-12000 13000-19000 16000-20000 
φ 0.02-0,15 0.04-0,1 0.02-0,11 0.09-0,3 
k (s-1) 1×108 - 4×108 N/A N/A 1×109 - 2×109 
solubility (H2O) Variable Variable Good Medium 
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The use of (coumarin-4-yl)-methyl cages in a biological context was first described in 
1984 for the release of phosphate esters (Givens and Matuszewski, 1984). The 
phosphate moiety was efficiently released from the 7-methoxycoumarinyl-4-methyl 
derivative by illumination at λ=360 nm, which is higher than the oNB systems 
discussed previously. The good absorption cross-sections at longer wavelengths made 
this photoprotection group centre-stage for later developments. The release rates of 
coumarins are much faster than oNBs, reaching ns timescales for the release of strong 
acid conjugate bases such as methyl sulfonates (Geißler et al., 2005). One last 
advantage of coumarins is the large extinction coefficients reported for this class of 
compounds.  
Upon absorption of a photon, the coumarin relaxes to an excited singlet state (Fig. 9.19, 
II), which can either decay back to the ground state (II→I) or undergo heterolytic bond 
cleavage (II→III). The cleavage event is very fast, reaching a rate of 2×1010 s-1 
(determined for coumarinyl protected phosphate esters) (Schade et al., 1999) and the 
ion pair formed can then either recombine to the starting material (III→I) or dissociate 
(III→IV) and react with a nucleophile in the medium (V) to complete the cleavage 
pathway. In this last step, the recombination reaction is the dominant pathway, making 
the ion-pair dissociation the rate determining step in coumarin photolysis (Schmidt et 
al., 2007). The choice of buffer also affects the rate of separation of the tight ion pair 
(III), altering the ratio of the recombination and separation pathways, and therefore, the 
quantum yield.  
 
 
Fig. 9.19 Mechanism of coumarin photocleavage, Upon absorption of a photon, the coumarin (I) is placed in an 
excited singlet or triplet state (II). This state can decay back to ground state by fluorescence or non-radiatively or 
cleave heterolytically giving a tightly bound ion pair (III). The ion pair can recombine to the initial photocaged 
compound (I) or separate, causing the release of the product (IV). A nucleophilic species (usually water) then 
quenches the carbocation (V).  
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Substitution to the ring 
The introduction of substituents in the coumarin ring mainly alters the absorption 
wavelength of the cage and can help with solubility issues of the compounds. The 
parent coumarin has an absorption maximum at λ~310 nm and introduction of hydroxyl 
or methoxy moieties at C7 increases the maximum absorption wavelength by 15-20 nm. 
C7 substitution with free or alkyl amines causes a significant shift in absorption to 350-
395 nm. Addition of methoxy groups at C7 and C6 further increase the absorption 
wavelength to 345 nm and a combination of C6-Br with C7-OH to 375 nm, whereas 
C6-Br/C7-OMe has its maximum absorption at λ=330 nm. Therefore, the exact effect of 
ring substitutions can’t be easily predicted. Table 13 shows a few examples of 
coumarinyl compounds and their maximum absoptions. The introduction of electron 
donating groups has an effect on the efficiency of cleavage, as it facilitates heterolysis 
and hinders ion pair recombination (Schmidt et al., 2007). 
Leaving group 
Just as described for oNB photocages, the leaving group has a significant effect on the 
efficiency of product release during photolysis of coumarins. Good leaving groups, such 
as phosphates and sulphates, cleave efficiently, whereas poorer leaving groups, such as 
alcohols or thiols, are resistant to heterolysis. Such groups are usually linked through a 
carbonate linker to the coumarin but have to undergo decarboxylation before complete 
release of the desired product (Klán et al., 2013).  
9.6.3 para-Hydroxyphenyl 
Table 14 Overview and general properties of para-hydroxyphenyl photocleavable groups 
 
   
λmax (nm) 285 280 304 
εmax (M-1cm-1) ca. 15000 ca. 9000 ca. 12000 
φ 0.2-0.9 0.03-0.04 0.03 
k (s-1) 1×107 - 2×109 ca. 2×109 ca. 2×107 
Solubility (H2O) Good Good Good 
 
para-Hydroxylphenyl (pHP) photoprotecting groups are much more recent than oNB or 
Cm photocages. These have found applications in neurobiology and enzyme catalysis 
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investigations (Klán et al., 2013). These groups present good solubilities and high 
quantum yields but have maximum absorption wavelengths in the 280 nm region 
(Klíčová et al., 2012), which is much lower than the preferred illumination region of 
biological samples. 
The groups cleave via an interesting mechanism, similar to a Favorskii rearrangement. 
The absorption of a photon leads to the excitation of the pHP moiety to a triplet state 
which then rearranges to a cyclopropanone intermediate (II) with release of the product. 
The cyclopropanone then hydrolyses to para-hydroxybenzoic acid (III, Fig. 9.20). The 
rate of cyclopropanone formation, and consequently of product release, is very fast, 
occurring in the ns timescale (Conrad et al., 2000), and is dependent mainly on the 
leaving group. 
 
Fig. 9.20 Cleavage mechanism of pHP protected molecules. Absorption of a photon leads to the formation of a 
cyclopropanone intermediate (also called the Favorskii intermediate) and decaging of the biomolecule. The 
intermediate then hydrolyses to a carboxylate (Klán et al., 2013).  
The leaving group 
pHPs have been mainly investigated for the release of strong conjugate bases, such as 
sulfonates, phosphates and carboxylates and lower quantum yields and rates of release 
have been reported for poorer leaving groups (Givens et al., 2008). Increasing the pKa 
of the corresponding acid of the leaving group causes a decrease in the quantum yield as 
well as a decrease in the rate of product release (Klán et al., 2013).  
Subsitution on the chromophore 
Alterations to the chromophore have effects on both the maximum absorption 
wavelength and quantum efficiency. The introduction of meta-electron donating groups 
causes an increase of the absorption wavelength, but lowers the quantum efficiencies of 
the compounds whereas electron-accepting groups increase the quantum yield.    
9.6.4 Summary 
There are three main scaffolds for photocages currently used in biological applications, 
each having different spectroscopic properties as well as cleavage rates. oNB 
photocages are the slowest (10-3-10-4 s), followed by coumarins and para-
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hydroxyphenyls (10-6-10-8 s). The cleavage rates depend on both the photocage scaffold 
and the protected substrate, as well as the buffer composition and pH.  
oNB photocages are the slowest and the benzaldehyde photolysis by-products are 
reactive and can act as light filters, however oNB photocaged compounds are easily 
synthesised. The disadvantages can be overcome by the introduction of a substituent at 
the benzylic site, but this leads to the creation of a new chiral centre, making the 
synthesis and purification of the compounds more challenging.  
Solubility is a problem for the use of both coumarins and oNBs. pHPs are much more 
soluble and synthetically available but have very short maximum absorption 
wavelengths, the major disadvantage of using these protecting groups.Therefore, 
choosing a photocage scaffold is not a straightforward process. Faster release rates 
usually come with either solubility problems or bad spectroscopic properties. Although 
the scaffold will have relatively predictable absorption spectra, the cleavage rates and 
quantum yields cannot be predicted and can only be completely defined once the 
compound is synthesised and characterised experimentally. 
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9.7 Protein sequence alignments 
9.7.1 Full PanD protein sequences from different organisms 
Semi-conserved residues are marked as . and conserved residues as *. The conserved C-
terminal region across all PanZ producing bacteria is highlighted in red. The alignment 
was performed using ClustalW2 (McWilliam et al., 2013). 
P. aeruginosa     1  MHAIMLKAKLHRAEVTHAVLDYEGSCAIDGDWLDLSGIREYEQIQIYNVDNGERFTTYA  59 
E. coli           1  MIRTMLQGKLHRVKVTHADLHYEGSCAIDQDFLDAAGILENEAIDIWNVTNGKRFSTYA  59 
E. carotovora     1  MIRTMLQGKLHRVKVTQADLHYEGSCAIDQDFMDAAGILEYEAIDIYNVDNGQRFSTYA  59 
Y. pestis         1  MIRTMLQGKLHRVKVTQADLHYEGSCAIDQDFLEAAGILEYEAIDIYNVDNGQRFSTYA  59 
C. glutamicum     1  MLRTILGSKIHRATVTQADLDYVGSVTIDADLVHAAGLIEGEKVAIVDITNGARLETYV  59 
S. coelicolor     1  MLRTLIKSKIHRATVTQADLHYVGSVTIDADLLDAADLLPGELVHIVDVTNGARLETYV  59 
M. tuberculosis   1  MLRTMLKSKIHRATVTCADLHYVGSVTIDADLMDAADLLEGEQVTIVDIDNGARLVTYA  59 
T. thermophilus   1  MKRVMFHAKIHRATVTQADLHYVGSVTVDQDLLDAAGILPFEQVDIYDITNGARLTTYA  59 
L. pneumophila    1 MAYRKMLKSKIHRACVTQADLDYEGSITISPELLKVANILPYEAVNVWNITAGTRFETYA  60 
C. crescentus     1  MLLTMLKAKLHRATVTQADLDYEGSIAIDRDLLDASGILPNEQVDVLNITNGARFTTYA  59 
B. subtilis       1  MFRTMMRAKLHRATVTEANLNYVGSITIDEDLMDAVNIVENEKVQIVNNNNGARLETYV  59 
S. aureus         1  MIRTMMNAKIHRARVTESNLNYVGSITIDSDILEAVDILPNEKVAIVNNNNGARFETYV  59 
H. pylori         1  MTFEMLYSKIHRATITDANLNYVGSITIDEDLAKLAKLREGMKVEIVDVNNGERFSTYV  59 
                         .   *.**  .* . * * ** ..  .      .     . .     * *  **  
 
P. aeruginosa     60 IRAENGSKMISVNGAAAHKAKVGDRVIICAYAHYSEAELASHKPRMLYMAPGNQLSHTS 118 
E. coli           60 IAAERGSRIISVNGAAAHCASVGDIVIIASFVTMPDEEARTWRPNVAYFEGDNEMKRTA 118 
E. carotovora     60 IAGERGSRIISVNGAAARCACVGDKLIICSYVQMSDEQARSHSPKVAYFSGENELQRQA 118 
Y. pestis         60 IAAERGSRIISVNGAAARCACVGDKLIICSYVQMSYAAARLHHPKVAYFEGENQLQRKA 118 
C. glutamicum     60 IVGDAGTGNICINGAAAHLINPGDLVIIMSYLQATDAEAKAYEPKIVHVDADNRIVALG 118 
S. coelicolor     60 IEGERGSGVIGINGAAAHLVHPGDLVILISYAQVTDAEARSLRPRVVHVDGDNRIVGLG 118 
M. tuberculosis   60 ITGERGSGVIGINGAAAHLVHPGDLVILIAYATMDDARARTYQPRIVFVDAYNKPIDMG 118 
T. thermophilus   60 LPGERGSGVIGINGAAAHLVKPGDLVILVAYGVFDEEEARNLKPTVVLVDERNRILEVR 118 
L. pneumophila    61 ITGEKGSTDICVNGAAAHLVTPGDLVIIASFTQILEEDCAAHEPTVVFVDQFNRLKEIR 119 
C. crescentus     60 IEAPRGSKVIGVNGAAARLVQKNDLVIVVTYCQMPAEEARNYAPTVVLLDEGNLIKKAA 118 
B. subtilis       60 IKGERGSGVVCLNGAAARLVQPGDKVIIICYGLVAEENIHKQEPKIAVLDDDNQIIEML 118 
S. aureus         60 IAGERGSGKICLNGAASRLVEVGDVVIIMTYAQLNEEEIKNHAPKVAVMNEDNVIIEMI 118 
H. pylori         60 ILGKK-KGEICVNGAAARKVAIGDVVIILAYASMNEDEINAHKPSIVLVDEKNEILEK  116  
                     .        . .****..    .* .*. ..            * .      *       
 
P. aeruginosa    119 EAIPIQVA                               126 
E. coli          119 KAIPVQVA                               126 
E. carotovora    119 KAIPVQVA                               126 
Y. pestis        119 KAVPVQVA                               126 
C. glutamicum    119 NDLAEALPGSGLLTS-RSI                    136 
S. coelicolor    119 ADASEPVPGSDQERSPQAVSA                  139 
M. tuberculosis  119 HDPAFVPENAGELLDPRLGVG                  139 
T. thermophilus  119 KG                                     120 
L. pneumophila   120 PERIGVKSRIPYPA                         133 
C. crescentus    119                                        118 
B. subtilis      119 GAEKAGTIL                              127 
S. aureus        119 HEKENTIVL                              127 
H. pylori        116                                        116 
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9.7.2 DNA sequence alignments for the different PanD constructs 
 
WT                     ATGCGGGGTT CTCATCATCA TCATCATCAT GGTCTGGTTC CGCgtGGATC  
H17C                   ATGCGGGGTT CTCATcatCA TCATCAtcaT GGTCTGGTTC CGCgTGGATc  
D19C                   ATGCGGGGTT CTCATCATCA TCATCATCAT GGTCTGGTTC CGCGTGGATC  
E23C                   ATGCGGGGTT CTCATCATCA TCATCATCAT GGTCTGGTTC CGCGTGGATC  
C26S                   ATGCGGGGTT CTCATCATCA TcatcaTCAT GGTCTGGTTC CGCGTGGATC  
A62C                   ATGCGGGGTT CTCATCATCA TCATCATCAT GGTCTGGTTC CGCgtGGATC  
C78A                   ATGCGGGGTT CTCATCATCA TCATCATCAT GGTCTGGTTC CGCgtGGATC  
H17CE23C               ATGCGGGGTT CTCATCATCA TCATCATCAT GGTCTGGTTC CGCgtGGATC  
H17CC26S               ATGCGGGGTT CTCATCATCA TCATCATCAT GGTCTGGTTC CGCGTGGATC  
H17CC78A               ATGCGGGGTT CTCATCATCA TCATCATCAT GGTCTGGTTC CGCgtGGATC  
D19CE23C               ATGCGGGGTT CTCATCATCA TCATCATCAT gGTCTGGTTC CGCgtGGATC  
D19CC26S               ATGCGGGGTT CTCATCATCA TCATCATCAT GGTCTGGTTC CGCGTGGATC  
E23CA62C               ATGCGGGGtT CTCATCATCA TCATCATCAT ggtCTgGtTC CGCgtgGATC  
E23CC78A               ATGCGGGGTT CTCATCATCA TCATCATCAT GGTCTGGTTC CGCGTGGATC  
C26SC78A               ATGCGGGGTT CTCATCATCA TCATCATCAT GGTCTGGTTC CGCGTGGATC  
H17CE23CC78A           ATGCGGGGTT CTCATCATCA TCATCATCAT gGTCTGGTTC CGCgtgGATC  
D19CE23CC78A           ATGCGGGGTT CTCATCATCA TCATCATCAT GGTCTGGTTC CGCGTGGATC  
E23CA62CC78A           ATGCGGGGTT CTCATCATCA TCATCATCAT GGTCTGGTTC CGCGTGGATC  
E23CC26SC78A           ATGCGGGGTT CTCATCATCA TCATCATCAT GGTCTGGTTC CGCGTGGATC  
H17CE23CC26SC78A       ATGCGGGGTT CTCATCATCA TCATCATCAT GGTCTGGTTC CGCGTGGATC  
D19CE23CC26SC78A       ATGCGGGGTT CTCATCATCA TCATCATCAT GGTCTGGTTC CGCgtGGATC  
E23CC26SA62CC78A       ATGCGGGGTT CTCATCATCA TCATCATCAT GGTCTGGTTC CGCGTGGATC  
 
WT                     CATGATTCGC ACGATGCTGC AGGGCAAACT CCACCGCgtG AAAGTGACTC  
H17C                   catgATTCGC ACGATGctGC AGGGCAAACt CCACCGcgtg AAAGTGACTT  
D19C                   CATGATTCGC ACGATGCTGC AGGGCAAACT CCACCGCGTG AAAGTGACTC  
E23C                   CATGATTCGC ACGATGCTGC AGGGCAAACT CCACCGCGTG AAAGTGACTC  
C26S                   CATGATTCGC ACGATGCTGC AGGGCAAACT CCACCGCGTG AAAGTGACTC  
A62C                   CATGATTCGC ACGATGCTGC AGGGCAAACT CCACCGCGTG AAAGTGACTC  
C78A                   CATGATTCGC ACGATGCTGC AGGGCAAACT CCACCGCgtG AAAGTGACTC  
H17CE23C               CATGATTCGC ACGATGCTGC AGGGCAAACT CCACCGCgtG AAAGTGACTT  
H17CC26S               CATGATTCGC ACGATGCTGC AGGGCAAACT CCACCGCGTG AAAGTGACTT  
H17CC78A               CATGATTCGC ACGATGCTGC AGGGCAAACT CCACCGCgtG AAAGTGACTT  
D19CE23C               CATGATTCGC ACGATGCTGC AGGGCAAACT CCACCGCgtg AAAGTGACTC  
D19CC26S               CATGATTCGC ACGATGCTGC AGGGCAAACT CCACCGCGTG AAAGTGACTC  
E23CA62C               CAtgATTCGC ACGATGCTGC AGGGCAAACT CCACCGCgtg AAAGTGACTC  
E23CC78A               CATGATTCGC ACGATGCTGC AGGGCAAACT CCACCGCGTG AAAGTGACTC  
C26SC78A               CATGATTCGC ACGATGCTGC AGGGCAAACT CCACCGCGTG AAAGTGACTC  
H17CE23CC78A           CATGATTCGC ACGATGCTGC AGGGCAAACT CCACCGCgtg AAAGTGACTT  
D19CE23CC78A           CATGATTCGC ACGATGCTGC AGGGCAAACT CCACCGCgtG AAAGTGACTC  
E23CA62CC78A           CATGATTCGC ACGATGCTGC AGGGCAAACT CCACCGCGTG AAAGTGACTC  
E23CC26SC78A           CATGATTCGC ACGATGCTGC AGGGCAAACT CCACCGCGTG AAAGTGACTC  
H17CE23CC26SC78A       CATGATTCGC ACGATGCTGC AGGGCAAACT CCACCGCGTG AAAGTGACTT  
D19CE23CC26SC78A       CATGATTCGC ACGATGCTGC AGGGCAAACT CCACCGCgtG AAAGTGACTC  
E23CC26SA62CC78A       CATGATTCGC ACGATGCTGC AGGGCAAACT CCACCGCGTG AAAGTGACTC  
 
WT                     ATGCGGACCT GCACTATGAA GGTTCTTGCG CCATTGACCA GGATTTTCTT  
H17C                   GTGCGgACCT GCACTATGAA GGTTCTTGCG CCATtgACCA GGATTTTCtT  
D19C                   ATGCGTGCCT GCACTATGAA GGTTCTTGCG CCATTGACCA GGATTTTCTT  
E23C                   ATGCGGACCT GCACTATTGT GGTTCTTGCG CCATTGACCA GGATTTTCTT  
C26S                   ATGCGGACCT GCACTATGAA GGTTCTTCCG CCATTGACCA GGATTTTCTT  
A62C                   ATGCGGACCT GCACTATGAA GGTTCTTGCG CCATTGACCA GGATTTTCTT  
C78A                   ATGCGGACCT GCACTATGAA GGTTCTTGCG CCATTGACCA GGATTTTCTT  
H17CE23C               GTGCGGACCT GCACTATTGT GGTTCTTGCG CCATTGACCA GGATTTTCTT  
H17CC26S               GTGCGGACCT GCACTATGAA GGTTCTTCCG CCATTGACCA GGATTTTCTT  
H17CC78A               GTGCGGACCT GCACTATGAA GGTTCTTGCG CCATTGACCA GGATTTTCTT  
D19CE23C               ATGCGTGCCT GCACTATTGT GGTTCTTGCG CCATTGACCA GGATTTTCTT  
D19CC26S               ATGCGTGCCT GCACTATGAA GGTTCTTCCG CCATTGACCA GGATTTTCTT  
E23CA62C               ATGCGGACct gCACTAttgt GGTTCTTGCG CCATtgACCA GGATTTTCTT  
E23CC78A               ATGCGGACCT GCACTATTGT GGTTCTTGCG CCATTGACCA GGATTTTCTT  
C26SC78A               ATGCGGACCT GCACTATGAA GGTTCTTCCG CCATTGACCA GGATTTTCTT  
H17CE23CC78A           GTGCGGACCT GCActATTGT GGTTCTTGCG CCATTGACCA GGATTTTCTT  
D19CE23CC78A           ATGCGTGCCT GCACTATTGT GGTTCTTGCG CCATTGACCA GGATTTTCTT  
E23CA62CC78A           ATGCGGACCT GCACTATTGT GGTTCTTGCG CCATTGACCA GGATTTTCTT  
E23CC26SC78A           ATGCGGACCT GCACTATTGT GGTTCTTCCG CCATTGACCA GGATTTTCTT  
H17CE23CC26SC78A       GTGCGGACCT GCACTATTGT GGTTCTTCCG CCATTGACCA GGATTTTCTT  
D19CE23CC26SC78A       ATGCGTGCCT GCACTATTGT GGTTCTTCCG CCATTGACCA GGATTTTCTT  
E23CC26SA62CC78A       ATGCGGACCT GCACTATTGT GGTTCTTCCG CCATTGACCA GGATTTTCTT  
 
WT                     GACGCAGCCG GTATTCTCGA AAACGAAGCC ATTGATATCT GGAATGTCAC  
H17C                   GACGCaGCCG gtATTCTCGA AAACGAAGCC ATtgATATCT GGAATGTCac  
D19C                   GACGCAGCCG GTATTCTCGA AAACGAAGCC ATTGATATCT GGAATGTCAC  
E23C                   GACGCAGCCG GTATTCTCGA AAACGAAGCC ATTGATATCT GGAATGTCAC  
C26S                   GACGCAGCCG GTATTCTCGA AAACGAAGCC ATTGATATCT GGAATGTCAC  
A62C                   GACGCAGCCG GTATTCTCGA AAACGAAGCC ATTGATATCT GGAATGTCAC  
  205 
C78A                   GACGCAGCCG GTATTCTCGA AAACGAAGCC ATTGATATCT GGAATGTCAC  
H17CE23C               GACGCAGCCG GTATTCTCGA AAACGAAGCC ATTGATATCT GGAATGTCAC  
H17CC26S               GACGCAGCCG GTATTCTCGA AAACGAAGCC ATTGATATCT GGAATGTCAC  
H17CC78A               GACGCAGCCG GTATTCTCGA AAACGAAGCC ATTGATATCT GGAATGTCAC  
D19CE23C               GACGCAGCCG GTATTCTCGA AAACGAAGCC ATTGATATCT GGAATGTCAC  
D19CC26S               GACGCAGCCG GTATTCTCGA AAACGAAGCC ATTGATATCT GGAATGTCAC  
E23CA62C               GACGCAGCCG GTATTCTCGA AAACGAAGCC ATTGATATCT GGAATGTCAC  
E23CC78A               GACGCAGCCG GTATTCTCGA AAACGAAGCC ATTGATATCT GGAATGTCAC  
C26SC78A               GACGCAGCCG GTATTCTCGA AAACGAAGCC ATTGATATCT GGAATGTCAC  
H17CE23CC78A           GACGCAGCCG GTATTCTCGA AAACGAAGCC ATTGATATCT GGAATGTCAC  
D19CE23CC78A           GACGCAGCCG GTATTCTCGA AAACGAAGCC ATTGATATCT GGAATGTCAC  
E23CA62CC78A           GACGCAGCCG GTATTCTCGA AAACGAAGCC ATTGATATCT GGAATGTCAC  
E23CC26SC78A           GACGCAGCCG GTATTCTCGA AAACGAAGCC ATTGATATCT GGAATGTCAC  
H17CE23CC26SC78A       GACGCAGCCG GTATTCTCGA AAACGAAGCC ATTGATATCT GGAATGTCAC  
D19CE23CC26SC78A       GACGCAGCCG GTATTCTCGA AAACGAAGCC ATTGATATCT GGAATGTCAC  
E23CC26SA62CC78A       GACGCAGCCG GTATTCTCGA AAACGAAGCC ATTGATATCT GGAATGTCAC  
 
WT                     CAACGGCAAG CGTTTCTCCA CTTATGCCAT CGCGGCAGAA CGCGGTTCGA  
H17C                   CAACGGCAAG CGTTTCTCCA CttatgCCAT CGCGGCAGAA CGCGgttCGA  
D19C                   CAACGGCAAG CGTTTCTCCA CTTATGCCAT CGCGGCAGAA CGCGGTTCGA  
E23C                   CAACGGCAAG CGTTTCTCCA CTTATGCCAT CGCGGCAGAA CGCGGTTCGA  
C26S                   CAACGGCAAG CGTTTCTCCA CTTATGCCAT CGCGGCAGAA CGCGGTTCGA  
A62C                   CAACGGCAAG CGTTTCTCCA CTTATGCCAT CGCGTGTGAA CGCGGTTCGA  
C78A                   CAACGGCAAG CGTTTCTCCA CTTATGCCAT CGCGGCAGAA CGCGGTTCGA  
H17CE23C               CAACGGCAAG CGTTTCTCCA CTTATGCCAT CGCGGCAGAA CGCGGTTCGA  
H17CC26S               CAACGGCAAG CGTTTCTCCA CTTATGCCAT CGCGGCAGAA CGCGGTTCGA  
H17CC78A               CAACGGCAAG CGTTTCTCCA CTTATGCCAT CGCGGCAGAA CGCGGTTCGA  
D19CE23C               CAACGGCAAG CGTTTCTCCA CTTATGCCAT CGCGGCAGAA CGCGGTTCGA  
D19CC26S               CAACGGCAAG CGTTTCTCCA CTTATGCCAT CGCGGCAGAA CGCGGTTCGA  
E23CA62C               CAACGGCAAG CGTTTCTCCA CTTATGCCAT CGCGTGTGAA CGCGGTTCGA  
E23CC78A               CAACGGCAAG CGTTTCTCCA CTTATGCCAT CGCGGCAGAA CGCGGTTCGA  
C26SC78A               CAACGGCAAG CGTTTCTCCA CTTATGCCAT CGCGGCAGAA CGCGGTTCGA  
H17CE23CC78A           CAACGGCAAG CGTTTCTCCA CTTATGCCAT CGCGGCAGAA CGCGGTTCGA  
D19CE23CC78A           CAACGGCAAG CGTTTCTCCA CTTATGCCAT CGCGGCAGAA CGCGGTTCGA  
E23CA62CC78A           CAACGGCAAG CGTTTCTCCA CTTATGCCAT CGCGTGTGAA CGCGGTTCGA  
E23CC26SC78A           CAACGGCAAG CGTTTCTCCA CTTATGCCAT CGCGGCAGAA CGCGGTTCGA  
H17CE23CC26SC78A       CAACGGCAAG CGTTTCTCCA CTTATGCCAT CGCGGCAGAA CGCGGTTCGA  
D19CE23CC26SC78A       CAACGGCAAG CGTTTCTCCA CTTATGCCAT CGCGGCAGAA CGCGGTTCGA  
E23CC26SA62CC78A       CAACGGCAAG CGTTTCTCCA CTTATGCCAT CGCGTGTGAA CGCGGTTCGA  
 
WT                     GAATTATTTC TGTTAACGGT GCGGCGGCCC ACTGCGCCAG TGTCGGCGAT  
H17C                   GAATTATTTC TGTTAACGGT GCGGCGGCCC ActGCGCCag tGTCGGCGAT  
D19C                   GAATTATTTC TGTTAACGGT GCGGCGGCCC ACTGCGCCAG TGTCGGCGAT  
E23C                   GAATTATTTC TGTTAACGGT GCGGCGGCCC ACTGCGCCAG TGTCGGCGAT  
C26S                   GAATTATTTC TGTTAACGGT GCGGCGGCCC ACTGCGCCAG TGTCGGCGAT  
A62C                   GAATTATTTC TGTTAACGGT GCGGCGGCCC ACTGCGCCAG TGTCGGCGAT  
C78A                   GAATTATTTC TGTTAACGGT GCGGCGGCCC ACGCAGCCAG TGTCGGCGAT  
H17CE23C               GAATTATTTC TGTTAACGGT GCGGCGGCCC ACTGCGCCAG TGTCGGCGAT  
H17CC26S               GAATTATTTC TGTTAACGGT GCGGCGGCCC ACTGCGCCAG TGTCGGCGAT  
H17CC78A               GAATTATTTC TGTTAACGGT GCGGCGGCCC ACGCAGCCAG TGTCGGCGAT  
D19CE23C               GAATTATTTC TGTTAACGGT GCGGCGGCCC ACTGCGCCAG TGTCGGCGAT  
D19CC26S               GAATTATTTC TGTTAACGGT GCGGCGGCCC ACTGCGCCAG TGTCGGCGAT  
E23CA62C               GAATTATTTC TGTTAACGGT GCGGCGGCCC ACTGCGCCAG TGTCGGCGAT  
E23CC78A               GAATTATTTC TGTTAACGGT GCGGCGGCCC ACGCAGCCAG TGTCGGCGAT  
C26SC78A               GAATTATTTC TGTTAACGGT GCGGCGGCCC ACGCAGCCAG TGTCGGCGAT  
H17CE23CC78A           GAATTATTTC TGTTAACGGT GCGGCGGCCC ACGCAGCCAG TGTCGGCGAT  
D19CE23CC78A           GAATTATTTC TGTTAACGGT GCGGCGGCCC ACGCAGCCAG TGTCGGCGAT  
E23CA62CC78A           GAATTATTTC TGTTAACGGT GCGGCGGCCC ACGCAGCCAG TGTCGGCGAT  
E23CC26SC78A           GAATTATTTC TGTTAACGGT GCGGCGGCCC ACGCAGCCAG TGTCGGCGAT  
H17CE23CC26SC78A       GAATTATTTC TGTTAACGGT GCGGCGGCCC ACGCAGCCAG TGTCGGCGAT  
D19CE23CC26SC78A       GAATTATTTC TGTTAACGGT GCGGCGGCCC ACGCAGCCAG TGTCGGCGAT  
E23CC26SA62CC78A       GAATTATTTC TGTTAACGGT GCGGCGGCCC ACGCAGCCAG TGTCGGCGAT  
 
WT                     ATTGTCATCA TCGCCAGCTT CGTTACCATG CCAGATGAAG AAGCTCGCAC  
H17C                   ATTGTCATCA TCGCCAGCtt cGTTACCATG CCAGATGAAG AAGCTCGCAC  
D19C                   ATTGTCATCA TCGCCAGCTT CGTTACCATG CCAGATGAAG AAGCTCGCAC  
E23C                   ATTGTCATCA TCGCCAGCTT CGTTACCATG CCAGATGAAG AAGCTCGCAC  
C26S                   ATTGTCATCA TCGCCAGCTT CGTTACCATG CCAGATGAAg AAGCTCGCAC  
A62C                   ATTGTCATCA TCGCCAGCTT CGTTACCATG CCAGATGAAG AAGCTCGCAC  
C78A                   ATTGTCATCA TCGCCAGCTT CGTTACCATG CCAGATGAAG AAGCTCGCAC  
H17CE23C               ATTGTCATCA TCGCCAGCTT CGTTACCATG CCAGATGAAG AAGCTCGCAC  
H17CC26S               ATTGTCATCA TCGCCAGCTT CGTTACCATG CCAGATGAAG AAGCTCGCAC  
H17CC78A               ATTGTCATCA TCGCCAGCTT CGTTACCATG CCAGATGAAG AAGCTCGCAC  
D19CE23C               ATTGTCATCA TCGCCAGCTT CGTTACCATG CCAGATGAAG AAGCTCGCAC  
D19CC26S               ATTGTCATCA TCGCCAGCTT CGTTACCATG CCAGATGAAG AAGCTCGCAC  
E23CA62C               ATTGTCATCA TCGCCAGCTT CGTTACCATG CCAGATGAAG AAGCTCGCAC  
E23CC78A               ATTGTCATCA TCGCCAGCTT CGTTACCATG CCAGATGAAG AAGCTCGCAC  
C26SC78A               ATTGTCATCA TCGCCAGCTT CGTTACCATG CCAGATGAAG AAGCTCGCAC  
H17CE23CC78A           ATTGTCATCA TCGCCAGCTT CGTTACCATG CCAGATGAAG AAGCTCGCAC  
D19CE23CC78A           ATTGTCATCA TCGCCAGCTT CGTTACCATG CCAGATGAAG AAGCTCGCAC  
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E23CA62CC78A           ATTGTCATCA TCGCCAGCTT CGTTACCATG CCAGATGAAG AAGCTCGCAC  
E23CC26SC78A           ATTGTCATCA TCGCCAGCTT CGTTACCATG CCAGATGAAG AAGCTCGCAC  
H17CE23CC26SC78A       ATTGTCATCA TCGCCAGCTT CGTTACCATG CCAGATGAAG AAGCTCGCAC  
D19CE23CC26SC78A       ATTGTCATCA TCGCCAGCTT CGTTACCATG CCAGATGAAG AAGCTCGCAC  
E23CC26SA62CC78A       ATTGTCATCA TCGCCAGCTT CGTTACCATG CCAGATGAAG AAGCTCGCAC  
 
WT                     CTGGCGACCC AACGTCGCCT ATTTTGAAGG CGACAATGAA ATGAAACGTA  
H17C                   CTGGCGACCC AACGTCGCCT ATTTTGAAGG CGACAATGAA ATGAagcGTA  
D19C                   CTGGCGACCC AACGTCGCCT ATTTTGAAGG CGACAATGAA ATGAAACGTA  
E23C                   CTGGCGACCC AACGTCGCCT ATTTTGAAGG CGACAATGAA ATGAAACGTA  
C26S                   CTGGCGACCC AACGTCGCCT ATTTTGAAGG CGACAATGAA ATGAAACGTA  
A62C                   CTGGCGACCC AACGTCGCCT ATTTTGAAGG CGACAATGAA ATGAAACGTA  
C78A                   CTGGCGACCC AACGTCGCCT ATTTTGAAGG CGACAATGAA ATGAAACGTA  
H17CE23C               CTGGCGACCC AACGTCGCCT ATTTTGAAGG CGACAATGAA ATGAAACGTA  
H17CC26S               CTGGCGACCC AACGTCGCCT ATTTTGAAGG CGACAATGAA ATGAAACGTA  
H17CC78A               CTGGCGACCC AACGTCGCCT ATTTTGAAGG CGACAATGAA ATGAAACGTA  
D19CE23C               CTGGCGACCC AACGTCGCCT ATTTTGAAGG CGACAATGAA ATGAAACGTA  
D19CC26S               CTGGCGACCC AACGTCGCCT ATTTTGAAGG CGACAATGAA ATGAAACGTA  
E23CA62C               CTGGCGACCC AACGTCGCCT ATTTTGAAGG CGACAATGAA ATGAAACGTA  
E23CC78A               CTGGCGACCC AACGTCGCCT ATTTTGAAGG CGACAATGAA ATGAAACGTA  
C26SC78A               CTGGCGACCC AACGTCGCCT ATTTTGAAGG CGACAATGAA ATGAAACGTA  
H17CE23CC78A           CTGGCGACCC AACGTCGCCT ATTTTGAAGG CGACAATGAA ATGAAACGTA  
D19CE23CC78A           CTGGCGACCC AACGTCGCCT ATTTTGAAGG CGACAATGAA ATGAAACGTA  
E23CA62CC78A           CTGGCGACCC AACGTCGCCT ATTTTGAAGG CGACAATGAA ATGAAACGTA  
E23CC26SC78A           CTGGCGACCC AACGTCGCCT ATTTTGAAGG CGACAATGAA ATGAAACGTA  
H17CE23CC26SC78A       CTGGCGACCC AACGTCGCCT ATTTTGAAGG CGACAATGAA ATGAAACGTA  
D19CE23CC26SC78A       CTGGCGACCC AACGTCGCCT ATTTTGAAGG CGACAATGAA ATGAAACGTA  
E23CC26SA62CC78A       CTGGCGACCC AACGTCGCCT ATTTTGAAGG CGACAATGAA ATGAAACGTA  
 
WT                     CCGCGAAAGC GATTCCGGTA CAGGTTGCTT GA 
H17C                   CCGCGAAAGC GATTCCGGTA CAGGTTGCTT GA 
D19C                   CCGCGAAAGC GATTCCGGTA CAGGTTGCTT GA 
E23C                   CCGCGAAAGC GATTCCGGTA CAGGTTGCTT GA 
C26S                   CCGCGAAAGC GATTCCgGtA CaGGTTGCTT GA 
A62C                   CCGCGAAAGC GATTCCGGTA CAGGTTGCTT GA 
C78A                   CCGCGAAAGC GATTCCGGTA CAGGTTGCTT GA 
H17CE23C               CCGCGAAAGC GATTCCGGTA CAGGTTGCTT GA 
H17CC26S               CCGCGAAAGC GATTCCGGTA CAGGTTGCTT GA 
H17CC78A               CCGCGAAAGC GATTCCGGTA CAGGTTGCTT GA 
D19CE23C               CCGCGAAAGC GATTCCGGTA CAGGTTGCTT GA 
D19CC26S               CCGCGAAAGC GATTCCGGTA CAGGTTGCTT GA 
E23CA62C               CCGCGAAAGC GATTCCGGTA CAGGTTGCTT GA 
E23CC78A               CCGCGAAAGC GATTCCGGTA CAGGTTGCTT GA 
C26SC78A               CCGCGAAAGC GATTCCGGTA CAGGTTGCTT GA 
H17CE23CC78A           CCGCGAAAGC GATTCCGGTA CAGGTTGCTT GA 
D19CE23CC78A           CCGCGAAAGC GATTCCGGTA CAGGTTGCTT GA 
E23CA62CC78A           CCGCGAAAGC GATTCCGGTA CAGGTTGCTT GA 
E23CC26SC78A           CCGCGAAAGC GATTCCGGTA CAGGTTGCTT GA 
H17CE23CC26SC78A       CCGCGAAAGC GATTCCGGTA CAGGTTGCTT GA 
D19CE23CC26SC78A       CCGCGAAAGC GATTCCGGTA CAGGTTGCTT GA 
E23CC26SA62CC78A       CCGCGAAAGC GATTCCGGTA CAGGTTGCTT GA 
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9.7.3 Protein sequence alignment for the different PanD constructs 
WT               -17   MRGSHHHHHH GLVPRGSMIR TMLQGKLHRV KVTHADLHYE GSCAIDQDFL 33 
H17C             -17   MRGSHHHHHH GLVPRGSMIR TMLQGKLHRV KVTCADLHYE GSCAIDQDFL 33 
D19C             -17   MRGSHHHHHH GLVPRGSMIR TMLQGKLHRV KVTHACLHYE GSCAIDQDFL 33 
E23C             -17   MRGSHHHHHH GLVPRGSMIR TMLQGKLHRV KVTHADLHYC GSCAIDQDFL 33 
C26S             -17   MRGSHHHHHH GLVPRGSMIR TMLQGKLHRV KVTHADLHYE GSSAIDQDFL 33 
A62C             -17   MRGSHHHHHH GLVPRGSMIR TMLQGKLHRV KVTHADLHYE GSCAIDQDFL 33 
C78A             -17   MRGSHHHHHH GLVPRGSMIR TMLQGKLHRV KVTHADLHYE GSCAIDQDFL 33 
H17CE23C         -17   MRGSHHHHHH GLVPRGSMIR TMLQGKLHRV KVTCADLHYC GSCAIDQDFL 33 
H17CC26S         -17   MRGSHHHHHH GLVPRGSMIR TMLQGKLHRV KVTCADLHYE GSSAIDQDFL 33 
H17CC78A         -17   MRGSHHHHHH GLVPRGSMIR TMLQGKLHRV KVTCADLHYE GSCAIDQDFL 33 
D19CE23C         -17   MRGSHHHHHH GLVPRGSMIR TMLQGKLHRV KVTHACLHYC GSCAIDQDFL 33 
D19CC26S         -17   MRGSHHHHHH GLVPRGSMIR TMLQGKLHRV KVTHACLHYE GSSAIDQDFL 33 
E23CA62C         -17   MRGSHHHHHH GLVPRGSMIR TMLQGKLHRV KVTHADLHYC GSCAIDQDFL 33 
E23CC78A         -17   MRGSHHHHHH GLVPRGSMIR TMLQGKLHRV KVTHADLHYC GSCAIDQDFL 33 
C26SC78A         -17   MRGSHHHHHH GLVPRGSMIR TMLQGKLHRV KVTHADLHYE GSSAIDQDFL 33 
H17CE23CC78A     -17   MRGSHHHHHH GLVPRGSMIR TMLQGKLHRV KVTCADLHYC GSCAIDQDFL 33 
D19CE23CC78A     -17   MRGSHHHHHH GLVPRGSMIR TMLQGKLHRV KVTHACLHYC GSCAIDQDFL 33 
E23CA62CC78A     -17   MRGSHHHHHH GLVPRGSMIR TMLQGKLHRV KVTHADLHYC GSCAIDQDFL 33 
E23CC26SC78A     -17   MRGSHHHHHH GLVPRGSMIR TMLQGKLHRV KVTHADLHYC GSSAIDQDFL 33 
H17CE23CC26SC78A -17   MRGSHHHHHH GLVPRGSMIR TMLQGKLHRV KVTCADLHYC GSSAIDQDFL 33 
D19CE23CC26SC78A -17   MRGSHHHHHH GLVPRGSMIR TMLQGKLHRV KVTHACLHYC GSSAIDQDFL 33 
E23CC26SA62CC78A -17   MRGSHHHHHH GLVPRGSMIR TMLQGKLHRV KVTHADLHYC GSSAIDQDFL 33 
 
WT                34   DAAGILENEA IDIWNVTNGK RFSTYAIAAE RGSRIISVNG AAAHCASVGD 83 
H17C              34   DAAGILENEA IDIWNVTNGK RFSTYAIAAE RGSRIISVNG AAAHCASVGD 83 
D19C              34   DAAGILENEA IDIWNVTNGK RFSTYAIAAE RGSRIISVNG AAAHCASVGD 83 
E23C              34   DAAGILENEA IDIWNVTNGK RFSTYAIAAE RGSRIISVNG AAAHCASVGD 83 
C26S              34   DAAGILENEA IDIWNVTNGK RFSTYAIAAE RGSRIISVNG AAAHCASVGD 83 
A62C              34   DAAGILENEA IDIWNVTNGK RFSTYAIACE RGSRIISVNG AAAHCASVGD 83 
C78A              34   DAAGILENEA IDIWNVTNGK RFSTYAIAAE RGSRIISVNG AAAHAASVGD 83 
H17CE23C          34   DAAGILENEA IDIWNVTNGK RFSTYAIAAE RGSRIISVNG AAAHCASVGD 83 
H17CC26S          34   DAAGILENEA IDIWNVTNGK RFSTYAIAAE RGSRIISVNG AAAHCASVGD 83 
H17CC78A          34   DAAGILENEA IDIWNVTNGK RFSTYAIAAE RGSRIISVNG AAAHAASVGD 83 
D19CE23C          34   DAAGILENEA IDIWNVTNGK RFSTYAIAAE RGSRIISVNG AAAHCASVGD 83 
D19CC26S          34   DAAGILENEA IDIWNVTNGK RFSTYAIAAE RGSRIISVNG AAAHCASVGD 83 
E23CA62C          34   DAAGILENEA IDIWNVTNGK RFSTYAIACE RGSRIISVNG AAAHCASVGD 83 
E23CC78A          34   DAAGILENEA IDIWNVTNGK RFSTYAIAAE RGSRIISVNG AAAHAASVGD 83 
C26SC78A          34   DAAGILENEA IDIWNVTNGK RFSTYAIAAE RGSRIISVNG AAAHAASVGD 83 
H17CE23CC78A      34   DAAGILENEA IDIWNVTNGK RFSTYAIAAE RGSRIISVNG AAAHAASVGD 83 
D19CE23CC78A      34   DAAGILENEA IDIWNVTNGK RFSTYAIAAE RGSRIISVNG AAAHAASVGD 83 
E23CA62CC78A      34   DAAGILENEA IDIWNVTNGK RFSTYAIACE RGSRIISVNG AAAHAASVGD 83 
E23CC26SC78A      34   DAAGILENEA IDIWNVTNGK RFSTYAIAAE RGSRIISVNG AAAHAASVGD 83 
H17CE23CC26SC78A  34   DAAGILENEA IDIWNVTNGK RFSTYAIAAE RGSRIISVNG AAAHAASVGD 83 
D19CE23CC26SC78A  34   DAAGILENEA IDIWNVTNGK RFSTYAIAAE RGSRIISVNG AAAHAASVGD 83 
E23CC26SA62CC78A  34   DAAGILENEA IDIWNVTNGK RFSTYAIACE RGSRIISVNG AAAHAASVGD 83 
 
WT                84   IVIIASFVTM PDEEARTWRP NVAYFEGDNE MKRTAKAIPV QVA 126 
H17C              84   IVIIASFVTM PDEEARTWRP NVAYFEGDNE MKRTAKAIPV QVA 126 
D19C              84   IVIIASFVTM PDEEARTWRP NVAYFEGDNE MKRTAKAIPV QVA 126 
E23C              84   IVIIASFVTM PDEEARTWRP NVAYFEGDNE MKRTAKAIPV QVA 126 
C26S              84   IVIIASFVTM PDEEARTWRP NVAYFEGDNE MKRTAKAIPV QVA 126 
A62C              84   IVIIASFVTM PDEEARTWRP NVAYFEGDNE MKRTAKAIPV QVA 126 
C78A              84   IVIIASFVTM PDEEARTWRP NVAYFEGDNE MKRTAKAIPV QVA 126 
H17CE23C          84   IVIIASFVTM PDEEARTWRP NVAYFEGDNE MKRTAKAIPV QVA 126 
H17CC26S          84   IVIIASFVTM PDEEARTWRP NVAYFEGDNE MKRTAKAIPV QVA 126 
H17CC78A          84   IVIIASFVTM PDEEARTWRP NVAYFEGDNE MKRTAKAIPV QVA 126 
D19CE23C          84   IVIIASFVTM PDEEARTWRP NVAYFEGDNE MKRTAKAIPV QVA 126 
D19CC26S          84   IVIIASFVTM PDEEARTWRP NVAYFEGDNE MKRTAKAIPV QVA 126 
E23CA62C          84   IVIIASFVTM PDEEARTWRP NVAYFEGDNE MKRTAKAIPV QVA 126 
E23CC78A          84   IVIIASFVTM PDEEARTWRP NVAYFEGDNE MKRTAKAIPV QVA 126 
C26SC78A          84   IVIIASFVTM PDEEARTWRP NVAYFEGDNE MKRTAKAIPV QVA 126 
H17CE23CC78A      84   IVIIASFVTM PDEEARTWRP NVAYFEGDNE MKRTAKAIPV QVA 126 
D19CE23CC78A      84   IVIIASFVTM PDEEARTWRP NVAYFEGDNE MKRTAKAIPV QVA 126 
E23CA62CC78A      84   IVIIASFVTM PDEEARTWRP NVAYFEGDNE MKRTAKAIPV QVA 126 
E23CC26SC78A      84   IVIIASFVTM PDEEARTWRP NVAYFEGDNE MKRTAKAIPV QVA 126 
H17CE23CC26SC78A  84   IVIIASFVTM PDEEARTWRP NVAYFEGDNE MKRTAKAIPV QVA 126 
D19CE23CC26SC78A  84   IVIIASFVTM PDEEARTWRP NVAYFEGDNE MKRTAKAIPV QVA 126 
E23CC26SA62CC78A  84   IVIIASFVTM PDEEARTWRP NVAYFEGDNE MKRTAKAIPV QVA 126 
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